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ABSTRACT 
The aim of this thesis is to enrich the understanding of institutional complexity. 
To that end, my research focuses on an emergent field, as the most acute 
instantiation of institutional complexity, in addition to being an understudied 
phenomenon. Theoretically, the approach is anchored in the institutional logics 
perspective and the concept of institutional work. My research design is an 
inductive multi-level, multi-case study, found adequate to investigate a poorly 
understood and complex phenomenon. The research setting is the emerging 
field of digital health, at the intersection of healthcare and consumer digital 
technologies fields.  
By means of the theoretical framework and the operational methodology, the 
research offers a robust understanding of the field emergence and of the 
institutional work undertaken by organisations in the midst of high institutional 
complexity. At field level, findings reveal the logics at play: the state, medical 
profession, market, science and citizen logics, as well as how the emerging role 
of the empowered patient mediates institutionalisation. A significant 
contribution of my research is a new theoretical model for field emergence. 
This research provides insights on the understudied phenomenon of bottom up 
institutionalisation through the organisational level analysis. The study reveals 
the institutional work new organisations undertake in an emergent field, 
depending on their position, plurality and ambiguity and their own identity. It 
shows how organisations hybridise logics, often by co-creating digital 
solutions with stakeholders and by acting as institutionalisation agents. This 
research makes significant contributions towards the role trust and leadership 
play in organisation’s success and the field institutionalisation itself. In 
addition, it reveals how new organisations contribute towards field emergence 
by adhering to distinctive categories and the promulgation of the new role of 
the empowered patient. Not last, my research contributes to the understanding 
of how digital technologies, by the virtue of their unfinished character, play a 
significant part in institutionalisation. 
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CHAPTER 1. INTRODUCTION 
1.1. STATEMENT OF MULTIDISCIPLINARITY 
My research is by mandate, as well as necessity, a multidisciplinary research. 
As a student of the Horizon Centre of Doctoral Training at the University of 
Nottingham, I was both trained and encouraged to draw connections between 
different disciplines in order to better understand various aspects of the digital 
economy. Moreover, the contemporary landscape, with digital technologies 
intertwined with all economic activities and everyday life, requires more lateral 
thinking, complex approaches in order to generate fresh insights. 
1.1. MOTIVATION 
My research is “open minded, problem-driven” (Santos & Eisenhardt, 2009, p. 
505) and grounded in the digitally transformed social and economic landscape. 
More precisely, it is situated at the intersection of consumer digital 
technologies and healthcare fields, where a new economic and innovation 
space is forming, hereinafter referred to as digital health. For the purpose of 
this thesis, digital health represents all things health informatics. 
The motivation for my research goes beyond the mandate I mentioned above 
and even my interests, to the fact that it is an emerging digital setting, which 
promises tremendous social, economic and scientific transformations, and 
therefore it is sitting high on political and innovation priorities in many 
countries. For instance, the European Union has recognised and nurtured its 
potential since 2004 (European Commission, 2014a). 
My research addresses several significant gaps in the literature. First, digital 
health is an emerging field and such fields have only been studied 
retrospectively. This study is actually looking at an emerging field as it 
happens. Acknowledging that retrospective approaches provide valuable 
insights, limitations are not to be overlooked (Aldrich & Fiol, 1994; Fligstein 
& McAdam, 2011; Greenwood et al., 2011). First, retrospective approaches 
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may have significant biases: “left-censoring of data” (Aldrich & Fiol, 1994, p. 
664) (not having insights in the early years of formation) and the survival bias 
(studying only fields that succeed, not those that fail in reaching maturity) 
(ibid., p. 665).  Second, I look at early ventures in an emerging field. Not only 
has this not been done before, but also retrospective research may have the bias 
of only observing the fittest. In addition to looking retrospectively at 
organisations that survived long enough, there is little information in the 
literature on how entrepreneurial firms navigate an early stage of a field or on 
how they may contribute to collective action (Aldrich & Fiol, 1994; 
Greenwood, Raynard, Kodeih, Micelotta, & Lounsbury, 2011). Not last, 
healthcare technology producers have not received much attention, despite the 
fact that technology has always been a major factor in the professionalisation 
of this field (Leicht & Fennell, 2008). The scarcity of studies during early 
stages of field emergence is due primarily to their lack of visibility (Morrill, 
2006), which implies that much is left to the researcher’s ability to discover 
and recognise it as a field in its own right.  
1.2. WORKING DEFINITIONS 
Before proceeding with the presentation of my research, I consider useful to 
provide definitions for the main terms: digital health, institutions, organisation, 
institutional logics and institutional work. 
The research setting is the emerging field of digital health, which is an 
umbrella term for all information technology (IT) solutions developed for 
healthcare. Digital health emerges as an interstice between healthcare and 
consumer digital technologies fields. Examples of digital health solutions are 
apps, wearables, virtual reality, but also electronic health records (more about 
terminology in appendix C).  
Institutions are “comprised of regulative, normative, and cultural-cognitive 
elements that, together with associated activities and resources, provide 
stability and meaning to social life” (Scott, 2008; p. 48). Our social life is 
guided, restricted and inspired by “social facts”, as Durkheim called 
institutions in 1895, which guide our way of thinking, acting as individuals and 
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as a society as a whole. Examples of institutions are marriage, religion, justice, 
family, or the state. Institutions, however resistant they may be, they do evolve 
over time. For instance, the institution of marriage has very deep roots, but in 
the modern society, it is predominantly understood a monogamous association. 
Until recently, marriage was allowed only if the partners had different sexes. 
Since 2001, when Netherlands was first to allow same sex marriage, many 
countries have modified the understanding and legal standing of “marriage” 
accordingly. 
Organisations are forms of social and economic life, with a structure, roles and 
purpose. They have a licence to operate, in the sense that they have to comply 
with state regulations, amongst other rules (i.e. professional or industry 
standards). Organisations could be public, private or non-governmental (NGO) 
and examples are hospitals, schools, companies or associations. 
Society can be understood as a “system consisting of institutional orders 
(fields) and their associated logics” (Gawer & Phillips 2013; p. 1038). As a 
mean to relate institutions to agency, materiality and structure, the institutional 
logics framework provided a modality to operationalise social life and 
processes of institutionalisation. Thornton and Ocasio (1999; p. 804) define 
institutional logics as the “socially constructed, historical patterns of material 
practices, assumptions, values, beliefs, and rules by which individuals produce 
and reproduce their material subsistence, organize time and space, and provide 
meaning to their social reality”. Institutional logics most invoked by scholars in 
their research are the state, profession, market or family. 
Institutions, although resistant to change, evolve over time via the actions of 
individuals, organisations or collective actors. In order to understand this 
evolution, institutional work is contributing to the institutional logics 
framework by connecting it to action. Institutional work refers to what 
individuals or collective actors actually do to create, maintain or disrupt 
institutions (Lawrence, Suddaby, & Leca, 2011) and therefore it brings an 
agentic perspective to balance the cognitive and normative understanding of 
institutions. 
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1.3. ABOUT THE RESEARCH 
My research aims to make contributions towards institutional complexity. To 
that end, I focus on an emergent field, as being the most acute instantiation of 
as this phenomenon. Most importantly, I research field emergence as it 
unfolds, not retrospectively. An emerging field presents itself as an interstice 
between other fields (Morrill, 2006; Rao et al., 2000; Greenwood et al., 2011; 
Stinchcombe, 1965), it lacks “stable social relationships” (Fligstein & 
McAdam, 2011, p. 12) and has “no agreement on means and ends” (ibid.). It 
follows that organisations entering such a field, have not only the “liability of 
newness” (Stinchcombe, 1965), but also operate in an institutional vacuum, a 
highly complex institutional environment (Morrill, 2006; Fligstein & 
McAdam, 2011, Van de Ven & Garud, 1993; Aldrich & Fiol, 1994). 
Theoretically, I anchor my approach in the institutional logics perspective and 
the concept of institutional work to understand institutional complexity. 
However, I draw from adjacent streams of literature, from institutional 
entrepreneurship or innovation studies, to science and technology studies 
(STS), and even insights from the medical literature, to add fresh insights to the 
understanding of a complex phenomenon. Gathering insights from other 
streams of literature is aligned to calls from inside the institutional theory itself 
(Fligstein & McAdam, 2011; Friedland, 2013; Greenwood et al., 2011; Kraatz 
& Block, 2008), as well as to calls emerging from studying contemporary 
settings of the digital economy (Gawer & Phillips, 2013; Nicolini, 2006; 
Orlikowski, 2010; Santos & Eisenhardt, 2009). 
My study aims to foster the understanding of field emergence and complexity 
and of the institutional work organisations undertake in such context. These 
aspects were understudied or approached retrospectively, after a field was 
stabilised, or they were only theoreticised. In contrast, my study takes place 
during the field is in the process of emergence. The two questions of the study 
are: 
How does a field emerge? 
How do organisations navigate an emergent field? 
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Answers to each question inform the answers to the other. However, it is 
necessary to capture first the institutional complexity of the field in order to 
situate and therefore better understand the organisations’ responses to 
complexity. It follows that my research design requires two levels of analysis: 
a field level (macro) and an organisational level (meso). Such complex studies 
are considered to bring rich theoretical insights (Aldrich & Fiol, 1994; 
Greenwood et al., 2011; Scott, 2008; Thornton, Ocasio, & Lounsbury, 2012). 
The macro level setting is the emergent field of digital health and the meso 
level is a collective case study (Stake, 2005) of three companies that are not 
“sheltered” (Aldrich & Fiol, 1994, p. 646) by a powerful actor. At the meso 
level, I look at collaborative digital health technologies (CDHT) producers, 
who build solutions that may (potentially) connect various stakeholders in 
digital health (chapter five and appendix C offer further terminology 
clarifications). It is relevant that these organisations are developing without the 
support of an influential actor, for two main reasons: they are not influenced by 
the institutional logic of the powerful organisation and they do no have easy 
access to resources.  
My research design is an inductive multi-level, multi-case study, found 
appropriate for investigating both poorly understood and complex phenomena 
(Gawer & Phillips, 2013; Santos & Eisenhardt, 2009). Such an approach 
provides a rich context, satisfying the need for a broad and an in-depth 
understanding. In addition, it is a “theory-building approach that is deeply 
embedded in rich empirical data” (Eisenhardt & Graebner, 2007, p. 25).  
1.4. CONTRIBUTIONS 
The theoretical contributions, besides addressing theoretical gaps, are towards 
the institutional theory, although they may inform other theoretical streams, 
like science and technology, social movements, institutional entrepreneurship 
or innovation studies. My findings allow for the rich theorisation of five 
institutional logics in digital health (state, medical profession, market, science 
and citizen), some not being previously defined in the literature. My research 
also shows how a new institutional logic, the citizen logic, is the beneficiary of 
the tensions generated by the plurality of logics at play. The rise of this new 
 6 
logic is mediated by the emergence of a new role: the empowered patient. Most 
importantly, I enrich the understanding of field emergence by building a new 
theoretical model of emergence with four distinctive phases: the ingenuous, 
legitimation, mobilisation and stabilisation stages. This model brings forth the 
granularity attribute of the mobilisation stage and the role of legitimising actors 
for field institutionalisation. 
This research enriches the understanding of institutional complexity and 
institutionalisation by revealing how organisations engage with various 
stakeholders in the field, based on their position, plurality and ambiguity, as 
well as their own identity project. It makes contributions towards the role that 
trust and leadership play in institutionalisation. It reveals how such 
organisations contribute towards the field emergence mainly by adhering to 
new distinctive categories, acting as institutional brokers and supporting the 
new role of the empowered patient. Significant insights regard the 
understanding of how digital technologies, by the virtue of their unfinished 
character (Garud, Jain, & Tuertscher, 2008) and compartmentalisation, play a 
role in institutionalisation, adding to insights from previous studies (Gawer & 
Phillips, 2013; Nicolini, 2006, 2007; Petrakaki, Barber, & Waring, 2012). Not 
last, I reflect on the merits of integrating values and materiality in research for 
the institutional theory at large and specifically for the institutional logics 
framework (Friedland, 2013; Hirsch, 2008; Kraatz & Block, 2008; Orlikowski, 
2010; Patriotta, Gond, & Schultz, 2011). 
Because my research is driven by a problem and it is rich in empirical data, 
there are several contributions of practical interest. Amongst them, it informs 
on the role of leadership on organisation’s resilience, with material effects on 
its performance. I offer practical tools for entrepreneurs to develop strategy and 
a model of evaluation for digital health startups. There are a few 
recommendations for policy makers in respect to fostering and regulating 
innovation. 
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1.5. THESIS STRUCTURE 
My work unfolds over nine chapters, with this first chapter presenting an 
overview. Chapter 2 provides the theoretical background on institutional 
complexity, the institutional logics perspective and the concept of and of 
institutional work. I give a significant space to the literature relevant to field 
emergence and I show how other theoretical streams of research inform this 
study. This chapter also presents previous contributions pertaining to 
technology and institutionalisation, as well as technology and healthcare. 
Chapter 3 describes my theoretical framework, as a middle ground sociological 
approach. I draw on the institutional logics framework and institutional work to 
research institutional complexity and guide interpretation for this multilevel 
study. In this chapter, I explain the constructivism approach, where both 
organisations and their institutional field are relevant for the institutionalisation 
process. Chapter 4 proceeds with establishing the aims and the research 
questions, and it describes the methodological approach, as well as the 
operational steps taken for data collection and analysis. 
Chapter 5 is a prerequisite stage primarily, which offers an overview of the 
historical institutional context of the main fields that converge into digital 
health – consumer digital technologies and healthcare. I found this stage of the 
research necessary, similar to other researchers that approached institutional 
transformation (Scott, Ruef, Mendel, & Caronna, 2000), because the 
phenomena in focus is both complex and understudied.  
Chapter 6 and 7 are dedicated to the field level findings. Chapter 6 provides an 
overview of the institutional logics at play in this field – the market, the state, 
the medical profession, the science and the citizen logics – and their 
representative stakeholders. Having established that, chapter 7 goes into 
revealing the institutionalisation process of the field emergence, as interplay of 
hybridisation and conflict between actors, and explores the stages of 
emergence: the ingenious, the legitimation, and the mobilisation and 
stabilisation phases. The last phase is only referred to based on previous 
theorisation of the field emergence (Morrill, 2006), because, by the end of data 
collection, the digital health field only just entered the mobilisation phase. 
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Chapter 8 focuses on the meso level of analysis and presents how organisations 
navigate the complexity of digital health, based on their position, plurality and 
ambiguity, as well as their own identity project. It highlights how both actions 
and theorisation contribute to the field institutionalisation process. The 
variability of the cases offers additional insights of theoretical and practical 
relevance. Chapter 9 summarises the findings and presents the main theoretical 
and practical contributions of the research. In closing, there are reflections of 
the possible limitations and discussion of future directions of research. 
This thesis builds upon and expands the preliminary findings of analysing the 
macro level, presented in a conference paper at the 31st EGOS Colloquium, 
July 2–4, 2015, Athens, Greece, accepted under the sub-theme 55: “Re-
examining the organization of healthcare: institutional, technological and 
clinical challenges”, but not published in the conference proceedings. The 
paper, “Plurality of institutional logics in digital healthcare: The rise of the 
hybrid patient”, was co-authored with Gerardo Patriotta, Lorraine Pinnington 
and Sujatha Raman (Macnaughtan, Patriotta, Pinnington, & Sujatha Raman, 
2015). As the first and main author, my contributions were significant and 
included the ground research, theoretical approach, methods, theoretical 
insights and conclusions. However, I acknowledge the invaluable guidance and 
input from all co-authors, who, at that time, were all my supervisors. Elements 
of this previous and preliminary work are mainly found in chapters 2, 6, 7, and 
9.  
Finally, the diagram below represents intuitively how the thesis is constructed.  
 9 
 
Fig. 1. Thesis structure 
 10 
CHAPTER 2. LITERATURE REVIEW 
2.1. INTRODUCTION 
This chapter sets the theoretical background of my research. Theoretically, it is 
anchored in the institutional logics perspective and the concept of institutional 
work, as found relevant for understanding institutional complexity. However, I 
draw on adjacent streams of literature, from institutional entrepreneurship to 
science and technology studies, and even insights from the medical literature, 
to add to the understanding of a complex phenomenon. It is, in essence, a 
multidisciplinary approach to allow for a deeper understanding of 
contemporary complexities of the digital economy. 
2.2. INTEGRATING INSIGHTS FROM SEVERAL THEORETICAL STREAMS 
In order to understand the contemporary socio-economic environment and to 
provide fresh theoretical insights, developments in the institutional theory are 
calling for perspectives that on one hand reconcile action and structure (Barley, 
2008; Barley & Tolbert, 1997; Beckert, 1999; Hirsch, 2008; Lawrence, 
Suddaby, & Leca, 2009; Orlikowski, 2010) and on the other hand are “open 
minded, problem-driven” (Santos & Eisenhardt, 2009, p. 505). Existing 
theories explain and guide stable environments very well, however the digital 
economy context may require lateral thinking, meta-theoretical approaches, 
because it may present characteristics that are not well explained or addressed 
by current theories or empirical research. Over the last decade, such meta-
theoretical approaches applied to the digital economy revealed significant 
insights related to the emergence of technological platform (Gawer & Phillips, 
2013), relationships with other organisations (Ozcan & Eisenhardt, 2009), 
digital market creation (Santos & Eisenhardt, 2009) and the continuous 
“morphing” of digital companies (Rindova & Kotha, 2001).  
Both the institutional logics framework and institutional work allow for meta-
theoretical approaches and have proven their usefulness to integrate broader 
perspectives over complex phenomena, as shown in this chapter. Additionally, 
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the institutional work approach offers a critical perspective over the interaction 
between agency and institutions, “one that avoids depicting actors either as 
cultural dopes trapped by institutional arrangements, or as hyper muscular 
institutional entrepreneurs” (Lawrence et. al., 2009, p. 1). 
2.3. INSTITUTIONAL LOGICS 
Institutional logics are “socially constructed, historical patterns of material 
practices, assumptions, values, beliefs, and rules by which individuals produce 
and reproduce their material subsistence, organize time and space, and provide 
meaning” (Thornton & Ocasio, 1999, p. 804). In other words, they are 
guidelines for how to make sense and engage in social situations, but they are 
also embedded in practices and material structures (Friedland & Alford, 1991; 
Gawer & Phillips, 2013; Greenwood et al., 2011; Jones, Boxenbaum, & 
Anthony, 2013; Thornton et al., 2012).  
These “rules of the game” (Fligstein & McAdam, 2011, p. 5), although 
resistant to change, are still evolving through cross-semination with rules from 
adjacent areas or through peak moments (field crisis) - wars, legislation, 
technological breakthroughs or economic depression (Aldrich & Fiol, 1994; 
Nigam & Ocasio, 2009; Scott, 2008). 
If our rationality is bounded by cultural norms we take for granted (Meyer & 
Rowan, 1977), where is change coming from? In 1991, Friedland and Alford 
introduce the ‘institutional logics’ term and provide a solution for what was 
becoming a problematic struggle for institutional scholars: the conciliation 
between structure and agency, stability and change. This view proposes the 
understanding of social life as intertwine of institutional orders, sometimes 
exerting conflicting expectations, nonetheless allowing for both continuation of 
social life and change. The institutional logics initially proposed by Friedland 
and Alford for the Western world were: bureaucratic state, democracy, 
capitalist market, Christian religion and the nuclear family. Scholars have 
either taken these into account or identified others, for instance the professional 
logic (Scott et al., 2000; Thornton, 2002) or the community logic (Thornton et 
al., 2012; Waldorff, Reay, & Goodrick, 2013). Many researchers combine the 
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societal level logics with more specific logics or field level logics (Dunn & 
Jones, 2010; Gawer & Phillips, 2013). 
Institutional scholars embraced this view, but only in the early 2000s it benefits 
from theoretical revisiting. As a consequence of the increased acknowledgment 
that institutional life is not limited to periodic drifts from one logic to another, 
Greenwood et al. (2011) propose a framework for addressing institutional 
pluralism and complexity. In 2012, Thornton et al. crystallise the overall 
streams of research in institutional logics and propose a multi-level theoretical 
framework and fleshed out further research directions. More recently, Jones et 
al. (2013) call for a timely revisitation of the original acceptation of 
institutional logics offered by Friedland and Alford (1991), which includes 
materiality alongside structure and practices. Friedland (2013) himself supports 
the necessity of bringing in both materiality (Orlikowski, 2010; Scott, 2008) 
and values (Patriotta et al., 2011) into the institutional logics approach.  
2.4. INSTITUTIONAL WORK 
To recognize the importance of both action and agency in institutional 
processes, a stream of research has emerged. The concept of institutional work 
– “practices of individual and collective actors aimed at creating, maintaining, 
and disrupting institutions” (Lawrence et. al., 2011, p. 52) - is enriching the 
institutional logics framework by bringing human action and agency more to 
the forefront of research. Likewise the institutional logics framework, the 
institutional work concept allows for the combination of different theoretical 
streams (ibid.).  
At the institutional field level, the institutional work approach was employed to 
study change, maintenance and even emergence. Several studies focus on the 
institutional work of maintaining and repairing institutions (Hirsch & Bermiss, 
2009; Zilber, 2009). Others bring insights into how change happens in a field 
with a moderately centralised structure, showing how scientists can be 
institutional entrepreneurs (Ritvala & Kleymann, 2012), or in a less centralised 
field, where a technology company succeeds to change institutional 
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arrangements by forging collaborative practices and moving towards a 
platform logic (Gawer & Phillips, 2013). 
Another relevant study (Zietsma & Lawrence, 2010) shows that some fields 
have change more embedded in their logic, hence institutional change is a 
constant, rather then an institutional crisis, as it is conceived most of the time. 
Such field movements can be understood as like lifecycles – “change and 
stability were the norm at different times, and transitions between cycles 
depended on particular mechanisms that shifted more gradually” (ibid., p. 216). 
An important insight this study brings is that different theoretical streams focus 
on certain institutional change aspects only; therefore much is left to 
understand by employing a unifying approach. For instance, “[t]he innovation 
cycle we found corresponds to research on institutional entrepreneurship or 
institutional design, which focuses on the creation of new institutions by 
interested actors, and their promotion to diverse constituencies” (ibid., p. 215). 
Another significant insight is the importance of situating the research more 
broadly in order to understand the field’s nature, as well as its development 
stage in order to shed light over the actors’ actions and the institutional 
processes. 
Studies like the examples above have employed the concept of institutional 
work both at field and organisational levels and they proved its usefulness in 
explaining complex institutional contexts and processes.  
2.5. INSTITUTIONAL FIELDS  
An institutional field contains all stakeholders who, “in the aggregate, 
constitute a recognized area of institutional life” (DiMaggio & Powell, 1983, p. 
148) and a field level logic (Scott, 2008, pp. 186–187) or “constellations of 
logics” (Goodrick & Reay, 2011).  
My understanding of a field is different from that of a market, in the sense that 
even though a market can be conceptualised as an instantiation of a field 
(Fligstein & McAdam, 2011), it is only a part of it (Scott, 2008). An 
institutional field is not limited to exchanges of goods and money between 
producers and consumers (Fligstein, 2002). One essential element in the 
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delineation of a field is the relationship between actors, and therefore fields 
develop around issues (i.e. technologies, markets, as well as social, political or 
cultural aspects) that bring actors together, not around needs. Moreover, 
“[o]rganizations may make claims about being` or not being part of the field, 
but their membership is defined through social interaction patterns (…) Field 
membership may also be for a finite time period, coinciding with an issue 
emergence, growth, and decline” (Hoffman, 1999 in Scott, 2008, p. 183). It 
follows that field boundaries can change, as well as the boundaries between the 
actors inside the field (Fligstein & McAdam, 2011; Scott, 2008). Boundaries of 
an institutional field are cultural and functional (Scott, 2008) and are subject to 
constraints - technologies, resources or regulations (Fligstein & McAdam, 
2011; Van de Ven & Gardu, 1993). 
Stakeholders engage with others in various forms: from symbolic acts to more 
formal relationships (commercial activities, associations, governing and 
regulatory bodies, conferences). Recently, the serendipitous associations via 
social media represent another form of stakeholders’ engagement (Beverungen, 
Böhm, & Land, 2015). The “thickness of ties” (Selznick 1992) reflects on 
stakeholders’ connection to the institutional infrastructure, and their 
commitment to particular logics.  
Various stakeholders carry their own logics in less pure forms. A field level 
logic is understood as presiding a field over a certain historical period (Scott 
2008). The more mature the field is, its logic becomes more “objectified” as 
consensus appears. A “thick socialization” (Selzenick, 1992, in Scott, 2008) 
relies not only on regulations, laws and standards, but also on taken for granted 
assumptions and deep network relations entangled in “reputation, friendships, 
interdependence, and altruism” (Scott 2008 p.) or salient conflict (Dunn & 
Jones, 2010; Reay & Hinings, 2009; Scott et al., 2000). Friedland (2013) 
highlights value substances and Patriotta et al. (2011) refer to higher orders of 
worth as additional repertoires in which institutional logics are anchored, that 
could explain both resilience and change. 
Much research developed at the field level is preoccupied with how a dominant 
field level logic transitions to another; change ignited by tensions between 
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society level logics (Thornton, 2002; Thornton & Ocasio, 1999), by actions of 
powerful actors (Scott et al., 2000) or even by actions of less powerful actors 
(Gurses & Ozcan, 2014; Haveman & Rao, 1997).  
The table below is synthesising forms of changes of institutional logics at field 
level, depending on the amplitude of change. It is based on and adds to the 
table offered by Thornton et al. (2010, p. 164). 
Forms of Change Definition Sample Studies 
Transformational 
Change 
More radical changes of symbols and practices 
Replacement One institutional logic replaces 
another 
 
Combining dimensions of 
diverse logics 
Rao, Monin, and Durand 
(2003) 
Gawer and Philips (2013) 
Hybridisation - 
Blending 
Glynn and Lounsbury 
(2005) 
Segregation Separation of logics from a 
common origin 
Purdy and Gray (2009) 
Dunn and Jones (2010) 
Developmental 
Change 
Majority of prevailing practices and symbols remain, while 
others change or appear (hybridisation and plurality). 
Hybridisation -
Assimilation 
Incorporation of external 
dimensions 
Murray (2010) 
Hybridisation -
Elaboration 
Endogenous reinforcement Shipilov, Creve, and 
Rowley (2010) 
Plurality - Expansion Shift from one logic to another Nigam and Ocasio (2010) 
Plurality - 
Contraction 
Decrease in logic’s scope Reay and Hinings (2009) 
Dunn and Jones (2010) 
Plurality – Persisting 
conflict 
 New “beneficiary” logic Scott et all (2000) 
Pouthier et al. (2013) 
Table 1. Forms of institutional logics change at field level 
2.5.1. FIELD EMERGENCE 
An emergent field is a social space, an interstice (Greenwood et al., 2011; 
Morrill, 2006; Rao et al., 2000; Stinchcombe, 1965) between other institutional 
fields, where various stakeholders acknowledge each other, relate and take 
actions towards each other, but there are “no stable social relationships, and no 
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agreement on means and ends” (Fligstein & McAdam, 2011, p. 12). Therefore 
there is high uncertainty (Aldrich & Fiol, 1994; Fligstein & McAdam, 2011; 
Rao et al., 2000; Santos & Eisenhardt, 2009). Emergent fields, due to their 
blurred boundaries, invite and attract various actors and therefore there are 
multiple institutional logics vying for dominance (Pache & Santos, 2010; 
Thornton et al., 2012).  
The usual triggers for crisis in institutional fields, which sometimes may cause 
new fields to emerge, are the actions of the state, wars or economic depressions 
(Fligstein & McAdam, 2011). However, Morrill (2007) signals that usually 
fields emerge around an innovation, a practical approach to problems in 
adjacent fields. Morrill considers that, at the very beginning, nascent fields are 
not very visible, but, as they develop, they redirect resources or support from 
established fields, causing contention (Fligstein & McAdam, 2011). Some 
actors in adjacent fields show resistance and hostility, whilst others show 
support (Greenwood et al., 2011; Morrill, 2006; Stinchcombe, 1965). The new 
space is characterised by intense competition over scarce resources (Aldrich & 
Fiol, 1994), a “shared sense of uncertainty” (Fligstein & McAdam, 2011, p. 9), 
intense segregation of stakeholders in incumbents and challengers and a 
general focus on the state’s actions (ibid.).  
“When a significant technological breakthrough appears in the public sphere, 
opinions tend to polarize between optimists, who emphasize the potentialities 
of the new technology, and pessimists, who tend on the contrary to stress the 
difficulties and the potential barriers to the adoption of the new 
instrumentality” (Nicolini, 2006, p. 2755). This leaves in between a liminal 
space characteristic to emerging activities and fields. The “liminal space” 
(Hirsch & Lungeanu, 2012, p. 9), at the confluence of existing and emerging 
social structures, is where rules, performances and regulations are uncertain. A 
liminal space or “space of uncertainty” (Beckert, 1999, p. 787) is characteristic 
to the emergent phase of an activity.  
Institutional stabilisation happens as a consolidation of logics and may spread 
over a few years or even over decades (Aldrich & Fiol, 1994; Van de Ven & 
Garud, 1993). Eventually, the outcome is a new hybrid field logic (Glynn & 
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Lounsbury, 2005; Thornton & Ocasio, 1999), a winning logic (Scott et al., 
2000) or a “constellation of logics” (Dunn & Jones, 2010; Waldorff et al., 
2013). Once stable, a field can still go through periods of contestations and 
crisis (Fligstein & McAdam, 2011).  
2.6. INSTITUTIONAL COMPLEXITY AND PLURALISM 
Institutional pluralism and institutional complexity become a central interest 
for institutional scholars (Greenwood et al., 2011). Institutional complexity 
rises primarily from pluralism, from conflicting institutional demands from at 
least two logics (Kraatz & Block, 2008). Institutional demands consist of 
“various pressures for conformity exerted by institutional referents on 
organizations in a given field” (Pache & Santos, 2010, p. 455). 
Greenwood et al. (2011, p. 325 - 331) offer an extensive summary of research 
conducted in institutional complexity, at different levels of analysis. They point 
out that most studies look at two logics only and that most of the times there 
are more logics at play. Consequently, some of the findings may not be 
generalisable because “the extent of complexity experienced may be 
underestimated or misinterpreted; and, the particular responses observed may 
not be properly understood” (ibid., p. 332). Greenwood et al. (2011) also plead 
for researchers to consider all logics at play and be clear in respect to the 
reasons they have included only certain logics in their analysis (ibid.). 
2.6.1. AT FIELD LEVEL 
Since the dawn of the institutional logics perspective, studies focused on 
transitions of field level logics and on how logics promoted conformity across 
their fields (Nigam & Ocasio, 2009; Reay & Hinings, 2005; Scott et al., 2000; 
Thornton, 2002). They were primarily historical accounts, often spreading over 
decades. Consequently, they took into account only a few logics, as they 
proved to be important over time. For instance, in her account of institutional 
change in publishing, Thornton (2002) considers only two logics: the editorial 
logic (as instantiation of professional logic) and the market logic. Scott et al. 
(2000) in their historic overview of healthcare institutional change take into 
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account the interplay between three logics: medical profession, bureaucratic 
state and managerial logic (steamed from the market logic). 
Over time, acknowledgement arises for the rivalry between logics (Reay & 
Hinings, 2005) as a source of institutional change. Additionally, it becomes 
clear that some fields have persistent rivalry between logics, leading to an 
“uneasy truce” (Reay & Hinings, 2005, p. 364) rather than a single, victorious 
field logic. However, this tension between logics is considered unsustainable, 
and so one of them would eventually dominate. The authors themselves review 
this assumption through a later study (2009), showing that the co-existence of 
rival logics can continue as an uneasy truce for long periods of time and that 
mechanisms are developed to accommodate both logics. Interestingly, one 
mechanism identified by authors is the creation of experimental sites where 
actors of rival logics came together to approach certain issues innovatively, and 
thus create change at practice level. Additionally, one motivation for 
collaboration is the counterbalancing of the more powerful state logic. 
Although not explicitly drawing on pluralism, Scott et al. (2000) show how the 
healthcare field logic changed in the US between 1945 and 2000, moving from 
an era of professional authority centred on quality (1945 - 1965) to an era of 
federal regulations (1966 - 1982) and, finally, to an era of managerial control 
and market forces (1983 - 2000). They show how the era of federal 
involvement fostering the logic of equity causes intense fragmentation, thus 
subsequently making space for the managerial and market logics to enter. 
“Market mechanisms have joined, but not replaced, state controls. What we see 
is a change in rhetoric and in the policy mechanisms that governmental actors 
employ as they attempt to steer the development of this sector specifically and 
govern the welfare state more generally” (ibid., p. 344). This shows how 
fragmentation and weak ties create a favourable environment for field level 
contestations (Dunn & Jones, 2010; Nigam & Ocasio, 2009; Scott et al., 2000). 
The conclusion of the study is that, paradoxically, different logics co-exist over 
time (institutional pluralism), with the medical profession logic being in 
decline. Moreover, the managerial logic in healthcare proves to be the 
beneficiary of the resistance of the medical professional logic against the state 
logic. Hence, none of the two competing logic wins, rather a third one 
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(managerial logic) emerges as a result. In this sense, managers “appear to have 
been the beneficiaries, not the agents, of the deinstitutionalization” (Scott et al., 
2000, p. 328). 
Similar findings showing resistance towards a cost effective approach in 
healthcare are presented by Nigam and Ocasio (2010) in their analysis of the 
Clinton’s healthcare reform initiative in the US (1992 - 1994). They show how, 
despite the intense push of the state towards a “managed care” approach, both 
physicians and patients resist and “the competing logic of physician authority 
was invoked to threaten legislative changes” (Thornton et el. 2010, p. 167). 
This time, a field crisis caused by a state’s action results in the strengthening of 
the medical profession logic, even if only for a while. 
Studies, like those presented above, show that sometimes less powerful actors 
can impose institutional arrangements at field level. However, they also show 
that the entrance of new actors and the actions of powerful ones caused over 
time the decline of the medical profession logic. 
Dunn and Jones (2010) acknowledge the competing logics of science (better 
represented by specialist doctors) and care (mainly carried by primary care 
doctors) in medical education and how these logics not only changed the 
medical schools over time, but they also created fragmentation, plurality and 
conflict inside the medical profession itself. Other authors show how multiple 
logics can co-exist in a certain field based on professional fragmentation (Dunn 
& Jones, 2010; Pouthier, Steele, & Ocasio, 2013), types of actors (Goodrick & 
Reay, 2011; Reay & Hinings, 2009) and geographical location (Greenwood, 
Diaz, Li, & Lorente, 2010). The complexity and the internal fragmentation of 
the medical profession logic itself make it more vulnerable to other logics 
(Dunn & Jones, 2010; Scott et al., 2000; Leicht & Fennell, 2008). 
Most studies in pluralism illustrate the irreconcilable differences between 
logics, but more recent work show that in a “constellation of logics” (Goodrick 
& Reay, 2011) there is not only rivalry, but also similarities between logics. 
Greenwood et al. (2010) point towards the facilitative effect logics can exert 
upon each other. Waldorff et al. (2013) show that logics could produce both 
constraining and facilitative effects over actions. This is consistent with the 
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idea that the existence of multiple logics opens up space for change, because 
stakeholders may access a wider range of possible justifications, actions, or 
paths (Friedland & Alford, 1991; Greenwood et al., 2011; Thornton & Ocasio, 
1999). 
Greenwood et al. (2011) remark that there are or could be significant 
differences in how institutional complexity manifests and is experienced in 
mature versus nascent fields. Most studies in institutional complexity are either 
focused on mature fields, or are historical and therefore consider a limited 
number of stakeholders and logics, as they proved to be important over time. In 
this light, there is a recognized need for exploration of emergent fields to test 
and enrich existing theorization (Aldrich & Fiol, 1994; Fligstein & McAdam, 
2011; Greenwood et al., 2011; Wooten & Hoffman, 2008). 
2.6.2. AT ORGANISATIONAL LEVEL 
Accepting the view of organisations as “sites where multiple institutional 
logics vie for dominance” (Thornton et al., 2012, p. 183) may bring new 
understandings of the organisational behaviour, including strategy and form, 
and therefore would enrich and refresh sociological insights. Similarly, it may 
lead to insights on field institutionalisation processes (Dunn & Jones, 2010; 
Gawer & Phillips, 2013; Santos & Eisenhardt, 2009; Van de Ven & Gardu, 
1993). 
Advancing the research agenda on institutional work proposed by Lawrence et 
al. (2009), as well as Thornton et al. (2012), should consider the cognitive and 
cultural dimensions, carried through by institutional logics. Such dimensions 
would contribute to a richer understanding of the institutional work at 
organisational level, not only at field level. Skilled actors use symbolic and 
cultural acts to undertake institutional work (Thornton et al., 2012; Greenwood 
et al., 2011; Kraatz & Block, 2008; Fligstein, 2001). Cultural and cognitive 
frames prove to have material impact on organisations and their access to 
resources, as showed for instance by the seminal work on categorisation 
(Santos & Eisenhardt, 2009; Tyler Wry & Lounsbury, 2013). Both studies 
show that organisations are more likely to access resources if they are 
satisfying existing industry categories. However, Navis and Glynn (2011) show 
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that in a nascent market, where categories are maladapted and emerging, new 
categories are actively constructed by entrepreneurial organisations and are 
used strategically to access resources. 
Cultural and institutional entrepreneurship traditions show that building 
legitimacy, one of the main undertakings of new organisations in the midst of 
institutional change or complexity, cannot be reduced to a power exercise. 
Legitimacy “is a generalized perception or assumption that the actions of an 
entity are desirable, proper, or appropriate within some socially constructed 
system of norms, values, beliefs, and definitions” (Suchman, 1995; p. 574). 
Legitimacy is “something” (Deephouse & Suchman 2008; p. 59) that affects 
the organisation’s access to resources (Aldrich and Fiol, 1995; Suchman, 1995; 
Beckert, 1999). Suchman (1995) considers that legitimacy was approached 
from strategic and institutional perspectives, but these should not be exclusive 
(Deephouse & Suchman, 2008; Pfeffer & Salanick, 2003; Suchman, 1995), 
because in order to obtain resources, one needs legitimacy and in order to 
obtain it, one needs to allocate resources - otherwise put, to undertake 
institutional work. 
Studies of nascent fields highlight that it is important for innovation 
entrepreneurs (individuals or organisations) to undertake institutional work, 
because of ambiguity and uncertainty. Aldrich and Fiol (1994) claim that in an 
emerging field, organisations’ actions require different strategies at different 
levels: institutional, interindustry, intraindustry and organisational. The authors 
focus on strategies for obtaining legitimacy. Aldrich and Fiol (1994) stress how 
different the strategies can be in a nascent field as opposed to a mature one. 
Although they recognise the struggle for resources for all enterprises, the 
authors believe that in nascent activities it is important to create legitimacy as 
the foundation for exchanges with the environment. 
Emergent fields are characterised by change, novelty and risk due to 
ambiguity. In this way, the organisations entering or starting up in such fields 
are entrepreneurial in nature. Entrepreneurial behaviour “always searches for 
change, responds to it and exploits it as an opportunity” (Drucker, 1994, p. 25). 
Studies of entrepreneurial actions either have a strategic or an institutional 
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perspective (Deephouse & Suchman, 2008; Hirsch & Wohlgezogen, 2009). 
These perspectives are not necessarily dichotomous; one emphasises resources 
and material constraints, whilst the other focuses on institutions (Suchman, 
1995).  
Various studies in entrepreneurship focusing on emerging worlds have 
analysed singular aspects of entrepreneurial firms: identity and legitimacy 
formation (Navis & Glynn, 2011), legitimacy building through design (Garud, 
Jain, & Kumaraswamy, 2002; Hargadon & Douglas, 2001; Rindova & Kotha, 
2001), formation of alliance portfolios (Ozcan & Eisenhardt, 2009) and 
networks (Gulati & Higgins, 2002), and alliance decisions for accessing or 
defending resources (Katila, Rosenberger, & Eisenhardt, 2008). Without 
underestimating the tremendous theoretical and practical insights of these 
researches, they maintain an atomistic view either by focusing on singular 
elements, or by focusing either on the internal aspects of the organisation or on 
its relations. 
Boundary is another overarching concept for investigating the entrepreneurial 
activities, in many ways similar to that of institutional work. Santos and 
Eisenhardt (2009) define organisational boundaries simply as “demarcations” 
with the environment. And so, boundaries serve as signposts or “tools by 
which individuals and groups struggle over and come to agree upon definitions 
of reality” (Lamont & Molnár, 2002, p. 168). Boundaries reduce ambiguity and 
uncertainty, support sense making and rule creation, and offer sense of 
belonging (insiders and outsiders) and legitimacy. Overall, boundaries point 
mainly to matters of governance and I define governance as concept related to 
purpose and control (Kraatz & Block, 2008, pp. 253–256), which has relevance 
for both the organisation and the field, as it reflects internal and external 
negotiations over institutional arrangements. Boundary work is often studied in 
the context of innovation, strategy or entrepreneurial activities, because it has 
profound material effects in acquiring resources and power (Lamont & Molnár, 
2002; Santos & Eisenhardt, 2005, 2009; Zietsma & Lawrence, 2010). 
Boundaries are particularly important in the formative stages of an activity. 
Santos and Eisenhardt (2005) propose four different types of boundaries: 
efficiency, power, competence and identity. The efficiency boundaries aim to 
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minimize the transaction costs, the power boundaries maximize the control 
over the organisation’s exchanges with the environment, the competence 
boundaries maximize resources and the identity boundaries ensure the 
coherence between what an organisation does and what it claims to be. Apart 
from contributing to the existent literature on boundaries with an integrative, 
meta-theoretical approach, the authors call for a “problem-driven boundary 
phenomena” (Santos & Eisenhardt, 2005, p. 505) as opposed to a theory driven 
approach, because of the new settings presented by the contemporary economic 
landscape. Santos and Eisenhardt (2009) actually use such an approach when 
looking at how entrepreneurial action unfolds in nascent fields (the confluence 
of IT and communication industries in the mid nineties). The study reveals that 
entrepreneurs do not always act rationally, but through a “blend of emergent 
and deliberate actions, together with mistakes and serendipitous learning” 
(Santos & Eisenhardt, 2009, p. 664). However, the authors do not explicitly 
address the nature of boundaries (power, efficiency, resources and identity) and 
the relation between these types of boundaries and the organisations’ relations 
with other stakeholders. Also, the setting is not an institutionally fragmented 
field, where institutional conflicts compound the problem of legitimacy and 
boundaries. 
However, one of the many contributions of this article is the view of 
interorganisational power through both institutional and competitive lenses. 
The soft-power techniques (persuasion) are more likely to be employed than 
hard-power ones based on competitive advantage (Santos & Eisenhardt, 2009). 
The use of soft power is similar to what Selznick calls co-optation – “the 
process of absorbing new elements into the leadership or policy-determining 
structure of an organization as a means of averting threats to its stability or 
existence” (Selznick, 1948, p. 34). Santos & Eisenhardt (2009) refer mainly to 
informal co-optation, bringing in constituencies that have some power to 
enforce demands. However, the authors have shown that co-optation can be 
employed strategically to obtain advantages, not only to annihilate threats. In 
this thesis, I use the term co-optation to refer to mechanisms of bringing in 
stakeholders, formally or informally, in order to either diminish pressures or to 
advance specific interests from a position of scared resources or of lack of 
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authority. In the context of soft power, the concept of coopetition is similarly 
relevant – when organisations simultaneously compete and collaborate 
(Walley, 2007). Coopetition in the emergent phase of a field is essential not 
only to obtain economic advantages, but also to survive (Aldrich & Fiol, 1994; 
Santos & Eisenhardt, 2009). 
2.7. TECHNOLOGY AND INSTITUTIONAL CHANGE 
Although the original article of Friedland and Alford (1991) pointed towards 
the material aspects of institutional logics, there are not many organisational 
studies that take material aspects into account. In his recent article, Friedland 
(2013) insists on the significance of materiality for the understanding of 
institutional logics. “Unobservable substances must be transmuted into 
observable objects – nested and interlocked – which are the means by which 
practices are anchored” (ibid., p. 37).  
Digital technologies have always escaped the rules of traditional technology 
markets, not only due to their constant morphing (Rindova & Kotha, 2001), but 
also due to their inherently unfinished and intangible character (Garud et al., 
2008; Orlikowski, 2010). These technologies morph with the user’s input, or 
they are rendered insignificant in its absence. With digital technologies, we 
find that “operations are emergent and fluid, goods and services are intangible 
and informational, authority is distributed and diverse, and accountability is 
multiple and shifting” (Orlikowski, 2010, p. 243). 
Gawer and Phillips (2013) show that “technological design of an interface 
allowed the conversation between social actors to happen, and during this 
process (characterized by a continuum of stages including recursive instances 
of design, testing, implementation and stimulation of complementary 
innovation), collective identities were specified and reinforced” (p. 1063). In 
other words, the interface design became an institutional work for social 
realignment, mediating a new institutional logic. 
2.7.1. TECHNOLOGY AND HEALTHCARE CHANGE 
Healthcare is inherently slow in adopting technology because it is regulated, 
from professional standards and treatment protocols to reimbursements 
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(Christensen, Grossman, & Hwang, 2009). Scott et al. (2000) reveal that 
healthcare has the ability to embrace technical complexity, but does not 
respond well to cost efficiency approaches (ibid., p. 333). An explanation could 
be that the medical profession logic is a blended logic of science (and 
technology) and care (Dunn & Jones, 2010; Oborn, Barrett, & Racko, 2013). 
Research in the use of information and communications technology (ICT) in 
healthcare is predominantly preoccupied with evidence for clinical, economic 
and social benefits from the perspective of healthcare service providers 
(organisations that deliver healthcare services, i.e. hospitals, general 
practitioners). “Several systematic reviews indicate that there have been few 
evaluations of sufficient quality to determine effectiveness” (Davies & 
Newman, 2011, p. 12), because such studies are either done on a small scale, or 
are focused on a single aspect, a single condition, or a single beneficiary, or 
they have small samples or are using methods that make their results difficult 
to compare and generalise (Davies & Newman, 2011; Jennett et al., 2003). 
Another limitation is represented by the assumption that benefits remain static, 
whilst in fact they are evolving with the interaction between beneficiaries and 
producers (Gawer & Phillips, 2013; Jacobides, Cennamo, & Gawer, 2018; 
Orlikowski, 2010). Although such literature sometimes points to the 
organisational issues related to the introduction of digital solutions, they have 
not benefited from similar attention (Waring, 2015). Healthcare innovation is a 
political process and scientific evidence represents only one forum for debates 
(Nicolini, 2010; Pearce & Raman, 2014). 
ICT has the effect of making objects, people, roles and relationships visible 
and explicit (Nicolini, 2006, 2007, 2009; Petrakaki et al., 2012). In this way, it 
has the potential to unveil unresolved, existent problems. In healthcare, for 
instance, an on-going debate is over the patient data: who owns it, who 
accesses it, who uses it and under what circumstances. Similarly, ICT 
potentially transforms existing social arrangements mediated by professional 
roles, because such roles may lose their distinctiveness through the 
introduction of expert systems, which emphasize efficiency or customer 
relations (Petrakaki et al., 2012). Nicolini (2006) reveals the consequences of 
the mismatch between the technological script and the existing work practices 
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in the field of telemedicine. The future script embedded in technology is based 
on the innovator’s view of the stakeholders and is pointing to an envisioned 
value/risk, practices and it “assumes that morality, technology, science, and 
economy will evolve in particular ways” (Akrich, 1992, p. 208). 
Acknowledging the social effects of ICT does not necessarily mean adopting a 
unidirectional or deterministic perspective on technology (Petrakaki et al., 
2012; Nicolini 2006, 2010; Orlikowski, 2007). More recently, based on 
insights from Science, Technology and Society (STS) studies, the relationship 
between technology and organisational structure is understood as being 
“constitutively entangled” (Orlikowski, 2007, p. 1437). I would add to this also 
the relationship between the technology and person (Prout, 1996). Adopting 
such a perspective seems particularly relevant when looking at dynamic and 
cross-disciplinary contexts like technology, biotechnology, nanotechnology or 
digital technologies (Orlikowski, 2010). 
Most of the studies on healthcare innovation focus on the service provider. The 
need to include other stakeholders apart from the service providers in 
researching innovation in the medical field is recognised by recent research. 
Service providers, patients and policy makers are included in the Neo-
Schumpeterian model of healthcare innovation by Windrum and Garcia-Goñi 
(2008). Studies of ICT in telemedicine and telehealth (Petrakaki et al., 2012) 
point out that in order to understand ICT innovation in healthcare there is a 
need to expand the attention to other stakeholders, such as technology 
producers, associations or reimbursement agents. 
Morrill (2007) signals that usually fields emerge around an innovation, a 
practical approach to problems in adjacent fields. Technology played a 
significant role in the professionalization and fragmentation of healthcare, and 
presently it is considered to be an imperative (Leicht & Fennel, 2008). 
However, technology producers remains an understudied segment, with few 
exceptions (Lebret, 2018; Lim & Anderson, 2016), despite technology having 
an increased impact on the healthcare environment: “there have been few 
analysis of that portion of the industry that has become increasingly more 
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important to the material/resource/technical environment: the producers of new 
healthcare technology” (Leicht & Fennell, 2008, p. 440).  
2.8. CONCLUSIONS 
In this chapter, I review the literature relevant to the theoretical approach, and 
the main concepts like institutional complexity, institutional logics and 
institutional work. I point out to their usefulness for unifying research from 
other theoretical backgrounds. I show that they are suited for researching a new 
phenomenon in an institutionally complex environment, both at field and 
organisational levels. Moreover, they allow for connecting meaningfully the 
two levels. I close the chapter with a brief overview of technology and its 
institutional relevance, in the spirit of considering the material aspects of 
institutions, an area that is understudied. In addition, several relevant concepts 
are also explained: boundary, legitimacy, governance, coopetition and co-
optation. The literature review points out several theoretical gaps, mainly in 
studying field emergence, institutional complexity and technology producers in 
healthcare: 
• Lack of research during an emergent phase of a field, as opposed to 
retrospective studies 
• Institutional complexity analysed by taking into account only some of 
the institutional logics at play 
• Scarcity of studies of medical technology producers, despite the 
technology becoming an imperative in healthcare. 
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CHAPTER 3 – THEORETICAL FRAMEWORK 
3.1. INTRODUCTION 
Having set the basis of the theoretical background for this research, as well as 
showing several theoretical gaps, in this chapter I synthesise my theoretical 
approach that allows me to answer the research questions. A middle ground 
sociological approach is taken, heterogeneous in nature, accepting that 
“technical, scientiﬁc, economic and political considerations are inextricably 
bound into an organic whole” (Nicolini, 2009, p. 15). By considering both 
action and structure, the research attempts to reveal explanations for 
phenomena in the richness of their context. To that end, I draw on the 
institutional logics framework and institutional work to research institutional 
complexity and guide interpretation for this multilevel study. 
3.2. INSTITUTIONAL LOGICS 
Institutional theory at large offers a template to understand broader 
environments, as well as the organisations populating them. To reiterate, 
institutional logics are “socially constructed, historical patterns of material 
practices, assumptions, values, beliefs, and rules by which individuals produce 
and reproduce their material subsistence, organize time and space, and provide 
meaning” (Thornton & Ocasio, 1999, p. 804). They offer templates and “rules 
of the game” (Fligstein & McAdam, 2011, p. 5) to organise social life and 
activity, which show endurance over time. 
3.2.1. IDEAL TYPES 
Ever since institutional logics were introduced by Friedland and Alford (1991), 
it was acknowledged that they operate on different levels and that there are 
inter-institutional systems in action. The higher the level, the more “pure” the 
logics are, the so called “ideal types” (Friedland & Alford, 1991; Thornton et 
al., 2012), such of those initially introduced by Friedland and Alford (1991) - 
religion, family, bureaucratic state, capitalist market, democracy – or the ones 
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proposed by Thornton et al. (2012, p. 72) – family, community, religion, state, 
market, profession, corporation. It is important to understand that the ideal 
types convey the essence, and that their manifestation in action is more 
complex. For instance, Dunn and Jones (2010) show in their study on medical 
education that this combines the logic of care with the logic of science. 
I conceptualize the ideal types as being instantiations of social, technical and 
institutional arrangements, which are linked to higher value spheres. 
Instantiation means that ideal types are still subject to change, evolution or 
even replacement. The ideal types manifest at field, organisational or 
individual levels, and provide principles, practices and symbols. Ideal types, in 
research and theory, are valuable constructs to allow for both understanding 
and generalising “observed institutional outcomes” (Thornton et al., 2012, p. 
53). They are also useful when using multiple levels of analysis to connect 
them, as it is the case with this research, which spreads between the field and 
organisational levels. 
3.2.2. INSTITUTIONAL LOGICS AS A TRIAD OF MATERIALITY, PRACTICES 
AND VALUES 
In a recent study, Patriotta et al. (2011) showed how “orders of worth” in 
societies provide equally legitimate, universal understandings for the common 
good. “Orders of worth are legitimate forms of common good, which provide 
universal principles of logical coherence as well as justice. Being universal, 
such orders of worth are symmetrical, i.e. they carry equal weight” (ibid., p. 
1809). This study resonates with the Friedland’s (2013) recent essay, drawing 
as well on Boltansky and Thévenot’s (2006) orders of worth and on Weber’s 
(1948) “value spheres”, which calls to bringing value back into institutional 
theory as a mean to better explain institutional life as well as change. 
“Institution is required to fix a type of action and its referential relation to a 
situation as a token of that type. This normative fixing is the core of institution, 
a primordially semantic function. This appears to undercut the previous 
insistence that orders of worth should not be socially located either in a group 
or a sector” (Friedland, 2013, p. 43). Looping back to Patriotta et al. (2011), 
their study show how these universal values offer a repertoire for institutional 
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work and that institutions are both rooted in and made fragile by these higher 
value orders.  
Values are carried and reproduced by people, but also by organisations and 
society at large. Selznick talks of an “organizational self” and “identity” to 
show that an organisation becomes not only distinctive in its technical 
capabilities, but also in its “character”. An organisation becomes “value-
infused” in itself. “The terms “institution”, “organization character” and 
“distinctive competence” all refer to the same basic process – the 
transformation of an engineered, technical arrangement of building blocks into 
a social organism” (Selznick, 1984, p. 120). 
Voronov and Vince (2012) propose a framework to include emotions when 
studying institutional work, given the increasing number of studies showing 
“that being cognitively aware that the current institutional order is suboptimal 
may often be insufficient to motivate agents to engage in institutional 
disruption or creation” (ibid., p. 2012) or maintenance. The authors consider 
useful to consider alongside a cognitive frame, a fantasmic one, that could be 
individual or collective. Such a frame is value and emotion infused and it is 
relevant for the formation of the organisational identity and for the new 
institutional arrangement of a field (Patriotta et al., 2011; Friedland, 2013). 
Technology is regularly considered a factor of production that increases 
efficiency or reduces costs. When it comes to ICT, technology is an aim in 
itself (Jacobides et al., 2018; Mulligan, 2011; Rindova & Kotha, 2001), 
therefore there are different selection and validation criteria. Digital 
technologies are complex artefacts, which challenge the separation between the 
organisation and its environment (Gawer & Phillips, 2013; Nicolini, 2007; 
Orlikowski, 2010; Petrakaki et al., 2012). Digital technologies bring complex 
social, economic and institutional change via democratisation of specialist 
knowledge, alternative channels for action and information through peer-to-
peer communications, and therefore they challenge temporary, spatial, 
ownership and governance conventions. Introduction of digital technologies 
also shape practices, sometimes leading to significant institutional processes, 
like simultaneous de-professionalisation and re-professionalisation (Petrakaki 
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et al., 2012). It follows that the introduction of digital solutions has material 
effects and involves institutional work, due to the emergence of new practices, 
and sometimes even new roles and governance conventions. 
Restating that healthcare is a technology intensive field and in the light of the 
increased acknowledgement of both materiality (Gawer & Phillips, 2013; 
Morrill, 2006; Thornton et al., 2012) and value in institutional logics research 
(Friedland, 2013; Kraatz, 2009; Kraatz & Block, 2008), I consider institutional 
logics as a triad of materiality, action and values. 
 
Fig. 2. “Institutional logics: duality articulations linking troika of object-practice-
Subject” (Friedland, Mohr, Roose, & Gardinali, 2014, p. 338) 
3.3. INSTITUTIONAL COMPLEXITY 
Institutional complexity rises from conflicting institutional demands from 
stakeholders participating in a field (Pache & Santos, 2010, p. 455). The more 
institutional logics there are, the more complexity increases. Therefore, 
pluralism is one of the main sources of complexity. 
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Below, I will add to pluralism other sources of complexity that are relevant to 
this research – fragmentation, centralisation and field structuration/stage 
(emergence in this case). Their importance for research was first underlined 
thoroughly by Greenwood et al. (2011) in their synthetic article and I find them 
particularly useful for my research embedded in a high complexity context. 
3.3.1. INSTITUTIONAL FIELDS AND COMPLEXITY 
An institutional field contains all stakeholders who, “in the aggregate, 
constitute a recognized area of institutional life” (DiMaggio & Powell, 1983, p. 
148). It may have a field level logic (Scott, 2008, pp. 186–187) or 
“constellation of logics” (Goodrick & Reay, 2011) that binds together 
meaningfully the social, technical and material arrangements.  
In that sense, I find conceptually useful the description of a social system 
offered by Van de Ven and Garud (1993) to reflect how I conceptualize an 
institutional field in this thesis. In the table below, I represent an institutional 
field as a complex connection of social, technical/material and institutional 
arrangements. 
 
Fig. 3. Elements of an institutional field (adapted from Van de Ven and Garud, 1993) 
It is no coincidence that studies on institutional pluralism evolve around 
healthcare, education and culture, because they provide a public service/good. 
They are often regulated (degree of centralisation) and accommodate many, 
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uncoordinated stakeholders. Such fields are fragmented, meaning they are 
entangled in conflicting demands (Pache & Santos, 2010), because the 
“collective nature of these goods places their producers at the intersection of a 
fragmented web of interests (direct and indirect beneficiaries, specialized 
interests groups, professionals, funders, local and national governments, 
regulatory agencies etc.)” (Pache & Santos, 2010, p. 472). The degree of 
fragmentation can evolve over time, due to pressure to access resources or the 
involvement of the state (Pache & Santos, 2010). Stakeholders can experience 
conflicting demands in fragmented fields in various degrees depending on both 
the compatibility between logics (Pache & Santos, 2010) and the degree of 
prescriptiveness (Goodrick & Salancik, 1996).  
Centralisation refers to the number of actors that can impose a normative 
thickness (Pache & Santos, 2010). Highly centralised fields are dependent on 
one authority, whilst the decentralised ones are loosely regulated. It is the 
moderately centralised fields that present the most challenging institutional 
context for its participants, as demands are issued by various stakeholders who 
hold enough influence that cannot be ignored (ibid.). 
The conflict may be over goals or means (ibid.), and sometimes it may take 
time for stakeholders to clarify where precisely differences lie (Pouthier et al., 
2013; Scott et al., 2000). This differentiation between conflict over goals and 
means is particularly relevant, because it explains how logics, however thick 
they may be, leave room for change. It also offers a more nuanced explanation 
of hybridisation and conflict between logics. Often the means are where 
negotiation mostly happens and goals where conflict is most enduring (Pache 
& Santos, 2010; Santos & Eisenhardt, 2009). An excellent example is given by 
Scott et al. (2000) study on healthcare transformation towards the logic of 
managed care, where this new logic was the non-intended beneficiary of the 
enduring conflict over goals between the medical profession and state logics. 
Interestingly, Pouthier et al. (2013) show how the managed care logic did not 
fully resist the medical profession logic and so, this time by the intentional 
mobilisation of actors, it was undermined and a new logic emerged as 
retaliation – the “hospitalist logic”. The enduring conflict was over goals – the 
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managed care logic prioritise financial objectives, whilst the medical 
professional logic prioritise patients’ best possible health outcomes. 
These two studies, when taken together, are particularly interesting as they cast 
three major insights. First, they show how complex and subject to crisis 
fragmented and moderately centralised fields are. Healthcare perhaps is one of 
the best examples of such fields and this may explain the volume of studies in 
this area. It is a territory where several logics co-exist under an “uneasy truce” 
(Reay & Hinings, 2005), with many moments of institutional turmoil at field, 
regional and organisational levels. “Patients receive diagnoses and treatments. 
Physicians carry out their practice. However, the two logics [n.b. medical 
profession and managerial logic] continue to co-exist and neither one can be 
considered dominant” (ibid., p. 630). Second, they reveal how conflict over 
goals can be persistent and how it gets to be revisited by moments of 
institutional crisis at various levels (Dunn & Jones, 2010; Goodrick & Reay, 
2011; Pouthier et al., 2013; Reay & Hinings, 2009, 2005; Scott et al., 2000; 
Waldorff et al., 2013). And third, they prove that new logics or new 
institutional arrangements can come into existence or demise by both 
intentional and unintentional actions of stakeholders.  
This last point would probably allow for a forth insight, the fact that sometimes 
less powerful actors can cause massive institutional change. Such individual 
actors are institutional entrepreneurs, as described by Schumpeter (1942), 
Drucker (2001) or Selznick (1948). In the example at hand (Pouthier et al., 
2013), in the early ‘90s, when the logic of managed care was enjoying a great 
support from very powerful actors, state being one of them, “several physicians 
began creating lists of those peers that they considered to be part of an 
emerging specialty – a body of physicians who spent most of their time, if not 
all of it, working with acutely ill hospitalised patients, as opposed to splitting 
their time between care in the hospital and care in the community. This 
emerging consciousness of a shared style of work, and perhaps even a shared 
set of problems and concerns, gave rise to a key 1996 article in the New 
England Journal of Medicine (Wachter & Goldman, 1996). It was in this article 
that the ‘‘hospitalist’’ was first named, and identified to a broad audience as 
part of an emergent and coherent specialty; one that was articulated largely 
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through the rhetoric of managed care” (Pouthier et al., 2013, p. 214). The use 
of the managed care rhetoric was used skilfully to gain acceptance and co-opt 
powerful actors. However, later on, the same actors offered other meanings, 
rationales and differentiations, for instance reframing “managed care” as 
“rationing of care”, undermining its legitimacy. The hospitalist movement was 
successful in gaining back some of the medical profession authority, 
strengthening its logic. 
3.3.2. FIELD EMERGENCE 
Institutional fields can be emergent, stable or in crisis (deinstitutionalisation 
that can lead either to repair, to the radical transformation of a field, or even to 
its disappearance) (Fligstein & McAdam, 2011; Gawer & Phillips, 2013; 
Patriotta et al., 2011; Scott et al., 2000). Morrill (2006, p. 6) defines an 
emergent field as “a mesolevel location that forms from overlapping resource 
networks across multiple organisational fields in which the authority of the 
dominant resource network does not prevail”.  
“One can conceive of emerging fields as a social space where rules do not yet 
exist, but where actors, by virtue of emerging, dependent interests, are being 
forced increasingly to take one another into account in their actions” (Fligstein 
& McAdam, 2011, p. 11). Emergent fields are institutional projects and 
therefore they have the most acute characteristics of an institutional crisis, 
contestations over goals, means, identities, legitimacy and governance. “The 
crisis of new fields reflects the fact that stable rules of interaction have not 
emerged and groups are threatened with extinction” (Fligstein, 2001, p. 115). 
A new field comes to life when several actors perceive new opportunities 
brought by unresolved issues of adjacent fields (Fligstein, 2001; Purdy & Gray, 
2009), technical innovation (Morrill, 2006; Van de Ven & Gardu, 1993), state 
interventions or significant social event (wars, economic recessions, acts of 
God). Several studies reveal how new fields emerge with the introduction of 
innovative technologies (Garud et al., 2002; Rindova & Kotha, 2001; Van de 
Ven & Gardu, 1993; T. Wry, Lounsbury, & Jennings, 2014), reflecting the 
profound socio-material consequences of technology adoption in various 
contexts: carbon nanotechnology, medicine or IT. Rindova and Kotha (2001), 
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through a two case inductive study of two internet search engine companies, 
explore the relation between structure and function in nascent fields. Other 
studies of nascent technological fields bring insights into an organisation’s 
struggle for clear boundaries of identity, i.e. studies on categorisation (Wry & 
Lounsbury 2013) and distinctiveness (Navis & Glynn, 2011). Such studies 
suggest that nascent and fragmented fields pose interesting settings and that 
organisational action in complex institutional environments still remains to be 
explored. 
 
Fig. 4. Representation of field emergence as liminal space, potential triggers and ties with 
other fields 
Purdy and Gray (2009) and Morrill (2006) describe the emergence of 
alternative dispute resolution field in the US as a response to failures of the 
judicial system to address timely and transparently conflicts, in addition to 
providing good decision that allows for disputants to be more involved. The 
studies highlight innovative practices creation, diffusion mechanisms that 
included champions or institutional entrepreneurs, industry association 
creation, and regulations amongst others. The emergence is analysed for almost 
thirty years, and yet, the field is not mature. “Still, the question remains, Just 
how long is long enough?” (Purdy & Gray, 2009; p. 376). 
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It is important to acknowledge that fields evolve over time, sometimes over 
decades (Purdy & Gray, 2009; Van de Ven & Gardu, 1993); some reaching 
stability, if the institutionalisation project is successful. Morrill (2006) 
identifies three stages of emergence: innovation, mobilisation and structuration 
(see figure 5 below). The first phase is mainly characterized by the isolation of 
actors as well as intense experimentation, mobilisation by accumulation of a 
critical mass of actors and better visibility, and structuration by the emergence 
of patterns of action and interaction, governance (Morrill, 2006; Van de Ven & 
Gardu, 1993). 
 
Fig. 5. Emergence stages based on Morrill (2006) 
Nascent fields are “liminal spaces” (Hirsch & Lungeanu, 2012) because they 
are unstructured and characterized by extreme uncertainty (Fligstein & 
McAdam, 2011). Some authors (Aldrich & Fiol, 1994; Santos & Eisenhardt 
2005) looking at nascent fields use the term ambiguity as well. Ambiguity is 
the “lack of clarity about the meaning and implications of particular events or 
situations.  Ambiguity arises from unknown cause-effect relations and lack of 
recurrent, institutionalized patterns of relations and actions” (Santos & 
Eisenhardt, 2009, p. 644). The difference between uncertainty and ambiguity is 
justified by Santos and Eisenhardt (2005, 2009) as being related to the 
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institutional structure, in the sense that uncertainty would involve a relatively 
stable structure as opposed to ambiguity where there is no structure. Ambiguity 
requires experimentation, learning, and sense making. “Sensemaking: an 
iterative cycle of action and retrospective interpretation to generate stable 
meaning and organized action” (Jay, 2013, p. 140). 
It is for all of the above reasons that emerging fields are the most challenging 
institutional contexts. In order to understand them, one has to understand their 
origins, their ties with the adjacent fields and their evolution (stages). 
3.3.3. ORGANISATIONS AND COMPLEXITY 
Organisations participate in a field and can be conceived as “sites where 
multiple institutional logics vie for dominance” (Thornton et al. 2012, p. 183). 
Similar to fields, they are part of a complex system with social, 
technical/material, and institutional elements (see figure 3 in this chapter). 
Organisations are developing identities to allow the co-existence of multiple 
logics and provide coherence.  Therefore, a new organization in a new field is 
an institutional project, not just a form of economic activity. Moreover, an 
organisation, through its institutional work, contributes to the structuration and 
institutionalisation of the field (Greenwood et al., 2011; Kraatz & Block, 2008; 
Selznick, 1984). 
The institutional work concept reconciles different streams of research and 
bridges institutionalism and agency, responding to multiple calls (Greenwood 
et al., 2011; Hirsch, 2008; Hirsch & Wohlgezogen, 2009; Santos & Eisenhardt, 
2009; Suchman, 1995) 
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Fig. 6. Framework for understanding organisational responses to institutional complexity 
(Greenwood et al., 2011, p. 324) 
In the figure above, Greenwood et al. (2011) represent how multiplicity of 
logics leads to complexity and that instigates organizations to adaptive 
responses that depend on several organisational characteristics, like position in 
the field, structure and governance, and, not last, identity. Organisations will 
face different challenges and perceive them differently depending on 
fragmentation, centralisation and the structuration stage (field emergence in 
this case).  
All organisations in complex environments are pluralistic organisations 
themselves. Kraatz (2009) considers that for understanding organisations 
facing pluralism, therefore complexity, researchers should consider the 
struggles for legitimacy, governance and organisational change, in their 
evolving institutional context. Legitimacy is often contested, as a pluralistic 
organisation has to satisfy various institutional demands, and shifts in the 
stakeholders’ institutional arrangement make it vulnerable. Such an 
organisation has to develop integrity by accommodating competing 
institutional logics internally and externally. Moreover, it has to possess 
capabilities to respond and adapt when various institutional logics change, 
whilst maintaining integrity, purpose and legitimacy.  
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One of the main concerns Kraatz (2009) has is that organisations reflect the 
institutionalisation process of the field, and therefore leadership, as in 
Selznick’s conception, should have a greater bearing when looking at such 
organisations. “The pluralistic organization does not automatically hold itself 
together. Naturally occurring social and political processes may facilitate 
institutionalization and the formation of an organizational-self” (ibid., p. 263). 
According to Selznick (1984), becoming a leader begins when one becomes 
preoccupied with missions and values, creates structures that embody them, 
and builds adaptive capabilities to a changing environment. A leader is 
concerned with the integrity of the organisation, identifies with it beyond their 
own interests. Rising above rivalries, a leader is still and at least a politician. 
“He may succeed in rising above this game (the very mark of statesmanship), 
but he must remain fully in it at the same time. This is a difficult (some would 
say impossible) trick” (Kraatz & Bloch, 2008, p. 66). This implies that leaders 
are simultaneously realists and idealists and not at last hold high moral 
standards. The morality of the leader would pay off in the long run, by 
guarding organisation’s integrity and by fostering the development of 
distinctive competencies, as it is mostly agreed in the leadership literature.  
The importance of leadership is enforced by other authors too, albeit not so 
forcefully (Aldrich & Fiol, 1994; Fligstein, 2001; Gawer & Phillips, 2013). 
However, studies rarely mention leaders that have a significant impact on 
institutional changes. Pouthier et al. (2013) identify Bob Wachter as “the 
hospitalists’ original theorist” (p. 216). Another exception is made by Purdy 
and Gray (2009) who mention Lawrence Susskind and Frank Sander as 
institutional entrepreneurs promoting new logics and defending them from 
incumbents.  
As also discussed in the previous section, emergent fields are characterized by 
ambiguity. “Liminality allows for the amalgamation of different realities. 
Defined as the ambiguous condition of “being ‘in between’, at the limits of 
existing social structures where new structures are emerging”, a liminal space 
blurs the means of identification with previously established identities” (Hirsch 
& Lungeanu, 2012, p. 9). Therefore, organisations acting in this space face the 
most complex environment. The lack of clarity and structuration makes them 
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“be more opened to possibilities and less tied to theory” (Van de Ven & Gardu, 
1993, p. 38) or, I would add, less tied to an institutional “iron cage”. Therefore, 
the representation of the future becomes an on-going determinant of 
organisational action too and the lack o visibility brings forth a lot of 
serendipity and the need to continuously revisit their trajectory (Rindova & 
Kotha, 2001). Studies highlighting the role or institutional entrepreneurs, 
leaders beyond their own organisation, reveal their relevance in complex 
environments, like emergent fields where there is ambiguity. That is because 
uncertainty and ambiguity amplify the need of sense making and sense giving, 
and institutional entrepreneurs play a crucial role in field orientation and 
negotiation. 
Insights from STS studies show that the introduction of new technologies calls 
for “lateral thinking, away from the present functionalities and prospects of the 
product” (Rip & Schot, 2002, p. 164). In order for a firm to create a meaningful 
value proposition in a shifting landscape, it should aim to “understand the 
value-creating system of offering, affordance, context, agency and resources 
and all its social, material and technological influences with other actors in the 
system” (Ng & Smith, 2012, p. 235). In other words, organisations are shaping 
from bottom up the institutional field by creating boundaries and relationships 
and so governance structures for themselves and the field. Anticipation based 
on scenarios of the future in conditions of ambiguity is another motivation for 
action or at least for readiness for action. In the case of nascent activities, 
anticipation is part of the learning process (Rip & Schot, 2002), just as much as 
of the institutionalisation process.   
It follows that  
• organisations reflect and contribute actively to institutional processes, 
at least as much as they are influenced by them 
• the higher complexity, the larger palette for choices 
• the higher complexity, the more relevant leadership becomes 
• organisations introducing technological innovation will guide 
themselves based on scenarios of the future as well. 
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3.3.4. ORGANISATIONS IN A NEW FIELD – VISIONARY OR FOOLISH? 
It becomes clear that organisations entering an emerging field, with little 
recipes to follow, face the most challenging environment, economically and 
institutionally. Such space has one stable feature: paradoxically, instability. 
“The status quo should be viewed as an ongoing, negotiated accomplishment, 
threatened at all times by challenger resistance and exogenous change 
processes. As such, this constantly produces shifts in the nature of the 
relationships, the tactics organised groups use to attain their goals, and the 
worldviews they use to make sense of their situations.” (Fligstein & McAdam, 
2011, p. 15) 
This leads to the straight question Aldrich and Fiol (1994, p. 465) ask: “Such 
foundings are risky, but are they also foolish?”. They explain further that 
“founders of new ventures appear to be fools, for they are navigating, at best, 
in an institutional vacuum of indifferent munificence and, at worst, in a hostile 
environment impervious to individual action. In addition to the normal 
pressures facing any new organisations, they also must carve out a new market, 
raise capital from skeptical sources, recruit untrained employees, and cope with 
other difficulties stemming from their nascent status” (ibid.). They are also 
knowledge and new competencies generators (Gawer & Phillips, 2013; Van de 
Ven & Gardu, 1993).  
Most importantly, perhaps, is that during all of the above, a new organisation 
in a new field “develops a logic of its own and attains the ability to give 
identity to its members, it accepts identities and logics” (Kraatz & Block, 2008, 
p. 252) from its constituents too. In other words, new organisations in new 
fields are building identities without a blueprint and that in itself is a significant 
institutional work. Kraatz and Block (2008) highlight the impact of 
organisations in complex environments over the institutionalisation of the field, 
embracing Selznick’s view that institutionalisation happens bottom-up, as a 
response to the anxiety experienced in the midst of complexity - “it is possible 
that some organizations may be able to forge durable identities of their own 
and to emerge as institutions in their own right” (ibid., p. 251). 
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Many authors highlight legitimacy as one of the most important assets an 
organisation needs for both strategic and institutional rationales (Aldrich & 
Fiol, 1994; Suchman, 1995). Whilst not disagreeing, Kraatz and Block (2008) 
show that organisations with a strong “self”, as Selznick conceives it, are less 
exposed to institutional pressure, to problems of legitimacy, demonstrate more 
endurance, and have a significant impact over the field structuration. 
This view is complementary to the “proto-institution” concept advanced by 
Lawrence, Hardy & Phillips (2002, p. 283) – “practices, technologies, and 
rules that are narrowly diffused and only weakly entrenched, but that have the 
potential to become widely institutionalized”. New organisations in new fields 
are in fact proposing institutionalisation models. If and to what extent these 
models diffuse would contribute to the field structuration. In respect to 
Selznick’s view, an organisation that can both integrate its constituents and 
develop distinctively becomes an institution in its own right (what he calls 
“entitativity”) and will be one of the main drivers of field institutionalisation. 
3.4. INSTITUTIONAL WORK 
I found the concept of institutional work appropriate for this research, because 
it is suitable to research complex problems and allows me to address 
meaningfully major theoretical gaps identified in the previous chapter. 
• Emerging fields – most studies have a historical approach; there is no 
study of emergent fields in their early phase 
• Organisations in the highest institutional complexity - field emergence 
at the confluence of several fields; one of them, healthcare, being a 
fragmented and moderately centralised field, therefore, very complex 
• Medical technology producers - understudied, although the impact of 
technology in healthcare has been studied from the medical provider’s 
perspective, only few studies consider the medical technology 
producer. 
Whilst lateral streams of research, particularly STS, inform my work, I take a 
middle ground sociological approach, where both action and institutions 
determine social and economic realities. “A significant part of the promise of 
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institutional work as a research area is to establish a broader vision of agency 
in relationship to institutions” (Lawrence et al., 2009, p. 1) that avoids 
extremes, like agents simply following institutional prescriptions or having 
superpowers. 
The institutional work concept is adequate in studying contemporary life in the 
digital economy context. The digital economy requires meta-theoretical 
approaches, because it presents new layers of complexity, which are not well 
explained by current theories. Examples of complexity would be the rapid and 
constant changes (Orlikowski, 2010; Rindova & Kotha, 2001; Zietsma & 
Lawrence, 2010), technology development as raison d’être instead of 
production support (Mulligan, 2011), or the development of platforms and 
ecosystems (Gawer & Phillips, 2013; Jacobides et al., 2018).  As shown in the 
literature review chapter, such meta-theoretical approaches reveal valuable 
insights about social and economic life driven by digital technologies (Gawer 
& Phillips, 2013; Nicolini, 2006; Petrakaki et al., 2012; Rindova & Kotha, 
2001; Santos & Eisenhardt, 2009). 
Hence, I consider that the digital economy may “demand a more holistic 
account of institutional action that moves beyond simple dyadic relationships 
and discrete logics, toward the assumption that actors, at any given time, are 
subject to pressures from many different institutions and are often responding 
locally, creatively, incrementally, and more or less reflexively” (Lawrence et 
al., 2011, p. 57). 
3.5. THEORETICAL FRAMEWORK IN A SHELL 
One of the remarkable insights of the institutional logics framework is that it 
recognizes that the institutional arrangement, composed by multiple logics, 
offers not only constraints, but also a repertoire for action. Therefore, it breaks 
from the traditional conception of institutions as “iron cages” (DiMaggio & 
Powell, 1983) that demand conformity and isomorphism from participants in a 
field. It makes space for agency and action, allowing for a nuanced explanation 
of social change. 
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Thus, I connect the institutional logics framework with the institutional work 
concept to investigate the complexity of being a new organisation in an 
emerging field, because it allows me for a more holistic approach. 
“Connecting, bridging, and extending work on institutional entrepreneurship, 
institutional change and innovation, and deinstitutionalization, the study of 
institutional work is concerned with the practical actions through which 
institutions are created, maintained, and disrupted” (Lawrence et al., 2009, p. 
1). 
In order to understand the institutional work organisations undertake in what I 
have identified with a degree of certainty from existing literature as being the 
most institutionally complex environment – field emergence, my task presents 
as a two folds endeavour: to capture the institutional complexity and the 
organisational responses. And so, the research develops on two levels – field 
and organisation. 
An emerging field can be considered as the most acute instantiation of 
institutional complexity. It is an interstice (Morrill, 2006; Rao et al., 2000; 
Greenwood et al., 2011; Stinchcombe, 1965) between other fields, with “no 
stable social relationships, and no agreement on means and ends” (Fligstein & 
McAdam, 2011, p. 12). As the result of this interstitial activity, adjacent fields 
may or may not experience institutional crisis to the far end of 
deinstitutionalisation.  
For the task at hand, at the field level, the focus is to capture the 
institutionalisation processes (stakeholders and logics, as well as their interplay 
via hybridisation and conflict) and the stages of the emergent field, in 
acknowledgement of its interactions with the adjacent fields. It is important for 
my research to understand not only the context of field emergence, but also the 
stage to better situate the organisational analysis. At organisational level, to 
capture and interpret the institutional work, it is relevant to understand the 
position in the field, their representation of pluralism and ambiguity, and their 
governance (in relation to ownership and leadership) as it unfolds.  
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Fig. 7. Theoretical framework for understanding complexity of an emergent field 
The diagram above builds upon the one offered by Greenwood et al. (2011, p. 
324) and it reflects a stronger interactionism stance. My approach reflects the 
importance of organisational responses both upon the institutionalisation of an 
emergent field and upon the organisation itself. I also readdress the field and 
organisational attributes that contribute to the dynamic, in the sense that I 
consider that in an emergent field, there is no centralisation just yet, and the 
degree of structuration/institutionalisation depends on the emergence stage of 
the field. Therefore, it is important to determine that stage. On the 
organisational attributes, I consider relevant the position in the field, the 
internal representation of pluralism and ambiguity (to the extent they are 
acknowledged), and its governance. The organisation identity attribute is not 
present, because new ventures are institutional projects, proto-institutions, so 
they do not have models to develop identities fast. Their identity is in flux and 
its formation constitutes a significant institutional work (Gawer & Phillips, 
2013) upon which their survival depends, and ultimately, collectively, the 
survival of the field.  
The interactionism and constructivism approach is in line with the conception 
of institutional work. Other authors employed the “negotiation” metaphor, 
referring to similar perspective, to understand the way innovating organisations 
are acting to mitigate the ambiguities of an emergent fragmented field, build 
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legitimacy and mobilize resources (Hirsch & Lungeanu, 2012; Hirsch & 
Wohlgezogen, 2009; Santos & Eisenhardt, 2009). The negotiation reflects that 
actions are directed both inward and outward and have effect upon the 
environment and the organisation itself. 
From the theoretical framework, it derives that in order to investigate 
organisations in the complexity of the field emergence, these three research 
stages are needed. 
• Understand what leads to the field emergence - precursors of change, as 
a prerequisite first stage 
• Understand the field institutional complexity 
o Identify institutional logics and their main carriers 
(stakeholders) 
o Identify the institutional stage of emergence, by looking at 
stakeholders interactions that reveal processes of hybridisation 
and conflict 
• Understand organisations’ institutional work in their situated evolving 
context 
In the structure of the thesis, the following chapters will unfold the theoretical 
framework, based on the methodology presented in chapter 4. Chapter 5 offers 
a brief overview of precursors of change, similar to how Scott et al. (2000) 
found necessary to provide for their healthcare field level change. Chapter 6 
identifies the main stakeholders and the institutional logics at play in digital 
health. Chapter 7 analysis the stages of emergence and identifies an emergent 
new field logic, and, after establishing the institutional setting in a 
comprehensive manner, chapter 8 presents organisations’ institutional work. 
The last chapter, linking back to the theoretical framework, integrates the main 
findings, presents the theoretical and practical contributions, the research 
limitations and further directions of research. 
3.6. CONCLUSIONS 
Before proceeding to the methodological approach, this chapter sets the 
theoretical stance and the main constructs deployed in this research. The 
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institutional logics, carried by stakeholders and represented as ideal types, are 
understood as a triad between materiality, practices and values, responding to 
recent calls for research to consider more such interactions. Leadership is also 
given attention, particularly because it is relevant in the midst of institutional 
contestations. Institutional complexity is grounded in the number of 
institutional logics at play, which may compete over goals and means, and also 
in the degree of fragmentation and centralisation. Field emergence is the most 
complex situation because it has a high degree of uncertainty and ambiguity. 
Moreover, it is the most complex when the new field overlaps a fragmented 
and semi-centralised field, like in the case of digital health. Organisations 
facing complexity deploy institutional work depending on the characteristics of 
the field and on their own attributes.  
The theoretical framework is synthesised at the end, accompanied by the 
research stages and a description of how it will unfold in the chapters of this 
thesis. The theoretical framework reflects a middle ground sociological 
approach, which is informed by other theoretical streams, i.e. STS or 
entrepreneurship studies. This framework connects the institutional logics and 
institutional work and most importantly connects theoretically and 
epistemologically the two levels of this research – field and organisation. It 
grounds the constructivism approach, where organisations and their 
institutional field are mutually relevant for the institutionalisation process. The 
theoretical approach combines the institutional logics approach with the 
concept of institutional work considered rich and valuable in researching 
complex and understudied phenomena. 
 
 49 
CHAPTER 4. METHODOLOGICAL APPROACH 
4.1. INTRODUCTION 
The previous chapters established the literature on which this research is based 
upon. In this chapter I elaborated on the aims and questions of the study, and I 
describe the methodological approach, as well as the operational process 
employed for data collection and analysis. 
4.2 RESEARCH OBJECTIVES AND QUESTIONS 
The primary aim of this research is to enrich the theoretical understanding of 
institutional complexity at its most acute instantiation – field emergence - and 
the institutionalisation work undertaken by organisations in a complex 
environment. An emerging field is an interstice (Morrill, 2006; Rao et al., 
2000; Greenwood et al., 2011; Stinchcombe, 1965) between other fields, with 
“no stable social relationships, and no agreement on means and ends” 
(Fligstein & McAdam, 2011, p. 12). It means that organisations entering such a 
field, not only have the “liability of newness” (Stinchcombe, 1965), but they 
also operate in an institutional vacuum, an environment of high uncertainty and 
ambiguity (Morrill, 2006; Fligstein & McAdam, 2011, Van de Ven & Garud, 
1993; Aldrich & Fiol, 1994). 
This study aims to foster the understanding of field emergence and of the 
institutional work organisations undertake during field emergence. Both areas 
are understudied or have been approached retrospectively when the field was 
already stabilised, or were only theoreticised. 
The two objectives are connected, in the sense that it is necessary to capture the 
institutional complexity at the field level in order to understand the 
organisations’ responses in their specific context (Aldrich & Fiol, 1994, p. 
646), and also to understand how institutionalisation happens as a bottom up 
phenomenon. It follows that the research has to reveal both the field emergence 
and the organisations’ institutional work. The two questions of the study are: 
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How does a field emerge? 
How do organisations navigate an emergent field? 
The first question, How does a field emerge?, aims to present a rich picture at 
the macro level, whilst the second one, How do organisations navigate an 
emergent field?, zooms in at the meso level.  
In order to answer the first question, I take an analytical and historical 
approach. I identify the institutional logics, the representative stakeholders and 
their interactions as revealed over time. Given that the focus is an emergent 
field, in order to be able to provide an understanding of the origin of 
emergence, I investigate the precursors of change in the adjacent fields. To 
cope with the complexity of the research itself, I limit the analysis to the main 
fields that overlap in the emergence process. Therefore, for clarity, I added the 
following empirical questions:  
• What caused the emergence of a new field? (prerequisite for field 
emergence) 
• What is the institutional complexity of the emergent field? (institutional 
logics and stakeholders) 
• What are the stages of emergence? (determined by interactions and 
institutionalisation processes, turning points)  
The unfolding of institutional processes and the historical approach helps better 
understand the institutional phases of emergence. It has been established that 
organisational processes may be different at certain stages of field existence: 
emergence, maturity or crisis. Furthermore, during field emergence the context 
and challenge may change in nature for entrepreneurial organisations (Fligstein 
& McAdam, 2011; Morrill, 2006; Van de Ven & Gardu, 1993), depending on 
how far towards maturity the field is.  
In order to answer the second main question, How do organisations navigate 
an emergent field?, I take a similar approach - historical and analytical. Some 
of the guiding empirical questions were:  
• How were they founded? 
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• What was their purpose? 
• How did they evolve over time? 
• Who were their main stakeholders? 
• What were the institutional logics at play? 
It is important to say that my research does not aim to forecast the evolution of 
the field or of the organisations themselves, as the field emergence did not 
reach stabilisation, and many aspects are still to be negotiated. 
4.3. EPISTEMOLOGICAL APPROACH 
Epistemologically, this research aligns with its theoretical framework - it has a 
social constructivist stance. More precisely, I see social life as the result of 
interactions in instantiated spaces, which filter and crystallise over time in 
certain institutional logics and institutional spheres. As such spaces are co-
created through social interaction, they maintain various degrees of 
vulnerability (Friedland, 2013). Such epistemological stand is embraced 
largely by social and organisational scholars, who agree “that much of the 
world with which we deal is essentially socially constructed” (Gioia, Corley, & 
Hamilton, 2012a, p. 2). 
4.4. RESEARCH DESIGN 
The research is qualitative and the design is based on two levels of analysis – 
macro (field level) and meso (organisational level), and so it responds to calls 
for multilevel studies to better understand institutional processes (Greenwood 
et al., 2011; Thornton & Ocasio, 1999). The methodological choice is 
motivated by limited theories to address the research questions and the scarcity 
of empirical research (Rindova & Kotha, 2001; Santos & Eisenhardt, 2005, 
2009; Eisenhardt & Graebner, 2007). Such methods allow for the 
understanding of complex processes that develop over time, and, in addition, at 
organisational level, by revealing the rationales for decision making (Santos &, 
Eisenhardt 2005; Eisenhardt & Graebner, 2007). Multiple case approaches 
retain the replicating relations and characteristics of the investigated 
phenomenon and therefore they result in more robust and generalisable theory 
(Stake, 2003; Eisenhardt & Graebner, 2007). 
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Theoretically, the field level can be considered a single case study, and the 
organisational level a multiple case study (Yin, 2009) or a collective case study 
(Stake, 2005). “Researchers that combine multiple levels of analysis in their 
research are more likely to observe a more accurate picture because, by 
observing across levels, they can see the workings of mechanisms and – 
according to the institutional logics perspective – the contradictory nature of 
the institutional logics” (Thornton et al., 2012, p. 14). Beyond this, it became 
clear from an early stage of my investigation that a multilevel approach would 
be appropriate to render much needed theoretical insights. Institutional scholars 
make similar arguments when discussing field emergence and 
institutionalisation (Aldrich & Fiol, 1994; Fligstein & McAdam, 2011; 
Thornton et al., 2012). 
 
Fig. 8. Multilevel research design 
My research follows an inductive research design. This choice resides 
primarily in the fact that I explore an area – field emergence - known only 
retrospectively or simply theorised by extrapolation. The logic of inductive 
inquiry is valuable when investigating poorly understood, as well as complex 
phenomena (Gawer & Phillips, 2013; Santos & Eisenhardt, 2009). An 
inductive approach provides by design a rich context, satisfying the need for 
both a broad and in depth understanding. 
An inductive inquiry is not just a description of a realm of social and economic 
life, but it is a “theory-building approach that is deeply embedded in rich 
empirical data” (Eisenhardt & Graebner, 2007, p. 25). My research is also 
phenomenon-driven, with two immediate consequences: the research questions 
remain broadly defined and it has a relatively opportunistic characteristic. The 
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research questions are maintained at a high level of specificity to allow for 
discovery, and therefore to benefit from the richness of data, characteristic of 
qualitative studies. The opportunistic characteristic will be further explained in 
the research setting and case sampling. 
The field level of analysis aims to reveal the institutional landscape of the 
emergent field. In that sense, I employ a narrative approach to understand its 
evolution by looking at the turning points reflected by new entrants, 
(de)regulations, events, industry associations, even vocabulary. To understand 
the institutional context of the new field, I analyse the adjacent fields, the 
institutional logics at play, the stakeholders and their interactions, as well as 
the evolution of innovations that fuel its emergence.  
The organisational level consists of three case studies of organisations. Here, I 
employ the institutional work concept to look at how they navigate the 
institutional complexity of the emergent field. Having identified the 
institutional logics, the institutional work concept allows me to analyse the 
narratives and actions of these producers as a problem solving process to cope 
with a complex, novel and ever-changing environment. In order to understand 
organisations in their context, I consider their history and the stage of field 
emergence when they entered.  
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Fig. 9. Empirical framework highlighting both levels of research - field and organisation 
4.5. RESEARCH SETTING 
Due to the nature of my programme, which is digital economy, naturally, my 
discovery was guided by innovation – smart digital technologies. Secondly, I 
had an interest in healthcare and technology that preceded my admission in the 
programme, so I was actively scanning the intersection of the two fields.  
The digital economy transformed the social and economic landscape over the 
last three decades and it is presenting us with new settings (Gawer & Phillips, 
2013; Jacobides et al., 2018; Nicolini, 2006; Rindova & Kotha, 2001; Santos & 
Eisenhardt, 2009) that call for a “problem driven approach” (Santos & 
Eisenhardt, 2005, p. 505). Digital technologies, along with other socio-
economical factors, contributed significantly to “a fundamental shift in the 
rules of competition and the way the game of competition is played” (Ilinitch, 
D’Aveni, & Lewin, 1996, p. 211) across industries.  
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Following my research mandate as well as my interest, in 2010 I ran a small 
research project aimed at understanding Assistive Technologies (how they 
were called at that time, basically technologies used in telemonitoring). I 
focused on business models for private and public sectors. In that research, I 
had two organisations, one public and one private, both based in the UK. The 
private company developed a wireless pregnancy monitor. The traditional ones 
were used only in hospital settings, whilst the new ones allowed for remote 
monitoring of risk pregnancies, and also allowed a carer or partner as a user. 
For healthcare providers, they offered continued monitoring, reduced 
hospitalisation and better health outcomes. The last two benefits were relevant 
for payers (insurers) too, as they were reducing care costs for mother and 
potentially for the infant. The public organisation ran a pilot remote monitoring 
programme, using fall sensors and alarm buttons mainly. The programme was 
originated in social services due to the increased demand for elderly assistance, 
but also involved general practitioners (GPs). It was during that time when I 
realized that it was indeed the beginning of a new era at the intersection of 
digital solutions and healthcare. The two cases offered me great insights on the 
potential and the demand for digital products in healthcare, some of the 
obstacles and some of the main stakeholders. In addition, they made it clear 
that the intersection of health, social services and digital technologies will 
create an emergence of a field in its own right, which came later to be known 
mainly as digital health. 
The research setting discovery, the research opportunity, was serendipitous, 
opportunistic, however, it was “problem driven” (Santos & Eisenhardt, 2005, 
p. 505). One of the main reasons there is not much research at an early stage of 
a field/industry, is because it is hard “to see” it (Aldrich & Fiol, 1994; Fligstein 
& McAdam, 2011; Van de Ven & Gardu, 1993). In that sense, I had to “test” 
my assumption by heavily researching this field further and by returning to the 
existing literature on field and industry emergence (Fligstein, 2002; Fligstein & 
McAdam, 2011; Hirsch & Wohlgezogen, 2009; Klepper & Graddy, 1990; 
Mulligan, 2011; Van de Ven & Gardu, 1993). 
Often, a field emerges following a technical innovation (Morrill, 2006; Van de 
Ven & Gardu, 1993), in this case digital smart technologies. Digital health’s 
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emergence was also fuelled by institutional tensions in the healthcare field 
(Nicolini, 2006; Nigam & Ocasio, 2009; Pouthier et al., 2013; Scott et al., 
2000), a highly fragmented and moderately centralised field. The role of the 
state cannot be overlooked, as its interventions caused historically several 
institutional changes in healthcare (Nigam & Ocasio, 2009; Pouthier et al., 
2013; Scott et al., 2000). In respect to digital health, the state sees it as a way to 
respond to the demographic changes and the rampant costs of care. There are 
three main political consequences: reforms or pressures to reform healthcare 
systems and governments searching to reduce healthcare costs and, more 
broadly, for creating new areas of economic growth. 
In sum, in order to research institutional complexity, my research setting is an 
interstitial field between healthcare and healthcare related fields (pharma, 
medical devices, even social services or academia) and the consumer digital 
technologies field. To reduce the complexity of the research itself, although 
acknowledging the other fields, I have conceptually looked at the two main 
ones (healthcare and digital technologies), but I acknowledge all stakeholders 
(streaming from other fields) as they enter the field of digital health. As the 
result of this interstitial activity, adjacent fields may or may not experience 
institutional crisis to the far end of deinstitutionalisation, however the focus 
remains the institutionalisation processes of the emergent field alone, although 
acknowledging the interaction with the others. In order to understand better the 
process of emergence, the institutional tensions and processes, it became 
necessary to track down the institutional transformations of healthcare and 
digital technologies field (see chapter 5). 
4.6. CASE SELECTION 
As stated previously, there are two levels of my research, the field level and the 
organisational level. 
I use the term “digital health” to designate the broad field where healthcare 
meets digital technologies, the focus of this research. This term covers all 
things health IT, similar to its use in the industry. At the organisational level, 
my research is looking only at collaborative digital health technologies 
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(CDHT) producers, so those who build interactive solutions for various 
stakeholders in digital health. (For more clarifications on terminology in this 
research, see chapter five, and for the terminology evolution, see appendix C.) 
4.6.1. FIELD LEVEL 
Digital health was chosen for its relevance to my theoretical aims (Yin, 2009): 
it presents institutional complexity (Greenwood et al., 2011; Pache & Santos, 
2010), from fragmentation to the high end of emergence. Most importantly, for 
both empirical and theoretical reasons, it is still in a nascent phase (Aldrich & 
Fiol, 1994; Fligstein & McAdam, 2011; Santos & Eisenhardt, 2009), allowing 
for conducting research during emergence. This addresses a major gap in our 
theoretical understanding both of institutionalisation in this phase (Aldrich & 
Fiol, 1994; Fligstein & McAdam, 2011) and of organisational behaviour in 
such an environment (Greenwood et al., 2011; Kraatz & Block, 2008). 
Digital health fragmentation is given by its proximity to healthcare related 
fields and it is enhanced by the intersection with the consumer digital 
technologies field. Healthcare is a highly regulated field where powerful actors 
vie for dominance (Nicolini, 2006; Nigam & Ocasio, 2009; Pouthier et al., 
2013; Reay & Hinings, 2009; Scott et al., 2000; Van de Ven & Gardu, 1993). 
Therefore change does not happen fast; it is often the consequence of political 
debate (Christensen et al., 2009; Nicolini, 2009; Scott et al., 2000). In contrast, 
digital technologies field is a low centralised space where technologies, 
preferences and resources move fast, with minimal regulation (i.e. data 
privacy, competition laws, intellectual properties), and it is mainly coordinated 
by industry standards (Gawer & Phillips, 2013; Jacobides et al., 2018; C. 
Mulligan, 2011; Rindova & Kotha, 2001; Santos & Eisenhardt, 2009). 
The digital health emergence is reflected by new organisations (startups 
mainly), new industry associations, private public associations (i.e. for 
research), increased funding from state and non-corporate investors, the 
evolving vocabulary and meanings (Macnaughtan, 2015b), the presence of 
opinion leaders (similar to social movements), overall sense of ambiguity, 
regulatory hesitations (Macnaughtan, 2014), the entrance of new stakeholders, 
and the changing debates over legitimacy, ownership, privacy and 
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accountability. This setting presents distinctive features, like an ever-increasing 
entrepreneurial activity, reflected in the numerous startups and the nature of 
funding (intense angel, venture capitalist funding), all indicative of an intense 
institutionalisation process. The timing of the research is perfect in the sense 
that it coincides with intensified activities in the field, accompanied by a high 
level of ambiguity (a liminal state). 
The context of field emergence is offered in chapter 5 and chapter 7 reveals its 
evolution. A summary of digital health evolution to the date data collection 
ended is available in the appendix D. 
4.6.2. ORGANISATIONAL LEVEL 
The organisational level can be conceived as a collective case (Stake, 2005). I 
looked to identify cases exemplary for this field (Eisenhardt & Graebner, 2007; 
Stake, 2005; Yin, 2009). To ensure the theoretical relevance, the guiding 
principles were the product developed and its intended audience. To elaborate, 
the product had to be a digital product, which connects or intends to connect or 
mediate the connection between at least two healthcare participants (i.e. 
patients, doctors, non-doctors personnel, insurers). It is important to mention 
that the recruitment remained focused on the aforementioned requirements, and 
it was not guided by geographies. Despite differences between healthcare 
systems (regulatory, insurance, public - private), these companies aimed, in 
different ways, to compensate for common perceived failures or tap into new 
areas in healthcare: low uptake of digital technologies, connections between 
stakeholders, prevention, health education etc. Selection also took into account 
their willingness to allow for multiple in depth interviews with several 
respondents inside the organisation. 
Another criteria for selection was for organisations not to be “sheltered by 
sponsoring organizations” (Aldrich & Fiol, 1994). This is relevant for 
theoretical reasons, because exploring the institutional work of organisations 
entering in an emergent field with limited resources and without a big 
institutional or corporate “shelter” is most relevant. Such organisations 
experience all the complexity of being a new organisation in a new field – 
scarcity of resources, uncertainty, lack of legitimacy and so on. In addition, the 
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companies should have had at least two years of existing at the end of my data 
collection, to allow them to experience and evolve inside the institutional 
complexity.  
In sum, organisations were selected based on their theoretical relevance, 
representativeness for the field and willingness to participate in research. Their 
variability ensures theoretical representativeness, generalisability and 
flexibility (Eisenhardt & Graebner, 2007). 
4.6.2.1. Recruiting 
A market report showed that the average age of a company in the field of 
digital health is 2.7 years (research2guidance, 2012). This means that when I 
started the research, such companies were difficult to find, due to lack of 
visibility. Many startups appeared in 2010 - 2012 and, alongside a big influx of 
investments, they came eventually to the forefront of innovation conversation. 
Adding to the discoverability problem, most companies were operating under 
scarce resources, with little to no willingness to invest in relations that were not 
perceived to bring them value. 
Therefore, the recruitment period was lengthy - between May 2014 and May 
2015. The targeted number of cases was minimum two, maximum three. All 
attempts to enrol organisations in my research via email were unsuccessful. I 
soon came to understand that I had to have a “presence” in the field for these 
companies to see value in engaging in my research and to make direct 
approaches to them. My academic program requested me to have an internship; 
therefore I took this opportunity to establish a “presence”. And so, I began a 
collaboration with nuviun (currently Innovate Medtech), a digital platform for 
the emerging digital health community founded in 2014. During and after my 
internship, I have published six articles, three of them “featured” by the 
platform for being relevant to the industry. I was already participating in 
conferences since early 2012, but during the recruitment phase, I intensified 
my presence to industry events. 
The recruitment of all organisations had the same pattern - I have made the 
acquaintance of the founders or the CEOs during my participation to industry 
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events (for a list of industry events attended, see appendix E). By May 2015, I 
had three companies enrolled. Due to lack of access to respondents, after 
conducting only three interviews, it became clear that there was not enough 
data to construct a case study for one of them. As a result, I have enrolled one 
more company, YouLife. 
At the end of the recruitment, I had three CDHT organisations: 11 Health, 
YouLife, and Mira Rehab. In all three cases, the initial contact was with 
founders and/or CEOs during an event. As part of the agreement to join the 
research, I offered and produced a business report for two organisations 
(YouLife and 11 Health) and an article that was published online for Mira 
Rehab (Macnaughtan, 2016). 
This sample offered a good degree of diversity in terms of type of product 
developed, source of funding, founding contexts and entrepreneurial profile. 
Having such a diverse set of organisations offered a firm grounding for 
developing theory (Eisenhardt & Graebner, 2007; Santos & Eisenhardt, 2009). 
Moreover, in the context of an emerging field, it would be challenging and less 
fruitful to pursue similar cases which may, in the future, be representative or 
not for a specific aim. As my approach is purposefully broad, the variety of the 
sample is beneficial as it allows for the emergence of theoretical insights that 
surpass specific contexts. 
Although the field data analysis was mainly documentarian, it was 
supplemented by observations during my participation to events and by ten 
opinion leaders interviews (see appendix A). Their identification was based on 
their presence online (articles, interviews, followers, quotations by articles 
written by other authors) and on their presence at industry events as speakers. I 
have met in person all opinion leaders prior to asking them to participate in 
research during industry events and similar occasions, with very few 
exceptions (i.e. Lisa Suennen with whom I first made first contact via email as 
when recruiting for this research). A decisive factor was their willingness to 
participate in research in the subject matter, as well as taking the time for an 
interview. 
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4.6.2.2. Brief presentation of the three organisations 
Mira Rehab is developing exergames, clinically based video games that 
incorporate exercises and movements with game interaction. To that end, they 
integrate sensors, at the time of study Microsoft Kinect, to support clinical 
physiotherapy, initially. 
 
Fig. 10. Mira Rehab rehabilitation games1 
The company was established in 2012 by four Romanian master level students 
(business and IT) who were part of the finalist teams of the international 
competition Microsoft Imagine Cup 2011. Following an invitation by 
HealthBox, a London digital health accelerator programme, they founded the 
company in 2012. Mira Rehab has been operating ever since in both the UK 
and Romania. Products were sold mainly in the UK and Romania, with 
commercial interest from other countries in Europe, mainly via a B2B model, 
although a B2C model was not dismissed, just not actively pursued as a line of 
business at the time of the study. 
YouLife is a company founded in the UK, in the early 2000s, which provided 
corporate clients (employers and insurers) tools for assessing personal health 
risks. Over the years, they have developed specific questionnaires, based on 
clinical guidelines for specific health risks. i.e. chronic diseases, cancer. Some 
                                                
1 Source (Geels, 2005, p. 18) (retrieved July 14) 
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of the tools were validated with UK universities. In 2014, the board decided to 
pivot into digital and change completely the business model – from business to 
business (B2B), to a business to consumer (B2C) model. YouLife had 
previously produced digital products like a website, with specific access for 
management and personnel, and an app, for corporate clients. Despite that, they 
considered the transformation as a radical change. And therefore, they have 
started a complete new product and business model, here named NewLife. The 
company self funded the development by diverting revenue from the legacy 
business. The NewLife app was first available to consumers late 2015, via app 
stores, with a B2C model. 
11 Health is a company based in the UK, founded in 2013. In 2015, it started 
operations in the US as well. The company produces a device containing a 
sensor that attaches to a stoma bag, and, via an app, it supports the health 
condition management for patients and later for medical professionals. Around 
this product, other digital products were developed – apps for different 
stakeholders. It was co-founded by Michael Seres, who came up with the idea 
following his own experience as a patient using a stoma.  
 
Fig. 11. 11 Health main product (first generation)2 
                                                
2 Image retrieved from company’s website (on may 2015). 
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An angel investor, who became a co-founder, funded the company initially and 
it launched in 2013, with a B2C model, followed later by a B2B and a B2B2C 
model. 
 
 
 
Characteristic 11 Health YouLife Mira Rehab 
Product A sensor which, via 
apps, supports 
patients with stoma 
bags, later medical 
professionals too 
An app which allows 
people to self asses 
their health risks 
A platform which 
integrates sensors 
(i.e. Microsoft 
Kinect) to support 
physical therapy 
Targeted users Patients 
Doctors 
Non-physician 
personnel 
Potential: Carer 
People 
Insurer 
Potential: Doctors or 
Public Health 
organisations 
Patients 
Doctors 
Physiotherapists 
Payers 
Year of founding 2013 Early 2000s 
Year of starting 
NewLife 2014, 
January 
2012 
Country of founding UK UK UK 
Maine countries of 
operations 
UK and US since 
2015 
UK 
Recently entering US 
Romania and UK 
Context of Founding A patient teamed up 
with a more 
experienced 
business man, 
Adam to bring to 
life a devise 
conceived on the 
hospital ward 
Due to the gradual 
shrinking of the 
business 
opportunities in the 
existing field, it was 
decided pivoting the 
business model into 
digital. 
A team of four 
master students 
following the 
success of their idea 
at an international 
student competition 
– Microsoft 
Imagine Cup, 2011 
Maturity Startup Mature business 
pivoting in digital 
Startup 
Funding Angel investments 
SBRI grant of 89 
450 GBP, spring 
2015 
In discussion with 
Self-funded initially 
Corporate investor 
end of 2015 
Self-funded initially 
Two angels 
investors in 
Romania 
Healthbox in 2012  
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Characteristic 11 Health YouLife Mira Rehab 
VC funds SBRI grant of 780 
000 GBP, spring 
2014 
Three more rounds 
of angel 
investments by the 
end of 2015 
Entrepreneurial 
profile 
Second time 
entrepreneur 
Long term patient 
Previous experience 
primarily in 
marketing 
Long term 
entrepreneurial 
experience 
Experience in 
insurance and 
employee benefits 
Board with 
experience in 
insurance, corporate 
wellness programs 
First time 
entrepreneurs 
IT and business 
students, master 
level degrees 
Advisory Board Two doctors, one 
digital health 
influencer, one 
health 
policy/insurance 
expert, one 
dietician 
5 healthcare advisors One clinical 
advisor, one 
business advisor, 
one technical 
advisor 
Human Resources Permanent 7 
Outsourced: less 
than 5 
Permanent: under 30 
Outsourced 
collaborators: about 
25 external 
developers 
Permanent 5 
Permanent 
outsourced 
developers 5 
Initial contact for 
research recruiting 
Digital Health Pit 
Shop Week, Dec 
2014, London UK 
Organiser: Digital 
Catapult 
 
The Role of 
Psychology in Digital 
Health 
Mar. 2015, London, 
UK 
Organiser: D Health 
Europe 
 
INTERFACE 2015 
September 2015, 
Vancouver, Canada 
Organiser: Interface 
Health Society 
Table 2. Organisations overview 
Only YouLife is a mature company. What is important here are that its 
undergoing efforts to pivot into digital gives it many of the characteristics of a 
startup. The notable differences are that there is an on-going stream of business 
generating a stream of revenue, more employees and a relative double goal. It 
is still self-funded, with limited resources and it is not “sheltered”. Funding of 
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the new company project continued to rely on internal sources until late 2015, 
when a corporate investor came in. Although the company has a long history, it 
manifests many of the characteristics of new ventures – limited resources, great 
uncertainty, long term and on-going organisational changes, regular visitation 
of strategy. My focus is the pivoting side of the business, YouLife, rather than 
the consequences of having two concurrent work streams. 
YouLife is also the only company that required a formal confidentiality 
agreement. Data pertaining to it is anonymised, not due to the confidentiality 
agreement, but mainly because participants requested often anonymisation of 
parts or entire interviews. Other companies did not demand formal agreements 
besides than the research consent form, but several participants were cautious 
in answering certain questions, or they highlighted the confidential nature of 
particular information whenever they deemed necessary: for instance, future 
product features, potential commercial or investment deals which were not 
finalised. All such concerns were treated based on the interviewee’s desire. The 
respondents’ desire to maintain anonymity was respected. 
4.7. DATA COLLECTION 
Data analysed in this research is collected between 2011 and February 2016. 
4.7.1. FIELD LEVEL 
For the field level case, the documentarian data represents the main source. 
This was supplemented by data collected during participation at industry 
events, by social media listening and through opinion leaders interviews. 
4.7.1.1. Documentarian data 
Archival data was collected from various sources: proceedings from industry 
conferences and events, academic and public articles, commercial and public 
organisations’ websites, webinars, video presentations and interviews, blogs, 
industry reports, and regulatory documents. I used a snowball approach to 
sample documentary data, guided by observations, industry events and 
materials available (Gawer & Phillips, 2013; Jay, 2013).  For instance, if a 
document referred to a report, I analysed that report too; if a technology was 
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discussed along others, I investigated them as well; if a website referred to a 
patient blog or community, that would be consulted too, and, if relevant, such 
sources were included. This technique proved particularly useful when 
examining an emerging field, simply because boundaries of the field are not 
yet formed, they expand slowly and overlap on various degrees with those of 
the adjacent fields, therefore the snowball approach allowed me to track 
significant developments in other fields, which proved to have had an impact 
on digital health (i.e. the relation between Obamacare and the drive for 
interoperability in the US). 
Data originates mainly in the US and parts of the EU (i.e. UK, Sweden, 
Denmark, The Netherlands, Germany, France, Romania) and was derived 
predominantly from English written sources, and several in French and 
Romanian. Some sources date back to 1999, however the focus is on sources 
from 2007 onwards, when the launch of the first smartphone marked the 
proliferation of pervasive and sensing consumer technologies. 
Of course, the Internet has proven to be a rich source of documentary data. As 
the field is still emerging, many of my searches led to the discovery of niche 
websites: MedCityNews, mobihealthnews, nuviun (currently Innovate 
Medtech), Medtech Engine, to name a few. Over time, the mainstream news or 
opinion websites began to offer more content on Digital Health: Forbes, The 
Wall Street Journal, The Guardian, or the BBC. To identify relevant news and 
opinion articles, I have used search engines like Google, Google Scholar, 
however many relevant articles have been identified via social media listening.  
4.7.1.2. Social media 
I have been involved with digital health social platforms (LinkedIn groups: 
Digital Health, Digital Health UK, Healthcare Denmark, eHealth Romania, 
mHealth; Nuviun), I followed Twitter hashtags and a number of accounts of 
private individuals and companies – i.e. HIMSS15, Data4health, digital health, 
wearables, patientsincluded, DHL2015, doctors20). In doing so, I was able to 
identify more sources of information, news and opinion articles. Social media 
platforms represent a public forum for debates and they prove to be useful in 
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analysing emerging social and economic realities (Beverungen et al., 2015; 
Lupton, 2014a, 2014b). 
Perhaps, in the last two years of the research, social media listening became 
one of the main tools to select relevant documents for digital health. This social 
media listening only guided identification of current issues, stakeholders, 
themes and, occasionally, of relevant archival data (Swirsky, Hoop, & Labott, 
2014), similar to my participation at industry events. It also helped identify 
opinion leaders, which led to supplementing the documentary data with several 
interviews.  
4.7.1.3. Industry events 
Data at field level was supplemented by data collected by my participation at 
industry events (see appendix E), where I observed the profile of participants 
(i.e. medical technology providers, doctors, regulators, pharma, CHDT 
produces), agendas, as well as significant topics raised by presenters or panels. 
All observations pertained to the public space, and therefore it can be 
considered a passive observation of the public space. Some of the events 
opened have made presentations available online. Several others have offered 
interviews or session recordings. Some of these online sources were used. 
4.7.1.4. Opinion leaders interviews 
Field data was enriched by ten opinion leaders interviews (see appendix A). 
Their identification was based on their presence online (social media, 
followers, articles, referrals to them inside events or articles) and at industry 
events. 
Interviews were semi-structured to allow for themes to emerge and were 
conducted mainly like conversations. In the case of opinion leaders, the 
opening question was to talk about themselves prior to their involvement in 
digital health. These interviews maintain a broader level of assertions in 
respect to the field evolution (see appendix F for an example). Most interviews 
with opinion leaders were taken over the phone or Skype, and lasted 30 - 40 
minutes. Majority were recorded, except two. One was returned in a written 
format and the other one was partially written, partially recorded. Michael 
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Seres was the only opinion leader who was also a participant in the 
organisational level, as co-founder and CEO of 11 Health. 
4.7.2. ORGANISATIONAL LEVEL 
In the case of organisation case studies, the main data source is interviews. As 
a primary source I also included presentations at industry events where I took 
part.  
4.7.2.1. Documentarian data 
Documentarian data varied from articles in the written press, company 
websites, online interviews and articles in which the company or founders were 
mentioned, competitor websites (where applicable). To observe changes in 
their public discourse, I have used the Wayback Machine website (an online 
archive that maintains selected images of websites over time) to track the 
changes companies brought to their websites. In the case of YouLife, I focused 
mainly on its evolution since the beginning of the pivoting phase.  
4.7.2.2. Social media 
For organisations, I have also followed their social media accounts (LinkedIn, 
Twitter and Facebook), also as another modality to analyse their public 
rhetoric. It is important to highlight that social media is enhancing what was 
previously achieved via Public Relations efforts only. Through their shares and 
endorsements on social media, companies are both enhancing their discourse 
and indirectly legitimise by association with reports, opinion pieces, and 
authority or influential figures (Brown, 2006).  
4.7.2.3. Industry events 
In several occasions, I participated to conference or events where talks were 
given by organisations’ representatives – Mira Rehab and 11 Health. 
4.7.2.4. Interviews 
Interviews conducted for organisations took place in person, over the phone, or 
via Skype (video or audio calls). Most of the interviewees were part of the 
company, most of them in middle, top management and board or founder level. 
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I would like to highlight that compared to the size of companies, their history, 
the degree of adequacy (Bowen, 2008), the number of respondents is 
satisfactory. Of course, inside of two of the companies, Mira Rehab and 11 
Health, respondents had more overlapping roles and most of them having great 
level of empowerment compared to similar roles in big companies. In addition 
to that, the high level of interaction led to the fact that most respondents had a 
very rounded understanding of their company. A few interviews were 
conducted with interviewees from outside the company – advisors or former 
advisors. Most respondents were interviewed twice. The second round 
(sometimes the third round of interviews) aimed to either clarify, expand on 
previously discussed topics, or to generate additional data on company 
developments. Most interviews lasted 60 minutes, although the second round 
usually lasted on average 30 minutes. In a few occasions, some clarifications 
via email were obtained in relation to specific issues and some drawings were 
used. 
 11 Health YouLife Mira Rehab 
Number of interviews 13 23 10 
Non-company 
representatives  
1 advisor 1 consultant 1 advisor 
1 investor 
Number of individual 
interviewees  
7 13 7 
Language of interviews English English English  
Romanian 
Table 3. Interviews in organisations 
Interviews were semi-structured to allow for the themes and topics to emerge 
(see appendix B). They usually started by asking the interviewee to talk about 
their experience prior to joining or founding their company. Interviews inside 
organisations started more broadly and ended up focusing on company 
strategy, product and more specific aspects (see appendix G for an example), 
but there were questions about the field aimed to elicit their understanding and 
perception over it and over the position of their company’s inside it. Interviews 
with company representatives ranged between 15 minutes to 90 minutes, on 
average 50 minutes. 
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4.7.3. SUMMARY OF DATA SOURCES 
The table below synthesizes data sources used for this research, for both field 
and organisational levels. 
Data source type Digital 
Health 
Macro level 
11 Health 
 
Meso level 
YouLife 
 
Meso level 
Mira Rehab  
 
Meso level 
Industry events 11 3  1 1  
Interviews 10 13 23 10 
Company websites 30 1 2 
Competitors: 3 
1 
NGO website: 1 
Press or online 
articles 
150 8 N/A 5 
Languages English, 
French, 
Romanian 
English English Romanian and 
English 
Countries US, UK, 
France, 
Canada, 
Romania, 
Netherlands, 
Denmark 
UK 
US 
UK Romania 
UK 
Recordings 
(interviews, TEDx 
talks, conference 
talks, podcasts) 
 
35 
Presentations: 
4 
Panel 
discussions: 2 
Interviews: 3 
“How to” 
recordings: 3 
Promotional: 
2 
TV: 1 
Others: 2 
Promotional: 2 Tedx: 1 
TV: 1 
Promotional: 1 
Social pages Twitter: 40 
accounts 
related to 
digital health 
LinkedIn 
Groups: 3 
Facebook, 
Twitter, 
LinkedIn 
Facebook, 
Twitter, 
LinkedIn 
Facebook, 
twitter, 
LinkedIn 
Related online 
content  
Various 
sources 
(personal 
websites, 
news 
websites, 
social 
platforms) 50 
On company 
website 16 
On founder’s 
website 20 
On other 
websites: 3 
On company 
website 2 
N/A 
Books 5 N/A N/A N/A 
Market reports 30 N/A N/A N/A 
Regulatory 
documents 
8 N/A N/A N/A 
Table 4. Summary of data sources 
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4.8. DATA ANALYSIS 
Data collection followed a concurrent and iterative approach (Eisenhardt & 
Graebner, 2007; Yin, 2009) between field data and theory, to allow for the 
emergence of themes and identification of additional sources. The high volume 
of data obtained was reviewed in its entirety. It was organised historically for 
longitudinal analysis in all cases, and, following several qualitative iterations, it 
was analysed based on the units of analysis and on the key themes, as they 
emerged over time. 
 
Fig. 12. Representation of how data analysis on each level informed the other 
The main units of analysis used in this research are institutional logics as ideal 
types and institutional work as defined in chapter 3. Institutional work is a 
useful concept because, as I have mentioned before, it allows me to refer to 
both actions and rationales. Action is important because, on one hand, it often 
embodies meanings, on the other hand, it can lead to a change in meaning. 
Actions can embody, in conditions of ambiguity, sometimes less intended 
reactions or irrational attachments (Santos & Eisenhardt, 2009), what Weick 
(1988) referred to as “enacted sensemaking”. Rationales (retrospective as well 
as anticipative) are captured through narratives and theorisations. Rationales 
“provide sufficient structure for people to get their bearings and then create 
fuller, more accurate views of what is happening and what their options are” 
(ibid., p. 310). Examples of such actions at the organisational level are hiring, 
alliances, subscriptions to professional associations, product development, 
branding etc. At the field level, a few examples of such actions would be 
formation of new associations, new social media groups or hashtags, market 
reports, regulations, events, prizes, contestations…The secondary units of 
analysis related to institutionalisation are hybridisation and conflict. 
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Hybridisation is understood as a process where logics combine and conflict 
represents a process where logics at best ignore and worst oppose each other. 
Analytic Level Activity Approach and supporting tools 
Field level Timeline for the field Table based on documentarian data and 
conferences notes organised in Zotero 
on categories (i.e. article, market report, 
startup, association, regulation) 
Reiteration between data and theory for 
institutional logics and stakeholders 
Tagging in Zotero of documentarian 
data and conferences notes, alongside 
with theoretical articles 
Tagging of interviews in NVivo guided 
by preliminary work on documentarian 
data 
Tables to represent logics and 
stakeholders as they emerged 
Reiteration between data and theory for 
institutionalisation processes 
Tagging in Zotero of documentarian 
data and conferences notes, alongside 
with theoretical articles 
Tagging of interviews in NVivo guided 
by preliminary work on documentarian 
data 
At this stage, the process was better 
informed by the previous stage and 
guided by certain units. 
Graphs to represent institutionalisation 
processes in various contexts. 
Reiterations between timeline, processes of 
institutionalisation and stakeholders, as well as 
existing theory, to generate field emergence 
stages 
Supported by the timeline and the 
previous stages of content analysis 
Tables and graphs were used to support 
findings 
Reiteration between data and theory led to 
identification of aggregation units for 
organisational level 
Tables and graphs, based on themes 
emerged and theoretical insights 
Organisational level Timeline for each organisation  Table based on both documentarian 
data and interviews 
Reiterations of data analysis guided by the 
content of institutional logics derived from 
previous level 
Tagging of interviews and 
documentarian data in NVivo 
Reiteration between data and theory for 
processes of institutionalisation 
Tagging of interviews and 
documentarian data in NVivo 
Tables to organise themes 
 
Open minded tagging for themes regarding 
institutional work 
Tagging of interviews and 
documentarian data in NVivo 
Iteration between theory and findings Graphs and table to represent and 
connect emerging themes with theory 
and allow for insights 
Grouping of emerged institutional work 
themes under the aggregation units identified 
at previous level 
Organisation of tags in NVivo 
Graphs and table to support ideas, 
organisation of categories and theory 
Abducting phase  
Connect the two levels 
& build theory 
Reconnect institutional logics content from 
both levels to enrich findings and generate 
theory 
Facilitated by previously generated 
theorisation, tables and graphs 
Reconnect processes of institutionalisation and 
institutional work between levels to generate 
theory 
Facilitated by previously generated 
theorisation, tables and graphs 
Build upon theory and findings to generate 
practical insights 
Tables and graphs  
Table 5. Summary of analytical steps 
The above table summarises the main steps of data analysis. However, the 
process was not as linear as it may seem from the table above; there were 
significant iterations at each level of analysis, as well as during the abducting 
phase. It is important to highlight that the two levels of analysis informed each 
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other, as my research takes both a top-down and a bottom-up approach (Scott, 
2008).  
4.8.1 LONGITUDINAL ANALYSIS 
Data was first organised historically and then synthesised based on milestones. 
Historical stages have been used previously to depict and explain 
institutionalisation processes (Morrill, 2006; Pouthier et al., 2013; Scott et al., 
2000; Thornton & Ocasio, 1999). At the field level, after several iterations, 
data was organised in two blocs: precursors of change and the phases of digital 
health emergence: the ingenuous phase (2007 - 2009), the legitimation phase 
(2010 - 2012) and the mobilization phase (2012 - present). At the 
organisational level, the history was constructed from online sources and 
interviews. Given the relative short lifespans, it was not difficult to build a 
brief history based on milestones (founding, product, funding…). One of the 
companies, 11 Health, has developed its own history on the website, which was 
very useful to see what the company recognised as milestones.  
4.8.2. CONTENT ANALYSIS 
Throughout my research, I engaged in numerous meetings, discussed the 
history of the case, themes and processes as they emerged, and sought to 
develop underlying explanations. These meetings included my supervisors, and 
also other academics and researchers. Moreover, through my participation at 
conferences, I had the opportunity to discuss my work with a variety of 
industry representatives. This iterative process allowed me to select data, 
display it in tables and diagrams, build narratives and develop and verify 
conclusions (Eisenhardt & Graebner, 2007; Miles & Huberman, 1994). 
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Fig. 13. Sample diagram presented at Interface conference (Vancouver, Canada, 2015) 
Due to the large amount of data, I used hand notes, tables and graphs, as well 
as softwares like NVIVO 11 and Zotero 4. Initially, I relied on Zotero 4, and 
later I found NVIVO to be helpful to manage interviews in particular. This 
allowed me to cope with the amount of data and cross-analyse the case studies. 
I used a multitude of means to support emerging processes of theory creation, 
but, in the end, I relied primarily on hand notes, tables, and diagrams to 
simplify and synthesise my analysis. That was the case mainly for the inductive 
approach when I determined broader themes, and when I undertook an intense 
adductive stance to build the theoretical insights. 
4.8.2.1. Field level 
The historical narrative allowed me to identify themes and to generate 
explanations and theoretical insights. At first, I used a multitude of codes, as 
they appeared to be relevant over time. I started doing that using Zotero 4, and 
then I added also NVIVO 11, particularly for interview data. 
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Fig. 14. Sample coding, as inductive approach, in Zotero 4 for field level analysis 
 
Fig. 15. NVIVO codes represented based on number of coding references 
Data was analysed through several iterations as themes emerged: institutional 
logics and stakeholders, hybridisation and conflict, and the hybrid role of the 
empowered patient. Data was tagged based on themes to allow for comparisons 
and formulation of theoretical contributions. 
The content of the institutional logics was derived through an iterative process 
between data collected and the institutional literature and it is explained 
extensively in chapter 6, along with representative stakeholders. For instance, 
professional logic means that their representatives have access to a body of 
knowledge, are licensed to employ it and have autonomy in their decisions 
(Abbot, 1988; Leicht & Fennell, 2008; Scott, 2008). Additionally, I consulted 
existing institutional logics studies in healthcare to guide both the identification 
and the formulation of logics. A special regard is owed to the identification and 
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formulation of the citizen logic. Although it is invoked by other healthcare 
studies (Dunn & Jones, 2010; Scott et al., 2000; Waldorff et al., 2013), it has 
not been formulated as such before. I guided my formulation more heavily on 
data collected in this case. Sample themes for this logic were “connected 
health”, “empowerment”, “patient participation”, “self management”, “patient 
management”, “collaboration”, “population health”, “quantified self”, 
“weareables”, or “personalized health”. Related to the citizen logic, the 
emerging role of the “empowered patient”, as ideal type, was also described. 
At the field level, the inductive approach was used to identify recurrent and 
emerging themes pertaining to the institutionalisation processes. My search 
was guided by new activities, declared needs, missions, resistance, target 
audience, delivery and communication channels, founders, hiring practices, 
board members, affiliations with industry or professional associations, 
engagement with or co-optation of stakeholders, and governing bodies. These 
aspects varied depending on stakeholders. For instance, when examining 
regulators, I looked at how they approached digital health, their declared 
intention versus actions, who do they recognise as other stakeholders, how they 
engage with them, or how they direct financial support and incentives. 
I will offer here an interesting example of how a stakeholder, by promoting a 
certain rhetoric, creates institutional logics hybridisation and conflict with 
different stakeholders. “This is not just about a change in service provision, but 
about a cultural change, allowing patients to be partners in their care, letting 
them decide what support they need, when they need it and how” (UK 
Department of Health, 2006). States’ push for consumerism stimulates in lay 
people the hybridisation of the medical profession and citizen logics. But 
enforcing the same idea to healthcare professionals, causes conflict with the 
market logic.  
Processes of hybridisation and conflict happen in the same time for many of 
the digital health stakeholders. CDHT producers though are one great example, 
as they try to hybridise with both medical profession citizen logic, but they also 
go at times into conflicts with both. “In this day and age, where the explosion 
of apps, etc., if you don’t walk in the shoes of the patient, that is going to be 
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using your technology, you’re gonna fail. You’re gonna absolutely fail!” 
(Michael Seres, patient entrepreneur, opinion leader). I have called 
ambivalence this process of simultaneous conflict and hybridisation that 
proved to be most common amongst stakeholders. It is perhaps explained by 
the uncertainty and ambiguity of the field emergence, as well as by the “uneasy 
truce” amongst market, state and medical profession logics present in the 
healthcare field. 
4.8.2.2. Organisational level 
It is relevant to say that this analysis started later in the research, and therefore 
the field level analysis informed and guided heavily the analysis at the 
organisational level. More specifically, the content of institutional logics were 
broadly identified along with other themes during the field level analysis and 
they guided the identification of these logics inside organisations. However, 
both levels of analysis continued to inform each other (Scott, 2008). 
For the organisational level, although Zotero 4 was still used, NVIVO was 
preferred due to better management of interview data. 
 
Fig. 16. NVIVO codes represented based on number of coding references for 
organisational level 
At this level, I looked to identify institutional logics (based on the field level 
work) and processes of institutionalisation (hybridisation, conflict and 
ambivalence) and institutional work. For the institutional work, I paid attention 
to symbolic acts, theorisation and actions, as resulted from the data gathered. 
Examples of such actions are hiring, partnerships, subscriptions to professional 
associations, product development, branding, funding, or presence at events. 
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Institutional logics were identified for each participant based on their previous 
experience and role in the company (founder, employee, investor, advisor), as 
well as based on the content of the logics as emerged through the field analysis 
(see chapter 6). This process was relevant to understand the prevalent or 
emerging institutional logic or logics at the organisational level, as well as to 
assess certain types of institutional work and understand the bottom-up 
institutionalisation. 
Institutional 
logic 
Example Institutionalisation 
process 
State logic “But after you’ve tested it, can it be prescribed? No! 
You can pay for it? Don’t know. So what’s the point? 
That’s what I mean about the disconnect between the 
big idea and stuff on the ground. I work very closely 
with NHS in the digital health thing. I think there are 
some fantastic people there who really have great 
visions, but they cannot solve everything. And that’s 
the problem. And sometimes, they don’t even 
understand the issues on the ground. (Michael Seres, 
CEO, founder 11 Health) 
Conflict - market and 
state logics. 
“Because, you can’t avoid the issue of data privacy, but 
it’s the people that don’t pay attention to data privacy 
won’t be around for very long.” (M. B., co-founder 
YouLife) 
Ambivalence – citizen, 
state and market logics 
Medical 
profession 
logic 
“It was from bags that leaked, it was from watching 
nurses. (…) I would time how long it took them to 
come in, empty the bags, measure it, put it on a flow 
balance chart and put it back again. And it was quite a 
lengthy process for them and also a difficult process for 
them… It’s not just about me, it’s about them 
managing it.” (Michael Seres, CEO, founder 11 Health) 
Hybridisation – citizen 
and medical profession 
logics 
“Yes, it’s the infrastructure and the staffing of the 
hospitals. Here they have enough difficulty having 
enough beds, let alone managing a new technology like 
this. It doesn’t seem to be a priority.” (D. B., 
communications, 11 Health) 
 
Hybridisation – citizen 
and medical profession 
logics 
Citizen logic “Being a participant patient is vital, in my opinion, in 
healthcare.” (Michael Seres, CEO, founder 11 Health) 
Ambivalence – citizen 
and medical profession 
logics 
“Especially with healthcare, I found a lot of patients 
don’t really want to deal with an app, they don’t want 
to experience 17:52 want to get things done.” (A. C., 
technical lead, 11 Health) 
Conflict – citizen and 
market logics 
“And I think educating people is the really important 
part of all of that, and I think that’s what excites me. I 
want to help people understand how healthy they really 
are, and I think that’s why I really like what we’re 
doing.” (I. D., business development, YouLife) 
Hybridisation - citizen 
and medical profession 
logics 
Market logic “The patient is not necessarily the forefront from the 
hospital’s perspective. Unfortunately, that’s the case, 
the hospitals may voice that they care about the patient, 
which they do, but not as much as they should. The 
hospital is a business.” (K.P., US business lead, 11 
Health) 
Conflict – citizen, 
medical profession and 
market logics 
“I am a big fan of gamification as principle. I believe it 
is a necessity to transform a boring process in a more 
interesting one is a very good thing. On the other hand I 
Conflict – citizen and 
medical profession 
logics 
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Institutional 
logic 
Example Institutionalisation 
process 
find it overused, it's applied in anything. I find serious 
games a wrong definition. It seems you need serious 
because games would point to something that it's not 
essential. From my point of view, games are essential 
to everything.” (Cosmin Mihaiu, co-founder Mira 
Rehab) 
Hybridisation – market 
and citizen logics 
Science logic “How many companies have actually done the research 
into the psychology of the way you ask the question, or 
the psychology of where a question appears in the list, 
or the psychology of the colour you write the letters in? 
How many companies are doing that? Because that 
takes a long time to do. And that’s what I mean about 
the validation work.” (M. B., co-founder YouLife) 
Conflict – market and 
science logics 
“We can follow what a patient does based on some 
parameters that could not have been monitored before. 
In that sense, we are bringing medical innovation.” 
(Alina Călin, co-founder Mira Rehab) 
Hybridisation – science, 
citizen and market 
logics 
Table 6. Institutional logics and institutionalisation processes at 
organisation level 
As observed in table above, each logic is accompanied by the 
institutionalisation process reflected in the quotation. The explanation is in the 
fact that institutional logics are ideal types and they are carried out in less pure 
forms and in greater diversity by field participants. Given the very nature of 
emergence, it is expected that institutional logics be represented at individual 
level in less pure forms, particularly because meanings and rules of the game 
are still negotiated. This is also relevant to show how field level analysis 
informed the organisational level, as an interpretation schema. 
For analysing institutional work, I used an iterative process to allow categories 
to emerge until I had a clear understanding of their relationship and their fit 
into the parameters set by the theoretical framework: position in the field, 
pluralism and ambiguity, and governance. As themes and relations emerged, I 
referred back to existing theories and literature, as highlighted in chapters 2 
and 3. I followed recommendations on coding (Gioia, Corley, & Hamilton, 
2012b) that provide guidance on organising and order of abstractions, which al 
facilitate theorising phase. However, due to the complexity of this research and 
the theoretical approach, I did not use the 1st and 2nd orders terminology, to 
avoid confusions. I have followed the coding and abduction strategy, but my 
aggregation themes were predetermined by my theoretical framework and 
research design. As Gioia et al. recognise, “different methodological 
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approaches will naturally rely on different conceptualizations of data” (ibid., p. 
25). 
Aggregation 
themes 
Institutional 
work 
Mechanisms Examples 
T
am
in
g 
lim
in
al
ity
 (P
os
iti
on
) 
Incumbent 
(mis)alignments 
Recognition of 
regulations or 
expectations that may or 
may not apply 
 
Conflict or ambivalence 
– avoidance of certain 
requirements, at least 
temporisation 
 
Preparation for the 
future changes in 
regulations or 
expectations 
Recognition of regulations or expectations 
that may or may not apply: “But after 
you’ve tested it, can it be prescribed? No! 
You can pay for it? Don’t know. So what’s 
the point? That’s what I mean about the 
disconnect between the big idea and stuff 
on the ground. I work very closely with 
NHS in the digital health thing. I think there 
are some fantastic people there who really 
have great visions, but they cannot solve 
everything. And that’s the problem. And 
sometimes, they don’t even understand the 
issues on the ground. (Michael Seres, CEO, 
founder 11 Health) 
 
Conflict or ambivalence – avoidance of 
certain requirements, at least temporisation: 
“If you are really agile and grow really fast, 
ahead of the curve, my advice is to stay 
away from the NHS. Because it will bog 
you down, absolutely drag you down, drain 
you every penny and the few resources 
you’ve got and you’ll end up with nothing.” 
(M. B., co-founder YouLife) 
 
Preparation for expected changes in 
regulations or expectations: “We prepare to 
test with a trust in UK. We work after a set 
of rules from the UK. We want to launch 
the online version that would link the home 
version to the hospital one and to secure 
them both. Here there are many aspects to 
take into account that are not necessarily 
related to usability, but they are necessary. 
(...) For now, for data security, we follow a 
set of UK guidelines.” (Andrei Cantea, co-
founder Mira Rehab) 
Legitimacy Association with 
legitimising actors – 
academia, healthcare 
professionals or 
organisations (on 
partnerships or advisory 
boards) 
 
Display of public 
awards or recognitions 
 
Display of evidence 
 
Good cause 
Association with legitimising actors:  Mira 
Rehab dedicated since very early on a lead 
for their academic and scientific 
connections. All three companies engaged 
with such stakeholders. 
 
Display of evidence: Mira Rehab and 
YouLife had extensive articles with 
evidence on their websites. 
 
Establish trust/Good cause: “And he talks 
[n.b. the founder] in away that’s not down 
to people, he’s truly a patient and people 
need that. I think people will believe in the 
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Establish trust 
product because they believe in him. I 
mean, he’s got nothing but the best interests 
at heart.” (D. B., communications, 11 
Health) 
Resource 
maximisation 
Co-optation of various 
stakeholders 
 
Temporisation of 
actions or engagements 
with other stakeholders 
 
Develop capabilities 
Co-optation of various stakeholders: “And 
it's beneficial to companies like ours who 
want good expertise in some ways that are 
often cheaper, because there is the 
reciprocal thing.” – on working with 
academia (M. R., finance, YouLife) 
 
Temporisation of actions or engagements 
with other stakeholders: 
“… if I can get the efficacy and show I can 
do that, this business will be of immense 
value because you’ve got something that 
the NHS is been trying to get to for years 
and years.” (M. B., co-founder YouLife) 
 
Develop capabilities, depending on 
perception of needs: For internal 
capabilities, 11 Health looks to invest in 
technical resources, whilst YouLife 
headhunting for Digital Experience Lead. 
For science capabilities, most companies 
established links with outsiders, particularly 
academia. For medical expertise, 11 Health 
and Mira Rehab developed long term, 
intense collaborations with healthcare 
organisations and co-opted doctors in the 
advisory boards. 
Forge a new 
market 
Establish partnerships 
with incumbents 
(academia, healthcare) 
 
Promote new practices 
 
Turn partnerships into 
distribution channels  
Establish partnerships with incumbents 
(academia, healthcare): Mira Rehab 
considers that healthcare professionals co-
created with them their solution.  
 
Promote new practices: “We can follow 
what a patient does based on some 
parameters that could not have been 
monitored before.” (Alina Călin, co-
founder Mira Rehab) 
 
Turn partnerships into distribution 
channels: Mira Rehab and 11 Health were 
looking into developing B2B2C models via 
their partnerships with healthcare providers. 
Similarly, YouLife was looking for 
commercial partners from consumer areas 
to use as distribution. 
T
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Scanning the 
environment 
Co-opetition and 
competition 
 
Scan broader 
technological 
environment 
 
Monitor incumbents 
evolution (i.e. state and 
healthcare) 
 
Gain market insights 
Co-opetition and competition: 
“Competitors… every month a few more. 
Competition validates the market. There is 
no dominant one. I am happy when I am 
told our product is better.” (Cosmin Mihaiu, 
co-founder Mira Rehab)  
 
Scan broader technological environment: “I 
think Apple is making steps towards that 
with their health kit. Honestly, I haven’t 
seen anything from Google, but I would say 
they’re doing something. It really needs to 
be kind of led, the app industry tended to 
kind of wait for the big players, like 
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Microsoft, Apple, Google to do things, and 
then they kind of moved on it.” (A. C., 
technology lead, 11 Health) 
 
Monitor incumbents evolution (i.e. state 
and healthcare): All companies realised for 
instance that data privacy and security are 
coming to the forefront and that eventually, 
this will not only be a competitive edge, but 
a regulatory requirement. 
 
Gain market insights: “…we have learned a 
lot over time, from many people, and how 
to spend and what would be more 
beneficial, to respect our strategy. (Andrei 
Dascalu, co-founder Mira Rehab) 
Institutional 
brokerage 
Compartmentalise by 
design for multiple 
logics 
 
Hold multiple identities 
 
Compartmentalise by design for multiple 
logics: “Specifically talking about the 
device that we have, it certainly delivers a 
high level of quality of life, its convenience, 
that the patient just did not have before and 
that they achieve with this device. And in 
terms of how hospitals at C-level, surgeons, 
and nurses view quality of life of the 
patient... surgeons are focused on just the 
result of what the device actually does, 
nurses are probably most concerned with 
the quality of life of the patient, and 
hospital C-level administration, they will 
say that they're concerned about the quality 
of life of the patient, but their focus is 
internal on the hospital, they’re concerned 
about making money and saving money. ” 
(K. P., US business lead, 11 Health) 
 
Hold multiple identities: “So we had to 
build something that a patient would read, 
but also a doctor could read and a 
pharmaceutical distribution company could 
read, so we had to please a lot of different 
audiences.” 
“We’re dealing with professionals, and 
doctors, and nurses and patients come 
across the spectrum. It’s such a diverse 
group and there are so many different, 
diverse areas. It’s been really a challenge. I 
think the fact that people are still trying to 
catch up with it, and define it, and disrupt it 
that makes it really exciting.” (D. B., 
communications, 11 Health) 
Build for the 
future 
Flexibility in product 
and business model 
development 
 
Develop concurrent 
business models 
Flexibility in product and business model 
development: Mira Rehab had designed 
their platform with inbuilt flexibility to be 
able interoperate with various technologies. 
 
Develop concurrent business models: Both 
Mira Rehab and 11 Health have a B2B and 
a B2B2C business models. 11 Health has 
also a B2C one, Mira Rehab aiming to get 
to develop that one. YouLife focused 
mainly on a B2C, but came to realisation 
that the B2B model was very important for 
monetisation. 
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Distinctiveness  Use new categories (i.e. 
“patient led 
innovation”, “digital 
health”, “connected 
care”) 
 
Use categories based on 
circumstances and 
stakeholders  
 
Separate from legacy 
health IT  
 
Use of stories to 
alleviate contradictions 
Separate from legacy health IT: “If you 
have something that’s digitally sound and 
something that’s new, people typically will 
embrace that, more so than something that’s 
been around for a while, something that’s 
not necessarily you know, run through a 
digital platform.” (K. P., US business lead, 
11 Health) 
 
Use categories based on circumstances and 
stakeholders: “Digital health” for instance 
is often used when connecting with 
investors, to associate the company with the 
booming market. Another examples is Mira 
Rehab avoiding the “exergame” label, of 
fear of trivializing their solution. 
Use of stories to alleviate contradictions: “It 
was from experiences in the hospital bed. It 
was from bags that leaked, it was from 
watching nurses.” (Michael Seres,  CEO, 
founder 11 Health) 
 
Use of stories to alleviate contradictions – 
leverage social media: “Yes, but I’d say 
that the brand is owned by your audience. 
Your company, we don’t even own the 
brand. Because they have so much 
influence on the way it’s going to perform, 
that I’d say that they own the brand. They 
are the ones there are going out there and 
do social media or talk about it. So they 
have a lot more power. (D. B., 
communications, 11 Health) 
Leadership Identity project based 
on scenario of the future 
 
Founding logic as 
catalyser or challenge 
 
From identity project to 
institutional change 
 
Adaptive strategy, with 
integrity  
Identity project based on scenario of the 
future: “I don’t believe that successful apps 
are necessarily the one that have lots and 
lots of features. I think that the apps that are 
really successful are the ones that have 
focused on what they do and do it very 
well.” 
 
Founding logic as catalyser: “I tend to just 
look at what needs to be done right now, 
Michael is a visionary.” (A. C., technical 
lead, 11 Health) 
 
Founding logic as challenge: “if we moved 
from getting people healthier into 
insurance, then I should know that” (J. K. 
technical lead, YouLife) 
 
From identity project to institutional 
change: “He [n. b. Michael Seres, 11 
Health], in many ways typifies the 
humanity of the digital health movement - 
of the citizen scientist, of the empowered 
patient. What he's done is leverage that 
enthusiasm that perspective as patient 
combined in the context of business, 
medicine and created a great company from 
that.” (John Nosta, opinion leader) 
 
Adaptive strategy, with integrity: “I’m very 
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Table 7. Institutional work at organisation level 
4.8.2.3. Abducting phase 
There were several iterations at each level, as I was following the insights 
provided by data, as well as theory. As well, findings at each level informed 
findings at the other. Moreover, having a unifying framework of analysis, it 
allowed for rich theoretical insights. The field level analysis informed the 
organisational level, as an interpretation schema, and the organisational level 
informed the field analysis, by making visible the bottom up 
institutionalisation. 
 
Fig. 17. Representation of how field and organisation levels informed each other 
The figure above shows the connections between the levels of analysis. For 
instance, refining the institutional logics at field level, orientated the 
identification of institutional logics at play in organisations, as well as of the 
clear to try and keep the company focused 
on improving the life of the patient. If we 
are keeping focus on this, then the company 
is going to continue to make more money. 
The priority is 'What are we trying to do?' 
And that is a hard balance, as we grow.” 
(Michael Seres,  CEO, founder 11 Health)  
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institutional work. For instance, the state logic was not that well represented at 
organisational level, except in terms of institutional work, particularly via 
processes of conflict or ambivalence. However, having a good understanding 
of this logic, as well as of the main moves of the state during the field 
emergence, it helped with the understanding of the rationales and actions of the 
organisations. 
The table below shows how institutional logics defined at the field level 
orientate the analysis of institutional logics at play in organisations. Further, 
alongside the institutional work at the organisation level, indications of the 
bottom up institutionalisation of the field are revealed. To illustrate this, in the 
table below, the organisation level processes and rationales are connected with 
field level themes. 
Institutional 
logic 
Example Institutionalisation 
process 
Field level theme 
State logic “But after you’ve tested it, can it be 
prescribed? No! You can pay for it? Don’t 
know. So what’s the point? That’s what I 
mean about the disconnect between the big 
idea and staff on the ground. I work very 
closely with NHS in the digital health thing. I 
think there are some fantastic people there 
who really have great visions, but they cannot 
solve everything. And that’s the problem. 
And sometimes, they don’t even understand 
the issues on the ground. (Michael Seres, 
CEO, founder 11 Health) 
Conflict - market 
and state logics. 
Reimbursement of 
new technologies 
“Because, you can’t avoid the issue of data 
privacy, but it’s the people that don’t pay 
attention to data privacy won’t be around for 
very long.” (M. B., co-founder YouLife) 
Ambivalence – 
citizen, state and 
market logics 
Privacy 
Ethics 
Medical 
profession 
logic 
“It was from bags that leaked, it was from 
watching nurses. (…) I would time how long 
it took them to come in, empty the bags, 
measure it, put it on a flow balance chart and 
put it back again. And it was quite a lengthy 
process for them and also a difficult process 
for them… It’s not just about me, it’s about 
them managing it.” (Michael Seres, CEO, 
founder 11 Health) 
Hybridisation – 
citizen and medical 
profession logics 
Efficiency 
Patient experience 
“Yes, it’s the infrastructure and the staffing of 
the hospitals. Here they have enough 
difficulty having enough beds, let alone 
managing a new technology like this. It 
doesn’t seem to be a priority.” (D.B., 
communications, 11 Health) 
Hybridisation – 
citizen and medical 
profession logics 
Adoption by 
healthcare 
professionals 
Citizen logic “Being a participant patient is vital, in my 
opinion, in healthcare.” (Michael Seres, CEO, 
founder 11 Health) 
Ambivalence – 
citizen and medical 
profession logics 
Empowered 
patient 
“Especially with healthcare, I found a lot of 
patients don’t really want to deal with an app, 
they don’t want to experience 17:52 want to 
get things done.” (A. C., technical lead, 11 
Conflict – citizen 
and market logics 
Adoption by 
patients 
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Institutional 
logic 
Example Institutionalisation 
process 
Field level theme 
Health) 
“And I think educating people is the really 
important part of all of that, and I think that’s 
what excites me. I want to help people 
understand how healthy they really are, and I 
think that’s why I really like what we’re 
doing.” (I. D., business development, 
YouLife) 
Hybridisation - 
citizen and medical 
profession logics 
Health literacy  
Market logic “The patient is not necessarily the forefront 
from the hospital’s perspective. 
Unfortunately, that’s the case, the hospitals 
may voice that they care about the patient, 
which they do, but not as much as they 
should. The hospital is a business.” (K.P., US 
business lead, 11 Health) 
Conflict – citizen, 
medical profession 
and market logics 
Healthcare 
systemic failure 
Patient centricity 
“I am a big fan of gamification as principle. I 
believe it is a necessity to transform a boring 
process in a more interesting one is a very 
good thing. On the other hand I find it 
overused, it's applied in anything. I find 
serious games a wrong definition. It seems 
you need serious because games would point 
to something that it's not essential. From my 
point of view, games are essential to 
everything.” (Cosmin Mihaiu, co-founder 
Mira Rehab) 
Conflict – citizen 
and medical 
profession logics 
Hybridisation – 
market and citizen 
logics 
Patient 
involvement  
Treatment 
adherence 
Legitimacy 
Science logic “How many companies have actually done 
the research into the psychology of the way 
you ask the question, or the psychology of 
where a question appears in the list, or the 
psychology of the colour you write the letters 
in? How many companies are doing that? 
Because that takes a long time to do. And 
that’s what I mean about the validation 
work.” (M. B., co-founder YouLife) 
Conflict – market 
and science logics 
Trust 
Legitimacy 
“We can follow what a patient does based on 
some parameters that could not have been 
monitored before. In that sense, we are 
bringing medical innovation.” (Alina Călin, 
co-founder Mira Rehab) 
Hybridisation – 
science, citizen and 
market logics 
Legitimacy 
Table 8. Institutional logics and institutionalisation processes reflected at 
organisation level and connections with broader field concerns (themes) 
The last phase of data analysis, was aggregating findings for the theoretical 
insights to be formulated. This was a constant validation through referring to 
extant theories, re-examining data and obtaining feedback from other 
researches (Eisenhardt & Graebner, 2007; Rindova & Kotha, 2001; Santos & 
Eisenhardt, 2009; Yin, 2009). Overall, data analysis is an iterative process to 
select data, display it in tables and diagrams, build narratives and develop and 
draw theoretical insights (Eisenhardt & Graebner, 2007; Gioia et al., 2012b; 
Miles & Huberman, 1994). 
 87 
4.9. CONSIDERATIONS OVER ETHICS, VALIDITY AND 
GENERALISABILITY 
4.9.1. ETHICS AND VALIDITY 
A common validity concern is the social desirability bias (Weaver, TreviÑo, & 
Cochran, 1999), which refers to the fact that people have the tendency to 
present themselves more as they believe they should, rather than how they are. 
This risk was higher when interviewing organisation members than in the case 
of opinion leaders. This may be due to the fact that organisational interviewees 
may feel that they are in the same time representing the organisation, or they 
may project what they would believe organisation outsiders would expect them 
to be like. In many cases, at the organisation level, I conducted two interviews, 
and this had a positive effect on establishing confidence and trust. In fact, on 
several occasions, respondents mentioned that they enjoyed the interview, as it 
offered them an opportunity to reflect on various matters. 
It’s been really interesting talking it through with you, because also 
you helped to make things more structured in my own mind. It’s the 
first time really that I’ve had a chance to talk through where my 
vision is, and what we’re trying to do. So it has been very interesting. 
(Michael Seres, CEO, founder 11 Health) 
For all respondents, I presented them the ethics consent form and I offered 
them the choice of being anonymised. For anonymised interviewees, I have 
used randomly assigned initials. Additionally, I stopped recording on request 
and I made notes on what was requested to remain out of records.  
All organisations in the research participated on average with 80% of their 
teams and some outside collaborators were also interviewed. This offered a 
good saturation of the interview data at organisational level. In addition, the 
variety of both interviewees and the documentarian data ensured the 
triangulation and a comprehensive representation of the companies’ contexts. 
At the field level, similarly, the data was gathered over a long period of time; it 
was rich and diverse to ensure both triangulation and saturation. 
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4.9.2. GENERALISABILITY 
This is one of the most important attributes of a research. To that end, I 
purposefully looked to ensure representativeness of cases and data, and 
appropriate variability to allow for robust theoretical insights. For each level of 
analysis, I ensured triangulation of primary and documentarian data.  
In respect to the research design, the aim of an inductive inquiry is not to 
describe an aspect of life, but to extract “accurate, interesting and testable” 
(ibid., p. 26) theoretical insights from “data collected from multiple sources, 
analysed through constant comparisons and validated both by extant theories 
and on-going re-examination of the data” (Rindova & Kotha, 2001, p. 1264). 
4.10. REFLECTIONS AND LIMITATIONS 
This methodology may not be perfect, but I found it adequate and well-adapted 
to the empirically unfolding of the theoretical framework. Additionally, I found 
it suitable for addressing a complex and understudied phenomenon. I therefore 
tried to render explicit most of my endeavours, as reasonably possible. I am 
certain, perhaps some sections would have benefited from more detailed 
descriptions. 
One drawback of my study is that it is spread geographically. Although this 
provides richness and variability of data, it is difficult to manage at times. The 
main reason for not limiting it on a certain geographical area, i.e. a country, 
was the field emergence itself, which made discoverability and recruiting 
difficult and lengthy. However, the geographical variety reveals interesting 
situations, for instance, a company originated in the UK, 11 Health, found a 
better market in the US, whilst one originated in Romania, Mira Rehab, found 
the UK to be the main market to grow into. This shows that different solutions 
had different appeals to different healthcare systems, but also that serendipity 
played an important part. For instance, in the case or Mira Rehab, the early 
connection with an academic institution favoured its reach in the UK 
healthcare system, due to early access to evidence research developed with 
academia and healthcare organisations. 
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Finally, due to time, resources and complexity constraints, I had to contain my 
analysis, despite the richness the data provided. However, the outcomes of the 
study, and the fact that it addresses a major theoretical gap make it worthwhile. 
4.11. METHODOLOGY REPRESENTATION 
Through the figure below, I represent the methodological approach and the 
operational unfolding of my research activities. This diagram includes some of 
the activities and insights that led to this research. 
 
Fig. 18. Methodology overview 
4.12. CONCLUSIONS 
This chapter addresses the methodology employed in this research. In order to 
investigate the institutional complexity at its most acute instantiation – field 
emergence - and the institutional work organisation undertake, I employ an 
inductive approach. The research develops at two levels – field and 
organisational levels – and it is based on a variety of data to ensure reliable 
theoretical contributions. 
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CHAPTER 5. PRECURSORS OF CHANGE 
5.1. INTRODUCTION 
This chapter presents the main economic, technological and institutional 
changes that led to the emergence of digital health, at the confluence of the fast 
moving digital technology field and the slow paced, regulated field of 
healthcare. A historical timeline is provided to guide the accumulation of 
events. This chapter aims to ground a deep understanding of the digital health 
complexity and emergence. 
5.2. DIGITAL TECHNOLOGIES 
In the last thirty years, information and communication technologies (ICT) 
have penetrated many economic sectors, with promises of increased efficiency, 
streamline processes, optimized decision systems, integrated information 
management and even led to opening of new markets (e-Commerce for 
retailers, for instance).  
ICT has a rationalisation effect on industries and organisations. For a business 
to be supported by an ICT system, it has to be broken down, more or less 
arbitrarily, to building blocks. With the penetration of the ERP (Enterprise 
Resource Planning) and subsequently CRM (Client Relationship Management) 
systems, more and more business activities were broken down and mapped as 
processes, entry and check points, roles and responsibilities. Initially, ERP 
systems took over production planning, logistics, accounting, financials, but 
then expanded into human resources, marketing, client management and even 
R&D activities. The ICT penetration introduces specific vocabularies, i.e. 
business modelling or six sigma (introduced by Motorola in 1986, refined in 
1995 in General Electrics). For instance, Ghaziani and Ventresca (2005) found 
that between 1975 and 1994, the term “business model” occurred 
predominantly in association with computer/system modelling talk. This 
process of breaking down activities and processes also makes interactions 
between actors more visible inside and outside the focal organisation. 
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The ICT industries undergo a conversion phase (Mulligan, 2011), moving 
towards platform economics (Baldwin & Woodard, 2009; Gawer, 2011) and 
more recently, ecosystems (Jacobides et al., 2018). 
 
Fig. 19. Towards the digital economy 
Until the 2000s, intellectual property (IP) rights were very important assets for 
an organisation. After this time, IP begins to be less a determinant of a 
company’s value; platforms and ecosystems become more prevalent. Recent 
research on digital platforms shows that contrary to existing views from 
transaction economics and resource based theories, guarding technology and 
intellectual property is not necessarily the way to gain competitive advantage 
in the digital economy. Companies may use technological resources from a 
“common” pool and the competitive advantage emerges from value added 
solutions and business models rather than control over resources (Gawer, 2011; 
Jacobides et al., 2018). The old value chains become value networks where 
customers have a seat. The open source trend benefits of a lot of attention. In 
this age, e-services enhance tremendously due to the mobility brought in by 
tablets, smartphones, and improved infrastructure for digital services.  
The ICT field gained a revived interest with the massive adoption of mobile 
phones and particularly of smartphones (since 2007 when the iPhone was 
launched). The iPhone was soon followed by other smartphones, and so the 
personal mini computer, truly mobile, proliferated. 
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None could have predicted that, certainly would not have predicted 
where we are today. I certainly would not have where we are today. 
(Denise Silber, Doctors 2.0 & You founder, opinion leader) 
Smartphones came on the grounds of an increasingly democratised digital 
technology environment - with prices for ubiquitous, sensing technologies 
dropping rapidly and the emergence of platforms. This resulted in the fast 
uptake, proliferation and innovation surrounding these new digital products. 
The social and economic impact of smartphones is based on several factors: 
they are more intuitive, they can incorporate sensors, they are closer to 
minicomputers than phones (Boulos, Wheeler, Tavares, & Jones, 2011) and 
they are in your palm.  
5.3. HEALTHCARE HISTORICAL CHANGE 
It is difficult to understand digital health without a broader historical 
understanding of how healthcare developed and morphed. 
Before the Second World War, healthcare was dominated by the medical 
profession logic, where medicine was illness centred. Vaccines created a logic 
shift and so preventive medicine came about. Preventive medicine, maybe 
along with socialist movements, created another shift in the healthcare logic - 
“medicine for all”. And hence, the state became more involved in making the 
medical act more affordable and available. Before this time, healthcare was 
essentially a capitalist market, based on offer and demand. 
Before the Second World War, healthcare was dominated by the medical 
profession logic, where medicine was illness centred. Vaccines created a logic 
shift and so preventive medicine came about. Preventive medicine, maybe 
along with socialist movements, created another shift in the healthcare logic - 
“medicine for all”. And hence, the state became more involved in making the 
medical act more affordable and available. Before this time, healthcare was 
essentially a capitalist market, based on offer and demand. 
 93 
 
Fig. 20. Brief history of healthcare with highlights in governance changes 
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The next period, 1965 – 1980, is dominated by regulations (Scott et al., 2000, 
p. 385) related to insurance (again, interfering with the previous capitalist 
market dominated by professionals). Emergence of many healthcare 
technologies (in the broad sense - vaccines, drugs, contraceptive pills, 
radiology) increased awareness for associated risks, and therefore regulations 
were expanded to medical devices and drugs. Regulation in healthcare did not 
always have the focus to constrain, but it was concerned with innovation too. 
“Patient advocacy groups influenced a law to stimulate industry interest in 
developing so-called orphan drugs for rare diseases, and they played a role in 
the agency's development of accelerated techniques for drug approval, 
beginning with drugs for AIDS” (Swann, 2003, p. 14). And so, regulations in 
this period facilitated the production of generic drugs (ibid.). These are also the 
times when patient voices began to be heard.  
In the 80s, managerial theories penetrated the healthcare sector. “...[F]ederal 
involvement in healthcare, designed to be compatible with professional 
interests, unseated professional dominance indirectly through the profusion of 
conflicting governance structures that followed the federal program” (Scott et 
al., 2000, p. 386). Adding to this, the state, which took upon itself the cost of 
most healthcare expense, realised that demand had to be controlled. 
“Managerial-market logics were not directly related to either of the two 
primary logics or to fragmentation. Legitimated by the rise of the medical 
costs, business interests appear to have been the beneficiaries rather than the 
cause of the decline in professional dominance” (ibid.). Managerial theories 
were dominated by value chain, efficiency, centralised procurement, and 
resource scarcity. This time marks the divide between the professional and 
managerial personnel in healthcare. 
In the mid-90s, the internet changes the rules of the game and terms like 
eHealth emerge. Information and knowledge become commoditized, 
democratised. The doctor – patient relationship is less asymmetrical when it 
comes to information, due to its escape into the digital space. What used to be 
knowledge accessible to elites only now becomes available to all. Managerial 
mind-set changes again, partially due to conflicts with healthcare personnel, 
partially due to discontent from patients. Patients become consumers with 
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expectations and healthcare is looking again for ways to satisfy doctors, 
patients and payers.  
In this context, the 2000 – 2010 period is characterized by an information 
afflux and is dominated by changes caused by the digital economy. Customers 
in all industries become more empowered. Partially due to the massive increase 
in healthcare costs due to change in demographics - aging population and huge 
increases in chronic diseases (diabetes, asthma, chronic congestive heart failure 
etc.) - and partially due to the widespread use of digital technologies (including 
the fast spread of mobile devices), the debates over the role of the patient 
intensify. Patients are seen as customers, drivers of change, resources for 
managing illnesses, contributors of data for research... The repositioning of the 
patients challenged again the relationship with healthcare professionals and the 
healthcare system as a whole.  
5.4. HOW DIGITAL HEALTH CAME ABOUT 
Around 2010, “eHealth”, “mHealth” and “digital health” terms become 
prevalent and intrinsically related to healthcare.  
5.4.1. BRIEF TERMINOLOGY CLARIFICATION 
Before I proceed, and even though this research does not aim to contribute to 
the terminological debate, acknowledgment of the main terms and the 
relationships between them is needed, in order to clarify the terms used in this 
thesis. I choose to use digital health to designate the broad field where 
healthcare meets digital technologies, as it became prevalent over the last 
decade. This is the emergent field that is the focus of my research. The term 
‘mHealth’ was used at least since 2005 (Istepanian, Laxminarayan, & Pattichis, 
2006), but it gained momentum once the smartphones were massively adopted. 
Although there are many years since the term ‘digital health’ emerged, 2007 
could be its official birth. A search (on July 2014) on Google Scholar for 
articles containing the exact phrase “digital health” between 1990 and 2014 
rendered 3310 results, of which 2740 are between 2007 and 2014. Similarly, 
eHealth term - used at least since 1999 (Della Mea, 2001) - for the same 
periods, Google Scholar returns 18,500 results and 17,300, respectively. 
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Except Twitter, “every platform including news publications favor digital 
health as the term” (Davis, 2015). Comprehensive explanations and definitions 
of the evolving terminology pertaining to this field are provided in appendix C.  
It’s a very broad field that involves everything from internet to apps 
to CT scanners, everything really. Every use of tech in healthcare, 
regardless of who uses it. (Sara Riggare, patient researcher, opinion 
leader) 
[Digital health is the] improvement of health and healthcare in the 
broad sense of the words, with the help of tools that are digitally 
connected. (Lucien Engelen, healthcare intrapreneur, opinion leader) 
Whilst I use the term “digital health” for all things health IT, in congruence 
with its use in the industry, it is important to point out that a distinction is 
needed between the administrative tools and tools employed for interacting 
with the patient (Djellal & Gallouj, 2005). At the organisational level, my 
research is looking at collaborative digital health technologies (CDHT) 
producers, who build interactive solutions for various stakeholders in digital 
health. These are digital technologies used in relation to health and wellness 
and involve (directly or indirectly) heterogeneous beneficiaries (herein called 
stakeholders) - amongst them technology producers, patients, carers, citizens, 
medical doctors, non-physician personnel, insurers, infrastructure providers, 
system integrators, technology service providers, health or social care 
providers, call centres, regulators… The definition of CDHT for the purpose of 
this thesis is pervasive and/or sensing digital technologies that are intended to 
support people’s wellbeing, either by helping them staying well physically, 
mentally or socially, or by helping manage medical conditions they are 
confronted with. CDHT are technologies that help medical and other 
organisations deliver wellbeing and healthcare to people. CDHT could be 
ambient or ubiquitous, allow for multiple user categories (patient, carer, doctor, 
healthcare organisation, support organisation...), involve user management or 
engagement, and, possibly but not necessarily, monitoring of body functions. 
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5.4.2. STARTING FROM THE BEGINNING 
It is beyond the purpose of this research to assess, predict or advocate the 
impact of digital technologies over the future of medicine and healthcare. What 
I present below is a broad picture of how ICT technologies impacted healthcare 
over time, with the purpose to situate the research, which begins from 2007 
onward, having as time mark the introduction of smartphone. 
„[T]he ‘smartphone industry’ is eating the world (…). As well as acting 
as the centralized repository for connected third-party devices the 
smartphone itself is packed with a range of intelligent sensors that 
can – and are – being used to help people improve their health”. 
(Stephen Davis, consultant, Bionicly online article) (Davis, 2013). 
I think that the smartphone is one of the pivotal aspects of digital 
health. It’s the conduit through which information flows, it can travel. 
And the development of the smartphone and its processing power has 
enabled people to create what I call "care at a distance”. So now we 
can measure and manage wellness using telemedicine, or for people 
around the world, not only around the corner. So this smartphone is 
an important tool that is part of digital health. (John Nosta, digital 
health evangelist, opinion leader) 
In May 2015, I wrote a brief history of digital health that was well received by 
the industry, via two articles. Based on these articles, the infograph below was 
produced by the Digital Catapult Centre, a UK governmental agency dedicated 
to foster innovation and collaboration across digital industries and academia,. 
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Fig. 21. Digital health infograph by the Digital Catapult UK (2015), based on my original 
articles published on nuviun (Macnaughtan, 2015b, 2015c) 
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I will use some extracts from the article “The Curious Case of Digital Health” 
(Macnaughtan, 2015b) to briefly describe these stages. 
5.4.2.1. Prehistory (1897 - 1985) 
“First, there was telemedicine... Darkins and Cary (2000) find that the first 
remote diagnosis reported in a journal was in 1897, when a child is diagnosed 
with croup cough via the telephone. Between the mid ’70s and the mid ‘90s, 
the interest in telemedicine is conserved for space and Antarctic expeditions, 
remote explorations or military interventions (ibid.). Imaging technology 
benefits most from digitization. Two significant industry associations are 
founded: COCIR (1959) and HIMSS (1961).” (Macnaughtan, 2015b) 
5.4.2.2. The hit wave (1985-1999) 
“This age is dominated by lateral creative thinking, the era of managerial 
visions and magic changes. “One size fits all” solutions are tested, not only 
related to information and communication technologies (ICT), but to many 
areas of healthcare. However, the ICT visionary bubble is not sustained 
because of a general disconnection between the main stakeholders - the ICT 
and medical community. (…) 
New terms emerge: Health Informatics, Telemedicine, Telecare  
Nonetheless, several professional associations appear, i.e. the International 
Medical Informatics Association (1989), the American Telemedicine 
Association (1993), the UK Telecare Services Association (1995), 
and EHTEL (1999). A few health information providers set ground as well 
(i.e. WebMD in 1996, Medline Plus in1998). 
Towards the end of this period, the demise of managed care makes the patient 
more visible. ‘The shift to consumerism is driven by a widespread scepticism 
of governmental, corporate, and professional dominance; unprecedented 
economic prosperity that reduces social tolerance for interference with 
individual autonomy; and the Internet technology revolution, which broadens 
access to information and facilitates the mass customization of insurance and 
delivery’ (Robinson, 2001).” (Macnaughtan, 2015b) 
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5.4.2.3. The insights age (2000 - 2009) 
“At this stage, there is a general impatience with digitizing healthcare. Several 
national Electronic Health Records initiatives are deployed with success 
(Israel), and relative success (Canada) — but mostly with sound failure 
(i.e. UK, Germany, Australia). 
New terms emerge: eHealth, Digital Health, mHealth, Connected 
Health, Personalised Health, Telehealth. 
A lot of effort is put into assessing the benefits of telehealth and telecare 
programs. ‘Evidence is the name of a battle that has been won’ 
concludes Nicolini (2009, [my addition p. 15]) - because healthcare innovation 
is a political process in which scientific arguments represent only a forum for 
debates (…). 
In January 2008, the European Union (EU) launches the Lead Market 
Initiative, where eHealth is identified as one of the most promising markets. 
The Health Information Technology for Economic and Clinical Health 
Act (2009) sets an agenda for the US to invest in promoting the use of ICT in 
healthcare. In the same year, a first of its kind industry event, the mHealth 
Summit (US) gives the market a positive indicator. 
Starting in 2006, the first niche market report on Digital Health is produced 
by Parks Associates. Several professional associations are formed, 
i.e. Continua (2006) and mHealth Alliance (2008). (…) 
Imaging technologies, health content providers (i.e. WellDoc founded in 2005) 
and patient networks (i.e. PatientsLikeMe founded in 2004) are the main 
beneficiaries of this period. There are only a few wireless sensing device 
companies, i.e. Monica Healthcare (2005) in the UK, or Fitbit (2007) in the 
US. 
‘Issues of scale and complexity in healthcare are only just beginning to be 
understood in relation to eHealth’ (EHTEL 2009). During this age, it is 
acknowledged that despite notable national ICT failures, the future of 
healthcare will require a digital framework. Additionally, there is a realisation 
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and understanding that the use of ICT in healthcare will include the need to 
address specific requirements - such as infrastructure, interoperability, legal 
issues, etc. There is an overall sense of disillusionment, which carries over to 
the next age.” (Macnaughtan, 2015b) 
5.4.2.4. The great expectations age (2010 – ...) 
The idea of patients being an underused resource in healthcare was launched 
long ago (Lott, Blazey, & West, 1992), but it is now that it becomes a political 
priority. This is a consequence of the demographic trends showing that more 
people are living longer with chronic conditions and of the rising costs of 
healthcare. In 2004, the EU eHealth Action Plan (European Commission, 
2004) highlights some of the barriers for adopting digital technology in health, 
i.e. regulations or infrastructure.  
“The pervasiveness of technology (mobile devices, open source, APIs...) 
converging with the urgency of overwhelmed governments burdened by 
demographic issues leads to the emergence of lay-people at the forefront of the 
Digital Health vision. What we see now is an intense interaction between 
stakeholders and industries, and an emerging/exploding market at the 
crossroads between consumer digital technologies, medical devices and 
healthcare. New terms emerge: Wellbeing, Wearables, Insideables, Apps, 
Quantified Self, Gamification, Health 2.0, Big (Health) Data. Presently, Digital 
Health is emerging as a standalone market, with multiple stakeholders 
stumbling in uncertainties and debates. Whilst the digitally geared up 
patient/person is still waiting for a role to be written, Digital Health will find its 
way only by negotiating a new logic of health, wellness and care.” 
(Macnaughtan, 2015b) 
The launch of the iPhone (2007) was a game changer not only for digital 
health, but for other industries too. However, there were many factors that 
stimulated a new wave of interest in using digital technology for health. 
Mobile, sensing and affordable technology was not the only factor responsible 
for the digital health rise, there were also economic, politic and even social 
factors.
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Fig. 22. Synthetic view of healthcare and digital health history 
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5.5. CONCLUSIONS 
In this chapter, I present a broad overview of the changes in the digital 
technologies and healthcare fields to reveal the institutional context of digital 
health emergence. I make a few terminological clarifications and I build a brief 
history of healthcare encounter with digital technologies. I have therefore 
completed the prerequisite for the analysis of the field, which unfolds in the 
next two chapters. 
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CHAPTER 6. DIGITAL HEALTH 
INSTITUTIONAL LOGICS AND STAKEHOLDERS 
6.1. INTRODUCTION 
Having laid out in the previous chapter the broad picture of what led to the 
emergence of digital health, this chapter focuses with one component of its 
institutional complexity – pluralism. This is exemplified by the multitude of 
institutional logics at play and their representatives. As discussed in the 
theoretical framework chapter, it is important that logics are documented as 
they unfold, with no prior preference for a limited number. Presenting all 
logics at play has theoretical relevance, particularly because the field is in a 
formative stage and any selection might present an undesirable bias. I describe 
each of the five logics identified – state, medical profession, citizen, market 
and science - and their representative stakeholders with their relative power – 
incumbent or challenging. Chapter 7 will continue with the other element of 
complexity, the field emergence, by describing the process of 
institutionalisation as it unfolds via concurrent processes of hybridisation and 
conflict. 
6.2. MAIN HISTORICAL INSTITUTIONAL CHANGES IN HEALTHCARE 
It is at the field level “where organizations in interactions construct their 
‘collective rationality’” (Scott, 2008, p. 217). This ‘collective rationality’ 
relates to the neoinstitutionalist understanding of institutions as “irrational 
influences... [and] frameworks for rational action” (ibid.). Understanding the 
logics of digital health will deepen and contextualise the understanding of how 
CDHT producers navigate the fragmentation and ambiguity of this field. “Just 
as the attributes and actions of a character in a play are not fully 
comprehensible apart from knowledge of the wider drama being enacted – 
including the nature and interest of the other players, their relationships, and 
the logics that guide their actions – so we can better phantom an organisation’s 
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behaviour by seeing it in the context of the larger action and meaning system in 
which it participates” (ibid., p. 209). 
It is generally agreed that healthcare went through three major stages of 
institutional framing (Currie & Guah, 2007; Scott et al., 2000), albeit with 
significant fragility (Currie & Guah, 2007; Nigam & Ocasio, 2009; Pouthier et 
al., 2013; Scott et al., 2000).  
 Institutional Ages 
US  
(Scott et al., 
2000) 
Era of professional 
dominance  
1945–1965 
Professional control 
Non-profit ethos 
Era of federal 
involvement  
1966– 1982 
Passage of Medicare and 
Medicaid – government 
regulation 
Public control 
Equity of access 
Consumer health 
movement 
Managerial control and 
price competition  
1983– 
Market and managerial 
mechanisms 
Cost containment 
Efficiency 
 
UK  
(Currie & Guah, 
2007) 
Era of professional 
dominance  
1948–1971 
Public sector ethos  
Professionalism  
Self-regulation 
Era of managerialism 
 
1972–1997 
Private sector ethos 
Performance  
Government regulation 
Era of market 
mechanisms 
1998– 
Patient-centered ethos 
Consumerism 
Public value 
Table 9. Change in the institutional context in two different systems – 
single and multi-payer health systems  
Although the names of the ages may be different, they point to similar 
institutional changes, with a slight temporary delay. As shown in the previous 
chapter, the evolution of healthcare as institutional field has many 
commonalities across countries. The increased involvement of the state, as well 
as the technological advances led to fragmentation. This fragmentation 
happens also inside the healthcare profession itself, being one of the factors 
that led to the demise of the professional power. The increasing bearing of 
technology and the change in state’s approach led to an increased number of 
stakeholders that make various claims. 
In the case of digital health field, due to its state of flux, it would be unfruitful 
to attempt a definition of the field logic. Instead, I will describe the institutional 
context through the logics at play and their relative influence. 
All participants in the emerging field of digital health are stakeholders, 
meaning they bring goals, expectations and institutional logics, which motivate 
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or constrain them. The figure below offers a simplified view of the changes in 
the dynamics between three of the main stakeholders in healthcare, doctors, 
payers and patients. However, many other stakeholders populate the healthcare 
field, even if they do not occupy such a central or visible place: technology 
producers, carers, pharmaceutical companies... The state, for instance, one of 
the main stakeholders, is not represented here. Nonetheless, it illustrates that 
changes in the institutional environment of healthcare are still on-going. 
 
Fig. 23. Evolution of some of the healthcare stakeholders (IMS, 2013, p. 3) 
6.3. INSTITUTIONAL LOGICS AND STAKEHOLDERS IN DIGITAL HEALTH 
Digital health develops mainly at the intersection of healthcare and digital 
technology and is populated by diverse stakeholders. Imminently, the 
accumulation of stakeholders brings both a diversity of logics and great 
complexity. In this chapter, my only aim is to focus on the main logics and 
their representative stakeholders. 
I have found and documented five institutional logics in the emerging digital 
health field: state, medical profession, citizen, market and science. As 
described in the methods chapter, the content of the institutional logics is 
derived through an iterative process between data collected and the 
institutional literature. 
The institutional logics are described as ideal types, and stakeholders carry 
them in more or less pure forms (Scott, 2008; Thornton et al., 2012).  For 
instance, doctors are dominated by their professional logic, but might make 
choices rooted as well in personal values (citizen logic). For example, along 
with the commitment to save lives, some medical professionals support the 
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assisted dying as a form of care and respect for the patient. Another example is 
that in the case of childbirth, some doctors consider natural birth safer; others 
favour caesarean interventions for the same reason. Stakeholders are identified 
through their field level interactions (Scott, 2008) and are relevant at the time 
of data collection. This is important to stress, because they may change with 
the evolution of the field.  
6.3.1. THE STATE LOGIC 
The state logic is focused on collective welfare through rationalisation and 
uniformity (Friedland & Alford, 1991; Scott, 2008). In the rational market 
view, the state should only guarantee the individual property (ownership) and 
the right to sell, and the market should be able to take care of the rest (Alford 
& Friedland, 1985; Fligstein, 2002). But, the welfare state doctrine has at its 
core the idea that capitalist markets are not capable to ensure the welfare of its 
citizens, and that disfranchised individuals (women, elderly, children, lately the 
unemployed) need protection. Therefore, the main function of the 
contemporary states remains to ensure a capitalist market and through a system 
of tax to redistribute wealth, despite the proliferation of the neoliberal agendas. 
The neoliberal philosophy is focused on the overall increased wealth of a state, 
rather than its redistribution. This economic approach had a slower uptake in 
sectors like education or healthcare, particularly in Europe (Beach, 2010). Or, 
when enforced, it did not prove necessarily a positive impact (Bates, 2014; 
Beach, 2010; Phillips, Henderson, Andor, & Hulme, 2006). 
While new ‘workfare’ principles have often emerged, these have not 
always led to improved social conditions. Indeed, the opposite has 
often been true and, as a consequence, concern has been directed to 
the origin and nature of social policy change. (Phillips et al., 2006, p. 
585) 
[A] lack of focus on redistribution has had a significant negative 
impact on many apparently wealthy societies in terms of both general 
wellbeing and economic growth and efficiency. It is clear that for 
many researchers in this field deepening inequality is not simply a 
moral issue, but one of social and economic inefficacy. (Bates, 2014, p. 
389)  
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The idea promoted by the neoliberal philosophy that there is no need to 
prioritise redistribution, as everyone will be better off simply by taking care of 
the bottom line wealth of the nation, leads to a shift from welfare to workfare 
including in healthcare.  
The collision and confluence at the site that is known as the 
individual, of contemporary influences such as neo-liberal thought, 
market-based notions of health and health care, individual 
responsibility for health, the individual’s right to choice and to choose, 
the quest for certainty (such as the evidence-based movement), and 
an increasingly uncertain world produce new and refracted 
understandings of health and health care. (Cheek, 2008, p. 980) 
Neoliberalism encourages individuals to give their lives a specific 
entrepreneurial form. (…). This participation has a ‘pricetag’: the 
individuals themselves have to assume responsibility for these 
activities and the possible failure thereof. (Swyngedouw, 2005, p. 
1997) 
In healthcare, the neoliberal view translates in transferring more responsibility 
to the citizen, to the patient, who becomes a consumer. Not simply a consumer, 
but a responsible one - both entitled to and responsible for their health choices 
(Cheek, 2008; Crawford, 1980; Phillips et al., 2006).  
Daily, governments and individuals speak of, or are spoken to, about 
pursuing health and/or healthy lifestyles, achieving health, having 
responsibility for and/or being responsible with respect to health. 
(Cheek, 2008, p. 974) 
Medical care, after all, is an area in which crucial decisions — life and 
death decisions — must be made. Yet making such decisions 
intelligently requires a vast amount of specialized knowledge. 
Furthermore, those decisions often must be made under conditions in 
which the patient is incapacitated, under severe stress, or needs 
action immediately, with no time for discussion, let alone comparison 
shopping. (Paul Krugman, 2011, The New York Times article) 
The state’s influence on healthcare began after World War II and, at first, it 
was preoccupied with supporting medical professionalisation. Before the ‘70s, 
it became preoccupied with social inclusion and affordability of the medical 
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act, to end up being increasingly concerned with limiting costs. “Finally, as 
health expenditures [...] escalated rapidly during the 1970s, cost containment 
began to overshadow the concern for equity and even to challenge the value of 
quality” (Scott et al., 2000, p. 217). The neo-liberal agenda placed further 
pressure on healthcare systems, already under the mantra of “managed care” 
and limited further the professional autonomy (Leicht & Fennell, 2008).  
I have faith that intelligent and educated people [n.b. doctors] 
understand by now that the sole difference between progressive and 
conservative agendas is a personal preference to have your serfdom 
managed either through a government intermediary, or directly by 
the business overlords. (Margalit Gur-Arie, doctor, Kevin.MD article, 
2015) 
Go ahead, take over the cockpit and storm the O.R. Fly your own 
plane, remove your own tumour. [...] Give the carcass of expertise a 
good kick as you go by. (David L. Katz, doctor, LinkedIn article, 2015) 
The state is operating on the basis of consensus and tries to regulate activities 
based on resources and general contribution to collective good (Thornton et al., 
2012). The greater good, however, is defined differently at different times in 
history. The participation of the electorate is discontinuous, through the 
democratic institution of vote. Sometimes, public organisations create ways for 
the citizens to get involved in a more continuous manner, other times, citizens 
get involved through activism, hacktivism (use of the digital to promote 
political change), non-governmental organisations (NGOs) or public 
manifestations. Current trends from governments to make public data available 
(“open data”) may be seen as a way to counteract existing neoliberal 
philosophy across the board, but voices remain sceptical if disclosures are not 
being controlled to rekindle public trust in the commodification of public 
services (Bates, 2014). However, access to public big data and information is 
still in its infancy and it is difficult to predict its transformative effect on 
economic sectors, societies and governments. 
Although perceived mainly in its coercive capacity, the state is also one 
important factor for facilitation of innovation, technical or social (Christensen 
et al., 2009; Fligstein, 2002; Mazzucato, 2013). Whilst there may be tensions 
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between the welfare and neoliberal doctrines, it may be that a new hybrid view 
is on the rise, at least when it comes to sectors like education or healthcare – 
the “entrepreneurial state” (Mazzucato, 2013). In this new view, the welfare 
supports the workfare function, as a function necessary for the expansion of 
capitalism, which converts “other value forms (e.g. the physical and emotional 
capital of education and care work) into objectively economic forms and their 
products” (Beach, 2010, p. 562). Arguably, the opposite is also true, in the very 
Schumpeterian sense that innovation, entrepreneurship is the engine of 
democracy and the overall social welfare (Mazzucato, 2013; Schumpeter, 
1950). In this paper, I only underline such tensions as they become relevant for 
the development of digital health. Being one of the pillars of the healthcare 
system, as we know it, the state logic is an incumbent logic in the emerging 
field of digital health. The representative stakeholders are the payers (or 
insurers) and regulators. 
6.3.1.1. Regulators 
The state operates through a bureaucratic apparatus, which tries to rationalise 
and implement policies or safeguard laws. The increased involvement of the 
state creates difficulties for the private sector, because it “constraints the 
corporate responsiveness to the changing markets and also because of the 
uncertainties created by unstable political control over bureaucracy” (Alford & 
Friedland, 1985, p. 430). The various agencies upon which the state relies to 
rationalise resources and safeguard policies, also bread professionals who have 
incentives to “maintain their positions, enhance their careers, mark off their 
jurisdictions” (ibid., p. 430). Because in a democratic state, civic participation 
is important, these institutions have to create or at least offer the appearance 
that public voice is captured (i.e. the Health Watch in the UK health system). 
“In this process of increasing the predictability of their specific environment, 
public bureaucracies incorporate external constituencies, blurring the boundary 
line between private and public sectors, as they establish powerful interest 
groups inside and outside the state with a stake in the preservation of the 
agency” (Alford & Friedland, 1985, p. 436). 
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These entanglements of public – private sectors and civic participation result in 
very complicated fields, such as healthcare (Christensen et al., 2009; Harvard i-
lab, 2014). 
There could be too many people in between, kind of getting in the 
way, the doctors and their patients. I think we unnecessarily 
complicate that and I think we have incentivised the wrong things 
(medical interventions over human interactions lots of times) and that 
had a ripple effect on what the system wants to do. (Dave Chase, 
entrepreneur, opinion leader) 
Similarly, pharma or medical device companies are subject to time consuming 
and very expensive regulatory and certification processes. Moreover, in some 
countries, these are topped up by other endeavours to produce evidence for 
economic or clinical benefits in order to access the healthcare distribution 
channels (i.e. NICE in the UK). This traps healthcare “in the expertise-
intensive world of high costs” (Christensen et al., 2009, p. xlviii), a market 
with high barriers to entry. 
Christensen et al. (2009) consider that innovation is enabled by technology, 
new business models or new networks of value. The last one, points to the 
institutional change at field level. I am using their representation below to 
show the importance regulators have in any industry to stabilise it and create 
“rules of the game”, but most importantly in regulated areas, like healthcare. 
The downside is that state agencies have a tendency to self-perpetuate. And so 
we have healthcare with regulations running so deep – reimbursements being 
only one aspect. “When the government is everywhere, innovators can’t go 
where the regulators aren’t, in order to initiate disruption” (Christensen et al., 
2009, p. 399). Obamacare, by introducing a new form of reimbursement based 
on population outcomes instead of individual medical acts, is an attempt to 
innovate the reimbursement model. 
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Fig. 24. “Elements of disruptive innovation” (Christensen et al., 2009, p. XX) 
Regulation is only one reason to explain healthcare’s resistance to change. 
Other reasons would be fragmentation of the field, safety and efficiency 
concerns, scarce resources, conflicting logics, but regulation remains one 
central concern. The same authors consider that regulators’ concern should not 
just be to stabilise a field, but also to enable competition, and, even further, to 
facilitate “disruptive competition” (ibid., p. 393). 
At the intersection of healthcare and technology, there is an on-going 
conversation about regulation and deregulation. There have been concerns that 
regulation would limit innovation, on the other hand supporters say that 
regulation could enhance it.  
There are those who believe that government should stay out of health 
IT altogether: it can only mock things up. I disagree. First of all, no 
one else can enforce public goods like interoperability and security – 
the market just won’t do it. (Bob Wachter, doctor and professor, 
opinion leader) (R. Wachter, 2015, p. 216) 
You can’t have a blanket statement. Just because you have a 
regulation, doesn’t mean it’s an intelligent one and often it exists to 
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protect incumbents and doesn’t serve patients very well. (David 
Shaywitz, doctor entrepreneur and journalist, opinion leader) 
Such opinions show that regulation is needed in healthcare and other markets, 
but it requires higher adaptability to the current economic and technological 
landscape.  
6.3.1.2. Payers  
Healthcare is expensive for all participants to the system: patients, carers, 
insurers, and, without the support of employers and the state, most people 
would not be able to afford it (Christensen et al., 2009). Regulators’ tendency 
to overreach in healthcare manifests often through the iron cage of 
reimbursement (ibid.). Christensen et al. (2009) offer an interesting history of 
reimbursement in the US (ibid., pp. 223 - 230). 
Payers are often state agencies, as most healthcare systems have a combination 
of state and private healthcare. Even when payers are entirely private, they 
have to comply with strict regulations and this makes them similar to public 
ones. Hence, payers mix the logics of the state (subject to regulations and/or 
budgets) and of the market, depending on how much their financial model 
relies on the state. They also have to embrace or create a relative equilibrium 
with the medical professional logic, and this depends on the proximity to 
healthcare providers. There are even healthcare providers that are also insurers 
(BUPA in the UK or Kaiser Permanente in the US).  
The balancing act between coordination and co-optation (of patient groups, 
private sector organisations) results in fragmented authorities to the extent that 
none of these organisations have enough authority for the whole, and so this 
adds to uncertainty and irrationality (Alford & Friedland, 1985; King’s Fund, 
2013). A great representation of this complexity is provided by King’s Fund 
representation of the NHS.
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Fig. 25. An attempt to simplify the very complicated system of the new NHS (King’s 
Fund, 2013)
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The logic of the payers (state or private) is based on resource utilisation and 
efficiency (market), not aimed at personal, but rather population health 
outcomes (state). They manage demand and offer through rationalisation of 
resources, and therefore innovation is welcomed as long as it proves to reduce 
costs, not always better health outcomes, as valued by healthcare professionals.  
6.3.2. THE MEDICAL PROFESSION LOGIC 
A professional logic means that its representatives have access to a body of 
knowledge, are licensed to employ it and have autonomy in their decisions 
(Abbot, 1988; Leicht & Fennell, 2008; Scott, 2008). Traditionally, 
professionals are legally mandated guardians of a body of knowledge, upon 
which they have autonomy, and they are licensed and overseen by self 
appointed peers and arbiters, usually through a lengthy or costly process 
(Abbot, 1988; Leicht & Fennell, 2008; Scott, 2008). Professionals are 
considered to be one of the forces that oppose the power of the state (Alford & 
Friedland, 1985; Selznick, 1951). 
6.3.2.1. Doctors (and other healthcare professionals) 
Over time, various players have penetrated the healthcare field, and 
consequently, the professional authority and legitimacy of doctors has been 
challenged, contracted (Leicht & Fennell, 2008; Scott et al., 2000) and their 
professional realm has been fragmented (Dunn & Jones, 2010; Pouthier et al., 
2013). Presently, the healthcare field is subject to a plurality of logics (Nigam 
& Ocasio, 2009; Pouthier et al., 2013; Waldorff et al., 2013), which gives 
space to vulnerabilities, lack of coordination, irrationalities (Alford & 
Friedland, 1985; Christensen et al., 2009; Waldorff et al., 2013). As shown in 
the previous section, “[t]he rationalization of each state agency renders the 
state bureaucracy as a whole increasingly irrational” (Alford & Friedland, 
1985, p. 437).  
The implication of the state in healthcare over time changed in scope: from 
making healthcare affordable and available, to making it efficient and, lately, 
to making it participatory.  
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I think that when you have the right processes in the right philosophy, 
I think you will have the patient naturally participate in that as a 
team member. (Dave Chase, entrepreneur, opinion leader) 
We haven’t understood the motivations well enough or there isn’t the 
payment structure in place that participation can be rewarded to the 
carers. (Colleen Young, communications, opinion leader) 
Healthcare, from a field where professional logic dictated what is best, became 
an arena where bureaucracy set in, as well as political struggle. This led to an 
increased fragmentation and politicisation of the medical profession, and to a 
salient conflict between the competing state, market and medical profession 
logics.  
The relationship between a doctor and a patient does not feel 
transactional now and I don’t think it will then. Rather it will remain 
vital, scary, ethically charged, and deeply human. (Bob Wachter, 
doctor and professor3, opinion leader) (R. Wachter, 2015, p. 277) 
Healthcare is really complicated, it’s hard to make things happen, and 
also human physiology, human disease is really complicated. Look at 
chronic diseases - heart problems. (David Shaywitz, doctor 
entrepreneur, journalist, opinion leader) 
Moreover, the digital changed profoundly the area of medicine, which used to 
be a confined space, reserved for professionals only (Lupton, 2013, 2014b; 
Nettleton, 2004). 
Analogue medicine Digital medicine 
Body as a standalone machine Cyborg 
Disease – pathological problem Disease – communication problem 
Insides of body seen by surgeons mainly 
(doctors) 
Insides of body seen possibly by all 
(internet) 
Medical knowledge Medical information 
Art of medicine Evidence based medicine - > Participative 
Patients have lay beliefs Patients produce medical knowledge 
Doctors manage disease Expert patients manage illness 
Table 10. Digital transformation of medicine, adapted from “The 
Emergence of E-Scaped Medicine?”, by Sarah Nettleton (Nettleton, 2004, 
p. 666) 
                                                
3 Interestingly, Bob Wachter, MD and Professor of Medicine (UCSF) is also the most known 
leader of the “hospitalist” movement, which went against the regulators (see Chapter 3 and 
Poulthier et al., 2013).  
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Apart from the exogenous factors like politics, markets and technologies, the 
medical profession logic has its own intricacies. For instance, although 
medicine is based on science, it can take a long time for scientific 
breakthroughs to enter clinical practice. For instance, it took 39 years for the 
cochlear implant to become marketable (Van de Ven & Gardu, 1993). Dunn 
and Jones (2010), in their analysis of the medical education, showed how 
doctors are performing under a blend of science and care logics. The science 
logic favours innovative and efficient diagnostic and treatments, whilst the 
logic of care represents “compassionate, preventive care to patients and treat 
them as whole people rather than simply diseases” (Dunn & Jones, 2010, p. 
117). Even if these logics co-exist, the specialist doctors would favour the first, 
whilst primary care doctors the later. I will refer to the care logic as citizen 
logic in this thesis. 
The gap between a scientific discovery and clinical practice is still debated, 
with focus on the endemic tribalism of the medical profession, where 
specialisation acts both as a fragmentation factor and as a barrier for 
knowledge sharing (Oborn et al., 2013). 
 [Healthcare is] operated almost by tribal knowledge, where you 
know the elders pass on information in their community. But this kind 
of stays in that area and a lot of how medical practice happens today 
is largely a function of where one receives medical training. (Dave 
Chase, entrepreneur, opinion leader) 
2004 is a long time ago, I would say no physical therapist knows this. 
(…) People are actually not getting treated according to the latest 
research. There is very little knowledge in Sweden of how much 
physical activity can help for Parkinson. Which means people are not 
as well as they could be. This is only in Parkinson, I expect this to be 
all over healthcare. (Sara Riggare, patient researcher, opinion 
leader) 
Specialised doctors are more likely to uptake the results of pure science, 
because it is the way they build up their status and power (Pouthier et al., 
2013), in comparison to primary care doctors where the logic of care is 
dominant (Dunn & Jones, 2010).  
 118 
Doctors are professionals, carrying the strong, complicated and fragmented 
institutional logic of their profession. Their professional logic is a hybridisation 
of science and citizen logic, and despite the resistance to managerial and state 
logics, there are hybridisation aspects. For instance, the financial incentives 
obliged doctors in time to rationalise to some extent the care act. The medical 
profession is a second incumbent logic in digital health. Carriers of this logic 
are doctors and other healthcare professionals, to the far end of healthcare 
managers.  
6.3.2.2. Healthcare managers 
This category of stakeholders embraces a highly hybrid logic over time, which 
combines the market, the state and the medical profession logics. It is 
important to mention that increasingly managers in healthcare have a medical 
background, and usually get additional qualifications in management (MBA or 
other healthcare management or public health degrees). Such qualifications 
became more available with the proliferation of the “managed care” logic, as a 
mean for doctors to have a say in running healthcare organisations. 
Consequently, healthcare managers are operating on the medical professional 
logic, the market logic, and the bureaucratic (state) one, with various degrees 
of balance or conflict. Managers inside traditional healthcare providers struggle 
not only with streamlining processes, legal requirements, contract 
management, but, most importantly, with deriving the maximum value from 
demand and resources.  
There is also a constant adjustment around the reimbursement model and 
bureaucracy. The reimbursement models are still difficult to get right in 
healthcare. Girard (Harvard i-lab, 2014), doctor and President of Steward 
Health Care Network (US), considers that healthcare management has a dual 
logic: a market and a utility one. The paradox or the limitation comes from the 
fact that there is a single reimbursement model. Doctor and healthcare 
manager, Tim Ferris, VP for Population Health at Partners Healthcare US 
(Harvard i-lab, 2014), highlights that is not uncommon that in order for 
healthcare providers to provide specific services, they shift costs from other 
areas (ibid.). This situation, at least in the US, may change for the accountable 
 119 
care organisations (ACO). There is an increased tendency towards sharing 
risks, not only within ACOs, but in healthcare everywhere, even in insurance. 
Girard (Harvard i-lab, 2014), doctor and President of Steward Health Care 
Network (US), gives an equation for deriving the most value: value being 
understood as quality divided by price times volume. This equation is in direct 
contradiction to the logic of a doctor, who is trained to focus on and do 
everything for one patient at a time, rather than a community or society as a 
whole. 
But ultimately, only the real patient counts, and only the real patient 
is worthy of our full attention. (Bob Wachter, doctor and professor, 
opinion leader) (Wachter, 2015, p. 277) 
Dr. Girard also considers that significant savings could be derived from the 
management of the chronically ill patients, ambulatory treatments, but also 
from remote consultations. But because not all good ideas are reimbursed, 
managers have to consider how to extract the maximum value given the 
constraints, including taking irrational measures (i.e. bringing people in the 
hospital instead of having a remote consultation). Managers are more risk 
averse and so medical devices or technologies used or recommended by a 
healthcare provider often need approval from management (ibid.). 
6.3.3. THE CITIZEN LOGIC 
This logic reflects that people choose based on personal values, with a sense of 
belonging to larger groups (Alford & Friedland, 1985; Dunn & Jones, 2010; 
Windrum & García-Goñi, 2008).  
Digital health brings forth the citizen logic as challenger to the incumbent 
medical profession and state logics, dominant in the traditional healthcare 
setting (Christensen et al., 2009). In previous healthcare studies, this logic has 
been implied by other logics, the care logic (Dunn & Jones, 2010) or the 
community logic (Waldorff et al., 2013). Overtime, with the introduction of the 
market logic in healthcare, the patient transformed from a passive recipient of 
care to a consumer of health (Christensen et al., 2009; IMS Institute, 2015). 
Such transformation was mainly led by political discourses of incumbent actors 
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of healthcare (Nigam & Ocasio, 2009), less by patients themselves. However, 
patients advocate groups can be tracked back a long time, associated with the 
civil rights movement, as shown in the previous chapter. One of the first 
patient advocate groups was founded in the UK in 1974, The Association of 
Parents of Vaccine Damaged Children (Harlow & Rawlings, 2013). 
Patients are essentially people and, despite the dramatic effect an illness may 
cast over their lives, illness remains only one aspect of their often-complicated 
lives. The medical act and treatment are not filtered by strong rationality, but 
get entangled in their systems of believes, lifestyle, idiosyncrasies and trust.  
Their first thought is hair loss, what about my children… my 
sexuality… Is my husband still going to love me, how is my body 
going to transform? And when they hear from the healthcare 
professionals that they might have a fever, they are like “Ah, fever! I 
get fever, you know… that’s easy to deal with” and they don’t realise 
that there is a different consequence of this fever under 
chemotherapy. And so, sometimes, you need to take care of what 
patients want to know in order that they can hear what they need to 
know. (Colleen Young, communications, opinion leader)  
Trust is one of the causes of non-adherence to treatment and, possibly, a way to 
improve adherence is through education and technology.  
And I think that even the choice of words matters: there is compliance 
and then even adherence is a bit better than compliance… and then 
participation is better than adherence. Compliance I think it’s not 
something that sets the right tone. Adherence is still… you are kind of 
adhering to what they say. Whereas participation recognises what a 
patient does and the factors in their life that have an impact. That’s a 
much better model, it works much better and forward-looking 
organisations look at how to achieve that. It’s great for the outcome 
for the patient and I think that the care team quite enjoys that. But 
there is a different approach than the status quo in a lot of places. 
(David Chase, entrepreneur, opinion leader) 
Actually being a patient though isn't just about me the patient, it is 
about finding a doctor then building a relationship like the one that I 
have with my transplant team and specially with the guy who is at 
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the top of the tree my transplant surgeon Anil Vaidya. (…) You see this 
whole journey is like no other (…). They become your second family, 
the one you literally have trusted with your life, they know you like no 
one else, even your mum and dad can do. Going right back to that 
walk to theatre, holding hands with my wife Anil would have been the 
only other person who could truly have known how scared we were 
and how that walk could have been the last time we held hands. 
(Michael Seres, patient entrepreneur, article on personal blog, 2013) 
Consumerism, later on patient empowerment or engagement, is very much part 
of the political agenda for a long time. Until recently, this engagement was 
realised through patient groups, associations or nongovernmental organisations 
(NGOs). Over the past few years, patient engagement took a hands-on 
approach. For instance, in the 2009 case of the swine flu, patients were 
encouraged to self diagnose by the NHS. A major cultural shift caused by the 
evolution in information technology is the redefinition of the patient role.  
By encouraging layfolk to be overly dependent on doctors we have all 
too often inadvertently disempowered the populace in health matters, 
turning potentially powerful, knowledgeable, health responsible 
citizens into ignorant, fearful, isolated clients of professionalized 
health care. The rise of consumer health informatics and online self-
help provides the perfect remedy this situation. (Tom Ferguson, 
doctor) (Ferguson, 1996) 
 Self care is an under-utilized resource. […] This is not just about a 
change in service provision, but about a cultural change, allowing 
patients to be partners in their care, letting them decide what support 
they need, when they need it and how. (UK Department of Health 
report, 2006) 
The engagement of the citizen, as opposed to being simply a recipient of 
welfare, spurs from the citizen’s rights, “the power to engage in the economic 
struggle and made it possible to deny him social protection on the ground that 
he was equipped with the means to protect himself” (Marshall 1964 in Alford 
& Friedland 1992, p. 155).  
The idea that patients are consumers is not much agreed by the medical 
community. I only mention here a few arguments offered by an online article 
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on Kevin.MD, by doctor Shirie Leng (2015): they are accessing services under 
a state of vulnerability, sometimes with no prior notice or planning; they don’t 
choose to buy services, rather are forced into this by circumstances; usually 
patients are not paying directly; they are not buying a product that a consumer 
would expect to derive positive returns; and, not last, what patients find 
satisfactory does not correlate with the quality of care provided. 
Since 2004, European Commission (EC) made clear that health consumers are 
also healthy citizens, not only patients (European Commission, 2004). This 
conception has roots in the dominant welfare state doctrine that still dominates 
healthcare in Europe. Similarly, in the US, the insured people are also healthy 
people.  
Etymologically, a patient is a person who suffers. Medical 
dictionaries also consider patients to be people registered with a 
doctor, irrelevant of their sufferings. Therefore, national health 
systems (i.e. the UK NHS) may conceive all citizens as patients by 
birth alone. (Macnaughtan, 2015a) 
In both cases, even if in different manners, both healthy people and people 
affected by an illness (patients) are recognized as stakeholders. Less so are the 
carers, although “[t]he demand for health services is determined in part by the 
patient and in part by the family/social group to which patients belong” 
(Windrum & García-Goñi, 2008, p. 654).  
Thirty percent of U.S. adults help a loved one with personal needs (…) 
Caregivers are significantly more likely than other internet users to 
say that their last search for health information was on behalf of 
someone else. (PEW report) (Fox & Brenner, 2012) 
Their importance as healthcare stakeholders is relatively recent - for instance, 
the UK Whole System Demonstrator (WSD, 2008 – 2011), the biggest 
randomized controlled trial in telehealth (which involved remote patient 
monitoring), recognized carers as key stakeholders, along with patients.  
“There are examples where patients’ carers and family members were 
involved in drawing up and ‘owning’ the care plan” (WSD report) 
(Giordano, Clark, & Goodwin, 2011, p. 8). 
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Therefore, I consider carriers of this challenger logic patients (if there is 
illness), carers and people, generally. Perhaps, it is important to stress again 
that citizens also engage in political activism and social movements, where 
occasionally, relatively powerless actors come to “mobilize and organize 
fields” (Fligstein & McAdam, 2011, p. 1). 
6.3.4. THE MARKET LOGIC 
This logic is guided by efforts to increase shareholders’ value through 
considering opportunity costs, potential returns, and competitive edge (Gawer 
& Phillips, 2013; Scott et al., 2000; Thornton, 2002). In this sense, technology 
is evaluated based on opportunity cost and market potential. Carriers of the 
market logic are intrinsically less risk averse and more likely to propose 
disruptive solutions to healthcare (Christensen et al., 2009).  
Now I think there's this fourth revolution building on the third, which 
is the digital revolution, this diffusion of technologies that are not well 
defined. And the interesting thing about the fourth revolution is that it 
is a little digital and a little physical. It’s about all these aspects of our 
humanity that are being transformed. Amazing changes in 
technology! (John Nosta, digital health evangelist, opinion leader) 
Although the market logic is part of the healthcare constellations of logics, it 
does not manifest as freely as in other contexts, due to the other powerful 
logics (state and medical profession). 
At the same time, because I was deeply rooted in healthcare, and 
trained in really rigorous research, I recognised that some of what 
people were discussing or hoping for was a little bit naive. Aspiration 
was to apply the tech to make healthcare better, but there was a lot of 
naivety about how complex human physiology is, how complex 
healthcare is. (David Shaywitz, doctor entrepreneur, opinion leader) 
Scott et al. (2000) showed how the era of state involvement, with the logic of 
equity, caused intense fragmentation, which allowed subsequently the 
managerial and market logics to enter. In this sense, managers “appear to have 
been the beneficiaries, not the agents, of the deinstitutionalization” (ibid., p. 
328). 
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The main stakeholders carrying this logic are most of the market players, with 
some hybrid representatives. Of these, the CDHT producers (apps, wearables, 
insideables, platform producers) will be treated in the chapters to come. There 
are other numerous players in this arena: medical devices companies, 
consultancy companies, traditional ICT and health IT providers (EHR and 
EMR), technology integrators, (big) data integrators, other health related 
service providers (i.e. non-physicians care providers), pharmaceutical 
companies or academic institutions. The list may not be complete, but it is 
relevant at the time of data collection. Most such stakeholders embrace 
predominantly the market logic (except pharma and medical devices, which 
have more hybridity due to their proximity to healthcare and strong regulatory 
constraints), but this becomes more blended, the closer they get to the 
healthcare field.  
6.3.4.1 Pharmaceutical and medical device companies  
These stakeholders operate under tremendous fragmentation and, similarly to 
healthcare stakeholders, they are under the influence of several logics 
coexisting, although the market logic remains dominant. They do have strong 
regulations, therefore the state logic applies, they produce directly and often 
exclusively for the healthcare professionals, therefore there are elements from 
medical professional logic, and they do operate under the science regime, and 
so there is science logic.  
6.3.4.2 Consultancy companies 
Consultancies have the role to apply experience from adjacent fields (in this 
case, digitalization of other types of businesses), to disseminate and create best 
practices, to fill in expertise gaps, manage implementation and organisational 
change. Bessant and Rush (1995) identify a number of roles that consultants 
fulfil for technological change, and they identified multiple “bridging 
activities”. 
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Table 11. Intermediary roles of consultants (Bessant & Rush, 1995, p. 101) 
Consultants have a mediating role and, however less visible, they play an 
important role in the maturation of a field. Consultancies, even though driven 
mainly by the market logic, drive hybridisation of institutional logics between 
fields through their exposure to different institutional contexts. 
6.3.4.3 Infrastructure providers 
They are mobile networks, telephone and data providers, even broadcasters. 
The infrastructure could be considered a barrier and an opportunity. With the 
infrastructure providers offering better and faster services and continuously 
covering more areas, the communication infrastructure becomes increasingly 
an opportunity. Infrastructure providers have the role of almost literally 
building the foundation for digital health. The communications industry is 
fundamental for the digital economy and it is one of the main facilitators of 
convergence of services. Although concerns with privacy of health data might 
lead to a hybridisation or plurality with state and citizen logics, as it will be 
shown in the next chapter, presently these providers are conducting their 
businesses based on the market logic, with focus on service diversification and 
exploitation of already existing distribution channels. Data collected by these 
providers may become an important revenue stream either by directly 
exploiting it or selling it forward. 
6.3.4.4. ICT technology producers 
Similar to the infrastructure providers above, ICT producers have a vested 
interest in promoting their products and so the more uptake of digital 
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technology in healthcare, new market leads open. Recently, many of the ICT 
providers offer cloud data services and therefore their logic might eventually 
combine with state and citizen logics, similar to the case of infrastructure 
providers. Most of them evolved to offer platforms and nurture their own 
ecosystems. Additionally, some become distributors for digital solutions (i.e. 
apps stores). 
6.3.4.5. Non-physician providers 
Examples could be other agencies (telehealth, social care services), 
professionals (nurses, assistants to doctors, wellness coaches), independent 
professionals (optometrists, mental health or physical therapists) who 
participate in care. Depending on goals and expertise, their logics will be 
possibly the most eclectic as the dust settles in digital health. They may work 
in teams with a doctor or independently. In the US, these roles increased by 
11% since 2008 (Weldon, 2014), possibly due to the recent changes in the US 
healthcare policies, which set the grounds for new incentives and 
organisational forms (i.e. Accountable Care Organisation - ACO). In ACOs, 
the continuum of care is to be rewarded throughout the system formed by 
different organisations (hospitals, primary care or social care organisations, 
NGOs). The main incentives (shared savings) are placed on the system 
performance related to the population served (Tim Ferris, Partners Healthcare, 
iLab, 2014). 
6.3.4.6. Integrators 
Digital technologies are “configurational technologies” (Fleck, 1994, p. 243), 
meaning that in order to be successful in their local implementation, there is a 
need of general technical knowledge (that healthcare providers may not 
possess) and local practical understanding. Integrators could fill in this space 
and therefore, their logic would end up hybridising the medical profession and 
a market logics.  
Sometimes, system integrators create platforms. “Industry platforms are 
products, services or technologies that are developed by one or several firms, 
and serve as foundations upon which other firms can build complementary 
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products, services or technologies.” (Gawer, 2011) Platforms (i.e. Microsoft, 
Intel, Apple, Google, Facebook…) offer a bundle of core components that can 
become technical standards, based on which other producers can create or 
build their own products (Baldwin & Woodard, 2009). Service integrators 
often address solutions, rather than insular pieces of technologies. 
Consequently, they are important players in the maturation of the market, 
because of their role to accommodate multiple logics. 
6.3.4.7. Distributors 
These could be medical device distributors, websites, app stores, ICT providers 
and others. In the case of the medical device distributors, given their proximity 
and generally long term relationship to the healthcare field, the logic is a blend 
of market, medical profession and state logics, in the favour of market logic. 
For instance, many of the Phillips, GE or Monica Healthcare devices are 
generally distributed through big medical distributor channels.  
In digital health, distributors are mainly online retailers or apps stores and these 
are driven by the market logic, with very little customisation to any particular 
field, therefore they are governed by the market logic.  
6.3.5. SCIENCE LOGIC 
This logic is concerned with advancing knowledge and is guided by 
“communalism, individualism, desinterestedness, originality, skepticism” 
(David, 2004, p. 573). As an institution, science is subject to penetration from 
the market logic of production and consumption (articles, books, discoveries 
and technologies) and from the state logic for access to resources (Alford & 
Friedland, 1985; David, 2004). 
As David (2004) suggests, there should be a difference between the republic of 
science and the republic of technology. The last one is “devoted to maximizing 
wealth stocks corresponding to the current and future flows of economic rents, 
and so requires the control of knowledge through secrecy or exclusive 
possession” (ibid., p. 576). Herein, I consider technology as an enabler of 
institutional change (Christensen et al., 2009; Petrakaki et al., 2012). The main 
stakeholders of this logic are traditionally the academic and research 
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organisations, which have the goal to create and disseminate knowledge, 
mostly as a public good. 
In healthcare, the logic of science “focuses on knowledge of diseases built 
through research and innovative treatments” (Dunn & Jones, 2010, p. 116). 
Historically, science has been a main driver of medical professionalisation, as 
well as professional fragmentation. 
Most research being done to date, is primarily done for the sake of 
research, secondarily for the sake of healthcare, and thirdly, if at all, 
for the sake of individual patients. This is a result of the very complex 
weave that makes up the current research process. And I am not 
saying that good or even great research cannot come from the 
current research process. (Sara Riggare, patient researcher, opinion 
leader) (Riggare, 2016) 
Academic and research organisations mix the logic of science, with market and 
state logics (Thornton & Ocasio, 1999), in the favour of science. However, 
now they are demanded to confront and accommodate citizen logic, as shown 
by the quotation above. Many of the traditional healthcare stakeholders are to 
various degrees engaged with the logic of science (pharma, medical device 
manufacturers, consultancies). That would also become the case with digital 
health players, overtime. 
The idea of scrutinizing an idea, of questioning its clinical validity, of 
looking at its real data to support its use, I think will, well out of 
necessity, come to the forefront. And with that might come some 
scepticism. (John Nosta, digital health evangelist, opinion leader) 
Apart from often being dependent on funding from the state, researchers are 
incentivised to produce private endeavours of economic value. Aside from the 
engineering dream the digital health represents (digestible sensors, 
machine2machine intelligence, artificial intelligence, nanochips...), such 
science organisations have a vested interest in the potential of big data for 
research, funding and IP exploitation.  
There is a difference between European academic institutions and the US ones 
(Goldfarb & Henrekson, 2003), in the sense that in Europe there are top down 
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policies that do not always make it easy for universities to commercialise 
scientific knowledge, whilst in the US the “institutional setting characterized 
by competition between universities for research funds and research personnel, 
which in turn has led to significant academic freedoms to interact with 
industry, including significant involvement in new firms” (ibid.: 639). Recent 
initiatives (for instance, in the UK or Australia) look to foster a closer 
interaction with the industry. Most recently, in Europe, an increasing number 
of grants require statements for economic, social and academic impact, or 
require academia-industry collaboration. Regardless of how the funds are 
flowing, it will become obvious in the following chapter that digital health 
developments are legitimised and encouraged by current trends and by 
academic work. 
6.5. CONCLUSIONS 
This chapter fulfils the first part of the second phase of this research - the 
analysis of the institutional context of the emerging digital health, by 
identifying the institutional logics at play and their main representatives. 
Institutional logics are understood as ideal types, and stakeholders carry them 
in more or less ideal forms (Scott, 2008; Thornton et al., 2012). Based on my 
analysis, five institutional logics coexist in the digital health field: state, 
medical profession, citizen, market and science. Stakeholders have been 
identified through their field level interactions (Scott, 2008), and are relevant at 
the time of data collection, as they may change with the evolution of the field 
(ibid.). Digital health introduces the citizen logic as a challenger logic to the 
incumbent medical profession and state logics, dominant in the traditional 
healthcare setting (Christensen et al., 2009). In previous healthcare studies, this 
logic has been implied by other logics, the care logic (Dunn & Jones, 2010) or 
the community logic (Waldorff et al., 2013). The other four logics are 
described in detail, alongside their historical evolution. The next chapter moves 
into presenting the evolution of this emergent field. 
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CHAPTER 7.  DIGITAL HEALTH EMERGENCE 
7.1. INTRODUCTION 
This is the third chapter situated at the field level of analysis. Here4, I explore 
the digital health field emergence, as a process. I reveal its institutional 
complexity via stakeholders’ interactions, driven by hybridisation, conflict and 
ambivalence. These interactions allow me to determine the institutionalisation 
stage. Given that the field emergence has not been previously investigated by 
other studies while it happens, only through retrospective lenses, I aim to 
provide a better and more vivid understanding of institutionalisation, 
particularly relevant for a fragmented field, with high complexity. Having 
established the precursors of the institutional change in chapter 5 and the ideal 
types of the institutional logics and their main carriers in chapter 6, in this 
chapter I analyse the digital health’s evolution from 2007 to February 2016.  
7.2. CONTEXT AND TRIGGERS OF THE DIGITAL HEALTH EMERGENCE  
Digital technologies contributed to the change in the rules of competition 
across industries (Ilinitch et al., 1996). The ICT industry itself changed 
dramatically from the introduction of personal computer and the rise of 
platforms and ecosystems (Gawer & Phillips, 2013; Mulligan, 2011; Jacobides 
et al., 2018). “This shift fundamentally altered the organizing principles of the 
industry: it changed how competition happened, as well as how innovation 
happened. […] The locus of competition also changed, as much innovation 
became focused on components and around the definition of ‘open standards’” 
(Gawer & Phillips, 2013, p. 1041). 
It is beyond the scope of this research to assess, predict or advocate the impact 
of digital technologies over the future of medicine or healthcare; what is 
                                                
4 This chapter builds upon the conference paper: “Plurality of institutional logics in digital 
healthcare: The rise of the hybrid patient” (Macnaughtan, Patriotta, Pinnington, & Raman, 2015), 
as explained in chapter 1. The analysis is enriched with data collected afterwards and expanded in 
depth and enlarged given that there are fewer limitations on its length. 
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important for this research is that they potentially pave the way to significant 
institutional changes.  
“We have learnt that, despite considerable investment, industry [n.b. 
ICT] does not yet have the capability to apply itself to health as it has 
done to most other industries; there is no effective global market and 
still no common solutions. Everything remains bound up with existing 
interests, politics, resources and essentially insular thinking” (EHTEL 
2009: 12). 
Healthcare and ICT have a long history, as presented in chapter 5. However, 
since 2007, there were several factors that instigated a revived interest in using 
digital technology for health. The launch of the iPhone (2007) was a game 
changer not only for digital health, but also for other industries. Other 
smartphones and tablets soon followed the iPhone, and so the personal mini 
computer, truly mobile, proliferated. Prices drop rapidly and allow for an 
accelerated adoption worldwide.  
Mobile, sensing and affordable technology was not the only factor that led to 
the emergence of digital health; there were also economic, politic and even 
social factors. The economic downturn (2008) or the demographics showing 
that population lives longer with chronic diseases translated in overwhelmed 
governments facing the ever-rising cost of healthcare. Governments became 
interested to stimulate new areas of economic growth and to identify areas for 
reducing costs. 
Healthcare has been a major political ground for decades. Regulators often 
interfered in healthcare in various ways, like reimbursement or measures that 
locked in technologies (Christensen et al., 2009) in a very expensive world. In 
the case of digital health, regulators are lagging behind, and seem torn between 
the urgency of cost containment and the maintenance of an over-reaching 
control (Macnaughtan, 2014). 
The more resources went towards innovation, the smarter, more affordable 
technology became. Given the diminishing return of investment on the stock 
market following the 2008 economic crisis, venture capitalists and angel 
investors looked for new opportunities for higher returns, and therefore 
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significant capital went towards early ventures. “[I]nnovation is occurring in 
more venues, not just governmental and industrial research labs but 
increasingly at technology companies, startups, small-team academic labs and 
by creative entrepreneurs and other individuals” (Swan, 2009, p. 493). This 
aspect itself is currently debated across the spectrum of life (Frellick, 2015; 
Ioannidis, 2015; Waters, 2015) and social sciences (Pearce & Raman, 2014), 
not only in relation to healthcare (Waring, 2015).  
7.3. STAGES OF FIELD EMERGENCE  
Based on my analysis, I identify three distinctive periods (ingenuous, 
legitimation and mobilisation) for the evolution of digital health to the time 
data collection ended (early 2016). I show how entrance of new players 
influence the institutionalisation processes, how logics have facilitative or 
degenerative effects on each other and how stakeholders, primarily those 
carrying the incumbent and challenger logics, develop ambivalent responses to 
institutional complexity. 
7.3.1. THE INGENUOUS AGE (2007 -2009) 
This is the time when developments in digital technologies challenge the status 
quo (Christensen et al., 2009; Fligstein & McAdam, 2011) and create a wave 
of awareness for several stakeholders of their potential to enable change in 
healthcare.  
The interest for using mobile technologies in health is often fostered at this 
stage by states’ commitment. In developed countries, such commitment is due 
to the need to identify areas of economic growth, the rising costs of healthcare, 
and the population demographic changes that additionally increase the 
financial burden on healthcare systems. In January 2008, the European Union 
(EU) launched the Lead Market Initiative and digital health was identified as 
one of the most promising markets for economic growth. Similarly, in the US, 
the Health Information Technology for Economic and Clinical Health Act 
(2009) sets a stimulating agenda for this field.  
A number of telehealth pilot studies are launched across the world, focused 
mainly on long-term conditions (LTC) management and aiming to produce 
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proof of economic and clinical benefits. Evidence dominates the acceptance of 
new technologies, treatments and practices in medicine. Under the influence of 
the managed care logic, requirements for evidence was extended from clinical 
to economic benefits too. 
You are not going to get paid for anything unless you can prove that 
you can save them money... In the world we’re moving into, more 
than ever, if you can’t justify the cost benefits, then you will fail.  
(James Sweeney, CEO of CardioNet) (mobihealthnews, 2009) 
This hybridisation process between the state, market and medical profession 
logics appeals to healthcare managers. The amalgamation of clinical and 
economic benefits may also represent a conflict with both citizen and medical 
profession logics. It may be a rhetoric that payers and state promote to continue 
to silence professional expertise by “taming complexity with numbers” (Pearce 
& Raman, 2014, p. 389) or by obscuring certain clinical and ethical issues. For 
instance, patients “may find the obligation of self-surveillance overwhelming, 
forcing them to confront their illness, engage in routine actions they would 
rather avoid” (Lupton, 2013, p. 261) or they may simply trick the system, if it 
does not live up to their expectations (Nicolini, 2007). 
States most often position the transfer of the medical gaze from hospital to 
home as an encouragement of consumerism and of patient choice, and thus it 
attempts to stimulate in people the hybridisation of the medical profession and 
the citizen logics. But they also present patients to doctors and healthcare 
managers as additional resources, and thus it tries to enforce the hybridisation 
of the medical profession and the market logics upon healthcare actors. This 
stance is arguably a reflection of the increasingly neoliberal state agendas 
(Ayo, 2012). “They position lay people as ready and willing to actively engage 
in their own healthcare and promote their own health, in the attempt to shift the 
burden of such responsibilities from the state to the individual” (Lupton, 2013, 
p. 266). Such cultural change is mainly demanded from doctors (conflict) and 
is presented to patients as a benefit. 
This is not just about a change in service provision, but about a 
cultural change, allowing patients to be partners in their care, letting 
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them decide what support they need, when they need it and how. (UK 
Department of Health, 2006).  
This is the period when it becomes evident that patients do not look for advice 
from doctors only, there are digital tools like symptoms checkers, patient 
networks (i.e. PatientsLikeMe, WellSphere), medical resources (WebMed, 
NHS library) and several other gadgets (later on called wearables) that allow 
them to self monitor (FitBit, ActiHealth) or self manage (Trixie Tracker, Keas, 
Google Health or Microsoft HealthVault) – for a comprehensive list of 
available solutions during this period, see Swan (2009). It is the time when 
patients, enabled by digital technologies, do engage with their own health, 
hybridising with the medical profession logic.  
Patient voices begin to be heard not only through NGOs or patients 
associations, but also through the voice of individual patients. Dave 
deBronkart, ePatient Dave, becomes a well-known activist for patient’s rights 
to take part in medical decisions and to own their personal health data (PHD). 
Regina Holliday turns into a patient advocate after she became a widow in 
2009. Two years later, she initiates an entire movement, The Walking Gallery 
(Holliday, 2011), which continues to grow to this day. At this stage, citizens 
mainly oppose the medical profession logic and mobilise via the internet. 
The world was talking about patients' rights and data access. This 
was caused in part by paint and social media. If using social media 
could get our message out to the world think of what could happen if 
the medical establishment and empowered patients embraced it. 
(Regina Holliday, carer and artist) (Holliday, 2009) 
Gone are the days when patients were passive recipients of care 
dispensed by healthcare providers in a one-sided “doctor knows best 
– and patients know nothing” model. Today engaged 
patients participate in their care, in an empowering partnership with 
nurses, physicians, staff and organizations who understand the new 
model. (Dave deBronkart, also known as ePatient Dave) (deBronkart, 
2009b) 
What would you say to policymakers who are discussing the 
implementation of a national health information infrastructure? 
Here’s what I’d say: E-patients want access to tools and 
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information.  Many will find what they need, many will not. You can 
help. - CTO US Department of Health, opinion leader, Susannah Fox 
(Fox, 2009) 
Digital technologies allegedly change the patient from a “minimally-informed 
advice recipient to an active participant, instigating collaborator, information 
sharer, peer leader and self-tracker engaged in participative medicine; a 
transition is underway from paternalistic health care to partnership models” 
(Swan, 2009, p. 513). This denotes an ambivalence in citizens’ response to the 
medical profession logic: on one hand they hybridise by accessing specialist 
information, on the other hand they attempt to change the existing practices 
where doctors render control over health data, diagnostic or treatment. 
It started when I found PatientsLikeMe. You can produce a pdf that 
you can bring to your doctor. He found it interesting. So I started 
exploring more. (Sara Riggare, patient researcher, opinion leader) 
 
Fig. 26. Sara Riggare’s representation of selfcare (2014). 
We started to add not only what does the patient need to know, but 
also what does the patient want to know. And it’s a significant shift 
there. (Colleen Young, communications, opinion leader) 
Doctors are only invoked by the actions and rhetoric of other stakeholders, 
although there is some awareness of the potential impact digital technologies 
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may cast over the doctor - patient relationship. Hybridisation with the medical 
profession logic at field level is indicated by conferences like Health 2.0, 
Medicine 2.0 (2008), or associations like Society for Participatory Medicine 
(2009) cofounded in the US by patient Dave deBronkart and doctor Daniel Zev 
Sands. Even the names of these conferences are indicative of a paradigmatic 
change. There are scattered digital health companies founded by healthcare 
professionals directed to patients (i.e. Ieso Digital Health, UK, which is 
founded by two psychotherapists). At this stage, doctors strongly oppose the 
consumerisation of medical knowledge or the escape of the lab from its 
traditional setting. 
In 2008, several consumer genetic testing companies were served by 
California’s Public Health Department with a cease and desist letter, which 
appeared to have been stirred by the medical community. This shows that the 
regulators are not comfortable with the new world, the direct to consumer 
health services that aim at what traditionally used to be governed by medical 
professionals only. Although that particular measure taken by regulators was 
not successful, some of that battle is still continuing today (Herper, 2015). 
We believe we are in compliance with California law and are 
continuing to operate in California at this time. Our testing is 
conducted in an independent CLIA-certified laboratory and we utilize 
the services of a California licensed physician. However, we would 
like to have continued discussions with the Department regarding the 
appropriate regulation of this unique industry. (23andMe in press) 
(Madrigal, 2008). 
The traditional ICT producers and service providers are encouraged by the 
incentives presented by states, the technological advancements (i.e. 
miniaturisation, sensors) and technological uptake from citizens. They attempt 
to organise in industry associations; Continua (2006) is credited for introducing 
patient remote monitoring in the reimbursement scheme in the US (Harbert, 
2009; mobihealthnews, 2009).  
The focus on patients as consumers, along with the increased availability of 
sensors for health self-tracking, opened the door for digital health. 
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Towards the middle of 2006 several start-ups began targeting 
healthcare using Web 2.0 technologies such as wikis, mash-ups, video, 
blogs, communities, and user-generated data. And to be fair Wondir 
which was sucked into the Revolution Health vortex started a now 
defunct blog called Health 2.0 in late 2005. In early November 2006 
Matthew did a podcast with 3 Health 2.0 companies on THCB (n.b. 
acronym for the website The Healthcare Blog), and the community 
was beginning to emerge. (“History Health 2.0,” n.d.) 
In 2007, a first of its kind industry event, the Health 2.0 (US) conference, gives 
this very young market a positive signal. 
Indu and Matthew started kicking around the idea of a next steps on 
Health2.0 in January 2006 and after a few changes in team, 
partnerships and timing they created an advisory board, and talked 
about holding a conference. After discussions with a couple of original 
charter sponsors (thanks to Mike Haymaker at Cisco, and Daniel 
Palestrant at Sermo for taking the plunge) they committed to holding 
a conference on September 20, 2007 in San Francisco. That 
conference massively exceeded expectations, with nearly 500 
attendees, and a hundred more on a wait list. (“History Health 2.0,” 
n.d.) 
Adding to this, at the end of 2009, resources are on the rise for wireless sensing 
devices - i.e. Monica Healthcare, FitBit, WellAware – as shown by one of the 
first market reports in this field, called “Wireless Health: State of the Industry, 
released by MobiHealthNews (US), at the end of their first year of publishing 
online (mobihealthnews, 2009). With the introduction of smartphones, the 
number of consumer health apps rise rapidly.  
From symptom navigators to chronic disease management tools; 
from medical reference guides to remote monitoring applications; 
from medication adherence apps to soothing relaxation applications. 
Chances are if you have thought of a potential health-related 
application, there's a version of it already in the iPhone App Store. 
(mobihealthnews, 2009) 
With their focus on consumers, digital health producers contribute to the 
escape of medicine (Lupton, 2013) from the confined space of specialist 
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knowledge. Therefore they come into conflict with the medical profession 
logic, despite the fact that they themselves hybridise with both citizen and 
medical profession logics, depending on their product/solution. 
Pharmaceutical companies (pharma) remain, by large, not involved. Pharma is 
dominated by a constellation of logics and, at this stage, it just contemplates 
hybridising the market and science logics with the citizen logic. 
So what we learned by that which I think it changed a lot of for the 
drug manufacturers. That having patients talk to one another helped 
with adherence rather than what they’d feared - people talking about 
side effects and therefore not taking them. (…) And sometime they 
would come on the conversations on the forums and talk about how 
difficult it was to manage their joint pain or whatever they were 
particularly experiencing. They were often giving tips to one another 
- maybe take pills in the evening rather then in the morning or vice-
versa. And also give to each other signs of encouragement: “You’re 
doing well. You’re doing this for your daughter. You don’t want not to 
use all of the ammunition that you have to fight this disease.” I hate 
using battle metaphors, but you want to give everything that is in 
your power to save your life. And so they really encouraged people to 
stay on the drug. (Colleen Young, communications, opinion leader) 
Pharma seems to be most interested by exploring potential benefits from 
having instant access to generous pools of clinical trial participants. For 
instance, in May 2008, Novartis collaborated with PatientsLikeMe for 
recruiting patients for clinical trials and they have claimed that this reduced the 
study duration by several months (Swan, 2009). 
Digital health has a quick, serendipitous start, with steady growth of digital 
health solutions. At the end of this period, some common themes surfaced: 
reimbursement, regulation, business models, evidence and patient as healthcare 
resource. The market and the state logics promulgated the citizen logic, for 
different reasons, nevertheless both contributing in their own right. The market 
fostered the independent, rebellious, sophisticated user, whilst the state 
fostered the resourceful, dignified, independent patient. Doctors remain a 
sounding board, their participation being subtle at best. 
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Fig. 27. Synthetic view of the stakeholders in the ingenious phase 
Although most stakeholders become aware of the possible impact ICT may 
have on healthcare, only few fully engage, particularly those who could put 
health information at patients fingertips. State, technology producers and 
citizens are such examples. Conflicts between logics are mainly between state 
(including payers), citizen and market (technology producers) on one hand, and 
medical profession (primarily doctors, and, to a lesser degree, healthcare 
managers), on the other hand. Ambivalent or neutral positions are maintained 
by pharma, for instance. 
7.3.2. THE LEGITIMATION AGE (2010 -2012) 
Terminology continues to change and morph in meanings. “Digital health” 
(Davis, 2015) becomes the favourite term, as opposed to mHealth or eHealth, 
although they all continue to be used. Digital health communities appear where 
professionals of various descents share ideas and connect. “The modern world 
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has created the “social movement,” the “organization,” and the idea that one 
can deploy networks to expand one’s power. Reflexive social actors have 
picked up on these inventions and used them” (Fligstein & McAdam, 2011, p. 
23). Opinion leaders have a significant role in establishing socio-political 
legitimacy and a social identity for challengers (Aldrich & Fiol, 1994; Fligstein 
& McAdam, 2011; Selznick, 1948). They also have the role to co-opt and find 
ways to reconcile certain aspects for the emerging field. 
A real page-turner for me was a conference in Dubai, where all the 
major telecom companies in the world were present. Everyone was 
talking about mHealth, how huge it would become, and how many 
people would be using it, and thereby earning many billions of 
dollars. When it was my turn to deliver my keynote, I asked the 
audience ‘How many patients are present here?’. Not one, it 
appeared. ‘And are there any doctors?’. Yes, just one, a doctor of 
dentistry who, it appeared, had walked into the wrong conference-
room by mistake” (Lucien Engelen, healthcare intrapreneur, opinion 
leader) 
I help people navigate health and technology. […] And I contribute to 
debates around the world about how data, social media, and 
technology can be used to support health. (Susannah Fox, at that time, 
PEW Associated Director, opinion leader) 
A doctor follows [the] Heisenberg principle: he's always somewhere 
else. Patients are 24 hours waiting for two minutes of a doctor who 
comes in like Superman and goes out again. (…) We are the last 
generation who will know so little about our health. (Walter de 
Brouwer, entrepreneur, opinion leader) 
These are examples of justifications opinion leaders invoked, using skilfully 
paradoxes, personal drives, personal stories or invoke powerful emotions – like 
a patient waiting for a doctor that is never there when needed.
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Fig. 28. Opinion leaders in the legitimation stage (Macnaughtan, 2015c)
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Like in any young field, consultancy companies have the role to apply 
experience from adjacent fields (in this case, digitalisation of other industries) 
to disseminate and create best practices, to fill in expertise gaps, manage 
implementation and organisational change, the so called “bridging activities” 
(Bessant & Rush, 1995). In the previous years, there were only rare niche 
market reports (Parks and Associates, mobihealthnews). Now, major 
consultancy firms enter the game, but they do not play a major role in 
hybridising logics and practices. Pricewaterhouse Coopers (PwC) has been the 
most active ever since this period. The startups research2guidance (2009) and 
Rockhealth (2010) set themselves apart for producing in-depth market reports 
on digital health, particularly on funding and general trends. 
The knowledge economy continues to challenge the information asymmetry 
paradigm that used to provide unilateral decision-making authority to doctors 
only.  
 
Fig. 29. Patients versus consumers (Keckley, Coughlin, & Eselius, 2012, p. 73)  
 143 
Patients become more empowered by gaining a seat at few healthcare 
conferences (Engelen, 2012), albeit most of them were new ones, designed to 
include patients - i.e. Doctors 2.0 & You (France), Stanford Medicine X (US), 
Medicine 2.0 Harvard. Lucien Engelen ignited the “patients included” in 
healthcare conferences movement in 2010 and, by the end of 2012, amongst 
the conferences listed in one of his LinkedIn posts (Engelen, 2013), only one 
was a medical conference as such, on Parkinson’s disease. 
 
Fig. 30. Patients Included logo by Lucien Engelen (2010) 
Some patients become opinion leaders through their online communities and 
participation to patient included conferences like Tedx, Doctors 2.0 & You 
(France) and Stanford Medicine X (US) - amongst them, Brittany Jones, Hugo 
Campos, Michael Seres or Sarah Kucharski. The growing online patient 
communities and blogs bring forth the idea of “peer-to-peer” healthcare (Fox, 
2011a) - people connect with each other, share other types of information than 
those exchanged with doctors and have other types of support from their peers 
(Fox, 2011a; Hartzler & Pratt, 2011; Swan, 2009). The growing number of 
online patients (also called e-patients or patient experts) and communities 
continue to reinforce the citizen logic. Some of the issues claimed by patients 
were: 
Data ownership, connectivity, low cost. But one thing is for sure. In 
this world of low cost connectivity, in which we live today, we all here 
should find it unacceptable for data to bypass the patient. (…) We all 
have the right to our health information, it’s a matter of fairness, it’s a 
matter of justice and it’s a matter of patients’ rights. (Hugo Campos 
TEDx Talks, 2011) 
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Patients being disfranchised by current business models of medical 
device manufacturers. Medical device companies really look at 
doctors as their customers, not patients. Patients are really the 
recipients of the therapy, and for the most part, are just expected to 
trust that everything is going to be alright. (ibid.) 
Online community/Peer-2-peer healthcare. Peer-to-peer healthcare 
acknowledges that patients and caregivers know things — about 
themselves, about each other, about treatments — and they want to 
share what they know to help other people. Technology helps to 
surface and organize that knowledge to make it useful for as many 
people as possible. (Susannah Fox, at that time, PEW Associated 
Director, opinion leader) (Fox, 2011b) 
Participation. What patients can really contribute to the process of 
participatory medicine, so that healthcare isn’t simply handed down 
from doctors, but it’s something that patients participate in to help 
further their progress. (Sarah Kucharski, epatient) (BasilStrategies, 
Sarah Kucharski, 2012) 
Crowdsource your health. People are contributing and participating 
in multiple ways. There are testimonies, art, poetry, suggestions, 
videos, performances. Many doctors have called in to propose their 
methodologies and technologies. I have had very interesting and 
profound discussions with people who are prepared to deal with very 
complex things every day of their lives. I’ve communicated with 
doctors who are perfectly open to the possibility of such a paradigm 
change for the word "cure". Artists, designers, activists, are giving me 
wonderful parts of "cure". Many "patients", "ex-patients", "relatives" 
and "friends" of "diseased people" are sharing their experiences, are 
opening discussions, are sharing the information I found on possible 
medical cures. (Salvatore Iaconesi, e-patient) (Lichty, 2012) 
Despite self-monitoring or self-quantification being on the rise (Fox, 2012a; 
PwC, 2012) and despite research showing positive economic and clinical 
outcomes, there is much left to explore about how people experience these 
technologies. Critical voices are barely heard. “The subject produced through 
the use of m-health technologies is constructed as both an object of 
surveillance and persuasion, and as a responsible citizen who is willing and 
able to act on the health imperatives issuing forth from the technologies and to 
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present their body/self as open to continual measurement and assessment” 
(Lupton, 2012). 
Digital health explodes with wearables, apps, and mobile devices (smartphones 
and tablets), whilst prices drop, making these technologies more affordable. 
Our joy of experiencing and creating new technologies may just 
outpace our need for them, or direct us towards the most-fun-to-use 
technologies rather than the most necessary ones. (Sanjay Basu, 
doctor) (Schiff 2012) 
Similarly, there are concerns of inequalities, but PwC (2012) showed that there 
is a better adoption rate of mHealth technologies in developing countries, 
pointing out that need and lack of legacy systems may encourage adoption of 
novel ways to improve access to healthcare. 
Business to consumer (B2C) models are emerging based on the assumption 
(hybridisation with citizen logic) that 
…the reason why individuals have NOT engaged with their health is 
because they have NOT been provided with tools that are beautifully 
designed, addictive to use, revealing on one’s health habits (a.k.a 
closing the feedback loop), and empowering. (Zussa, 2012) 
Another interesting trend: The price of consumer health apps 
continues to drop […] making the average price for all consumer-
facing health apps as of April 2012: $2.05. (Dolan, 2012) 
There is ambivalence, in the sense that digital health producers enable lay 
people to take upon themselves actions traditionally performed by doctors 
(they hybridise with medical profession and citizen logics in a manner that puts 
these two logics in conflict). For instance, Scanadu’s mission is to bring the 
emergency room in people’s home. They are making a device for consumers, 
which is easy to use outside the doctor’s office and it can monitor body 
functions. 
“Check your health as easily as your email.” (Scanadu, 2010) 
The attention patients and lay people get from digital health producers evolves 
as ambivalence, but hybridisation with citizen logic is dominant and therefore 
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it gets stronger. It expands the health focus from patients to all citizens, from 
illness to health. The interest in empowering lay people through digital health 
is also signalled by industry competitions like Qualcomm Tricorder Prize and 
Nokia Sensing xChallenge, both launched in 2012. Funding becomes more 
available at seed and early stage investment levels and so many start-ups 
appear. In the US, whilst most healthcare related fields had a decrease in 
investments in 2012, digital health had 45% increase, mainly going towards 
wearables and patient engagement (Rockhealth, 2012a). 
CDHT producers are joined by established ICT producers (i.e. Intel, Microsoft, 
Philips), who have the interest that the new market uses their products or 
standards (Garud et al., 2002). In 2012, most players are existing technology 
companies, not traditional health IT companies (Rockhealth, 2012b). 
Despite the overall excitement with healthcare innovation, medical 
communities remain sceptical, at best. 
Doctors resistance is likely to hold back some aspects of mHealth... 
still, most interviewees believe that doctors will be unable to resist – 
especially as payers join patients in demanding change. (PwC, 2012, 
p. 16) 
In “The Creative Destruction of Medicine: How the Digital Revolution Will 
Create Better Health Care”, Eric Topol prophesies a “new medicine” that will 
render the “old medicine” obsolete. Old medicine is understood by the author 
similar to Voltaire: “Doctors prescribe medicine of which they know little, to 
cure diseases of which they know less, in human beings of which they know 
nothing” (Voltaire in Topol, p. XII). New medicine is the consequence of the 
“digitized human”, the “consumers coming together to demand a new, 
individualized medicine will be the most powerful means of changing the 
future of health care” (E. Topol, 2012, p. 261). However, doctors’ voices begin 
to be more exposed, even if only because of their resistance. 
The Whole System Demonstrator (WSD), the biggest randomized control trial 
(RCT) in telehealth in the world (at the time of writing), did not even manage 
to convince in its home country, the UK. Most importantly, technologies used 
were outpaced by the time the results were published in 2011. However, it 
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proved that there are economic and clinical benefits from remote monitoring 
implementation at scale. Although most RCT studies at this point have a 
double focus on the economic and clinical outcomes continue, they are not at 
the forefront of the digital health adoption debate anymore. The propensity for 
specialist doctors to be more opened to embracing innovation than primary 
care doctors has also been remarked by previous studies (Dunn & Jones, 2010; 
Scott et al., 2000), contradicting Christensen et al.’s assumption (2009) that 
innovation will take on from the periphery of healthcare. This becomes more 
and more obvious with the evolution of digital health, where adoption by the 
healthcare establishment started from specialised areas. However, states try to 
convince mainly primary care doctors to uptake digital solutions, possibly 
because they have the role of system gatekeepers or because they often have to 
manage chronic diseases, where most of the healthcare costs go. States’ focus 
remains costs, access or prevention. 
Academia plays a major role during this period. By becoming actively 
involved, it confers the field the much-needed social legitimacy. This is the 
time when the research potential of PHD becomes evident and the term “Big 
Data” enters healthcare. Academic organisations are attracted by the digital 
health field mainly for access to funding and industry partnerships, or for 
access to data for science.  
Patient Reported Outcomes. “Although observational studies using 
unblinded data are not a substitute for double-blind randomized 
control trials, this study reached the same conclusion as subsequent 
randomized trials, suggesting that data reported by patients over the 
internet may be useful for accelerating clinical discovery and 
evaluating the effectiveness of drugs already in use” (Wicks, Vaughan, 
Massagli, & Heywood, 2011). 
Remote interventions/Lifestyle changes. “The review provides a 
framework for the development of a science of Internet-based 
interventions, and our findings provide a rationale for investing in 
more intensive theory-based interventions that incorporate multiple 
behaviour change techniques and modes of delivery.” (Webb, Joseph, 
Yardley, & Michie, 2010) 
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Big Data. “For example, my post last June about IBM Watson’s foray 
into medicine generated a spirited debate in the comments about 
what source material Watson would be fed and what other models 
might emerge to take advantage of health care data. Strata Rx 2012 
featured multiple speakers on data & analytics, as did the Wired 
Health Conference: Living By Numbers.” (Fox, 2012b) 
New academic organisations appear, and interestingly, abandon to some extent 
the established focus on evidence and randomised control trials (Pearce & 
Raman, 2014). “Metrics, targets and star ratings clouded the picture. […] The 
task changed in 2010, when the National Institute for Health Research called 
for studies on organisational culture, the role of the patient, the costs and 
financial implications of patient safety and the boundaries between elements in 
the whole system” (Waring, 2015). 
The academic community hybridises with both market and citizen logics, and 
so it gives digital health further legitimacy, as an authority stakeholder. A few 
academic programs in digital health appear, i.e. Institute of Digital Healthcare, 
University of Warwick, UK (2010) or CATCH, Univ. of Sheffield, UK (2012). 
Because of the science focus, academia creates a bridge to the medical 
profession logic, albeit in ambivalent terms. In an emerging field, “researchers 
and organizations linking universities and commercial activities are engaged in 
practices that fit neither the logics of "basic" or "applied" research” (Morrill, 
2006, p. 7). Academic organisations add to the overall socio-political 
legitimacy (Patriotta et al., 2011; Raman & Mohr, 2014), in conjunction with 
the state, ICT and CDHT producers and citizens. 
The state remains one of the drivers of digital adoption at the level of 
healthcare providers. In the UK, there are investments towards researching new 
care models, such as telehealth, and, in the US, the Accountable Care Act 
(ACA, 2010) incentivises providers to innovate and collaborate across sectors. 
I think when the Affordable Care Act was passed in the US, it was 
really the catalyst for it. There were other things - the economy 
pushing people to cut costs. By the time ACA was passed, the tech 
caught up with the idea. (Lisa Suennen, investor, opinion leader) 
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States begin to experience difficulties in balancing opportunities and 
challenges (governance, privacy, safety) brought in by digital health. The 
Federal Drug Administration (FDA) publishes some draft guidance in 2011, 
and the EU publishes guidance for medical software (2012). Most other 
countries do not have any policies or follow the guidance issued by the US and 
the EU (PwC, 2013). The EU continues to invest in programs to foster 
interoperability, PHD exchange and adoption of digital health across member 
countries (European Commission, 2012). 
The lack of clear reimbursement models for digital solutions represents an 
obstacle for adoption by the medical community. However, given the claims of 
savings, some payers are willing to adopt them, for instance the NHS (UK). 
There are differences between the private and public insurers (PwC, 2012), but 
it is reasonable to assume that both want value for money, rather than only cost 
reductions. Based on a PwC report (ibid.), payers are more likely to encourage 
patients to self-monitor (40%) than doctors (25%). Payers seem to be overall 
supportive to the promises of digital health, so they are becoming a supporter 
of the citizen logic and oppose the medical profession logic. 
Payers are likely to shift even closer to the patient position because 
they will bear most of the economic consequences if healthcare 
systems fail to reform. (PwC, 2012, p. 14) 
During this period, the digital health field continues to grow and expand its 
boundaries, letting in or even bringing in new stakeholders. Institutionalisation 
processes are more intense, with ambivalent responses from carriers of the 
state, market and citizen logics. The conflict between medical profession and 
citizen logics continues. Digital health consolidates its socio-political 
legitimacy, particularly because of the involvement of academic organisations, 
but also because of more neutral players (other ICT providers, consultancies) 
that form a critical mass. This stimulates and mediates the hybridisation 
between the science, market and medical profession logics.  
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Fig. 31. Synthetic view of the stakeholders in the legitimation phase 
At the end of this period, there is a rise of a health citizen, consumer and 
stakeholder. Debates are multiplied and diversified: doctors’ resistance versus 
patient empowerment, peer-2-peer healthcare, quantified self, data protection 
and potential, infrastructure, interoperability, to governance, regulation and 
business models (including reimbursement). 
7.3.3. THE MOBILISATION AGE (2013-2016) 
This stage could also be called ‘democratisation’ (Beverungen et al., 2015; 
Selznick, 1951), because it reflects the levelling of forces in the digital health 
field. ‘Democratisation’ is primarily used in the context of digital technologies 
to signify affordability and access. In healthcare, the term denotes on one hand 
the escape of medical knowledge, of the body and the lab from the traditional 
realm of the healthcare field, to become more accessible and controllable by 
lay people; on the other hand it refers to the availability and affordability of 
technology, which allows for innovation to come from unconventional 
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channels. Not to forget the social side of the digital technology – the sharing 
economy. 
[T]his collective intelligence of this type of group is fundamentally 
superior to that of a traditional position based organisation. I think 
it’s both the emotional and the cognitive drive that creates a reality 
that is unstoppable. (John Nosta, digital health evangelist, opinion 
leader) 
At this stage, most stakeholders (PwC, 2015) enter the field, recognize each 
other as co-participants, establish relationships or build barriers, co-opt and 
negotiate openly. 
State’s uncertainties perpetuate, with difficulties to balance the medical 
profession and market logics. However, the state faces increased pressure from 
digital technology makers who organise and lobby. In the US, the FDA keeps 
changing the guidelines. For instance, in 2015, before data collection ended, 
the FDA exempted wellness applications from regulatory oversight. Alongside 
the FDA, other departments get involved, the National Coordinator for Health 
Information Technology (ONC), the Federal Communications Commission 
(FCC), the Health and Human Services (HHS) and the Centre for Medicare and 
Medicaid Services (CMS). The EU only gets to launch a public consultation on 
mHealth as late as in 2014.  
The eHealth Action Plan 2012-2020 indicated that the rise of mHealth 
is blurring the distinction between the traditional provision of clinical 
care and self-administration of care and wellbeing; and that different 
actors were seeking clarity on their roles and responsibilities in the 
value chain of mobile health. (European Commission, 2014b, p. 10) 
Such hesitation from the state generates uncertainty, confusion and resistance 
from most stakeholders: ICT and CDHT producers, patients, doctors or 
healthcare managers. It seems that neither the state’s actions, nor inactions are 
satisfactory (Macnaughtan, 2014; research2guidance, 2014). More critical 
voices claim that the state is not going to enforce real change (ambivalence) in 
healthcare, due to its own bureaucratic structures and lobby groups. 
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Technology can – and will help – but all too often it’s a tactical 
overlay to try and patch the flawed system we’re living with today. 
(Dan Munro, Forbes healthcare contributor, opinion leader) (Munro, 
2013) 
The technology part is easy. We know how to make this work, but we 
lack the societal will to make it happen. The government can do much 
to push the system along, but device manufacturers, technology 
companies and hospitals need to do the rest. (Anna McCollister-Slipp,  
patient and judge on Qualcomm Tricorder XPRIZE) (McCollister-
Slipp, 2014) 
Despite such turmoil, the use of digital health solutions continues to take off. 
Most medical treatments have been designed for the “average 
patient.” As a result of this “one-size-fits-all-approach,” treatments 
can be very successful for some patients but not for others.  This is 
changing with the emergence of precision medicine, an innovative 
approach to disease prevention and treatment that takes into account 
individual differences in people’s genes, environments, and lifestyles. 
(Office of the Press Secretary, 2015) 
Some commentators have focused only on diagnostic tissue testing, 
but with advances in Genomic testing, big-data collation and linkage 
between large data-pools such as the NHS, the UK is in a prime 
position to exploit a strong scientific base and leadership in this 
nascent market by creating the newest Catapult centre. (Lewis, 2015) 
DeSalvo [at the time ONC Director, then assistant secretary to DoH] 
appears to be listening (“We’re taking a step back”, she told me), but 
voluntarily shrinking one’s own bureaucracy and power has never 
been among our government’s core competencies. (Bob Wachter, 
doctor and professor, opinion leader) (Wachter, 2015, p. 217) 
HHS Chief Technology Officer Susannah Fox5 first told FedScoop in 
June 2015 of her ambitions to drive medical innovation in the hacker 
and maker movement — a phenomenon created by the re-emergence 
of do-it-yourself inventors and physically handy manufacturers 
                                                
5 Susannah Fox was quoted before in this thesis as Assistant Director at PEW Research Centre, 
based on her role at that time. 
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using technological advances like 3-D printers and 
cheap microcomputers. (Mitchell, 2016) 
With the explosion of solutions and PHD volume, ethics and privacy come 
more and more to the forefront. Doctors are being one main stakeholder who is 
wary about these aspects, as being the first line in protecting patient privacy; 
and the state is expected to react, as ultimate guarantor of citizen rights. 
The justification of the means by the end may sound good in theory, 
but I’m concerned about who may get hurt along the way. (…) I’m 
grateful for the thoughtful voices in digital health, who are willing to 
hold up their hands to balance the bright and shiny with the 
responsibility to put it to use within optimal ethical frameworks in 
which it can do the most good. (Sue Montgomery, nurse, opinion 
leader) (Montgomery, 2015) 
Doctors and healthcare managers are now in a state of limbo, in between 
evidence based and personalised approaches, between efforts to increase 
patients adherence to treatment and offering them choice, between the best 
outcomes for populations and the best outcomes for individual patients, 
between what they know and what patients want. 
Like most systems — politics, weather, nutrition — these polarized 
extremes, autocratic paternalism versus loosey-goosey patient 
autonomy, simply lead to degradation of relationships and societal 
frameworks. (Cardin, 2015) 
Most of the time people with good ideas come in (…) but they have so 
little understanding of the context of healthcare that they don't 
understand all the reasons of why it's not going to be successful. (Tim 
Ferris, doctor and manager, Senior Vice President of Population 
Health Management at Partners HealthCare) (Harvard i-lab, 2014) 
These doc-entrepreneurs have waded into the most challenging 
patient populations – the so-called Hot Spotters – and become 
population health heroes. (David Chase, entrepreneur, opinion 
leader) (Chase, 2016) 
If the key to improved healthcare is better knowledge of individuals, 
and if we have better tools for this, where is the breakout success of 
applied data science in healthcare – a company whose success is tied 
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not to selling the promise of individualized care and improving 
health, but who has demonstrably and reproducibly used this strategy 
to deliver better real-world outcomes, in a fashion persuasive enough 
to convince to someone to pay for it? (David Shaywitz, doctor 
entrepreneur, opinion leader)  
[On other obstacles for digital health] Behaviour - making it part of 
regular business processes. Now people are asking for extra money to 
do digital health, while I think it should come out of regular 
improvement. (Lucien Engelen, healthcare intrapreneur, opinion 
leader) 
But where is the integration and the motivation for healthcare 
providers to take part in these conversations in a way that is 
beneficial to their work? And we may have technologies out-there 
saying that ‘you can invite your care providers and you’d have better 
access to them’ and they’re pretty much failing on that promise. We 
haven’t understood the motivations well enough or there isn’t the 
payment structure in place that participation can be rewarded to the 
carers. (Colleen Young, communications, opinion leader) 
Payers are also more willing to consider and reimburse novel solutions, 
especially in the US, following the Obamacare. New, innovative health 
insurers appear - Oscar is one of them, born at the end of 2012, and considered 
to be “[a] post-Obamacare health insurer in New York has big-name backers, a 
tech pedigree, and an eye for data” (Ungerleider, 2014). 
At this stage, there is an increasing digital health uptake from the medical 
community, so there is more hybridisation with both market and citizen logics. 
There are even healthcare providers who have app stores (NHS, Cleveland 
Clinic, Partners Healthcare). In the UK, there is guidance issued by the Royal 
College of Physicians for medical apps (Comstock, 2015b). Several healthcare 
providers (NHS, Cleveland Clinic, Mayo Clinic) have created innovation 
executive roles or departments to facilitate digital transformation. Sometimes 
they hire experts from ICT, showing intense hybridisation with the market 
logic. But, there are still on-going unresolved issues between doctors and other 
participants in the emergent digital health field. 
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Digital health producers continue to grow at a fast pace. Investments keep 
growing year after year and so the number of deals - 2014 almost matches the 
combined funding from the previous three years, and funding in 2015 
surpasses that of 2014. There are mergers and acquisitions (sign of market 
validation and beginning of coagulation). 
2015 was another year of big numbers for digital health—the year 
closed out with over $4.5B in funding flooding into the space, a sizable 
increase in the number of later stage rounds, and 187 M&A deals. 
(Wang, King, Perman, & Tecco, 2016) 
 
Fig. 32. Funding 2011 – 2015 based on RockHealth (Wang et al., 2016) 
In 2013, Scanadu runs the most successful crowdfunding campaign of a digital 
health company (Wikipedia, 2015), proving the faith the market and the 
citizens place on digital health. This also sends a strong signal that innovation 
in healthcare is not innovation as usual and it hints to the democratisation of 
the space. 
[T]his crowdfunding where you say “Come and we will build”, you 
know the reverse of this [n.b. of developing a product first and then 
put it on the market]. Plus, at the same time, you are building it - you 
are building it with a community and also crowdsourcing the legal 
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aspects of this community, and the usability aspects… I think that’s 
one of the biggest new trends of building medical devices now… 
(Walter de Brouwer, entrepreneur, opinion leader) 
I believe it in many ways digital health is defined by the collaborative 
experience. It's no longer about control - where the doctor has 100% 
control or the pharmaceutical industry has 100% of control around 
the messaging for a particular drug product or service. Today control 
is replaced by collaboration. (John Nosta, digital health evangelist, 
opinion leader) 
Research2guidance (2014) finds that 36% of the app developers entered the 
market in 2013 and the first quarter of 2014. The same report shows that there 
are solutions developed by medical specialists (20%) and highlights even a 
category of app developers, ‘helpers’ (32%), with the primary intention to help 
others (ibid.), demonstrating strong hybridisation with citizen logic. Market 
logic is found to hybridise with both challenger (citizen) and incumbent 
(medical profession) logics, and hence its carriers are prone to ambivalence. 
Because it's not what you do, it's not how you do it, it's why you do it. 
You see this all the time in digital health. People come up with new 
ways of measuring blood glucose or a wearable to measure some 
wellness aspect. We know how they do it - leverage technology to 
support some aspect of health. But WHY they do it… the centre of our 
human brain. And human brain is not about function, is about 
emotion. The nonverbal drive - because you want to change the 
world, because you want to save a life, because you want to have a 
better life with your child. (John Nosta, digital health evangelist, 
opinion leader) 
In this day and age, where the explosion of apps, etc., if you don’t 
walk in the shoes of the patient, that is going to be using your 
technology, you’re gonna fail. You’re gonna absolutely fail! (Michael 
Seres, patient entrepreneur, opinion leader)  
The hybridisation process between the market and medical profession logics is 
also reflected in hiring practices, co-founding structures or organisational 
governance. An increasing number of digital health companies have doctors on 
advisory boards. Similarly, hybridisation is revealed by the time and money 
CDHT producers (i.e. Monica Healthcare, SmartInhaler, Wellframe) put into 
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offering their technologies to healthcare or academic organisations for 
research, in the effort to legitimise their products and obtain contextual 
information for perfecting them. More companies present mission-orientated 
founders’ stories. Such founders could be clinicians (Alivecor, Ieso Digital 
Health), caregivers (i.e. Scanadu, myTomorrows) and even patients (i.e. 
11health, mySugr, Sleepio) or other technology or life science specialists (i.e. 
Theranos, 23andMe). 
I would not be in this business if I did not have unrealistic 
expectations of what this company can do in society. (Anne Wojcicki, 
biologist entrepreneur)  
When my father had no more treatment options and was dying of 
lung cancer, I could have given him access to promising unapproved 
therapies because I worked in the biotech industry. When he passed 
away I realized how unfair it was that only I had that option. That’s 
why I founded myTomorrows. (Ronald Brus, doctor and carer) 
Deborah Kilpatrick, CEO at Evidation Health, says during the Innovation 
Summit at Stanford Medicine X (2015) that there are no digital health 
specialists and so we see a dance between data and clinical specialists, which 
leads to the redefinition of outcomes. Such remark shows how digital health 
develops as distinctive field, which requires distinctive capabilities. 
Apple continues to disrupt. It launches the Apple Watch and the HealthKit 
development platform in 2014, but most notably, it creates the Apple Research 
Kit (2015). 
It's really incredible... in the first 24 hours of research kit we've had 
11,000 people sign up for a study in cardiovascular disease through 
Stanford University's app. And, to put that in perspective-- Stanford 
has told us that it would have taken normally 50 medical centers an 
entire year to sign up that many participants.  (Tim Cook, Apple CEO) 
Only a few days after, Apple announces an ethical approval from an 
independent board required for scientists willing to use the Research Kit for 
research (hybridisation with medical profession logic). 
As researchers become comfortable with the idea of running a trial 
exclusively through an app, studies might become riskier. If that 
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happens, developers will likely have to make some changes — changes 
that may include coming up with more secure ways of keeping minors 
from participating in these trials, for instance. (Duhaime-Ross, 2015) 
Similarly, Theranos (US) becomes a disruptor by ‘democratising’ the lab 
(hybridisation with citizen logic). It brings lab testing close to patients, with 
convenient (via Walgreens), cheap, independent of insurance, pain free blood 
tests, patient online access and control over test results. Theranos is perceived 
to defy the traditional peer review process of scientific discovery, by taking 
discovery out of the academic reach (conflict with science and medical 
profession logics) and protecting it through secrecy (market logic) (Loria, 
2015). Its board of directors looks more like a state department than a 
company’s board. Theranos follows all regulatory requirements, but it is not 
shy to push for political change (Office of Arizona Governor, 2015), joining 
other companies, for instance 23andMe, and more recently Walgreens or 
MDlive. Theranos though is shattered by a scandal over regulatory and clinical 
robustness. At the end of data collection, debates were on-going. This is a 
fulsome example of ambivalence in an emerging, fragmented field, as well of 
the vulnerability new organisations have.  
Now everyone is like “Oh, it’s all going to hell! All overrated! Look at 
Theranos… ”. I think now, in contrast, people are getting overly 
negative. And instead of saying “Well, you tried to be disruptive, and 
look at how it’s not worked out”, you think that people were foolishly 
naive to try. (David Shaywitz, doctor entrepreneur, opinion leader) 
The idea of scrutinizing an idea of questioning its clinical validity, of 
looking at its real data to support its use, I think it will, well out of 
necessity, come to the forefront. And with that might come some 
scepticism. I think that companies like Theranos have hurt and helped 
the digital health space. Digital health space because it may have 
directly impacted venture capital, engaging in some ideas that may 
not be completely, fully baked, it may mean investors may not to be 
happy to take the risk. It failed up digital health by a lack of 
transparency and failure to rise above the scrutiny. (John Nosta, 
digital health evangelist, opinion leader) 
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I find both very interesting, and some discouraging, especially the 
Theranos one. So much money has gone into it and it was just a 
balloon. I think there is something there, but the media hype makes 
you unable to see it. No one will ever know because that company will 
never come back I think. (Sara Riggare, patient researcher, opinion 
leader) 
There is perhaps more maturity in how technology is evaluated and various 
shortcomings become exposed and discussed. 
There will be more focus on evidence and proof of value. Federal 
government fined Luminosity a few days ago… I don’t think 
regulatory wise is going to become such a big burden. I think there is 
some good to the regulation, that things function as they say. The 
biggest issue is going to be too many companies and too little 
evidence. And the ones who can’t prove it are not going to make it. 
(Lisa Suennen, investor, opinion leader) 
However, CDHT companies begin to expand on their solutions. There is still a 
significant amount of experimentation, serendipity and business model 
morphing.  
I spoke to her [n.b. one of Empatica’s co-founders] at the ethics 
conference last summer, and I think one of the things they are doing: 
extending applications of existing technologies. (…) With Empatica - a 
device to help with communications, one of her students took it home 
over the Christmas break because her brother was autistic and 
wanted to work with him. And she was monitoring the data in the lab 
and she saw this tremendous spike in his brother’s data at one point. 
A few minutes later… her brother has a seizure. And so they found 
that they could anticipate when these seizures happen. (Sue 
Montgomery, nurse, opinion leader) 
The enthusiasm for wearables is apparently curved (Mark Sullivan, 2015). 
There are perceptions that digital health looks to empower the super-healthy, 
less a person who suffers from an illness. 
A fitness tracker could be programmed to encourage more activity up 
to a point, and then warn the user to slow down as the step count 
grew too high. But the marketing campaign for that type of product 
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would discourage sales growth. (…) When people develop technology 
for patients, they often don’t even consult with a single patient. (Carly 
Medosch, patient) 
Despite such concerns, Rock Health releases in 2015 a report on consumers’ 
attitudes towards digital health, which shows that wearables occupy the 
majority of the landscape and that there is actually a spike in adoption by 
people with health problems. 
 
Fig. 33. Rock Health data on wearables adoption (Gandhi & Wang, 2015) 
Although health apps download rates are increasing, so are the uninstall ones 
(research2guidance, 2014), and engagement remains modest (Ayogo, 2015; 
Dias, 2014; Fox, n.d.; Pennic, 2015; Salber, 2015). This becomes a major 
preoccupation for CDHT producers, as user engagement represents part of the 
market validation of the product. Nonetheless, the market is learning fast given 
the estimated 160000+ health apps on the major app stores in 2015 (IMS 
Institute, 2015). 
There are more than twice as many health apps as there were in 2013, 
but whether those apps are better tools for doctors and patients is a 
mixed bag: while apps today are more likely than two years ago to 
connect to another device or wearable and more likely to connect to 
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social media, they are no more likely to connect to provider systems 
or to have more than one function, according to a new report from 
IMS Health. (Comstock, 2015c) 
 
Fig. 34. Apps segmentation in 2015 (IMS Institute, 2015, p. 4) 
Many connectors, integrators, and data analytics companies who mitigate 
various aspects of adoption, integration, security, and interoperability enter the 
field. Such intermediary services (i.e. Validic) appear to have the highest 
revenues (Research2guidance, 2014), proving the need for filling in 
information and skill asymmetries across fields – i.e. healthcare and digital 
health, pharma and patients, or CDHT and patients. Such multifaceted 
hybridisation points forge crossovers, new practices, new boundaries, and 
therefore reflect the on-going process of institutionalisation in the nascent 
digital health field. 
Overall, there is a light segmentation of the market, although categories remain 
fluid. Such categories may be: wearables/insideables, artificial intelligence, 
telemedicine, consumer engagement, health tracking, analytics and big data, 
payer or hospital administration, EHR, gamification and virtual reality. 
I think we are already seeing that: there are enterprise-focused 
technologies (employer, insurer, government, provider), there are 
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patient and consumer focused solutions and there are different 
verticals - administrative focus, clinical focus. (Lisa Suennen, 
investor, opinion leader) 
During this age, the most significant entrance is made by pharma. A report 
claims that patients consider pharma companies “responsible” to engage with 
them (Accenture, 2014). A similar message came across during the Patient 
Opinion Leaders and Pharma session (at Doctors 2.0 & You, Paris 2015). 
“Responsible” being the right choice of words or not, the fact remains that 
pharma looks to engage with patients via CDHT, and therefore to hybridise 
with the citizen logic. Dr. Wolfgang Renz, Corporate Vice President, 
Boehringer Ingelheim, says that pharma gets the idea that wellness, preventive 
medicine, and mobile health are the future, but their regulatory regime is so 
strict that the industry did not yet find a formula (plenary talk mHealth 
Summit, Berlin 2014). Neil Jordan, Worldwide Director of Microsoft Health, 
considers that pharma is the game changer in digital health (plenary talk DHL, 
Dubai 2015). With the release of the Apple Research Kit, 2015 seems to bring 
a new wave of enthusiasm in the pharma industry. Some pharma companies 
branch out and start investing in digital health (i.e. Bayer’s Grants4Apps), as a 
‘beyond the pill’ approach (Jain, 2015). Other promising avenues for pharma 
mediated by CDHT are personalised medicine, genomics and lifestyle 
(Accenture, 2014; Gerber, 2015; Jain, 2015; Merrill Thompson, 2015; Validic, 
2015; Xavier, 2015).  
That said, there are a lot of efforts underway to address medication 
adherence, from Boehringer Ingelheim and others’ pilots with 
AdhereTech, to Novartis’ work with Proteus Digital Health, to 
Johnson and Johnson’s huge, unbranded Care4Today mobile 
platform. (…) “And the intent is to show that the drug plus the digital 
solution is more efficacious than the drug itself, and the competing 
drug. I think it’s that kind of success that will prove to the industry 
this is no longer a science experiment, this is something that can be a 
game changer”. (Comstock, 2015a) 
The academic world continues to explore (with ambivalence) new digitally 
mediated avenues: patient engagement, service redesign, genomics, 
personalised medicine and so on. There is a push for using PHD for the “public 
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good” (RWJF, 2015; University of California, 2014). It has been shown that in 
times of crisis (emergence is similar to institutional crisis because it is a 
contested space), different actors have to negotiate over different definitions of 
the “common good” (Patriotta et al., 2011). Opinions are divided on the need 
for privacy and PHD use for scientific advancement (Heubl & Saafeld, 2014). 
“In some contexts, digital users are the willing generators of personal data; in 
others they are the objects of imposed data surveillance. Programs for eliciting 
and responding to these data are proliferating within government and 
commercial environments” (Lupton, 2014c, p. 8). In this context, a new 
business opportunity appears: health data banks for citizens to allow them to 
own, control and share their health data (Our Data Mutual in UK, healthbank in 
Switzerland, or datacoup in US, Cancer Moonshot initiative in the US). When 
debating the PHD worth, ownership and control, there is increased 
ambivalence between citizen, market, science and medical profession logics. 
This type of debate proves that digital health is still emerging, with no clear 
rules of the game or ownership (Fligstein, 2002). 
While you might dismiss this as a publicity stunt, I was struck by the 
comments of the company’s founder and CEO, Charles Dunlop, who 
has been diagnosed with advanced prostate cancer, according 
to Times, and is keen to share rather than hoard or sell Ambry’s data 
because, in his words, “I don’t want to wait an extra day.” (David 
Shaywitz, doctor entrepreneur, opinion leader) (Shaywitz, 2016) 
Atul Butte, professor at University of San Diego, considers that we got so far 
in the democratisation of science and technology, the transformation runs so 
deep, that we should expect to see biotech garage startups soon (Atul, 2015). 
Citizens mobilise and their voices are getting louder, more empowered.  
Patients and caregivers need to bravely step forward again and 
again to talk about the problems in the healthcare system. (Regina 
Holliday, carer, opinion leader) (Holliday, 2015, p. xx) 
Social change and technical change are hard. But people’s lives are at 
stake, and that’s something worth doing hard things to improve. We 
can do it; they can do it. (…) Plan for action, and bring friends. It will 
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affect them, too. (Dave deBronkart, epatient, opinion leader) 
(deBronkart, 2015) 
For those of us with chronic disease, a digital health revolution is the 
best chance we have. We need it to succeed. We’re desperate for 
innovation that works. We have experienced tremendous 
developments and intuitively grasp the potential, but when we peruse 
the app store and download a few, their usefulness rates as “meh” at 
best. (McCollister-Slipp, 2014) 
Patients are for the first time recognized by a medical journal, The British 
Medical Journal, as legitimate stakeholders.  
“The BMJ‘s patient partnership strategy, launched in 2014, 
introduced innovative internal editorial changes aimed at making 
patient partnership integral to the way the journal works and thinks. 
We did this because we see partnering with patients, their carers, 
community support networks, and the public as an ethical imperative 
essential to improving the quality, safety, value, and sustainability of 
health systems.” (The BMJ, n.d.) 
The role of the patient is now more and more theorised. There are now patient 
advocates/opinion leaders (i.e. Regina Holiday, Dave deBronkart, Michael 
Seres, Britt Johnson), patient experts (usually the ones who are suffering from 
a chronic condition), patient researchers (i.e. Emily Kramer-Golinkoff or Sara 
Riggare), patient entrepreneurs (patients who design solutions based on their 
personal experience with the disease – i.e. Michael Seres). The conversation 
around the patient role moves from patient engagement to empowerment, to 
participation and even to leadership. 
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Fig. 35. Patient engagement represented by a CDHT producer (Ayogo, 2015) 
Learning to take emotion out of a decision is hard. It is especially 
hard when you are building a technology based on your own personal 
experience. Every day I strive to make our technology the best it can 
possibly be. (Michael Seres, patient entrepreneur, opinion leader) 
(Seres, 2015b) 
 
Fig. 36. Synthetic view of stakeholders in the mobilisation phase 
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During mobilisation, by the time data collection ended, digital health gets 
crowded, not only with apps, wearables, insideables, but with new players 
(pharma, integrators, intermediaries). The language diversifies, with some 
terms becoming prevalent and new ones appearing: wearables, insideables, 
apps, expert patient, gamification, health 2.0 or Big (Health) Data. This period 
marks the beginning of some digital health differentiation: based on focus 
(wellness, health), type of information collected or offered (monitoring, disease 
management, education), users (wellness users, patients or doctors) and finally 
by type of interaction (consultation, diagnostic, disease management, education 
or administration). It is important to bear in mind that these new categories are 
in flux, as reflected for instance in market reports like those produced by Rock 
Health. This means that the field is still evolving and revolving, in pockets of 
negotiations. I call this granularity of the field, when categories and 
relationships are still in flux, and evolve in fluid, morphing ecosystems. 
 
Fig. 37. Type of market segmentation (incomplete) (Wang et al., 2016) 
Debates over the role of each stakeholder are on-going, showing the 
institutional complexity, the unfinished institutionalisation, and the power 
struggles in this field. An excellent example is offered by the “Twitter 
firestorm” caused by Mark Cuban, a US businessman, who on April 1, 2015 
wrote three tweets that caused intense debates: 
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 1) If you can afford to have your blood tested for everything 
available, do it quarterly so you have a baseline of your own personal 
health 
2) create your own personal health profile and history.It will help you 
and create a base of knowledge for your children,their children, etc 
3) a big failing of medicine = we wait till we are sick to have our blood 
tested and compare the results to "comparable demographics (Mark 
Cuban, business man) 
The intense social media turmoil over the next 48 hours was documented by 
Dan Munro, who concluded:  
Simply saying we shouldn't do something because we don't know the 
value ‒ and there is risk ‒ seems to be an especially weak argument at 
the same time as trying to engage people more directly in their health 
and well being. Mark knows this personally and just pre‒empted 
what he's already seeing in the market. We may not elect to 
participate in the experiment ‒ but that doesn't mean the experiment 
itself doesn't have value ‒ or that it shouldn't be recommended for 
those who can afford it by someone who's actually doing it. The 
technology has arrived. Patients will decide what works best for them 
and we should let them. 
7.4. DIGITAL HEALTH, A MELTING POT OF POSSIBILITIES AND ISSUES 
In this chapter, I show how digital health interstitial emergence takes place 
with the gradual involvement of stakeholders. Their engagement with 
innovation opens up the digital health space, by tackling discontinuities in the 
healthcare system, expanding the understanding of healthcare from illness to 
disease and connecting stakeholders in ways that were not possible before. 
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Fig. 38. The digital health continuum 
The diagram above intends to present intuitively how digital solutions impact 
across the spectrum, from the social side to healthcare and science. All players 
have their specific inputs into the field expansion and institutional evolution. 
For instance, on the social side, we have examples from patient forums/groups 
to patient networks, and even to citizens donating via crowdfunding. Moreover, 
there are citizens contributing to medical science too – Cancer Research UK 
develops games where lay people could help scientist fight cancer. 
Play to Cure: Genes in Space is Cancer Research UK’s second Citizen 
Science project – last October the charity launched Cell Slider TM in 
partnership with the Citizen Science Alliance, which reduced the time 
it would take for researchers to analyse a subset of archived breast 
cancer samples from 18 months to just three months – with more than 
200,000 people classifying almost 2 million cancer images. The aim is 
to help Cancer Research UK scientists with their research to better 
understand breast cancer risk and response to treatment. (Cancer 
Research UK, 2014) 
Without the digital intermediation, such mass contributions from people to 
science would have not been possible. The orange dotted line shows how the 
social side and the science converge towards healthcare, barriers being eroded 
over time. Similarly, the conversation shifted from healthcare being focused on 
illness only, to prevention and enhancing health. However, the closer an 
innovation came to illness, the heightened pressure to comply with incumbent 
 169 
logics (medical profession, state and science). The purple dotted line represents 
how new connections are made across the spectrum via digital solutions and 
devices. 
These new interactions challenge the traditional power relationships and thus 
lead to a continuous morphing of all roles, pushing the citizen to the forefront. 
Solutions like those above developed by Cancer Research UK allow people to 
contribute to science. There are also other examples of solutions where 
stakeholders outside the traditional healthcare field contribute to the demise of 
status quo (Scanadu’s crowd funding campaign for instance, 23andMe and 
Theranos getting involved in changing legislation and working with 
regulators). Such diversified participation gives the sense that digital health 
develops similarly to a social movement. 
 
Fig. 39. Digital health’s inflated agenda - citizen centred representation (Macnaughtan, 
2015c) 
The figure above shows how all these innovations brought to the fore a 
multitude of opportunities that have at centre a new patient or health aware 
citizen. However, various challenges accompany these opportunities, from new 
roles and practices, to adoption, to evidence or regulation.  
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During this phase, the terms “democratisation” and “uberisation” of healthcare 
are very much used and even if they would fade over time, they have a great 
bearing on the sense making and sense giving at the field level. They are 
metaphors for misalignments and desired realignments between the digital 
technologies and healthcare fields. They also indicate the increasing influence 
of the market logic. Democratisation reflects primarily the change in the 
balance of power, with the increased influence of the citizen logic. Eric Topol 
writes a second book in 2014, as influential as the first one, The Patient Will 
See You Now, dedicated to precisely the role the patient and technology will 
disrupt healthcare at its core. He considers the proliferation of smartphones to 
be a moment similar to the Gutenberg one (E. J. Topol, 2015).  
So we are seeing a magical time in human history that some people call 
Gutenberg moment, the printing press moment. I would argue that it’s even 
bigger than that - it’s not only one technological achievement, it’s multiple 
technological, human and social achievements. (John Nosta, digital health 
evangelist, opinion leader) 
Just as the printing press democratized information, the medicalized 
smartphone will democratize health care. Anywhere you can get a mobile 
signal, you’ll have new ways to practice data-driven medicine. Patients 
won’t just be empowered; they’ll be emancipated. (Eric Topol, doctor, 
opinion leader) (E. J. Topol, 2015) 
They [n.b. the smartphones] will perform blood tests, medical scans, and 
even parts of the physical examination. Topol calls this “bottom-up 
medicine”, in which digitally empowered patients will truly take charge of 
their own health care. Just as smartphones and social networks powered the 
uprisings of the Arab Spring, in Topol’s view they are now poised to bring 
democracy to medicine. (Jauhar, 2015) 
The democratisation of healthcare also means that innovation is now coming 
from unconventional routes, not only from clinical/research centres, pharma or 
medical device companies, but also from CDHT producers and even citizens. 
The implications are that basic roles, practices, business models and 
governance are being challenged. The state finds itself eventually not being 
able to grasp and cope with the pace of innovation. “Regulators seem to have 
difficulties in both identifying and clarifying the basic principles in which to 
ground these (de)regulations. There are a few themes which return obstinately 
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in regulatory debates: data, patient, disease and medical device” 
(Macnaughtan, 2014). 
With the democratisation of healthcare, there is an increasing debate over the 
democratisation of medical education itself, a field that didn’t change in over a 
century - from 3D models of the human body, collaborative learning, gamified 
information delivery systems and evaluation, to the potential of virtual and 
augmented reality. Stanford Medicine X launched in 2015 the first event on 
medical education.   
Medicine X | Ed will focus on the future of medical education in the new 
Millennium, the role technology and networked intelligence might play in 
driving educational innovation, the new challenges facing health care 
education in the new Millennium, as well as the need to change the culture of 
medical education to be more patient-centered, participatory and patient-
safety-focused. (Stanford Medicine X, 2015) 
The uberisation of healthcare points to the dream of a perfect market in 
healthcare, where demand will instantly match the need, for the right price and 
the right quality. This means that low cost medical providers will disrupt the 
expensive ones; that telemedicine, do-it-yourself and other models will disrupt 
what we know about doctor-patient, patient-payer, doctor-payer relationships. 
Uberisation also is also about connectivity and ubiquity and the unfinished 
character of digital technologies. Digital health opens doors for both new modi 
operandi and new connections to be made. Inherent to mobile, digital, sensing 
technologies are attributes like availability, universality, serendipity, 
affordability and immediacy. Digital technologies respond to and enable a 
highly “adaptive” generation (Sculley, 2014), with little regard for traditional 
ways of doing business, prescriptions and channels. Such behavioural and 
cultural propensities would eventually transfer to expectations from healthcare, 
as an essential part of an autonomous, mobile and connected life. 
  
 172 
7.5. INSTITUTIONALISATION PROCESSES 
Institutionalisation processes are both hybridisation and conflict, with 
increased prevalence of the former. The conflict unfolds initially as resistance 
from powerful incumbents (doctors) and almost ignorance from challengers 
(CDHT producers and citizens). The entrance of other players with more 
neutral stances towards the rival logics (consultancy companies, academic 
organisations) allows for increased hybridisation. This does not mean that 
conflict evaporates, but only that the interstitial space constantly opens up, 
forming a critical mass. 
The ambivalent responses of most stakeholders denote the on-going 
negotiation and legitimation processes, as well as the heightened degree of 
ambiguity. The granularity of the field allows for the development of 
concurrent pockets of negotiations that represent proto-ecosystems (i.e. 
alliances, networks, research initiatives, hybrid organisations, industry 
associations). This granularity allows for ambivalence, without being a threat 
in itself for the field or incumbent organisations (Waldorff et al., 2013). 
The multiplication of players and institutional logics erodes the incumbent 
logics (state and medical profession) and facilitates the rise of the citizen 
challenger logic. This makes the digital health emergence resemble a citizen 
rights movement (Fligstein & McAdam, 2011). And last, access to resources 
plays a significant part in the interstitial emergence of the field, from the 
creation of a bandwagon effect, to the co-optation of incumbents (doctors, 
pharma) via incentives and penalties (from payers and regulators) or prospects 
of alternative resources (investors, crowd-funding, academic centres, new 
market opportunities). Digital health is possibly one great example of 
disruptive innovation, as Schumpeter envisions it, because it causes a 
paradigmatic change. Not only the technology evolved, but… 
[t]he combination of passive (sensor mediated) observation and 
proactive life-style strategies for disease suppression can define a new 
era of health and wellness. (John Nosta, digital health evangelist, 
opinion leader, (Nosta, 2013) 
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7.6. THE DIGITAL HEALTH FIELD EMERGENCE  
I show how digital health emerges through three phases, by the time data 
collection ended, the ingenious, the legitimation and mobilisation stages. The 
ingenious phase is characterized by genuine experimentation, serendipity, 
opportunity recognition and by the fact that initially the interstitial emergence 
goes unnoticed by some incumbents (i.e. healthcare, pharma). Mobilisation 
engages a critical mass of stakeholders and brings in alternative practices, 
which cause intense institutional negotiations. My findings introduce a stage 
between the ingenious and mobilisation stage – legitimation, as a stepping-
stone between the two. In digital health’s case, political legitimacy was 
conferred from the outset by state commitment and citizen uptake, during the 
ingenuous phase. Social legitimacy is co-constructed through the initial 
interaction of stakeholders and, more importantly, through legitimising 
(academia) and mediating actors (consultancies, other intermediaries) who are 
capable to co-opt more resistant stakeholders (herein doctors and pharma). 
At the time I finished the field research, digital health was still in its 
mobilisation stage, with most stakeholders being active in the field. During 
mobilisation, there is certain granularity in the emergent field. This is different 
from segmentation, which takes place only when there is significant decrease 
in uncertainty and ambiguity that allows stakeholders to organise on various 
levels and around value propositions. This degree of clarity was not attained by 
digital health by the time my research ended. However, the granularity of the 
field, means that there are proto-ecosystems, where stakeholders try, 
experiment and negotiate various aspects of certain innovations (Jacobides et 
al., 2018), without threatening field survival.	  
It is beyond my research to foresee the future of digital health - if this field is 
going to get to stabilisation, how it’s going to be segmented, if it’s going to be 
absorbed by adjacent fields… It is clear though this is a space where healthcare 
related innovation comes from untraditional places as well – digital consumer 
technology producers, patients, and citizens, at large. To this end though, many 
others in this rising field share Lisa Suennen’s observation: 
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I am not sure that digital health should be a concept at all anymore, 
or ever. In no other industry we talk about the technology driving 
that industry separate from the industry itself. (Lisa Suennen, 
investor, opinion leader) 
7.7. THE HYBRID ROLE OF THE EMPOWERED PATIENT 
Digital health brings forth a new hybrid role: the empowered patient. An 
empowered patient, who self-educates and manages their own health and 
wellbeing, challenges the traditional healthcare settings at its core: professional 
authority (Abbot, 1988; Nicolini, 2006; Petrakaki et al., 2012). In this way, this 
role is a proto-institution, the epitome of the citizen logic in digital health. 
  Old Patient New Patient 
Doctor encounter Illness 
Illness, wellness or neither (DIY, 
peer 2 peer, CDHT) 
Control over 
interactions 
Doctor Convenience 
 
Discontinuous Continuous, via data streams 
Focus of attention Symptoms In addition, self-generated data 
Validation of diagnostic Lab tests 
Over the counter tests, self 
quantification  
 
Doctor expertise 
Doctors, peers, crowd wisdom, 
automated analysis/processes 
 
Physiological measurements 
by doctors 
Self-generated data 
Treatment Doctor Patient choice 
 
  Peers, alternative references 
Control over treatment Treatment adherence 
 
Patient participation 
Transparency 
Support and education 
Doctor and other non-doctor 
medical personnel 
Peers, internet sources 
Outcome Cure illness  Personal satisfaction/values 
 
 
Clinical outcomes 
Cure illness, improve health or 
wellness 
Patient reported outcomes and 
satisfaction 
Table 12. Towards the empowered patient/citizen 
Between the view of an empowered patient who quantifies themself, self 
manages, even diagnoses, provides knowledge advancements and the view of 
the vulnerable patient (Lupton, 2013, 2014d) who faces illness, confronts with 
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specialist data, needs support from doctors and even the state, there is still a 
large gap, where the concept of “loosey-goosey patient autonomy” (Cardin, 
2015) reigns, for which even digital health does not offer a solution yet. I name 
this a hybrid role, because it brings together the vulnerability of a person, with 
the right to choose, the ability to choose (Seres, 2013b, 2013c) and the 
combined ability and desire to self quantify, self manage or even self diagnose. 
The conflict between the citizen and the medical profession logics may present 
in many ways. To mention a few: patients may expect to have total control 
over PHD, patients may not consider doctors as the only source for medical 
advice, or patients may expect to be partners in their diagnosis and treatment. 
Doctors, who used to rely on statistical evidence for groups of patients, are 
now under pressure to take more precise, personalized approaches. How would 
all these changes impact healthcare providers, insurance or pharma companies 
in the long run is difficult to predict. It may create new roles - health data 
specialists, health coaches, health management and wellness providers - or 
completely new lines of business and research; time will tell. 
7.8. CONCLUSIONS 
This chapter reveals the evolution of the emergent digital health field and so it 
provides context for the analysis at organisational level. Changes in the 
institutional space are marked by intense processes of hybridisation and 
conflict, which eventually allow for the citizen logic to strengthen. The 
evolution by the time data collection ended goes through three main stages: 
ingenious, legitimation and mobilisation phases. During the last phase, the 
digital health space expands, opens up to many stakeholders, blurs boundaries, 
allows for unconventional paths to innovation in healthcare and challenges the 
existing power relationships, practices and even regulations. All these 
processes are possible due to the granularity of the field during mobilisation. I 
highlight the emerging role of the empowered patient/citizen as being central to 
the field institutionalisation as a whole and to the institutional work at 
organisational level, as it will become clear in the next chapter. 
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CHAPTER 8. ORGANIZATIONS IN DIGITAL 
HEALTH COMPLEXITY 
8.1. INTRODUCTION 
In this chapter, I analyse how three organisations undertake institutional work 
to navigate the complexity of the digital health emergent field. My findings 
indicate that there are several conditions that influence organisational 
responses to complexity: the position in the field, the plurality and ambiguity 
of the field, the represented future and the identity project. The position in the 
field determines the co-optation of key stakeholders to allow organisations to 
build competencies, access resources, gain legitimacy and build a market. Such 
co-optation processes allow for the hybridisation of logics. The institutional 
pluralism and ambiguity of the field present both challenges and opportunities 
for organisations. Organisations show flexibility and adaptability and become 
true institutional agents. And not last, organisations will respond differently to 
complexity depending on the represented future and their identity project. 
Social skills and leadership prove to have material consequences in 
organisational development in a new world. 
8.2. BRIEF OVERVIEW OF THE ORGANISATIONS 
Before proceeding, it is useful provide a brief refresh on the three companies: 
Mira Rehab, YouLife and 11 Health. 
Mira Rehab is developing exergames, clinically based video games that 
incorporate exercises and movements with game interaction. To that end, they 
integrate sensors, at the time of study Microsoft Kinect, to support clinical 
physiotherapy. It all started when four Romanian master level students 
(business, engineering and IT) decided to join a student competition and they 
ended up amongst the ten finalist teams of the international competition 
Microsoft Imagine Cup, 2011. Following an invitation by HealthBox, a 
London digital health accelerator, to participate in their programme, they 
founded the company in 2012. Mira Rehab has been operating ever since in 
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both the UK and Romania. It is relevant to mention that at the time of 
founding, the company had a minimal viable product (MVP). They had 
investments from two angels in Romania, followed by HealthBox. Products 
were sold mainly in UK and Romania, with commercial interest from other 
countries in Europe, mainly via a B2B model, although a B2C model was not 
dismissed, just not actively pursued as a line of business at the time of the 
study. 
YouLife is a company founded in the UK, which provided corporate client 
solutions for assessing personal health risks. Over the years, they have 
developed specific questionnaires, based on national clinical guidelines for 
specific health risks (chronic diseases, cancer), and also offered an overall 
score. Some of these were developed in collaboration with universities in the 
UK. In 2014, the board decided to pivot into digital and change from a 
business to business (B2B) to a business to consumer (B2C) model. YouLife 
had produced digital products previously for corporate clients: a website with 
specific access for management and personnel and an app (OtherLife). Despite 
that, they considered that the transformation of the company needed to be 
separated from its previous endeavours, as a radical change. Therefore, they 
have started a completely new product and business model, here named 
NewLife. The company self funded the development by diverting revenue from 
the legacy business. The NewLife app went live in 2015, via app stores, as a 
B2C model. 
11 Health is a company based in the UK, founded in 2013. In 2015, it started 
operations in the US as well. The company produces a device, containing a 
sensor, which is attached to a stoma bag and, via an app, it supports the 
condition management for patients, and later for medical professionals. 
Michael Seres, the founder, came up with the idea following his own 
experience as a patient using a stoma. An angel investor invested in the 
company initially and so it was funded in in 2013, having a prototype ready, 
with a B2C model, followed later by B2B and B2B2C models. 
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8.3. TAMING LIMINALITY 
As part of a new emerging field, organisations are peripheral to the adjacent 
fields, in this case to healthcare, academia, other digital technologies fields, 
amongst others. I have shown in chapter 7 how the liminal field of digital 
health expands from fundamental science and research to the consumer digital 
technologies, and how different logics have greater relevance on organisations 
depending on their position on the continuum. The figure below shows where 
on the digital health continuum each organisation is situated, based on the 
solution offered. 11 Health is the closest one to healthcare, offering a solution 
initially designed for patients living with chronic conditions who have a stoma 
bag attached and are hospitalised during the process of their medical condition. 
Mira Rehab is also close to healthcare, because it’s initially designed for 
patients who need physical recovery, but are not necessarily hospitalised 
during the management of their medical condition. YouLife, with its NewLife 
offering, situates closer to the consumer digital market. It offers a health risk 
assessment and it’s not meant to diagnose or treat a medical condition. 
 
Fig. 40. 11 Health, Mira Rehab and YouLife on the digital health continuum 
Their position determines their orientation and interaction with other 
stakeholders. This position is not static; it is subject to evolution, given the 
emergent nature of the field and the novelty of the ventures. All three 
companies, since their inception and even at short interview intervals (a few 
months), showed a realignment of their product and/or strategy. For instance, 
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11 Health evolved from a product designed for patients only to having more 
products for other stakeholders. At the end of 2015, they were launching an 
app for hospital staff – doctors and nurses. The app designed for patients also 
got an enhancement by getting integrated with the Apple Watch (a wearable). 
 
Fig. 41. 11 Health product offering at the beginning of 2016 
Mira Rehab, following an SBRI grant, began developing their product to 
accommodate specific needs for the aging population, i.e. cognitive 
improvements and fall prevention. This became a new business segment, closer 
to a consumer model. 
Most companies recognised their main stakeholders, including the regulator. 
With one exception, 11 Health, none of them got directly involved with 
regulators, aside from complying with the rules they recognised as being 
applicable to them. Mira Rehab and 11 Health had the CE mark for their 
patient facing technologies, and 11 Health also had FDA approval.  
In 11 Health’s case, Michael Seres had previous interactions with regulators as 
a consequence of his active presence online as a patient.  
My big breakthrough came on the World Inflammatory Bowel 
Disease day, in May 2012. I was invited to speak in Brussels, at the 
European Parliament. Flights were booked and then I caught an 
infection. (…) So we agreed to do a Skype live link to the European 
Parliament, except the nurses came in and told me I need to swallow a 
radioactive egg to see how my stomach was emptying. So, from the 
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depths of some CT scanner, we did a Skype link to Brussels. If only 
they would have actually known where I was and what I was doing, it 
could have been interesting, but they didn’t. (Michael Seres, CEO, 
founder 11 Health) (Seres, 2013a) 
Michael Seres maintained his involvement with regulators in the UK in 
different capacities. For instance, he was collaborating with NICE to bring in 
patients for evaluating technologies. His company was also working with 
regulators to find ways to prescribe and reimburse digital products inside the 
NHS. This type of involvement is representative for the type of work early 
ventures in an emergent field have to undertake and that requires additional 
resource which are already scarce (Aldrich & Fiol, 1994). This kind of work 
would benefit the entire field, in time. To that end, Michael’s double capacity, 
founder and patient advocate, turns him into an entrepreneur beyond his 
organisation - an institutional entrepreneur. 
Mira Rehab worked within the existing regulatory constraints and did not 
engage directly in specific actions aimed at regulators. However, the 
significant SBRI grants in the UK not only gave them legitimacy, but also 
informed the state agency on the value of their products. YouLife, on the other 
hand, did not engage with regulation further than considering the broad 
requirements for handling personal data in the digital space. It may be that it 
did not see itself as a healthcare company and therefore did not make any 
formal moves in that direction. However, they had to comply with certain 
regulations in relation to data privacy for the healthcare sector, as they found 
out in France, more than in the UK. Therefore, their business representative in 
France was a strong advocate for a role designed to make sure that compliance 
related to data is ensured for every region. 
Data is far more then this; it’s all the legal compliance. (…) To me it 
would be the key knowledge within the company. (…) If we intend to 
use this free app as trigger to sell (…), we have to be aware of possible 
issues that may be local. Only if we understand where the limits are, 
we can move forward. (B. F., business development, YouLife). 
In respect to other stakeholders, all organisations engaged for two main 
reasons: product development and legitimacy. Mira Rehab recognised itself as 
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agnostic of healthcare. Despite the fact that the first product layout was to 
support patients to undergo physical therapy at home, their main, longstanding 
efforts were to engage with clinicians. The advice they recognised as most 
significant and often encountered even before they formed the company, was 
that they needed clinical input. Consequently, they looked to engage with 
doctors and physiotherapists from the very beginning. They needed the clinical 
knowledge, as they considered that they only put a digital layer over a specific 
medical practice, as Cosmin Mihaiu (co-founder Mira Rehab) expressed it. To 
that end, they established connections with medical professionals before they 
founded the company, in Romania at first. Then, they brought in very early on 
an advisor, Bibhas Roy, consultant orthopaedic surgeon, with whom they 
maintained a long lasting working relationship. They also ran significant 
research with the University of Manchaster, UK. On the side, they continued to 
work with orthopaedists, neurologists and physiotherapists in Romania. 
However, they had a significant role in developing the product, even in matters 
that were apparently more pertaining to the clinical side. 
We were reading on the internet and then we were going to a medical 
specialist and we were asking if it's ok that movement. (Andrei 
Dascalu, co-founder Mira Rehab) 
Interviews inside Mira Rehab reveal how much regard they have for healthcare 
professionals’ input and how much this helped improve their product. They 
also show appreciation of how open-minded medical professionals were 
towards them, even though they were “only IT” people, with no medical 
background. They recognise that their product is co-created with their external 
collaborators with medical background. 
As for the patient perspective, the product was actually built around the idea 
that Cosmin Mihaiu had, based upon his own experience as a patient. Cosmin, 
in his TED talk at the beginning of 2015, tells his own story and explains the 
purpose of the company. 
When I was growing up, I really liked playing hide-and-seek a 
lot. One time, though, I thought climbing a tree would lead to a great 
hiding spot, but I fell and broke my arm. I actually started first grade 
with a big cast all over my torso. It was taken off six weeks later, but 
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even then, I couldn't extend my elbow, and I had to do physical 
therapy to flex and extend it, 100 times per day, seven days per 
week. I barely did it, because I found it boring and painful, and as a 
result, it took me another six weeks to get better. (Cosmin Mihaiu, co-
founder Mira Rehab, 2015) 
In Mira Rehab’s case, the involvement with the patient was also mediated by a 
foundation set up in Romania, called Un zâmbet cu Mira (A Smile with Mira). 
This foundation offered physiotherapy to children, particularly children with 
difficulties in accessing that type of medical care. 
Their involvement with medical professionals drove their further involvement 
with patients and carers. On the blog section of their website, there are singular 
case studies that reflect some very profound interactions. 
Trying to quantify Timi’s progress after 2-3 months of using MIRA 
and Kinesiotherapy is certainly not easy. (…) Beyond this, whether 
playing as Izzy the Bee trying to pick up flowers or The Submarine 
searching for treasures, Timea has improved her ability to focus and 
her willpower. ”She’s like a CD, you just have to burn files on it, day 
after day, with patience and confidence”, says her mother while tying 
Timi’s shoes. (Teodora-Gabriela Fleseru, MD, Paediatric Resident, 1st 
Paediatric Clinic, Cluj-Napoca and Silaghi Ciprian, Kinesiotherapist 
at A smile with MIRA, Cluj-Napoca) (Fleseru, 2016) 
With their focus on clinical evidence, they recognised early on the relevance of 
interacting with the academia. So much so, that Alina Călin started very early 
on to manage the scientific side of the business, and they proved to be 
successful in securing several research and combined research and 
development grants. The interaction with the clinical and academic world, also 
offered Mira Rehab the legitimacy needed for investors, and healthcare at 
large, based on all four co-founders accounts. They turned their business model 
around from an initial B2C to a B2B model, as explained by Andrei Dascalu 
(co-founder Mira Rehab), in terms of strategic priorities: obtain validation by 
prestigious institutions, try to transform them into sales contracts and home 
recovery became last. They considered that the ground work with clinicians 
and academia would establish them as trustworthy all around, as well as 
keeping transparent communications via their website and social media. In 
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2015, they have launched the blog side of their website in order to maintain an 
on-going presence online and to offer more insights into what they were doing 
and what their company was about. 
11 Health, being founded by a long-term patient, came into being with a deep 
understanding of both being a patient and having that specific medical 
condition. Michael Seres had been a patient since he was 12 years old. Before 
even thinking of a company, he started a blog online, “Being Patient isn’t 
Easy”, which, amongst others, documents a large part of his experience as an 
adult patient. In that way, he was involved on social media with patients, 
doctors and general public too.  
Most of you here today that use social media, you’ll recognize this 
social media stage. I used about six out of nine of these tools to 
communicate with patience, healthcare professionals, family and 
friends around the world. (Michael Seres, CEO, founder 11 Health) 
(Seres, 2013a) 
In this way, the company involved a priori both with patients and medical 
personnel. 
It was from experiences in the hospital bed. It was from bags that 
leaked, it was from watching nurses. (…) I would time how long it 
took them to come in, empty the bag, measure it, put it on a flow 
balance chart and put it back again, and it was quite a lengthy 
process for them and also difficult process for them… It’s not just 
about me; it’s about them managing it. And it was that that I had a lot 
of time in hospital to think: ‘You know what? It got to be another 
way.’ (Michael Seres, CEO, founder 11 Health) (Seres, 2015a) 
From the outset, their product was designed for patients and the involvement 
with them was and remained intense. In respect to the healthcare professionals 
and providers, formal relationships came in much later and it was a lengthy, 
and in parts, frustrating process. Michael Seres maintained a continuous 
connection with his bowel transplant surgeon, Anil Vaidya, who joined the 
advisory board. A formal collaboration with a medical organisation came only 
in 2015, with Stanford University Hospital. This collaboration was also 
relevant for developing the app for the in-hospital use by medical 
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professionals. 2015 was also the year when the company started to attend more 
medical conferences in relevant specialties. Similar to Mira Rehab, the 
company started with a B2C model, to come to the realisation that it was 
difficult to grow that way only, and so a B2B and a B2B2C model came about.  
[M]ainly through social media and word of mouth at the moment. We 
have not yet reached a big enough market share in the hospitals for it 
to filter down from the doctors to the patient. (…) The idea is that the 
grassroots know about the device, and then the doctors know about it, 
and the two come together. (Michael Seres, CEO, founder 11 Health) 
Given that the UK was found to be not well suited for either B2C or B2B2C 
model at that time, the B2B and B2B2C model was mainly pursued in the US, 
where the first dedicated sales person was employed. In the UK, all 
developments proved to be lengthy and resource consuming. 
Because we had a landscape that says people don’t pay for anything 
yet. The NHS pays for everything. (…) We lost an investor in the 
business because he didn’t believe the NHS would adopt technology 
quickly enough. So we lost investment and ironically, the other 
investors that invested in the business discounted the UK market. 
(Michael Seres, CEO, founder 11 Health) 
Healthcare professionals were needed to reach out to more customers, as 
distribution channels. But, more importantly, the product development itself 
got to a stage where the medical input was important. 
“We can definitely do it, technology wise, the question is 'it is 
beneficial to doctors and patients to be able to measure that?' Or is it 
worth the time to do that versus the value of having that.” (A. C., 
technical lead, 11 Health) 
11 Health had intense interactions with patients, healthcare professionals, 
regulators and investors, and also with the IT world, as it was one of the core 
competencies that needed the most development inside the company. 
Therefore, following the VC investment, significant resources went towards 
growing the technical capabilities of the organisation. 
YouLife focused on engaging with customers, as this was the core objective of 
the pivoting – moving away from the corporate clients (B2B) towards 
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consumers (B2C). Engaging consumers proved to be challenging. Their 
position in the field of digital health was on the consumer side, which was the 
most crowded segment. Acknowledging that, the search for potential partners 
who could bring in large numbers of users began and it lasted to the end of my 
data collection period. YouLife engaged in discussions with diverse potential 
partners on the consumer market, from different sectors (i.e. digital technology 
producers, insurance). The constant searching was also due to the fact that 
there was no agreement over the utility of the product. Should it be a platform 
and build an ecosystem or a “village” as V. D. (customer lead) called it? Or a 
plug in, something that can be added to other apps or digital products? Several 
scenarios were analysed concurrently at this stage. In the end, the “village” 
won. That meant the company was to develop strategic partnerships with other 
companies for monetisation. Given that the process of going to the market 
proved to be a source of disappointment, in the sense that the app did not take 
off either as downloads or engagement, despite having a significant mobile 
platform distribution partner, the attraction of potential commercial partners 
proved to be difficult too. The app could not prove on two relevant 
uptake/success indicators, downloads and engagement. Those were indicative 
for showing market value and potential and so for closing partnership deals. 
[“Village” strategy] If we can work with the right partner apps and 
device manufacturers to build that ecosystem, I think that’s really 
powerful, so they will be able to actually understand what the risks 
are. (I. D., business development, YouLife) 
[“Village” strategy] By doing this with multiple partners, I suddenly 
got a huge distribution network that I couldn’t possibly achieve on my 
own. So we just do what we do well, and we integrate with best 
partners, and we cross-fertilize with data and with consumers. (M. B., 
co-founder YouLife) 
[“Plug in” strategy] When you register in a website, occasionally you 
get that image that you have to type in a code to prove that you are a 
human being, not a computer, and if you look at that it says ‘powered 
by such and such’. Look, that's what we need NewLife to be. We need 
people to just accept that when you talk about your health as a 
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number, you talk about NewLife. (J. K., technical development, 
YouLife) 
A board decision was made late 2015 for the “village”, and so the product 
ended having the health assessment at the core, a conversation part and a 
suggestion part where consumers would find products for health and wellness 
deemed relevant for them. The conversation part was intended to drive 
engagement, as the health score was not calling for much interaction. People 
would try it and then not engage or uninstall the app. The conversation was 
meant to be an automated health/wellness coach that would assist people in 
choosing goals and would guide them on how to achieve them. The 
conversation engine had as ultimate goal behavioral change, considered at that 
time the Holy Grail of prevention. The topic of behavioral change was debated 
intensively at the field level, also in the context of treatment adherence and 
chronic diseases (for instance, type 2 diabetes). 
Although the focus remained the consumer, no proactive action (focus group, 
questionnaire, user experience) was taken in that direction, despite the 
realisation that it was not easy to get easily their interest in engaging with a 
health risk app. In addition, there was the discoverability problem on a market 
that had tens of thousands of wellness and fitness apps. With the user – app 
experience, the company made an attempt to analyse recordings of app usage, 
but it did not render much insights, based on company’s respondents. 
Moreover, an internal resource with previous experience in another company in 
engaging people online in health matters was not given a voice. A strategic 
decision was made to bring in a new competence in digital, meaning hiring a 
person with a proven record in designing successful digital consumer products.  
There was one stakeholder that YouLife engaged constantly, the academia. It 
was based on an early realisation, prior to the NewLife app, that academia 
brings value in terms of trust, product development and resources. They 
engaged with academia for clinical validation of questionnaires, for working on 
the conversation part and for insights on the business model.  
[A university] provided some validation for one of our algorithms, 
which is really, really good. It's good for PR and it's good for 
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establishing our point in the marketplace. We had a business student 
who presented his project based on what partners we could work 
with. (…) So there are advantages for them working with businesses. 
And it's beneficial to companies like ours who want good expertise in 
some ways that are often cheaper, because there is the reciprocal 
thing. (M. R., finance YouLife) 
The advisory board shows the tight connection with academia and the content 
of the website’s blog contains mainly articles about scientific facts on wellness. 
Also, one of the team members, the clinical lead, was well promoted online. 
Although the “clinical” and “health” terms came up a lot in conversations as 
well as on online and promotional materials, and the company was aiming to 
make an impact on people’s health, there were no direct connections shown 
and made with the healthcare world. However, the potential benefits towards 
healthcare systems were acknowledged. 
I think there’s a lot of noise made around m-health, the fact that you 
have it on you all the time, it’s easier, it’s easily accessible, it’s actually 
pretty cheap, relatively, and there’s a lot of work that can be done in 
the preventative space to impact the services at the end of it, the NHS. 
(I. D., business development, YouLife) 
All companies had scarce resources (time, money, knowledge), therefore all 
had to make choices, prioritise stakeholder involvement to build core 
competencies and forge a market for their products. Nonetheless, all 
stakeholder interactions are a source of valuable learning. 
Even if we would have gotten funding in the first year Mira appeared, 
I don't think we would have been capable to manage the money. 
Second, we have learned a lot over time, from many people, and how 
to spend and what would be more beneficial, to respect our strategy. 
(Andrei Dascalu, co-founder Mira Rehab) 
Legitimacy is an on-going preoccupation for all, shown not only by engaging 
with experts and academia, but also by co-opting them on advisory boards. 
Mira Rehab even sets up its governance structure to have a dedicated lead for 
science (Alina Călin, co-founder). This shows how important building trust and 
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legitimacy is felt by new ventures, as previous studies have also shown (Navis 
& Glynn, 2011; Santos & Eisenhardt, 2009; Suchman, 1995). 
All three companies prioritise stakeholders that are deemed to bring the highest 
value for forging the market, bridging the expertise gap, or for creating 
legitimacy. For 11 Health and Mira Rehab, the regulatory compliance confers 
legitimacy too. All three companies co-opt legitimising actors in their advisory 
boards from academia, healthcare or digital health. Another way to indirectly 
get endorsed by legitimising actors is to associate with institutions like medical 
or patient associations and prestigious organisations. Similar to previous 
research, legitimacy is indeed perceived as a core resource by young ventures, 
particularly in a new field. Other modalities to build legitimacy are: displaying 
achievements and awards, providing organization history – show persistence 
(both Mira Rehab and 11 Health), having a blog to provide information, 
educate, tell stories, build a market, show endorsement (by publishing articles 
written by stakeholders or influential names in the field) and provide evidence. 
 
Fig. 42. Additional source of legitimacy for Mira Rehab – A Smile with Mira NGO in 
Romania, set up early 2015 (picture from personal archive, Interface conference, 
Canada) 
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All organisations are very preoccupied to establish trust and legitimacy. “The 
role of trust is central to all social transactions (ranging from marriage to 
international affairs) where there is ignorance or uncertainty about actions and 
outcomes. (…) Trust is a critical first-level determinant of the success of 
founding entrepreneurs because, by definition, there is an absence of 
information and evidence regarding their new activity” (Aldrich & Fiol, 1994, 
p. 650). 
In summary, the more long-term relationships were, the more symbiotic, and 
therefore the more hybridising. Such relationships develop mainly where the 
expertise gap was larger, as shown by Mira Rehab and 11 Health. Andrei 
Cantea (co-founder Mira Rehab) considers their medical collaborators as part 
of the team and acknowledges their contributions to the product development. 
Both Alina Călin (co-founder) and Priya Maloni (consultant business 
development) look into continuously improving their connections in the field, 
find avenues to expose and foster research. Both organisations show how 
collaboration is driving understanding and understanding is driving 
hybridisation of logics (Nicolini, 2009; Prout, 1996; Van de Ven & Gardu, 
1993). 
8.4. TAMING CONTRADICTIONS 
In an emerging field, there are multiple logics vying for dominance, and 
ambiguity does not give many clues as to how the institutional arrangement is 
going to unfold. In this section, I present how all three organisations deal with 
these two aspects that create contradictions - plurality of logics and ambiguity.  
8.4.1. PLURALITY 
All the organisations are CDHT producers and therefore they may connect 
multiple stakeholders. My analysis shows that predominantly they did not 
choose to overtly confront incumbent stakeholders, or the most powerful ones 
in adjacent fields - in this case, medical professionals and regulators. Their 
main mechanism is co-optation and it is driven by genuine business needs, like 
knowledge and competencies gaps and market development, not by ideology.  
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The engagement with various stakeholders generates significant learning and 
opportunity detection. Most companies went through several iterations of their 
business model. To support this, I give the example of 11 Health who first 
featured patients on their website, then briefly stated that it is a patient led 
technology company, to finally position itself as a connected device company 
for healthcare, and three major beneficiaries (users) were given equal 
representation. This reflects the learning from interactions with stakeholders 
and from the evolution of the field itself. 
 
Fig. 43. 11 Health’s landing page with three user categories (beginning of 2016) 
Similarly, Mira Rehab was initially presenting patients the value of exercising 
at home, to end up presenting its value propositions to more user categories: 
healthcare professionals/providers, patients and payers. 
 
Fig. 44. Mira Rehab Opportunity page with three beneficiaries (beginning of 2016) 
In that sense, both organisations end up being positioned similarly to medical 
device companies. YouLife only addressed the consumer in their 
communications or inside the app and maintained throughout its positioning as 
a consumer digital health solution. 
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Regardless of how they communicated, all organisations, through the virtues of 
the intangible character of their digital solutions, were able to both 
compartmentalise and hybridise logics. Compartmentalisation is realised by 
having different categories of users having their own “entry” – interface, log 
in, even their own application (11 Health or Mira Rehab). In this way, all 
stakeholders are “safe”, do not feel threaten and they can pace themselves in 
what they want to do. Additionally, their feedback and involvement is valued 
and encouraged. In the same time, all user categories are informed on the needs 
and practices of the others and even play a role in designing practices. 
Consequently, companies take on the function to centralise, prioritise, design, 
accommodate these needs, acting as an institutional broker. 
YouLife did not get to that level of morphing by the time my data collection 
ended, when the NewLife app was only consumer facing. When discussing 
partnerships and how data is going to be accessed and by whom, there were 
contradictory ideas inside the organisation. What remained certain was that 
they intended to co-opt other players. However, the consumer app was itself 
compartmentalised, so the consumer would choose the level of engagement, as 
well as if wanting to engage with other types of users. The consumer had 
access to the health assessment core, the conversation part and the partners’ 
part where products were recommended.  
We are using the data, but we’re not going to sell that data to any odd 
person. It’s there to benefit you, and the products we will be 
introducing will be there for a specific reason, to benefit you, to prove 
your health, not just a blanket product or a blanket service because 
we make money out of it. It’s to make sure that it impacts your health, 
that it improves your health. That’s really important. (I. D., business 
development, YouLife) 
In the case of YouLife, the user/consumer was not that much in control, had no 
input in the creation of the product, it was not co-opted. Given the little 
involvement the main stakeholder had in the product development, YouLife is 
most similar to direct to consumer digital technology market. 
It’s the same with the pharma - they want the data. Microsoft wants 
the data, because probably they’re better able to market products and 
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services to the end user. I don’t think they would ever want to be 
viewed as a health company, but they would probably rather be 
viewed as a health ecosystem, with preferred partners that focus on 
the best areas and various areas. So I don’t think they have ever 
announced themselves as a health company, more as a... I don’t know 
what the right word is… it’s the ecosystem I think they’re trying to 
build. . (I. D., business development, YouLife) 
For the hybridisation process, I provided examples of co-creation in the 
previous section on Mira Rehab and 11 Health. I have highlighted mostly how 
they worked towards co-opting external stakeholders. But the exchanges were 
mutual. Healthcare professionals got fresh insights and contributions too. There 
were physiological parameters that they were not able to measure before, or, at 
least, not that accurately, efficiently and continuously. 
We were reading on the internet and then we were going to a medical 
specialist and we were asking if it's ok that movement. (...) Because if 
we would have asked ten physiotherapists what is good for something 
specific, it wouldn't have been very constructive from the beginning, 
because there are different opinions between specialists. The best way 
was to ask them: is this movement ok for this problem?" (Andrei 
Dascalu, co-founder Mira Rehab) 
Because it is a very innovative technology in the marketplace, and 
myself being in front of the most important surgeons and hospitals in 
the world for the past several months... the level of interest is 
something I’ve never seen before. (K. P., US business lead, 11 Health) 
Digital technologies allow CDHT companies to be more things to different 
people, to accommodate multiple identities (Jacobides et al., 2018; Kraatz & 
Block, 2008; Selznick, 1984). The hybridisation also happens because the 
CDHT producers act as brokers between logics. For instance, the “patient 
engagement” idea has less push back from healthcare professionals if it proves 
to lead to better health outcomes or that healthcare has a scientific benefit (i.e. 
“we can follow what a patient does based on some parameters that could not 
have been monitored before” – Alina Călin, co-founder Mira Rehab). 
Hybridisation is facilitated by the congruent aims between logics (Pache & 
Santos, 2010). When logics are instantiated, when the situation is contained, 
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understood, evaluated, and when healthcare professionals have a say, an 
“empowered patient” becomes a desirable notion or at least a neutral one. 
Similarities to other digital ecosystem (Jacobides et al., 2018) can be drawn, in 
the sense that CDHT producers design solutions that accommodate different 
roles in such a way that each role derives more value through the new practice, 
that surpasses the cost of the relative changes from their previous roles or 
practices. 
8.4.2. AMBIGUITY 
An emergent field is a liminal space, suspended somehow in time, between the 
old and the new. This situation makes organisations permanently scan the 
environment. Apart from keeping an eye on the state/regulator (Aldrich & Fiol, 
1994), payers and healthcare, they keep scanning broadly for technology 
trajectories (Akrich, 1992; Gawer & Phillips, 2013; Geels, 2005; Rip & Schot, 
2002). 
YouLife looks at how digital platforms are evolving (i.e. Apple, Samsung, 
Microsoft), but it’s reserved on committing to certain technological paths, out 
of fear of betting on the wrong one. Similarly, the technical lead of 11 Health 
was not taken by the Apple Watch (a wearable) for instance, but the company 
eventually integrated with it. Mira Rehab is also scanning, but, on the contrary, 
they are confident that the proprietary modular architecture allows integration 
with a variety of sensors and technologies and therefore they show fewer 
concerns about what platform or technology would eventually win. Their 
product is flexible by design. Aside the problem of committing technologically 
too early, there is the question of efficiency in allocating resources (as stated 
by technology leads inside all organisations), at a particular development 
phase. 
In terms of competition, 11 Health did not identify a competitor, although it 
had the expectation that other companies would enter the area. YouLife 
identified competitors and they were monitoring them. In Mira Rehab’s case, 
there were several companies that approached physiotherapy through games in 
various ways. They were not only watching their competitors, but also got in 
touch with several. Moreover, they shared news related to competitors on 
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social media, as a way to foster a market (Andrei Dascalu, co-founder) and 
contribute to the “cognitive legitimacy” (Aldrich & Fiol, 1994) of their niche. 
Competitors… every month a few more. Competition validates the 
market. There is no dominant one. I am happy when I am told our 
product is better. (Cosmin Mihaiu, co-founder Mira Rehab) 
There is a lot of learning happening at all levels: individual, organisation, or 
the field itself. 
There’s a lot of people out there who say they’re health experts, people 
who say they’re digital experts, bit actually some of them don’t even 
know how to spell the word digital and I’m not being mean about it, 
but they are no experts in digital health. (M. B., co-founder YouLife) 
The ambiguity makes organisations more focused on the future than on the 
past, and therefore less tributary to an institutional iron cage. The 
representation of the future (Akrich, 1992; Gawer & Phillips, 2013; Geels, 
2005) becomes the most important determinant of organisational action. 
I believe that all new technologies can apply to healthcare (Cosmin 
Mihaiu, co-founder Mira Rehab) 
I think in time we will get more digital interventions; we will get 
using more and more things. I think technology will allow us to do so 
much more, but I think we are still a long way away from the 
practical use on the ground everywhere, at the moment. (Michael 
Seres, CEO, founder 11 Health) 
And if we can work with the right partner apps and device 
manufacturers to build that ecosystem, I think that’s really powerful, 
so they will be able to actually understand what the risks are. And if 
they have risks, put them in contact with the right services to help 
them reduce those risks. (I. D., business development, YouLife) 
As shown in the section on taming liminality, YouLife, did not engage with 
healthcare. But they were aware that if they could prove that consumers would 
adopt their app, then healthcare would become interested in it.  
If I can get the efficacy and show I can do that, this business will be of 
immense value because you’ve got something that the NHS has been 
trying to get to for years and years. How do you encourage 
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consumers to take control of their own health and to improve their 
overall health? (M. B., co-founder YouLife) 
The quote above also informs on the “conflict” between medical profession, 
state and citizen logics. The involvement with the healthcare field was not as 
much avoided, as it was temporised. At this stage, it was deemed not to be 
efficient to engage with without evidence of people engagement. This is also 
an example of a judgement over the evolution of the field and its stakeholders. 
Another call from the future, in respect to technology, is interoperability or 
integration. Therefore, some concerns are related to committing too early (Rip 
& Schot, 2002; Van de Ven & Gardu, 1993) on a technological path (11 Health 
and YouLife). However, all companies are aware of their need to integrate in 
time with other solutions and technologies. 11 Health integrated their hospital 
app with Epic, one of the main EHR providers in the US, and their patient app 
with the Apple Watch. This is moving towards the vision of the continuum of 
care that the digital health promises. 
Institutional constraints are sometime better understood in hindsight.  
Even if it would have got funding from the beginning and we were 
very good, I still believe we wouldn't have succeeded, because the 
market, in my opinion, was not ready for such technologies. (Andrei 
Dascalu, co-founder Mira Rehab) 
The statement above shows the relevance of understanding the emergence 
phase when looking at an organisation in its context. During mobilisation, the 
legitimacy of such solutions is established enough. The next two quotes, also 
add to the understanding of the difference between the stages of field 
emergence - first is about the ingenious phase and the second one is about the 
mobilisation phase: 
[2013] I then realised that I needed some money in order to take a 
very basic prototype and turn it into a proper device so I went to look 
for an investor to put in a bit of money and through recommendations 
of recommendations I, in the end, presented it to a gentleman called 
Adam Blooms who agreed to invest in the business and he gave me the 
first bit of money to take the prototype and see whether we could 
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build a proper device. He was the first investor. (Michael Seres, CEO, 
founder 11 Health) 
[End of 2015] It’s disruptive innovation in the marketplace, there is 
nothing like it, so I think there is a high level of support inside and 
outside and a lot of excitement as well because it addresses a need 
that simply cannot be addressed right now. (K. P., US business lead, 
11 Health) 
Given their focus on the potential of technologies and their vision of the future 
social arrangements, all these organisations, through their value propositions, 
are in fact promoting “proto-institutions”. 
8.5. BRAVE NEW WORLD 
It follows that, in a way, all these “fools” (Aldrich & Fiol, 1994) are 
institutional entrepreneurs. One of the dimensions they guided themselves by 
through the tremendous complexity of this emerging field is the identity project 
of the organisation. I am pointing here to agency and its projective quality (J. 
Battilana & D’Aunno, 2009). As I’ve shown above, all organisations are 
guiding themselves based on scenarios or scripts of the future, therefore they 
have an identity project. Their identities are becoming, not following existing 
recipes. Consequently, each organization represents a proto-institution in its 
own right, and, if successful, it will fulfill their desired identity. For instance, 
Mira Rehab’s dream is to make their platform available to as many patients as 
possible, so they can recover in a fun way, in the comfort of their homes and 
with the safety of being overseen or guided by a healthcare professional. At the 
time my data collection ended, they were launching the home version of their 
solution integrated with the hospital version. Their identity project is that Mira 
Rehab allows fun recovery at home, but it is not there yet, it is on its journey. 
This is relevant, because their projected identity guides their actions. 
The future script embedded in technology is based on the innovator’s view of 
the stakeholders and is pointing to envisioned value/risk, practices and it 
“assumes that morality, technology, science, and economy will evolve in 
particular ways” (Akrich, 1992, p. 208). There is value infused in the way the 
organisations project themselves in the future, with an ideal identity – their 
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own identity project. And not only value, there is emotion. As Voronov and 
Vince (2012) show, cognition is simply not enough for action. In conditions of 
ambiguity, grounding actions on hard facts is impossible; therefore emotions 
are an important determinant for action. 
YouLife considers itself as being part of the consumer empowerment future. 
Mira Rehab is dedicated to make physiotherapy more fun, as “games are 
essential for anything” (Cosmin Mihaiu, co-founder Mira Rehab) and at home. 
“At the heart of it [n.b. 11 Health], it is a device trying to improve the lives of 
patients” (Michael Seres, CEO, founder 11 Health). 
8.5.1 DISTINCTIVENESS MATTERS 
As trapped in between worlds, organisations attach their identities to digital 
health, as being the umbrella for digital innovation in health IT. Even if at 
times digital health may be a blurry, inconvenient term (contestation in the 
field, for instance, Theranos case mentioned in chapter 7), it remains a 
distinctive category that not only offers a sense of belonging, but also gives an 
advantage in relation to certain stakeholders (i.e. initially investors, academia 
and state agencies offering grants). Similar to findings of another research in 
categorisation, new fields and access to funding, having a distinctive category 
proves to be a competitive advantage (Navis & Glynn, 2011).  
However, their attachment to digital health is not overt. Organisations do not 
label themselves as digital health companies on their websites or 
communications, particularly Mira Rehab and 11 Health, which are closer to 
healthcare; perhaps to avoid potential institutional logics conflict. However, as 
time passes, the ‘digital health’ label becomes a positive differentiator from the 
legacy, traditional health IT producers, inside the healthcare field itself. As I 
have shown in chapter 5, before 2007, the healthcare and IT fields had a long 
history, mainly dominated by disillusionment. 
If you have something that’s digitally sound and something that’s 
new, people typically will embrace that, more so than something 
that’s been around for a while, something that’s not necessarily you 
know, run through a digital platform. (K. P., US business lead, 11 
Health) 
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“Digital platform” term in the quote above points to the legacy health IT 
systems, not any digital platform. 
However, all organisations are careful in how they adhere to new emerging 
categories. I have given the example of 11 Health, which settled at some point 
for being a “connected device” company - not a medical device one (too much 
legacy, powerful incumbents), not a digital health one (too vague and 
contrary), not a patient led one (too radical, alienating from incumbent 
players). Mira Rehab designs games for recovery, but it does not position itself 
as a gamification or serious games company, terms very much used in the 
realm of digital health.  
I am a big fan of gamification as a principle. I believe it is a necessity 
to transform a boring process in a more interesting one and is a very 
good thing. On the other hand I find it overused, it's applied to 
anything. I find serious games a wrong definition. It seems you need 
serious because games would point to something that it's not 
essential. From my point of view, games are essential to everything. 
(Cosmin Mihaiu, co-founder Mira Rehab) 
Yes, we do build serious games, but it’s more than games. Because we 
have a platform that does more than that, in the sense that we can 
follow what a patient does based on some parameters that could not 
have been monitored before. It is something very new for the medical 
professionals. And so it is a medical device. (Alina Călin, co-founder 
Mira Rehab) 
The versatility in attaching different categories in different occasions relates to 
the concept of “social skills”. Entrepreneurs need soft skills to navigate 
complexity and give meaning (Fligstein, 2001). “Actors’ conceptions of 
themselves are highly shaped by their interactions with others. When 
interacting, actors try to create a positive sense of self by engaging in 
producing meaning for themselves and others” (ibid. p. 112). 
Another way to generate meaning for both the organisation and others is 
through stories (Maclean, Harvey, & Chia, 2012; Patriotta et al., 2011; Zilber, 
2009). Stories allow for contradictions to evolve and dissolve, for conflict and 
hybridisation to unfold at the same time. And what else would institutional 
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work be but a “creative” approach to contradictions (Hargrave & Van de Ven, 
2009)?  Stories are also vehicles to connect to higher orders or values (Patriotta 
et al., 2011; Weick, Sutcliffe, & Obstfeld, 2005). Cosmin Mihaiu’s (co-founder 
Mira Rehab) TED talk had over 1 million views at the time of data collection. 
Such outreach could not have been achieved any other way, given their limited 
resources. What made Cosmin’s talk so impactful was that it had a great 
narrative. Although Mira Rehab did not intend to generate this type of content, 
that TED talk continues to serve them well. However, they have started 
publishing individual case studies, stories of using their technologies.  
11 Health also has a great narrative. In this case, Michael Seres’ advocacy 
work made his story known to large online communities before the company 
was founded. On their website, there are videos with Michael’s story, as well 
as company’s story. They also have a milestones page where one can trace the 
company’s evolution. Moreover, on the blog and social media channels, patient 
stories are also promoted. YouLife, on the other hand, has a video that shows a 
healthy lifestyle, not differentiating itself from traditional marketing materials 
in consumer fields, pharma or insurance, for instance. On their blog, there are 
articles that promote healthy lifestyle, providing scientific, clinically valid 
information, but no narratives. 
Aside from patients, carers, citizens, scientists and healthcare professionals, all 
three companies recognized digital health producers at large as stakeholders. 
All technical leads were aware of the wearables and other evolutions in this 
area. But most importantly, all organisations were participating and scanning 
for events in digital health. Such events represented platforms to showcase, 
learn from others in this field, network, find investments and other 
opportunities (see also chapter 7). 
8.5.2 LEADERSHIP MATTERS 
Each company provides significant insights in the role leadership plays in the 
context of high institutional complexity. 
YouLife, as I explained in the previous sections of this chapter, had more 
difficulties setting a vision or a strategic path. There was a perceived 
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disjunction at its high-level management structure. Most respondents identified 
W. M., the person responsible for innovation until the end of 2015, as being the 
creative mastermind and the force behind the company’s transformation. Most 
of them described him in flattering terms, on the line of “he is the creative 
genius; incredibly inspiring” (M. R., finance YouLife). All information I 
gathered about him was secondary, as he became unavailable to interview due 
to internal developments in the organisation.  
He’s the madman in our office. He’s so innovative; he couldn’t care 
less whether we make money out of it. In his eyes, it’s an idea. He 
wants to impact health, he wants to improve people’s health, that’s it. 
Now, obviously, it’s a business and we do have to make money 
somehow, but he would like to be in the position of a kind of a Steve 
Jobs, to have the little room downstairs in the bunker that just has a 
team thinking of the next big thing. Maybe we’ll get there, I don’t 
know... M. B. needs to be in that kind of space as well, but our CEO 
will only be there once we are probably in a better place financially. 
Because we need to prove the model, we need to get it monetised, we 
need to work out what works and what doesn’t and we’ll do it pretty 
quickly, I’m confident. (I. D., business development, YouLife) 
Despite the value (creativity, inspiration) the team saw in him, there was a 
board decision that led to W. M. only having a vague advisory role to the board 
of directors; he was not to interact with the team going forward. This created a 
low morale throughout the company. The picture below is a representation 
during an interview that is trying to show that the product development will be 
affected without having an important driver, creativity. 
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Fig. 45. Leadership as creativity (V. D., customer focus, YouLife) 
Only a few respondents seemed to settle with this board decision, for instance 
M. R. from finance: “we are at the stage where we understand these ideas”, but 
most of the team felt this was a significant drawback. 
I think W. M. would still want to be here right now. (…) We are 
already missing W.M. (V. D., customer focus, YouLife) 
If we moved from getting people healthier into insurance, then I 
should know that. (J. K., technical development, YouLife) 
Adding to W. M.’s departure, there was an increased sense of lack of 
communication with the top management, and amongst the team members. 
Several employees did not feel valued or felt that the direction of the company 
was decided at top level and it did not filter down. Some members even 
experienced a loss of purpose, as they considered their mission was moving 
away from doing “good” by people - making them healthier. They felt that this 
strategic decision was not serving well that mission, as they understood it when 
the company had decided to pivot. 
It is relevant that the company was trying to pivot from the world of employer 
benefits and insurance with the identity project of becoming a consumer 
focused organisation with the purpose to make people healthier. The initial 
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vision was to go for the consumer engagement, consumer health education and 
prevention, away from its legacy. In this case, it seems that the founding logic, 
the legacy or the “iron cage” won, or at least it won that phase of the battle. 
The return to the founding logic (market logic) had innovative elements, but 
further away from the citizen logic than the initial vision was. If that was just 
another morphing or if that return to the legacy logic was permanent, it was 
impossible to assess at the time data collection ended. Alternatively, if that was 
a leadership failure, it might as well have been the case. 
In contrast, Mira Rehab and 11 Health offer two interesting examples of 
leadership. Mira Rehab is a case of shared leadership, as I name it. Although 
Cosmin Mihaiu (co-founder) was the CEO and became very popular due to his 
TED talk, he always circled back to the team of co-founders when discussing 
his role or the company. So much so that I felt appropriate to leave the CEO 
part aside when referring to him in this research too, as it would have given a 
sense of extra authority when they all proved and affirmed that it was shared. 
Each co-founder talked in the same terms, very consistently, about the other 
founders: how they were each responsible for a side of the business, although 
helping each other, how each was “pushing” (Andrei Dascalu, co-founder) for 
their own part, despite any personal discomfort with their roles at times. This 
transformation of the team was much influenced (based on their accounts) by 
the early interaction with a mentor who remained in their advisory board, Jake 
Arnold–Forster. I find this an interesting case of collective/shared leadership, 
not documented in literature, to my knowledge. In terms of identity, they kept 
the sense of a technology team who placed a digital veil on an arid part of 
healthcare to make it fun and engaging, and so to have better health outcomes 
for patients, whilst contributing to science. 
As highlighted by previous authors (Kraatz, 2009, 2009; Kraatz & Block, 
2008), and most notably theoreticised by Selznick (1984), subtle substances of 
leadership transform both the organisation, providing it with a “self”, and the 
leader.  
We can say that we are doing ‘Un zâmbet cu Mira’ [n.b. an NGO] 
because we are helping others. But in the end, for us, for myself, as I 
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do not do anything else on the side, for me is... I don't know... a 
lifestyle. And if Mira succeeds, I can say I succeeded too. I cannot be 
hypocritical and say the financial side does not motivate me. On the 
other hand, when we take part at the testing of the product, and when 
we see... there are also children with various problems... it's super 
motivating when you see their joy. (Andrei Dascalu, co-founder Mira 
Rehab) 
11 Health is an example of entitativity (Campbell, 1958) or of a company that 
becomes an institution in its own right (Kraatz & Block, 2008; Selznick, 1984). 
11 Health embodies the citizen logic of digital health expressed best by the role 
of the empowered patient.  
He does have the two roles: he is the advocate on one side, and an 
entrepreneur. But he also got to run a company and I think he’s still 
trying to maintain that balance. I think it’s a tremendous load on his 
part, like travelling schedule and demanding hours, but I think I can’t 
see that really changing because he’s always been that driven. (D. B., 
communications 11 Health) 
Michael himself is holding more roles and one identity and this may be 
challenging at times, requiring a permanent balancing act (Kraatz, 2009; 
Selznick, 1984). 
I’m very conscious of not wanting to impose my patient voice on 
consumers so I come across as someone that is just trying to sell 
people that I engage with on a daily basis. I really don’t want to be 
seen as someone that is just using my voice to purely benefit my 
company. There is a line, which I try not to cross, and so my personal 
voice is about trying to raise the role of the patient, trying to promote 
patients as innovators, and within that I talk about the business. But 
the business also has to have its own social media presence. So there is 
a fine line. (Michael Seres, CEO, founder 11 Health) 
Although deeply rooted in humanistic values, like helping people to lead better 
lives, 11 Health maintains a balance that allows it to be multiple things to 
multiple entities. In other words, it can contain multiple logics (Kraatz & 
Block, 2008). It is a receptacle of identities, whilst fostering a new collective 
frame. And those identities do not come into conflict, they hybridise by the 
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very hybrid nature of their receptacle. In this case, Michael is recognised both 
inside and outside the company as the “expert” and the business driver. It 
embodies the role of the empowered patient, and therefore, for the field at 
large, he is a connotative leader (Kraatz, 2009); “both an agent of 
institutionalisation and a defender and steward of the living social entity that 
ultimately emerged from this perspective” (ibid., p. 62). 
I tend to just look at what needs to be done right now; Michael is a 
visionary. (A. C., technical lead, 11 Health) 
People like Michael are leading the way. That’s what makes it really 
exciting. This is the first time I’ve ever been a CEO and a CEO is so 
connected with the product and the vision. (D. B., communications 11 
Health) 
It’s not about going on to be a businessman. It’s a real solution to a 
real problem that can help you or other patients. And it’s your inbuilt 
passion and your drive that gets you through. Business just comes 
later. (Michael Seres, CEO and founder 11 Health) 
Leadership proves to be a significant factor for organisations’ success. 
Additionally, their identity projects, even if failing as businesses, contribute to 
the field institutionalisation, its structure and its governance (Aldrich & Fiol, 
1994; Fligstein, 2001; Kraatz & Block, 2008). 
In a sense, Mira Rehab represents a less mature form of statesmanship 
(Selznick, 1984), of the type of leadership that builds institutions, even though 
its leaders are not necessarily as aware of the process. Perhaps, in time. 
If I connect what I have shown on organisations and their search for legitimacy 
and, more than that, trust (via symbolic actions as well, like stories), with the 
findings on leadership, this collective case study shows the importance of 
leadership for building trust inside and outside the organisation. Trust is a 
concept that links all levels: personal, organisational and the field level, and is 
a basis for exchanges in condition of ambiguity. And so, the “social process of 
gaining legitimacy is shaped by the interpersonal processes of achieving trust 
in the organizing process” (Aldrich & Fiol, 1994, p. 650).  It follows that 
leadership is indeed a major resource in a complex institutional context for a 
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new organisation, and for an emergent field as well, as leaders become agents 
of institutionalisation (Kraatz, 2009; Kraatz & Block, 2008; Selznick, 1984).  
8.6. CONCLUSIONS 
New organisations facing extreme institutional complexity are influenced in 
their engagements with stakeholders by their position in the field. Their 
motivation resides mainly on closing the knowledge and competencies gap and 
obtaining legitimacy, in other words to access basic resources. They also 
prioritise engagements, as they operate under serious resource constraints. At 
an early stage of company formation, relationships with stakeholders are often 
mediated by mechanisms of co-optation that lead to co-creation. Co-creation 
facilitates significant hybridisation processes.  
In an emergent field, institutional work is less tributary to the “iron cage” and 
more orientated by scenarios of the future and perceived opportunities. 
Additionally, in a pluralistic environment, digital technologies concurrently 
support the compartmentalisation of various logics, as well as their 
hybridisation. Not last, leadership is instrumental for organisations, being in 
itself a strategic resource. Organisations with strong leadership become 
institutionalisation agents that contribute to the emerging structure and 
governance of the new field. Such examples offer insights on the “bottom up” 
institutionalisation, as opposed to the “iron cage” dominant perspective. 
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CHAPTER 9. DISCUSSIONS AND 
CONCLUSIONS 
9.1. INTRODUCTION 
My research fosters the understanding of institutional complexity in conditions 
of pluralism and high ambiguity. It employs a theoretical framework based on 
institutional logics and institutional work, and, empirically, it unfolds as a 
multi-level, multi-case inductive inquiry set in an emergent field. In this 
chapter, I summarise the main findings, I present the theoretical implications for 
the institutional theory and I revisit the theoretical model presented in chapter 3. I 
also reflect on wider implications and offer practical insights. The chapter ends 
with general reflections on my research and future directions of study. 
9.2. SUMMARY OF FINDINGS 
The main contributions are related to the emergence process of a field (a 
phenomena that was only studied retrospectively or it was theoretically 
inferred) and institutionalisation processes in conditions of high complexity, 
given by a pluralistic, fragmented and ambiguous field. The institutionalisation 
processes were analysed both at field level and at organisational level. The 
institutional work undertaken by organisation informs on the bottom up 
institutionalisation. 
9.2.1. FIELD EMERGENCE 
9.2.1.1. Institutional context of adjacent fields 
My analysis starts with the historical presentation of the main institutional 
fields that influence the interstitial emergence of the digital health – the ICT 
and the healthcare fields. This analytical stage is a prerequisite for the 
understanding of field emergence, because it shows how changes in the two 
fields made it favourable for digital health to emerge. In healthcare, I show 
how the role of the state supported, at different times, both the 
professionalisation and the demise of the medical professional authority, or 
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how it played a role in the dissemination of certain medical technologies 
(vaccines, for instance). The state also tried to push for the adoption of health 
IT in many countries (i.e. Germany, UK, Australia, US), but these efforts were 
less successful (see chapter 5 for more history). Furthermore, I show how the 
state logic itself underwent significant transformations, from the welfare to the 
neoliberal doctrine. Such changes brought about significant shifts in the 
healthcare field fragmentation and, most importantly, in its governance: the 
emergence of managed care approach or the rise of consumerism. This 
historical part also highlights unintended consequences, for instance the 
increase in healthcare agency bureaucracy (i.e. the NHS). The state facilitated 
the transition from a healthcare field where professional authority was 
dominant to one under a managed care approach, and last to one fostering a 
self-management approach. Therefore, the brief healthcare history has merits 
beyond these contributions, as it highlights the role of technology in the field’s 
institutional transformation. 
The digital technology field also went through significant transformations of 
governance and rules of the game. Over the past three decades, there were 
important changes regarding the locus of innovation and rules of competition. 
Digital technologies, given their open character and the fact that they are 
completed by the user’s input, became increasingly democratised. And so 
platforms and ecosystems came about and users become more powerful in 
determining technological trajectories. Digital technologies made space for 
new forms of organising the social and economic life, social media being also 
indicative for this phenomenon. Not last, the digital technologies field went 
through an intense process of convergence (Mulligan, 2011; Jacobides et al., 
2018), which accelerated their expansion as well as innovation. 
The histories of the two fields also bring forth contrasts between them. For 
instance, digital technologies field is a rapidly changing environment, where 
innovation is worthy in its own right, and it has high user centricity. On the 
other hand, healthcare is a fragmented field, with discontinuities and tensions 
between stakeholders, where change happens slowly and technology takes a 
long time to be adopted. For instance, the cochlear implant took 39 years to 
become marketable, but a close loop insulin system developed by a patient and 
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her partner as an open source DIY device became worldwide spread within the 
type 1-diabetes online communities in a few years only. This is an example of 
the speed innovation disseminates in the digital world when there is a well-
defined need, even if it is health related. 
9.2.1.2. Stages of emergence 
Morrill (2006) depicts three stages of emergence: innovation, mobilisation and 
structuration, each being dependent on the previous stage’s success. Innovation 
is characterised by experimentation and opportunity and the interstitial 
emergence goes generally undisturbed by incumbents. Mobilisation engages a 
critical mass of supporters and, finally, structuration presents legitimated 
alternative practices. My findings refine this model entirely and introduce a 
new stage - legitimation, and bring theoretical insights into interstitial 
emergence and institutionalisation. 
In the ingenuous phase (similar to innovation phase), most active stakeholders 
are coming together voluntarily based on shared interests or unsatisfied needs. 
Initially, the main stakeholders are the digital health producers, the state and 
citizens. Therefore, the inherent characteristics of the consumer digital 
technologies field are dominant, such as fluidity, experimentation and 
serendipity (Santos & Eisenhardt, 2009). My findings suggest that such 
characteristics take the field genuinely beyond the market logic, towards the 
ludic aspect of technology and invention, where innovation is gratifying in its 
own right. It is possible that the ludic and serendipity aspects are characteristic 
to emergence around technical innovations. Morrill (2006) theorised the model 
of emergence in the context of new practices in the dispute resolution area, 
close to the legal field. Moreover, it may be that these aspects are specific in 
the digital age, because, as I have shown in previous chapters, digital 
technologies changed the locus of innovation and the rules of competition. 
For the ingenious phase to complete successfully, a significant mass (Morrill, 
2006) along with promising solutions or resources have to form primarily via 
facilitative (hybridisation) institutional processes. This phase confers cognitive 
legitimacy (Aldrich & Fiol, 1994), it makes the field visible and this attracts 
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stakeholders capable to confer socio-political legitimacy (ibid.) during the next 
phase - the legitimation phase. My research indicates that only after socio-
political legitimacy is established, the mobilisation phase is possible. Socio-
political legitimacy means that a new idea, practice, innovation is considered 
appropriate and possible (ibid.). In digital health’s case, political legitimacy 
was conferred from the outset by state commitments and citizen uptake, during 
the ingenuous phase. However, socio-political legitimacy is co-constructed 
through the initial interaction of stakeholders and, more importantly, through 
legitimising (academia, researchers, medical professionals) and mediating 
(consultancies, other intermediaries) actors, who are capable to co-opt more 
resistant stakeholders (herein, doctors and pharma). I highlight the legitimation 
phase as a stepping-stone for mobilisation. It is possible that this phase is 
specific to field emergence close to adjacent fields that are fragmented and 
have some degree of centralisation, because of the existence of multiple and 
often powerful stakeholders. Morrill’s model was developed for the emergence 
of a field closed to a more centralised one and the actors involved had previous 
established authority. What was contested was a new practice only. In contrast, 
in digital health, due to its proximity to a semi-centralised fragmented field – 
healthcare, contestations ran deep: from actors to practices and higher societal 
values. Therefore, legitimation was easier to reveal as a phase in its own right, 
as it required the co-optation of more diverse stakeholders and it lasted a longer 
period of time. 
Mobilisation is the most contested phase of field emergence. There is 
democratisation (Beverungen et al., 2015; Selznick, 1951), because most 
stakeholders have to face a range of possible alternative identities and futures 
(Aldrich & Fiol, 1994; Fligstein & McAdam, 2011), due to the ambiguity of 
rules and governance. Consequently, the incumbents’ power, if not contested, 
is significantly diminished. This is when the role of socially skilled actors 
(Fligstein, 2001) is most important, i.e. opinion leaders, social and moral 
entrepreneurs. They have the capacity to induce cooperation and frame the 
future linking to higher order of values - “better future”, “common good”. 
They give sense via stories, theorisation and the use of distinctive categories. 
Interestingly, opinion leaders, or influencers, play a bigger role at the 
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beginning because they are capable to depict a possible attractive future, make 
compelling arguments on the merits of change (connect to higher order of 
values) and promote stories that allow for contradictions to settle. The 
leadership role of the entrepreneurs at field level becomes relevant later on - 
almost as in adventure stories, with heroes and sometimes antiheroes (i.e. 
Elizabeth Holmes of Theranos). They often legitimise their endeavours by 
connecting to higher orders – for instance, research2guidance even named a 
category of innovators as “helpers” (2014). Furthermore, leading entrepreneurs 
inspire action by offering much-needed lessons and recipes for other 
entrepreneurs or for aspiring ones. 
When I finished the field research, digital health was still in its mobilisation 
stage, when most stakeholders had entered the field. During mobilisation, there 
is field granularity. I introduce this term to differentiate from segmentation, 
which happens only when there is a significant decrease in ambiguity and 
stakeholders can organise around well-defined categories of products and value 
propositions. Such a degree of clarity was not attained by digital health when I 
data collection ended. The granularity of the field allows for fluidity and no 
hard fixings. Granularity means that there are concurrent pockets of 
negotiations between various stakeholders, proto-ecosystems (i.e. alliances, 
networks, research initiatives, hybrid organisations, industry associations). 
Most importantly, this granularity allows for both conflict and 
action/innovation to happen (Waldorff et al., 2013), it is not a threat for the 
field’s survival and coagulation. In such proto-ecosystems, different 
stakeholders come together to negotiate or test the materialisation of a value 
proposition (Jacobides et al., 2018). 
Finally, based on existing theorisation (Morrill, 2006), if the nascent field 
survives the intense contestations of the mobilisation phase, there is 
stabilisation (similar to Morrill’s structuration) - a new institutional order 
settles in. I call this stage stabilisation, because structuration efforts begin 
during mobilisation. Stabilisation is reached when there is less ambiguity and a 
structure is better defined, with easily identifiable roles, practices and rules of 
the game. 
 211 
9.2.2. INSTITUTIONALISATION IN COMPLEXITY 
9.2.2.1. Plurality of logics 
Chapter 6 identifies the institutional logics and their carriers as presented in 
digital health by the time data collection ended: medical profession, state, 
market, citizen and science logics. Medical profession logic means that their 
representatives have access to a body of knowledge, are licensed to employ it 
and have autonomy in their decisions (Abbot, 1988; Leicht & Fennell, 2008; 
Scott, 2008). State logic is focused on collective welfare through 
rationalisation and uniformity (Alford & Friedland, 1992; Scott, 2008). Despite 
the rise of the neoliberal doctrine (Swyngedouw, 2005), healthcare remains an 
area where the state continues to manifest in its welfare capacity. The market 
logic is guided by the need to increase shareholders value through the 
consideration of opportunity costs, potential returns and competitive edge 
(Gawer & Phillips, 2013; Scott et al., 2000; Thornton, 2002). The citizen logic 
refers to the fact that people choose based on personal values, with a sense of 
belonging to larger groups (Alford & Friedland, 1985; Dunn & Jones, 2010; 
Windrum & García-Goñi, 2008). I choose the term “citizen” to reflect that 
“when exercising one’s autonomy and freedom, it is expected that the 
responsible citizen will allow his or her lifestyle to be guided under the 
auspices of knowledgeable experts and normative prescriptions of what it 
means to be healthy” (Ayo, 2012, p. 104). Science logic is focused on 
advancements of knowledge and is guided by “communalism, individualism, 
desinterestedness, originality, skepticism” (David, 2004; Dunn & Jones, 2010). 
In the next table, I present a synthetic view of the institutional logics acting in 
digital health and some of their representative stakeholders. 
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Table 13. Digital health institutional logics as ideal types and 
representative stakeholders 
The merits of this endeavour are threefold. First, it accounts for all institutional 
logics at play, which is most relevant when studying an area that is both new 
and understudied (Greenwood et al., 2011). Second, the content of the 
healthcare logics is assumed in most studies and not well explained. This is 
often the case for the stage logic, for instance. However, the state logic 
suffered significant transformations over time and therefore its logic shouldn’t 
be taken for granted by researchers. In addition, the market logic has its own 
specificity in the digital technologies context, where competition and 
innovation have a different meanging. My research also defines the science 
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logic in the context of healthcare, for the first time. Third, I bring forth a new 
emergent logic that was not identified and theoreticised before, the citizen 
logic. 
9.2.2.2. Institutionalisation in emergence 
My findings at the field level show that in the early stage of a field, the 
ingenious phase, there is intense hybridisation mainly because stakeholders 
enter voluntarily. Over the next stages, hybridisation, conflict and ambivalence 
manifest concurrently. I define ambivalence as the process of simultaneous 
conflict and hybridisation and it is the most common institutionalisation 
process amongst digital health stakeholders. Ambivalence is present because of 
the uncertainty and ambiguity of the field emergence, and because there are 
unsettled tensions between the incumbent logics (market, state and medical 
profession logics) in the healthcare field. Not last, due to the high ambiguity, 
there is a significant orientation to possible scenarios of the future, and 
ambivalence manifests also as a consequence of the conflict between the past, 
the present and the future. 
The organisational level analysis shows that organisations engage with 
stakeholders mainly to close the knowledge and competency gaps, to gain 
resources and to nurture the market. It becomes clear that due to intense 
learning processes, there is intense hybridisation to the far end of co-creation at 
organisational level. Conflicts are avoided by new organisations either by 
delaying engagement with powerful stakeholders, by using categories skilfully 
or by compartmentalisation of solutions and value propositions. 
State actions or lack of prove to have significant influence both at field and 
organisational levels. I find that the citizen institutional logic is the beneficiary 
of existing conflicts inside the healthcare field, where more logics reside in an 
“uneasy truce” (Reay & Hinings, 2005). This institutional outcome is similar to 
how the managerial logic came into ascendance (Scott et al., 2000) at a 
previous time. 
A new role, the empowered patient, is representative for the increase in power 
of the citizen logic in the emergent field. It represents a proto-institution 
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(Zietsma & McKnight, 2009) and it is being negotiated intensively in the 
digital health. Previous studies similarly show how technology redefines roles 
in healthcare and may causes redistribution of power between actors (Barley, 
1986; Nicolini, 2006).  
9.2.2.3. The hybrid role of the empowered patient 
The idea of patients having more choice in their health has been recurrent in 
political discourses (Scott et al., 2000) during the past decades. What changed 
now is that digital technologies, an exogenous factor for healthcare (Pache & 
Santos, 2010; Scott, 2008), offer the means for patients to engage in ways that 
were not previously possible.  
The state, the CDHT producers and academic representatives form a critical 
and significant mass, with facilitative effect on the rise of the citizen logic. 
This effect is both intentional and unintentional. For instance, the CDHT 
producers encourage patients/citizens to self-quantify by designing attractive 
products. They do not mean to undermine doctors’ authority, at least not 
always and not in the first place. Additionally, they realise the value of health 
data – big data, but so do the citizens who begin to demand control over PHD, 
creating a conflict. The state wants to enforce patient self-management, but it 
does not foresee that eventually this self-management would generate a 
conflict precisely with the empowered patient it helps create. There is 
“bounded intentionality” (Thornton et al., 2012, p. 80) of stakeholders, which 
lie paradoxically on rational constraints, like “social identity, goals, cognitive 
limitation” (ibid.). “Where a formal authority has been accustomed to the 
assumption that its constituents respond to it as individuals, there may be a 
rude awakening when organizations of those constituents on a non-
governmental basis creates nuclei of power which are able effectively to 
demand a sharing of power” (Selznick, 1948, p. 35). 
Lately, one of the common debates is about patients’ health literacy, as pointer 
to the information asymmetry between doctors and patients. CDHT solutions 
may pose as mediator for this expertise gap, as shown by two of the 
organisation case studies (Mira Rehab and 11 Health) and partially by the 
YouLife case study. When the empowered patient is instantiated, there is less 
 215 
conflict with the medical profession logic, as the apparent conflict is not over 
the goals (often better health outcomes or increased efficiency). In this way, 
the change in incumbent practices has a higher benefit than the cost of change. 
Consequently, organisations act intentionally or not as institutional brokers for 
and promoters of the empowered patient.  
The organisational level shows how the citizen logic is advanced not 
necessarily as opposed to the incumbent logic of the medical profession, but by 
providing the means to patients/citizens to get more control over their own 
health. Both field and organisational levels reveal how the citizen logic is the 
beneficiary of the unsettled contestations between the incumbent logics in the 
healthcare field: state, market and medical profession logics. 
9.2.2.4. Institutional work at organisational level 
My research shows that during the mobilisation stage of the institutional 
emergence, organisations mostly engage with stakeholders in their field 
proximity to close the competence and knowledge gap, access resources and 
nurture a new market. These interactions are dominantly mediated by 
hybridisation and compartmentalisation of logics. This situation may be due to 
the fact that organisations in my study were not backed by powerful 
organisations, they were relatively new and operating under scarce resources, 
that they did not pursue conflict between logics. The main mechanisms were 
collaborative to the far end of co-creation. Case studies show that legitimacy 
and trust are perceived as important resources and much internal and external 
institutional work is directed towards building them. In a highly complex 
environment, trust is the main exchange currency. 
Organisations compartmentalise for different stakeholders, but they also create 
and mediate interactions, acting as institutionalisation agents between logics. 
Both compartmentalisation and hybridisation were best supported by the digital 
technologies intrinsic characteristics that allow deploying concurrently 
multiple interfaces, levels of interactions, customisations, as well as by their 
unfinished character, meaning that on-going readjustments or additions can be 
managed. In terms of engaging with the state logic, organisations closer to 
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healthcare, a regulated fragmented field, are more prone to getting involved 
with state agencies. 
Another commonality, albeit specific to most digital technology companies 
(Jacobides et al., 2018), is the morphing of products and business models. 
Moreover, organisations end up running concurrent business models, 
sometimes monetising from other stakeholders than the main beneficiaries (i.e. 
payers versus patients). “Firms identify what drives value to users (B2C), but 
do not always charge the users for it; often they charge other clients (B2B), 
who are willing to fund a venture to acquire its client information or access, or 
to show that they are affiliated with value-adding services (B2B2C)” (ibid., p. 
2264).  
The three case studies show that amidst plurality and ambiguity, firms orientate 
mainly based on the scenarios of the future, rather than the pre-existing 
institutional arrangements. All organisations remained true to their founding 
logics, albeit the founding logic suffered intense transformations in its 
enactment. This shows the importance of the founders’ logic in the early stage 
of a new venture. Orientation based on scenarios of the future is reflected in 
their projective, ideal identities, which are the main determinant for action. In 
itself, building an ideal identity represents an important form of institutional 
work. 
9.3. THEORETICAL CONTRIBUTIONS TOWARDS THE INSTITUTIONAL 
THEORY 
9.3.1. FIELD EMERGENCE AND INSTITUTIONALISATION 
Building on previous research, the field level study enriches the theoretical 
understanding of field emergence and institutionalisation. The figure below 
synthesises my model for field emergence, with four phases: ingenious, 
legitimation, mobilisation and stabilisation, showing the dominant 
institutionalisation processes during each phase. For stabilisation, I present 
possible and alternative outcomes. The model assumes that all stages are 
necessary for emergence to be successful, although returns to previous stages 
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are possible. The arrow indicates that this model can explain institutional crisis 
in mature fields as well.  
 
Fig. 46. A new model for field emergence and institutionalisation processes 
Although in this case the field did not reach the maturity phase, stabilisation, I 
gathered significant insights to refine the model of emergence adding to 
existing theorisations. Compared to Morrill’s emergence model, I define an 
additional phase, legitimation. I show the relevance of the legitimising actors, 
individuals (opinion leaders and social entrepreneurs) or organisations 
(healthcare, academia). This phase indicates that for mobilisation to happen, it 
is not enough to have only a critical mass (Morrill, 2006), but a significant 
mass, which confers socio-political legitimacy. This phase shows how digital 
health emergence resembles a social movement, by promoting the citizen logic 
amongst powerful incumbents. The role of opinion leaders is to connect the 
past to a possible future, link to higher order of values, connect to a common 
good and a good cause and promote stories to alleviate contradictions. Several 
entrepreneurs grow beyond their organisations to become social entrepreneurs, 
who have significant impact for the coagulation and the institutional 
configuration of the field. They provide templates for action, encourage risk 
taking, offer proof of change, generate new practices and knowledge and 
provide compelling stories. 
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During mobilisation there is a certain granularity, which allows for 
negotiations and conflicts to continue (Purdy & Gray, 2009; Waldorff et al., 
2013), without endangering the survival of the field. Finally, stabilisation 
happens only when roles, practices and rules of the game are easier to identify; 
hence ambiguity decreases significantly. Stabilisation means the survival of the 
field, with its own new field logic or a constellation of logics (Goodrick & 
Reay, 2011). If stabilisation fails (Aldrich & Fiol, 1994; Gray, Purdy, & 
Ansari, 2015), several scenarios are possible: the field is cannibalised by 
adjacent ones, gets segmented and partially assimilated to one or a few fields, 
or is segmented into several niche fields. Stabilisation may reverse to 
mobilisation, if certain events forcefully influence its course (exogenous or 
endogenous triggers). These iterations between stabilisation and mobilisation 
could explain mature field crisis, when a field has to regain its stability or face 
extinction. Nonetheless, the longer the field survives, the more likely it is to 
produce changes in adjacent fields. For instance, Apple’s introduction of the 
Research Kit caused a rapid shift in rethinking how clinical trials could be run, 
impacting pharma. 
The digital health case shows that interstitial emergence is not a mere response 
to “a real or perceived institutional failure” (Morrill, 2006, p. 2) in nearby 
fields, as suggested by previous studies (Morrill, 2006; Purdy & Gray, 2009). It 
is mainly a response to perceived opportunities - resources and technologies 
(Gurses & Ozcan, 2014). An interstice may appear as a result of endogenous 
factors in adjacent fields, for instance institutional failures or practical 
problems (Fligstein, 2002; Morrill, 2006). In this case, healthcare has its own 
institutional failures generated by internal fragmentation and institutional 
constellation of logics (Goodrick & Reay, 2011; Reay & Hinings, 2009; Scott 
et al., 2000): for instance, the conflict between “care” and “science” (Dunn & 
Jones, 2010), or failure to “care” about health, not just illness. Practical 
problems of healthcare could be cost inefficiencies, incapacity to treat all 
illness, transparency, access and so on. This research shows how digital health 
appears at first to address wellness and illness via patient education, or “care” 
via peer networks. It then evolves towards “do it yourself” healthcare and 
eventually expands to the far end of medicine, even offering new ways to find 
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cures via Big Data, algorithms or citizen science (Candido do Reis et al., 
2015). Additionally, this case does not support the theoretical assumption that 
challengers, in order to have impact, have to offer a view “premised on what 
exists and how goods are already delivered” (Fligstein & McAdam, 2011, p. 
18). Digital health is based precisely on what may be missing and new delivery 
channels. 
9.3.2. INSTITUTIONALISATION ALL THE WAY 
The field level shows that during field emergence, there is great complexity 
because of ambiguity, lack of integration, high number of stakeholders and 
institutional logics, new roles and practices or organisational forms (Aldrich & 
Fiol, 1994; Julie Battilana & Dorado, 2010; Fligstein & McAdam, 2011; Purdy 
& Gray, 2009). This study supports previous findings that high specificity of 
institutional logics creates a complex institutional arena (Greenwood et al., 
2011; Thornton et al., 2012). Therefore less prescriptive logics tend to 
hybridise at a higher pace, for instance market, science and citizen logics. 
Vocabulary, attention and justifications accumulate and change from one stage 
to the other (Nigam & Ocasio, 2009; Thornton et al., 2012), due to the gradual 
assimilation of stakeholders and the experimentation with technologies and 
new practices. At first, an emerging field attracts stakeholders who carry more 
similarities between their logics (Greenwood et al., 2011). This allows for 
mutually facilitative effects (Waldorff et al., 2013) and contribute to the 
cognitive legitimacy of the field. The more stakeholders step in, conflicts 
appear and debates become more intense (i.e. over interoperability, safety, 
validity, privacy, evidence or ownership), but so does engagement. 
The organisational level analysis offers valuable insights on the institutional 
work that organisations undertake. It shows how organisations represent proto-
institutions (Zietsma & McKnight, 2009), in the sense that they bring an 
identity project and orientate themselves based on future scenarios. They also 
adhere to distinctive categories and form connections in the emergent field, 
contributing to its coagulation. They act as knowledge and competency 
generators who contribute to the field maturation. Both field and organisational 
levels showed how medical professionals, patients and entrepreneurs enabled 
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by digital technologies were not only changing practices, but were co-creating 
new practices. Additionally, they create new organisational and technological 
structures that generate new conceptions of control and governance.  
Due to the digital technology unfinished character, organisations are able to 
compartmentalise for various stakeholders, in a way that allows them to 
develop new practices and identify common goals. In this way, organisations 
become institutional brokers. They mediate hybridisation processes between 
stakeholders, even if there is a significant knowledge and expertise gap 
between them (patients and doctors, for instance). Part of their institutional 
work is also building trust and legitimacy for themselves, but in doing so they 
contribute to the entire field’s cognitive and socio-political legitimacy. The 
diagram on the next page shows how institutionalisation processes intensify 
and how field emergence is also a bottom up process. 
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Fig. 47. Institutionalisation all the way 
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Organisations represent institutional agents to the point where they can become 
“institutions in their own right” (Kraatz & Block, 2008). One of the 
organisations in my research, 11 Health, represents a Selznickian institution, in 
the sense that it not only becomes a receptacle for multiple identities, but 
develops an organisational “self” (Kraatz & Block, 2008; Selznick, 1984). This 
means that it becomes infused with value, humanistic value (ibid.). Its founder 
in fact represents the empowered patient at its best, capable to find solutions to 
improve patients lives, engages in political actions and maintains his own and 
his company’s integrity (Greenwood et al., 2011; Kraatz, 2009; Kraatz & 
Block, 2008; Selznick, 1984). In relation to this, both the field and 
organisational levels of analysis bring forth the importance of trust and 
leadership (Aldrich & Fiol, 1994; Fligstein, 2001; Kraatz, 2009; Kraatz & 
Block, 2008) for the institutionalisation and institutional work in complexity. 
Leadership builds internal capabilities for the organisation to hold multiple 
identities and act as institutional agent. A leader makes sense and gives sense 
in a world of uncertainty. A leader also projects an identity that is tributary to 
the future, not to the ambiguity of the present or the legacy of the past. In that 
sense, the creativity trait, however subtly manifested, is important for the 
organisation survival: it supports the creation of new values and meanings for 
multiple stakeholders and finds competitive edges by new approaches.  
Organisations find it difficult to respond to diverse and often competing 
demands, therefore, they need “something” to hold them together and help 
them navigate the change. For a new organisation, leadership is not only a 
condition for success, but for its survival in a forever changing landscape, due 
to its ability to build trust. Trust links all levels, personal, organisational and 
the field levels, and is the main basis of exchange in conditions of high 
complexity. Leaders enable organisations to build strong strategies, co-opt 
partners and raise resources from often sceptical and inexperienced sources. 
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Fig. 48. Institutionalisation in complex environments 
The figure above enhances the theoretical framework that guided and was 
validated by this research to reflect the importance of leadership all the way - 
for the field and organisational survival. Leadership is hardly noticed when 
things go well or when there is a stable and predictable environment. However, 
this is not the case of digital health that proposes new modus operandi, new 
scientific avenues, and new roles for stakeholders involved: doctors, patients, 
citizens, pharma, technology companies, insurers, investors or regulators. 
This research shows that institutionalisation of a new field is also a bottom-up 
process (Selznick, 1984) and how less powerful actors, particularly in 
conditions of high institutional complexity, can cause massive change 
(Greenwood et al., 2011; Kraatz, 2009; Kraatz & Block, 2008; Santos & 
Eisenhardt, 2009; Selznick, 1984). 
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9.3.3. FURTHER IMPLICATIONS 
My research adds to previous work showing that institutional logics do not rely 
on cognitivism solely (Friedland, 2013; Patriotta et al., 2011; Thornton et al., 
2012) and joins the calls for researchers to consider more prominently the role 
of values, emotions and materiality in institutionalisation.  
“Institutional logics all bind value, practice, and object. Institutional logics are, 
one might say, practical forms of value rationality” (Friedland, 2013, p. 36). 
Therefore, altering any of these cause further consequences on the institutional 
arrangements. Different debates use varied justifications (Boltanski & 
Thévenot, 2006; Friedland, 2013; Patriotta et al., 2011) in the attempt to reach 
common understanding over a common good (i.e. patient safety, privacy, 
rights). Such changes in debate framings is explained by individuals being able 
to simultaneously access and combine different orders of worth (Patriotta et al., 
2011) or value rationales, grounded in “myriad moments of located passion” 
(Friedland, 2013, p. 44). This research shows the impact of leadership at field 
and organisational levels, because one of its main functions is to rise above 
uncertainties and debates and present a better future by association with higher 
order values. 
“Ideals are called ideals for a reason” (Kraatz & Block, 2008, p. 262) and the 
fact that they are not perfectly reflected in the real world, does not mean they 
have no practical implications. They can drive collaboration to the far end of 
co-creation, as shown in this research. Institutional logics maintain a subtle 
connection between practices and values, not as simple cognitive deductions, 
but as simultaneous value attachments, which maintain them humbly in the 
realm of social possibilities (Friedland, 2013). This conception may well 
explain the “foolishness” of entrepreneurs in emergent fields, “for they are 
navigating, at best, in an institutional vacuum of indifferent munificence and, 
at worst, in a hostile environment impervious to individual action” (Aldrich & 
Fiol, 1994, p. 645). 
And if I had to start a company and fail a thousand times and start it 
over again and fail, I would do that. And so when I realized that, then 
it was about doing whatever it takes to make this a reality. Because 
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it's a change that can happen and has to happen in our world! 
(Elizabeth Holmes, founder Theranos) (Computer Society, 2014) 
The rise of the empowered patient may be considered in the broader context of 
a socio-political evolution towards “governance-beyond-the-state” 
(Swyngedouw, 2005, p. 1991), a consequence of the interaction between a 
neoliberal state, digital innovation and citizens. The capacity of new roles and 
identities to survive depends upon a successful negotiation of a new conception 
of control (Fligstein & McAdam, 2011). In order for a new conception of 
control for doctor – patient/citizen to emerge, many aspects have to be 
negotiated and possibly renegotiated, as “[n]o value sphere can justify the 
ultimate value upon which it depends. Each depends on an intellectual 
sacrifice” (Friedland, 2013, p. 31). 
Voronov and Vince (2012) show that emotions are very relevant for 
institutional work and propose a fantasmatic frame, alongside a cognitive one. 
Such frame is connected to the power concept, as it is constantly driven by 
desires, tested against reality and orientated towards future. As stated before in 
this thesis, the sense giving process is future orientated and concerned with 
influencing the environment (Gioia & Chittipeddi, 1991). My research shows 
that such a fantasmatic frame (i.e. ideal identity or future script) is indeed 
infused with emotions, but it is mostly value orientated, rather than power. 
Consequently, it is relevant to consider emotions, values and representation of 
the future when researching emerging institutional fields, given their high 
degree of uncertainty and ambiguity that require institutional work. In this way, 
I am echoing other scholars like Friedland (2013), Kraatz and Block (2008) 
Kraatz (2009) and Voronov and Vince (2012) in arguing that values and 
emotions are most relevant for understanding institutional processes and 
institutional work at all levels of analysis. 
Digital technologies are complex artefacts that challenge the separation 
between the organisation and its environment (Gawer & Phillips, 2013; 
Nicolini, 2007; Orlikowski, 2010; Petrakaki et al., 2012). They bring change 
via democratisation of specialist knowledge, alternative channels for action and 
information through peer-to-peer communications, and therefore they 
challenge temporary, spatial, ownership and governance conventions.  
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In the light of the increasing acknowledgement of materiality in institutional 
logics research (Gawer & Phillips, 2013; Morrill, 2006; Thornton et al., 2012), 
I add a few remarks on collaborative digital health technologies as enablers and 
mediators for institutional complexity and change. The encounter of healthcare 
and ICT has been dominated by managerial approaches (Macnaughtan, 2015b; 
Scott et al., 2000) until 2007, with the evolution of smart, affordable, mobile 
and sensing consumer devices. I show that CDHT solutions open up space and 
mediate the negotiation and renegotiations of roles, practices, ownership and 
governance, by revealing existing tensions or presenting new avenues. 
Additionally, digital health opens up space for broader participation in health 
innovation, which in return, stimulates further technical and institutional 
innovation. 
Innovation is a constant aim for technology producers as it drives both the 
competitive edge and higher returns. It has been theorised that technology has 
its own logic (David, 2004) driven by rationales of economic returns, therefore 
secrecy is important. However, the digital technologies changed this paradigm 
with its evolution towards platforms and ecosystems (Mulligan, 2011; Gawer 
& Phillips, 2013; Jacobides et al., 2018). Additionally, change is intrinsic to the 
digital technologies field, given their very unfinished character. As previous 
research showed, change manifests rather as a constant in the digital 
technologies field, rather than an institutional moment or crisis (Rindova & 
Kotha, 2001; Santos & Eisenhardt, 2009; Gawer & Phillips, 2013). In that 
sense, digital technologies may have their own institutional logic, where 
change is a core value and therefore an institutional constant. This may be 
fruitful to consider by further research. 
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9.4. PRACTICAL CONTRIBUTIONS 
9.4.1. REGULATION, MEDICAL PROFESSION AND INNOVATION 
Regulations can foster innovation (Fligstein, 2002; Mazzucato, 2013), lock it in 
(Christensen et al., 2009) or hinder it simply due to lack of understanding of all 
contingencies (Macnaughtan, 2014). Contrary to existing theorisation (Aldrich 
& Fiol, 1994; Fligstein, 2002), this study shows how early or lack of regulatory 
intervention does not necessarily stabilise an emergent field, but it may open it 
further to contestation. Decision makers and regulators may want to consider 
other ways to fuel innovation and channel change, like creating spaces for 
experimentations (Rip & Schot, 2002) and opening space for innovation (Fox, 
2017), where various stakeholders can meet, try new practices, roles and 
technologies. 
As discussed in chapter 6, regulation is required to watch over the development 
of the healthcare and digital technologies innovation trajectory. However, the 
digital economy calls for a smarter, more adaptable regulatory approach in 
healthcare as well. Over the past decades, governments tried to enforce 
adoption of IT solutions in health, and despite significant resources, no 
transformative progress was made. Causes are complex and beyond the scope 
of this research, although they are touched upon in chapter 5. But one of these 
causes was the medical professionals’ resistance. This in itself is a complex 
phenomenon, however studies show that healthcare is driven by technology. 
The paradox is that doctors’ resistance resides mainly to solutions that are 
designed from a managed care perspective, rather than from a science or care 
perspectives. 
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Fig. 49. Alternative regulatory design (with deregulation of healthcare) (Macnaughtan, 
2014) 
Therefore, my research shows that the return to the medical professional 
expertise is most powerful to stimulate adoption of innovation. In that sense, 
deregulation in some areas may be considered. Through the diagram above, I 
offer a potential model for healthcare deregulation based on patient risk to 
allow for adoption of innovation, by relying more on sector coordination 
governed by the healthcare professional authority. “Perhaps the time for 
(de)regulation inside healthcare itself has arrived, to let innovation tackle a 
wide range of problems in different, creative and - why not - cheaper ways” 
(ibid.).  
However, setting the rules of the game, like interoperability, privacy and 
ownership of data, should remain the primary concern of the regulators. By 
following the advise on deregulation of practice and expertise and regulation of 
the rules of the game, regulators would embrace more the characteristics of an 
“entrepreneurial state” (Mazzucato, 2013). Excellent examples of leadership 
for unlocking the creative potential of the digital health and healthcare are 
offered recently by two former executives in the US Department of Health, 
Karen DeSalvo (ONC Director, then DoH assistant secretary) and Susannah 
Fox (CTO in DoH). NHS, via the app library, for instance, is another example 
of an entrepreneurial regulator. “Doctors and hospitals, regulators, and policy 
makers need to convert to this religion [...]. The fact that cost-lowering, 
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accessibility-enhancing disruptive enablers can address only the simplest of 
problems at the outset is indeed a gospel of good news” (Christensen et al., 
2009, p. xlviii).  
Another call for regulators, medical professionals and academia is the need to 
reinvent medical innovation to stimulate interaction with technology and 
entrepreneurship. Adoption of innovation inside healthcare calls for 
intrapreneurial skills at the very least, as my research indicates. In order for 
innovation to disseminate systemically, there is a need to shift the culture for 
medical profession to stimulate creativity and entrepreneurship as well. 
9.4.2. ENTREPRENEURS AND INVESTORS 
Several practical implications can be drawn for new organisations, particularly 
for building internal capabilities. One recommendation is to keep the 
communications opened inside the organisation. As simple as it may seem, in 
young organisations, with limited resources, it was shown that there was a lack 
of communication. This is important because it allows for learning to 
disseminate, it fosters competencies, it keeps focus and it allows individual 
team members to adapt, assimilate or contribute to vision and strategy. 
A second recommendation is towards allowing job ownership to emerge. In 
this research, only one company demonstrated this fully (Mira Rehab), and this 
proved to unlock creativity, lateral thinking, and better coordination inside and 
outside the organisation.  
All organisational cases showed that values are important, as well as leadership 
and identity. Conflict at top level creates disengagement. However, having a 
good cause has material effects on the evolution of a company. A good cause 
offers a sense of purpose to organisational members and stimulates learning 
and creativity. For outsiders, it projects a sense of integrity and creates good 
will. My research indicates that leadership is an essential indicator of 
organisational survival and success in a complex institutional environment, 
where trust becomes the main basis of transactions. Additionally, creativity as 
leadership trait indicates that such organisations are more adaptive and capable 
to attract co-optation from powerful stakeholders. A recent “poll of fifteen 
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hundred CEOs identified creativity as the number-one “leadership 
competency” of the future” (Dyer, Gregersen, & Christensen, 2009, p. 1), in 
the fast changing digital economy. 
Young organisations in digital health, having scarce resources and a complex 
environment to navigate, have to establish strong collaborations to access 
expertise, and in doing so to maximise their resources. My research shows that 
co-creation of new to the world digital solutions alongside the end-users is the 
most strategically meaningful and resourceful mechanism. It also opens space 
for learning and even fosters the market itself. In a multi-stakeholder context, 
organisations have to offer clear value propositions to each and communicate 
clearly and efficiently with each category. In order to that, different 
vocabularies may apply. Similarly, in a context where technology happens fast, 
and demand is evolving and shifting, it is important to coordinate and integrate 
with other solutions, integrate in an ecosystem or build one. 
Not last, I have shown that legitimacy has material consequences on 
organisational survival and access to resources. Amongst modalities to obtain 
legitimacy in digital health, I mention: 
• Association with credible actors – via partnership (academia or 
healthcare organisations) or co-optation in advisory boards, association 
with opinion leaders 
• Proof of persistence – via a detailed history of the organisation, 
founding stories 
• Stories - as a way to transition from status quo to the future 
• Build trust – founder stories, display of achievements 
• Good cause articulation  
• Meaningful value propositions for all significant stakeholders 
• Scientific or economic evidence communicated for a broad audience 
• Strategic social media engagement 
Through this study, I show that organisations act mostly serendipitously. 
Drawing maps of stakeholders and potential ones, along with how value can be 
generated from engaging with them, may better orientate and help new 
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organisations to build strategies, value propositions and concurrent business 
models in a complex institutional context. As this research demonstrates, most 
organisations changed their products and business models significantly, as 
learning and interactions with stakeholders intensify. 
The next table is mapping YouLife’s stakeholders, as developed during data 
collection. The green colour marks existing congruence in goals, yellow marks 
ambivalence (on-going negotiations or uncertainties) and the lack of colour 
shows untapped territories or no identify overlap. At the bottom, there are 
several indicators to take into account when engaging with particular 
stakeholders. Decisions to engage with stakeholders should depend and be 
phased on such indicators, the particularities of the solution offered and 
resources available. For instance, Mira Rehab considered that its solution needs 
intense expert input from medical professionals, and therefore their efforts 
went initially towards building strong partnerships within medical communities 
relevant to their products: at the beginning orthopaedists and physiotherapists, 
followed by neurologists. In time, they learned that clinical connections offered 
them also a competitive market advantage - access to resources and distribution 
channels. Therefore, they prioritised the engagement with this stakeholder 
(doctors) and the deployment of the B2B model, and delayed the B2C and 
B2B2C models. 
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Table 14. Sample stakeholder map for YouLife 
 233 
In the digital economy, the main beneficiaries do not always represent the main 
revenue stream (Jacobides et al., 2018). And this is most often the case in 
digital health, too. It is therefore important for young ventures to have a 
stakeholder plan (see also fig. 14), not only a business plan. Consequently, a 
good practice may be drawing roadmaps for stakeholder evolution to guide and 
prioritise product development and business models, to maximise resources 
and legitimacy. Given scarcity of resources and a fast changing environment, 
this is a fine line to walk for many, indeed. 
The most important practical insight of this research for CDHT producers, 
investors and other stakeholders is that in digital health an organisation needs 
four licenses to succeed. 
 
Fig. 50.  Four licences to succeed in digital health 
The figure above proposes an evaluation model for digital health innovations 
and a high level guidance on how to assess and respond to these four pillars. 
The business licence takes into account the constant changes and complexities 
of a fragmented field where there are multiple stakeholders. Provided resources 
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are limited, organisations have to prioritise and phase their product and 
business development. The regulatory licence relates to the fact that digital 
health is subject to regulations (laws and regulations) and professional (codes 
and standards) scrutiny. Science relates to professional authority and more 
broadly to building trust and confidence for a new product and a new 
organisation. The social licence becomes more relevant in the digital economy, 
where people connect and disconnect simultaneously and rapidly, where word 
travels fast and unmerciful. Social engagement is also a way to maximise 
resource, for instance via crowd funding and crowd wisdom, or via increasing 
impact and building a bandwagon adoption. It also facilitates co-creation, 
engagement and brand attachment. 
However, the weight of each licence is dependent on the position of the 
organisation on the digital health continuum. For instance, YouLife found the 
market logic to be most accommodating, so it had less attention for regulations 
that apply in healthcare. However, it did not deploy successfully for engaging 
efficiently with their target audience. However, 11 Health is an example of 
successfully getting to the point where it was satisfying all four licences.  
Not last, young organisations in digital health benefit from the capacity to 
articulate their development in terms of product and business model over time, 
in a compelling mode both internally and externally. Roadmaps for 
development and stakeholders engagement ensure just that, and by that, they 
can attempt to satisfy all licences above over time and corresponding to their 
solution on the digital health continuum. 
9.5. REFLECTIONS AND FUTURE DIRECTION OF RESEARCH 
My research makes several and complex contributions to the institutional 
theory in the realm of institutional complexity, field emergence and 
institutionalisation. In its complexity also reside some of its limitations, in the 
sense that it may have been better suited for a team of researchers to undertake, 
due to the volume and richness of data. 
In respect to the field level analysis, the main limitation is inherent to single 
case studies; therefore further explorations of emergent fields are needed. For 
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instance, the legitimation phase may be specific to interstitial emergence 
adjacent to fragmented fields (Fligstein & McAdam, 2011). To further research 
agenda, I suggest that studies of the evolving roles of digital health 
stakeholders may render not only practical insights, but also theoretical ones on 
how conceptions of controls and governance (Fligstein & McAdam, 2011; 
Gawer & Phillips, 2013; Swyngedouw, 2005) may change in the digital world. 
Additionally, building on this study, further explorations of the digital health 
field will advance insights in field emergence, particularly because digital 
health is still far from stabilisation.  
At the organisational level, due to the diversity of solutions in the field, further 
research may look at organisations that are more similar to allow for finer 
contributions on specific areas. My research did not focus on the relevance 
leadership has for new organisations in institutional complexity. However, it 
proves that leadership has material effects on organisational survival and 
success. Therefore, I concur to the existing opinions (Kraatz, 2009; Kraatz & 
Block, 2008) that this is an area of research that could produce interesting 
theoretical insights, as the cases of “shared leadership” or the “entitativity” an 
organisation has reached under a connotative leader that were revealed by my 
research. 
Not last, digital technologies allow for new forms of organising the social and 
economic life (Gawer & Phillips, 2013; Jacobides et al., 2018). Their impact 
on institutionalisation has been explored but they deserve further understanding 
(Gawer & Phillips, 2013; Rindova & Kotha, 2001; Santos & Eisenhardt, 2009). 
It would perhaps be of theoretical and empirical interest to explore digital 
technologies as an institutional logic in its own right, as has been suggested 
before that technology and science logics are different (David, 2004). Digital 
technologies may have change as a core value and constant rather than an 
institutional disruptor as conceptualised until today. Considering digital 
technologies as an institutional logic in its own right may render interesting 
insights of the digital econony. 
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9.6. CONCLUDING REMARKS 
“The future has arrived — it’s just not evenly distributed yet" (attributed to 
William Gibson) 
I used this quote in one of my first articles about digital health - a quote that is 
invoked in the digital health space very often. Digital technologies connect and 
disconnect us in various ways, at a very fast pace. They remain a significant 
driver of social, economic and scientific change. Much research in this field is 
needed to keep pace, understand, let alone control these changes. There is 
tremendous opportunity in digital health, as it is indeed built upon intangible 
value substances. 
 237 
REFERENCES 
Abbot, A. (1988). The System of Professions. Chicago: University of Chicago 
Press.  
Accenture. (2014). Great Expectations: Why Pharma Companies Can’t Ignore 
Patient Services 2014. Retrieved Jan. 2015, from Accenture website: 
http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-
Great-Expectations-Why-Pharma-Companies-Cant-Ignore-Patient-
Services-Survey.pdf 
Akrich, M. (1992). The De-Scription of Technical Objects. In Wiebe E Bijker 
and John Law (Eds.), Shaping technology/building society: studies in 
sociotechnical change. Cambridge: MIT Press 
Aldrich, H. E., & Fiol, C. M. (1994). Fools Rush in? The Institutional Context 
of Industry Creation. The Academy of Management Review, 19(4), 645–
670. https://doi.org/10.2307/258740 
Alford, R. R., & Friedland, R. (1985). Powers of Theory: Capitalism, the State, 
and Democracy (6th ed.). Cambridge University Press. 
Atul, B. (2015). UCSF’s Atul Butte on the future of big data and the potential 
for “garage biotech.” Retrieved Jan. 2016, from 
https://www.youtube.com/watch?v=pY5_KSMlAUQ&t=36s 
Ayo, N. (2012). Understanding health promotion in a neoliberal climate and 
the making of health conscious citizens. Critical Public Health, 22(1), 
99–105. https://doi.org/10.1080/09581596.2010.520692 
Ayogo. (2015). Patient Engagement Definition: What Does it Mean to You?. 
Retrieved March 2016, from Ayogo website: 
http://ayogo.com/blog/patient-engagement-definition/ 
Baldwin, C. Y., & Woodard, C. J. (2009). The Architecture of Platforms: A 
Unified View. In Annabelle Gawer (Ed.), Platforms, Markets and 
Innovation.. Cheltenham, U.K. and Northampton, MA: Edward Elgar 
Publishing. 
Barley, S. R. (1986). Technology as an Occasion for Structuring: Evidence 
from Observations of CT Scanners and the Social Order of Radiology 
Departments. Administrative Science Quarterly, 31(1), 78–108. 
https://doi.org/10.2307/2392767 
Barley, S. R. (2008). Coalface Institutionalism. In Royston Greenwood, 
Christine Oliver, Roy Suddaby & Kerstin Sahlin (Eds.), The SAGE 
Handbook of Organizational Institutionalism (491–518). London, UK: 
SAGE Publications Ltd.  
Barley, S. R., & Tolbert, P. S. (1997). Institutionalization and Structuration: 
Studying the Links between Action and Institution. Organization 
Studies, 18(1), 93–117. https://doi.org/10.1177/017084069701800106 
 238 
Basil Strategies. (2012). Interview with Sarah Kucharski -- Doctors 2.0 & You. 
Retrieved Nov. 2015, from 
https://www.youtube.com/watch?v=3JPO9Qq1AFU 
Bates, J. (2014). The strategic importance of information policy for the 
contemporary neoliberal state: The case of Open Government Data in 
the United Kingdom. Government Information Quarterly, 31(3), 388–
395. https://doi.org/10.1016/j.giq.2014.02.009 
Battilana, J., & D’Aunno, T. (2009). Institutional Work and the Paradox of 
Embedded Agency. In B. Leca, R. Suddaby, & T. B. Lawrence (Eds.), 
Institutional Work: Actors and Agency in Institutional Studies of 
Organizations (31-58). Cambridge, U.K.: Cambridge University Press 
Battilana, Julie, & Dorado, S. (2010). Building Sustainable Hybrid 
Organizations: The Case of Commercial Microfinance Organizations. 
Academy of Management Journal, 53(6), 1419–1440. 
https://doi.org/10.5465/AMJ.2010.57318391 
Beach, D. (2010). Neoliberal Restructuring in Education and Health 
Professions in Europe Questions of Global Class and Gender. Current 
Sociology, 58(4), 551–569. https://doi.org/10.1177/0011392110367998 
Beckert, J. (1999). Agency, Entrepreneurs, and Institutional Change. The Role 
of Strategic Choice and Institutionalized Practices in Organizations. 
Organization Studies, 20(5), 777–799. 
https://doi.org/10.1177/0170840699205004 
Bessant, J., & Rush, H. (1995). Building bridges for innovation: the role of 
consultants in technology transfer. Research Policy, 24(1), 97–114. 
https://doi.org/10.1016/0048-7333(93)00751-E 
Beverungen, A., Böhm, S., & Land, C. (2015). Free Labour, Social Media, 
Management: Challenging Marxist. Organization Studies, 36(4), 473–
489. https://doi.org/10.1177/0170840614561568 
Boltanski, L., & Thévenot, L. (2006). On Justification: Economies of Worth. 
Princeton, NJ: Princeton University Press. 
Bort, J. (2015). Thanks to Apple, 11,000 people signed up for a heart disease 
study in one day. Retrieved March 2015, from Business Insider 
website: http://uk.businessinsider.com/apple-makes-heart-disease-
study-go-nuts-2015-3 
Boulos, M. N., Wheeler, S., Tavares, C., & Jones, R. (2011). How smartphones 
are changing the face of mobile and participatory healthcare: an 
overview, with example from eCAALYX. BioMedical Engineering 
OnLine, 10(1), 24. https://doi.org/10.1186/1475-925X-10-24 
Bowen, G. A. (2008). Naturalistic inquiry and the saturation concept: a 
research note. Qualitative Research, 8(1), 137–152. 
https://doi.org/10.1177/1468794107085301 
Brown, R. E. (2006). Myth of symmetry: Public relations as cultural styles. 
Public Relations Review, 32(3), 206–212. 
https://doi.org/10.1016/j.pubrev.2006.05.022 
 239 
Campbell, D. T. (1958). Common fate, similarity, and other indices of the 
status of aggregates of persons as social entities. Behavioral Science, 
3(1), 14–25. https://doi.org/10.1002/bs.3830030103 
Cancer Research UK. (2014). Cancer Research UK launches ‘spaceship’ 
smartphone game to seek cancer cures. Retrieved March 2015, from 
Cancer Research UK website: https://www.cancerresearchuk.org/about-
us/cancer-news/press-release/2014-02-04-cancer-research-uk-launches-
spaceship-smartphone-game-to-seek-cancer-cures 
Candido do Reis, F. J., Lynn, S., Ali, H. R., Eccles, D., Hanby, A., 
Provenzano, E., … Pharoah, P. D. P. (2015). Crowdsourcing the 
General Public for Large Scale Molecular Pathology Studies in Cancer. 
EBioMedicine. https://doi.org/10.1016/j.ebiom.2015.05.009 
Cardin, T. (2015). Powerless in the setting of patient autonomy? Try 
maternalism. Retrieved May 2015, from KevinMD.com website: 
http://www.kevinmd.com/blog/2015/05/powerless-in-the-setting-of-
patient-autonomy-try-maternalism.html 
Chase, D. (2016). Large Companies Ally To Target Healthcare Problem 
Already Solved By Smaller Companies. Retrieved Nov. 2016, from 
Forbes website: 
http://www.forbes.com/sites/davechase/2016/02/05/large-companies-
form-alliance-to-study-problem-already-solved-by-smaller-companies/ 
Cheek, J. (2008). Healthism: A New Conservatism? Qualitative Health 
Research, 18(7), 974–982. https://doi.org/10.1177/1049732308320444 
CHM Revolutionaries. (2014). Theranos Founder & CEO Elizabeth Holmes in 
Conversation with Michael Krasny. Retrieved Jan. 2015, from 
https://www.youtube.com/watch?v=UKY3scPIMd8&feature=youtube_
gdata_player 
Christensen, C. M., Grossman, J. H., & Hwang, J. (2009). The Innovator’s 
Prescription: A Disruptive Solution for Health Care. New York: 
McGraw-Hill. 
COCIR. (2010). COCIR telemedecine toolkit. For a better deployment and use 
of telehealth. Retrieved Aug. 2012, from 
http://www.cocir.org/uploads/documents/-903-
cocir_telemedicine_toolkit_march_2010.pdf. 
COCIR. (2011). COCIR eHealth toolkit for an accelerated deployment and 
better use of eHealth. Retrieved Aug. 2012, from 
http://www.cocir.org/uploads/documents/eHealth%20Toolkit%20LINK
2.pdf. 
European Commission. (2015). Health care and long-term care. Retrieved Jan. 
2016, from 
http://ec.europa.eu/economy_finance/structural_reforms/ageing/health_
care/index_en.htm 
Comstock, J. (2015a). In-Depth: Pharma steps up digital health efforts. 
Retrieved Nov. 2016, from MobiHealthNews website: 
 240 
http://www.mobihealthnews.com/39778/in-depth-pharma-steps-up-
digital-health-efforts 
Comstock, J. (2015b). UK’s Royal College of Physicians lays out guidelines 
for medical apps | mobihealthnews. Retrieved May 2015, from 
http://mobihealthnews.com/43278/uks-royal-college-of-physicians-
lays-out-guidelines-for-medical-apps/ 
Comstock, J. (2015c). IMS: 1 in 10 health apps connects to a device, 1 in 50 
connects to healthcare providers | MobiHealthNews. Retrieved Oct. 
2015, from http://mobihealthnews.com/46863/ims-1-in-10-health-apps-
connects-to-a-device-1-in-50-connects-to-healthcare-providers/ 
Crawford, R. (1980). Healthism and the Medicalization of Everyday Life. 
International Journal of Health Services, 10(3), 365–388. 
https://doi.org/10.2190/3H2H-3XJN-3KAY-G9NY 
Currie, W. L., & Guah, M. W. (2007). Conflicting institutional logics: a 
national programme for IT in the organisational field of healthcare. 
Journal of Information Technology, 22(3), 235–247. 
https://doi.org/10.1057/palgrave.jit.2000102 
David, P. A. (2004). Understanding the emergence of ‘open science’ 
institutions: functionalist economics in historical context. Industrial 
and Corporate Change, 13(4), 571–589. 
https://doi.org/10.1093/icc/dth023 
Davies, A., & Newman, S. (2011). Evaluating telecare and telehealth 
interventions. WSDAN briefing paper. Retrieved Jan. 2012, from 
King’s Fund website: 
https://www.kingsfund.org.uk/sites/default/files/Evaluating-telecare-
telehealth-interventions-Feb2011.pdf 
Davis, S. (2013). 2014 Essays: The Role of the Smartphone in Digital Health. 
Retrieved Apr. 2015, from Bionicly website: http://bionicly.com/2014-
essays-the-role-of-the-smartphone-in-digital-health/ 
Davis, S. (2015). The Smartphone Is The Platform For The Digital Health 
Stack. Retrieved Apr. 2015, from Bionicly website: 
http://bionicly.com/digital-health-stack/ 
deBronkart, D. (2009a). e-Patient Dave. Retrieved Apr. 2015, from 
http://www.epatientdave.com/ 
deBronkart, D. (2009b). Ushering in the Era of the Participating Patient. 
Retrieved Oct. 2016, from e-Patient Dave website: 
http://www.epatientdave.com/2009/08/26/the-participating-patient/ 
deBronkart, D. (2015). “No MU without ME”: join the campaign to fight 
health data hiding | e-Patients.net. Retrieved May 2015, from http://e-
patients.net/archives/2015/04/no-mu-without-me-join-the-campaign-to-
fight-health-data-hiding.html 
Deephouse, D. L., & Suchman, M. (2008). Legitimacy in Organizational 
Institutionalism. In Royston Greenwood, Christine Oliver, Roy 
Suddaby & Kerstin Sahlin (Eds.), The SAGE Handbook of 
 241 
Organizational Institutionalism (pp. 49–77). London: SAGE 
Publications Ltd. https://doi.org/10.4135/9781849200387 
Della Mea, V. (2001). What is e-Health (2): The death of telemedicine? 
Journal of Medical Internet Research, 3(2), e22. 
https://doi.org/10.2196/jmir.3.2.e22 
Dias, J. (2014). Is the Phrase “Patient Engagement” Overused?. Retrieved Nov. 
2014, from HIT consultant website: 
http://hitconsultant.net/2014/04/21/is-the-phrase-patient-engagement-
overused/ 
DiMaggio, P. J., & Powell, W. W. (1983). The Iron Cage Revisited: 
Institutional Isomorphism and Collective Rationality in Organizational 
Fields. American Sociological Review, 48(2), 147–160. 
https://doi.org/10.2307/2095101 
Djellal, F., & Gallouj, F. (2005). Mapping innovation dynamics in hospitals. 
Research Policy, 34(6), 817–835. 
https://doi.org/10.1016/j.respol.2005.04.007 
Dolan, B. (2012). Just launched: Our 2012 Consumer Health Apps Report | 
mobihealthnews. Retrieved Apr. 2015, from 
http://mobihealthnews.com/17925/ 
Drucker,  Peter. F. (1994). Innovation and entrepreneurship: Practice and 
principles. (6th ed.). Oxford: Butterworth-Heinemann. 
Duhaime-Ross, A. (2015). Apple makes ethics board approval mandatory for 
all medical research apps. Retrieved Apr. 2015, from The Verge 
website: http://www.theverge.com/2015/4/29/8513367/apple-research-
kit-ethics-board-mandatory-clinical-trial 
Dunn, M. B., & Jones, C. (2010). Institutional Logics and Institutional 
Pluralism: The Contestation of Care and Science Logics in Medical 
Education, 1967–2005. Administrative Science Quarterly, 55(1), 114–
149. https://doi.org/10.2189/asqu.2010.55.1.114 
Dyer, J. H., Gregersen, H., & Christensen, C. M. (2009). The Innovator’s 
DNA. Harvard Business Review, (December 2009). Retrieved from 
https://hbr.org/2009/12/the-innovators-dna 
European Commission. (2014). EC launches Green Paper consultation into 
mHealth. 1. Retrieved Sept. 2014, from https://ec.europa.eu/digital-
single-market/en/public-consultation-green-paper-mobile-health 
Eisenhardt, K. M., & Graebner, M. E. (2007). Theory Building From Cases: 
Opportunities And Challenges. Academy of Management Journal, 
50(1), 25–32. https://doi.org/10.5465/AMJ.2007.24160888 
Engelen, L. (2012). No-Show patients on conferences  : Patients IncludedTM. 
Retrieved May 2015, from Gras groeit niet door er aan te trekken  ! 
website: https://lucienengelen.wordpress.com/2012/02/15/no-show-
patients-on-conferences/ 
Engelen, L. (2013). (2) No-Show patients on conferences  : Patients IncludedTM. 
Retrieved July 2018, from LinkedIn Pulse website: 
 242 
https://www.linkedin.com/pulse/20130326140319-19886490-no-show-
patients-on-conferences-patients-included/ 
Engelen, L. (2015). What’s a Hospital Without Beds? Much Better. Retrieved 
March 2015, from LinkedIn Pulse website: 
https://www.linkedin.com/pulse/come-out-bed-move-lucien-engelen 
European Commission (2004). eHealth action plan 2004 2010. Retrieved Sept. 
2014, from http://eur-lex.europa.eu/legal-
content/EN/ALL/?uri=CELEX:52004DC0356 
European Commission. (2012). eHealth Action Plan 2012-2020: Innovative 
healthcare for the 21st century. Retrieved Sept. 2014, from 
ec.europa.eu//digital-agenda/en/news/ehealth-action-plan-2012-2020-
innovative-healthcare-21st-century 
European Commission. (2014a). mHealth, what is it? - Infographic. Retrieved 
Nov. 2014, from Digital Agenda for Europe website: 
ec.europa.eu//digital-agenda/en/news/mhealth-what-it-infographic 
European Commission. (2014b). Green Paper on mobile health (“mHealth”). 
Retrieved Jan. 2015, from 
file:///C:/Users/psxlm/Downloads/GreenPaperonmobilehealth%20(6).p
df 
European Parliament, & European Council. (2011). DIRECTIVE 2011/24/EU 
OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 9 
March 2011 on the application of patients’ rights in cross-border 
healthcare. Retrieved Jan. 2014, from http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:00
65:EN:PDF 
Ferguson, T. (1996). Health Online: How to Find Health Information, Support 
Groups and Self-help Communities in Cyberspace. Reading, Mass: Da 
Capo Press Inc. 
Fleck, J. (1994). Learning by trying: the implementation of configurational 
technology. Research Policy, 23(6), 637–652. 
https://doi.org/10.1016/0048-7333(94)90014-0 
Fleseru, A. (2016). Case study on a 14 years old girl with a very rare condition: 
Congenital Disorder of Glycosylation. Retrieved July 2018, from 
MIRA Blog website: http://blog.mirarehab.com/2016/02/23/case-study-
on-a-14-years-old-girl-with-a-very-rare-condition-congenital-disorder-
of-glycosylation/ 
Fligstein, N. (2001). Social Skill and the Theory of Fields. Sociological 
Theory, 19(2), 105–125. https://doi.org/10.1111/0735-2751.00132 
Fligstein, N. (2002). Markets as Politics: A Political-Cultural Approach to 
Market Institutions. In N. W. Biggart (Ed.), Readings in Economic 
Sociology (pp. 197–218). Blackwell Publishers Ltd. 
Fligstein, N., & McAdam, D. (2011). Toward a General Theory of Strategic 
Action Fields*. Sociological Theory, 29(1), 1–26. 
https://doi.org/10.1111/j.1467-9558.2010.01385.x 
 243 
Fox, S. (2009). Health IT Policy: E-patients want access-. Retrieved Oct. 2016, 
from Susannah Fox website: 
http://susannahfox.com/2009/09/17/health-it-policy-e-patients-want-
access/ 
Fox, S. (2011a). Peer-to-peer Health Care. Retrieved Apr. 2015, from Pew 
Research Center’s Internet & American Life Project website: 
http://www.pewinternet.org/2011/02/28/peer-to-peer-health-care-2/ 
Fox, S. (2011b). Mind the Gap: Peer-to-peer Healthcare. Retrieved Oct. 2016, 
from Pew Research Center: Internet, Science & Tech website: 
http://www.pewinternet.org/2011/08/02/mind-the-gap-peer-to-peer-
healthcare/ 
Fox, S. (2012a). What’s the future for self-tracking? Retrieved Oct. 2016, from 
Pew Research Center: Internet, Science & Tech website: 
http://www.pewinternet.org/2012/09/28/whats-the-future-for-self-
tracking/ 
Fox, S. (2012b). Thinking critically about Big Data and health care. Retrieved 
Oct. 2016, from Susannah Fox website: 
http://susannahfox.com/2012/12/30/thinking-critically-about-big-data-
and-health-care/ 
Fox, S. (2017). Creating space for innovation. Retrieved July 2018, from 
Susannah Fox website: https://susannahfox.com/2017/10/08/creating-
space-for-innovation/ 
Fox, S. (2012). The e is for engagement. Retrieved Apr. 2015, from Pew 
Research Center’s Internet & American Life Project website: 
http://www.pewinternet.org/2012/10/29/the-e-is-for-engagement-2/ 
Fox, S., & Brenner, J. (2012). Family Caregivers Online. Retrieved July 2018, 
from Pew Research Center: Internet, Science & Tech website: 
http://www.pewinternet.org/2012/07/12/family-caregivers-online/ 
Frellick, M. (2015). Research Claims Are Skirting the Peer Review Process. 
Retrieved May 2015, from www.medscape.com website: 
http://www.medscape.com/viewarticle/840267 
Friedland, R. (2013). God, Love, and Other Good Reasons for Practice: 
Thinking Through Institutional Logics. In Michael Lounsbury and Eva 
Boxenbaum (Eds), Research in the Sociology of Organizations: Vol. 39. 
Institutional Logics in Action, Part A (pp. 25–50).  
Friedland, R., & Alford, R. R. (1991). Bringing Society Back In: Symbols, 
Practices, and Institutional Contradictions. In W. W. Powell & P. 
DiMaggio (Eds.), The new institutionalism in organizational analysis 
(pp. 232–263). Chicago, IL: University of Chicago Press. 
Friedland, R., Mohr, J. W., Roose, H., & Gardinali, P. (2014). The institutional 
logics of love: measuring intimate life. Theory and Society, 43(3–4), 
333–370. https://doi.org/10.1007/s11186-014-9223-6 
Gandhi, M., & Wang, T. (2015). Digital Health Consumer Adoption: 2015. 
Retrieved Oct. 2015, from Rock Health website: 
https://rockhealth.com/reports/digital-health-consumer-adoption-2015/ 
 244 
Garud, R., Jain, S., & Kumaraswamy, A. (2002). Institutional Entrepreneurship 
in the Sponsorship of Common Technological Standards: The Case of 
Sun Microsystems and Java. Academy of Management Journal, 45(1), 
196–214. https://doi.org/10.2307/3069292 
Garud, R., Jain, S., & Tuertscher, P. (2008). Incomplete by Design and 
Designing for Incompleteness. Organization Studies, 29(3), 351–371. 
https://doi.org/10.1177/0170840607088018 
Gawer, A. (2011). What Managers Need to Know about Platforms. The 
European Business Review. Retrieved June 2015, from 
http://www.europeanbusinessreview.com/managers-platforms/ 
Gawer, A., & Phillips, N. (2013). Institutional Work as Logics Shift: The Case 
of Intel’s Transformation to Platform Leader. Organization Studies, 
34(8), 1035–1071. https://doi.org/10.1177/0170840613492071 
Geels, F. W. (2005). Technological transitions and system innovations  : a co-
evolutionary and socio-technical analysis. Cheltenham, UK : Edward 
Elgar Publishing 
Gerber, Z. (2015). What Can Pharma Learn From J&J and Sanofi About 
Reaching Millennials? | PM360. Retrieved Oct. 2015, from 
http://www.pm360online.com/what-can-pharma-learn-from-jj-and-
sanofi-about-reaching-millennials/ 
Getmyhealthdata. (2015). Electronic Health Info Petition [Noncommercial]. 
Retrieved May 2015, from http://getmyhealthdata.org/ 
Gioia, D. A., & Chittipeddi, K. (1991). Sensemaking and sensegiving in 
strategic change initiation. Strategic Management Journal, 12(6), 433–
448. https://doi.org/10.1002/smj.4250120604 
Gioia, D. A., Corley, K. G., & Hamilton, A. L. (2012a). Seeking Qualitative 
Rigor in Inductive Research: Notes on the Gioia Methodology. 
Organizational Research Methods, 1094428112452151. 
https://doi.org/10.1177/1094428112452151 
Gioia, D. A., Corley, K. G., & Hamilton, A. L. (2012b). Seeking Qualitative 
Rigor in Inductive Research Notes on the Gioia Methodology. 
Organizational Research Methods, 16(1), 15–31. 
https://doi.org/10.1177/1094428112452151 
Giordano, R., Clark, M., & Goodwin, N. (2011). Perspectives on telehealth and 
telecare. Retrieved April 2015, from The King’s Fund website: 
http://www.kingsfund.org.uk/publications/articles/perspectives-
telehealth-and-telecare 
Glynn, M. A., & Lounsbury, M. (2005). From the Critics’ Corner: Logic 
Blending, Discursive Change and Authenticity in a Cultural Production 
System*. Journal of Management Studies, 42(5), 1031–1055. 
https://doi.org/10.1111/j.1467-6486.2005.00531.x 
Goetz, T. (2008). Attention, California Health Dept.: My DNA Is My Data. 
Retrieved May 2015, from WIRED website: 
http://www.wired.com/2008/06/attention-calif/ 
 245 
Goldfarb, B., & Henrekson, M. (2003). Bottom-up versus top-down policies 
towards the commercialization of university intellectual property. 
Research Policy, 32(4), 639–658. https://doi.org/10.1016/S0048-
7333(02)00034-3 
Goodrick, E., & Reay, T. (2011). Constellations of Institutional Logics 
Changes in the Professional Work of Pharmacists. Work and 
Occupations, 38(3), 372–416. 
https://doi.org/10.1177/0730888411406824 
Goodrick, E., & Salancik, G. R. (1996). Organizational discretion in 
responding to institutional practices: Hospitals and cesarean births. 
Administrative Science Quarterly, 41, 1–28. 
Gray, B., Purdy, J. M., & Ansari, S. (2015). From Interactions to Institutions: 
Microprocesses of Framing and Mechanisms for the Structuring of 
Institutional Fields. Academy of Management Review, 40(1), 115–143. 
https://doi.org/10.5465/amr.2013.0299 
Greenwood, R. C., Magan Diaz, A., Xiao Li, S., & Lorente, J. C. (2010). The 
Multiplicity of Institutional Logics and the Heterogeneity of 
Organizational Responses. Organization Science, 21, 521–539. 
Greenwood, R., Raynard, M., Kodeih, F., Micelotta, E. R., & Lounsbury, M. 
(2011). Institutional Complexity and Organizational Responses. 
Academy of Management Annals, 5(1), 317–371. 
https://doi.org/10.1080/19416520.2011.590299 
Gulati, R., & Higgins, M. C. (2003). Which ties matter when? the contingent 
effects of interorganizational partnerships on IPO success. Strategic 
Management Journal, 24(2), 127–144. https://doi.org/10.1002/smj.287 
Gurses, K., & Ozcan, P. (2014). Entrepreneurship in Regulated Markets: 
Framing Contests and Collective Action to Introduce Pay TV in the US. 
Academy of Management Journal, amj.2013.0775. 
https://doi.org/10.5465/amj.2013.0775 
Harbert, T. (2009). Healthcare reform gives health-monitoring electronics a 
new diagnosis. Retrieved April 2015, from EDN website: 
http://www.edn.com/electronics-blogs/other/4313018/Healthcare-
reform-gives-health-monitoring-electronics-a-new-diagnosis 
Hargadon, A. B., & Douglas, Y. (2001). When Innovations Meet Institutions: 
Edison and the Design of the Electric Light. Administrative Science 
Quarterly, 46(3), 476–501. https://doi.org/10.2307/3094872 
Hargrave, T. J., & Van de Ven, A. H. (2009). Institutional work as the creative 
embrace of contradiction. In B. Leca, R. Suddaby, & T. B. Lawrence 
(Eds.), Institutional Work: Actors and Agency in Institutional Studies of 
Organizations (120–140). Cambridge, U.K.: Cambridge University 
Press 
Harlow, C., & Rawlings, R. (2013). Pressure Through Law. London: 
Routledge. 
 246 
Hartzler, A., & Pratt, W. (2011). Managing the Personal Side of Health: How 
Patient Expertise Differs from the Expertise of Clinicians. J Med 
Internet Res, 13(3), e62. https://doi.org/10.2196/jmir.1728 
Harvard i-lab. (2014). Opportunities & Challenges: Digital Health and Health 
System Collaborations. Retrieved Dec. 2014, from 
https://www.youtube.com/watch?v=mFP2ioCDdjs 
Haveman, H. A., & Rao, H. (1997). Structuring a Theory of Moral Sentiments: 
Institutional and Organizational Coevolution in the Early Thrift 
Industry. American Journal of Sociology, (102), 1606–1651. 
Healthstartup. (2014). The Ultimate Guide To The World’s Digital Health 
Ecosystem  » HealthStartup. Retrieved May 2014, from 
http://www.healthstartup.eu/the-ultimate-health-startup-resources-
guide/ 
Herper, M. (2015). What 23andMe’s FDA Approval Means For The Future Of 
Genomics. Retrieved May 2015, from Forbes website: 
http://www.forbes.com/sites/matthewherper/2015/02/20/what-
23andmes-fda-approval-means-for-the-future-of-genomics/ 
Heubl, B., & Saafeld, N. (2014). Jump off the privacy train: your data will 
make us all healthier! Retrieved May 2015, from nuviun website: 
http://nuviun.com/content/jump-off-the-privacy-train-your-data-will-
make-us-all-healthier 
Hirsch, P. (2008). Been there, Done that, Moving On: Reflections on 
Institutional Theory’s Continuing Evolution. In Royston Greenwood, 
Christine Oliver, Roy Suddaby & Kerstin Sahlin (Eds.), The SAGE 
Handbook of Organizational Institutionalism (783–789). London: 
SAGE Publications Ltd. 
Hirsch, P., & Lungeanu, R. (2012). Between Endogenous Logics: 
Deinstitutionalization of Mortgage Lending as Carnival, Not Tsunami. 
National Convention of the Academy of Management, Boston, MA. 
Hirsch, P. M., & Bermiss, Y. S. (2009). Institutional “dirty” work: preserving 
institutions through strategic decoupling. In B. Leca, R. Suddaby, & T. 
B. Lawrence (Eds.), Actors and Agency in Institutional Studies of 
Organizations (262–283). 
https://doi.org/10.1017/CBO9780511596605.010 
Hirsch, P. M., & Wohlgezogen, F. (2009). Negotiating Actor-Environment 
Relations: A Framework for Comparative Research. in Brayden G 
King, Teppo Felin, David A. Whetten (Eds.), Studying Differences 
between Organizations: Comparative Approaches to Organizational 
Research (Research in the Sociology of Organizations, Volume 26) 
(153–182). Emerald Group Publishing Limited. 
History Health 2.0. (n.d.). Retrieved July 2018, from Health 2.0 website: 
https://health2con.com/about-2/ 
Holliday, R. (2009). Thoughts on Medicine and Social Media. Retrieved Apr. 
2015, from Regina Holliday’s Medical Advocacy Blog website: 
http://reginaholliday.blogspot.co.uk/search?updated-min=2009-01-
 247 
01T00:00:00-08:00&updated-max=2010-01-01T00:00:00-08:00&max-
results=39 
Holliday, R. (2011). Regina Holliday’s Medical Advocacy Blog: The Walking 
Gallery. Retrieved Apr. 2015, from 
http://reginaholliday.blogspot.co.uk/2011/04/walking-gallery.html 
Holliday, R. (2015). The Writing on the Wall. CreateSpace Independent 
Publishing Platform. 
Ilinitch, A. Y., D’Aveni, R. A., & Lewin, A. Y. (1996). New Organizational 
Forms and Strategies for Managing in Hypercompetitive Environments. 
Organization Science, 7(3).  
IMS Institute. (2015). Patient Adoption of mHealth: Use, Evidence and 
Remaining Barriers to Mainstream Acceptance. Retrieved Dec. 2015, 
from 
http://www.imshealth.com/portal/site/imshealth/menuitem.c76283e8bf8
1e98f53c753c71ad8c22a/?vgnextoid=0b96ccb4c3402410VgnVCM100
00076192ca2RCRD 
Ioannidis, J. A. (2015). Stealth research: Is biomedical innovation happening 
outside the peer-reviewed literature? JAMA, 313(7), 663–664. 
https://doi.org/10.1001/jama.2014.17662 
Istepanian, R., Laxminarayan, S., & Pattichis, C. S. (Eds.). (2006). M-Health: 
Emerging Mobile Health Systems. New York, U.S.A.: Springer-Verlag 
Jacobides, M. G., Cennamo, C., & Gawer, A. (2018). Towards a theory of 
ecosystems. Strategic Management Journal, 39(8), 2255-2276. 
https://doi.org/10.1002/smj.2904 
Jain, S. H. (2015). How Pharma Can Offer More than Pills. Retrieved July, 
2015, from Harvard Business Review website: 
https://hbr.org/2015/07/how-pharma-can-offer-more-than-pills 
Jauhar, S. (2015). ‘The Patient Will See You Now,’ by Eric Topol. The New 
York Times. Retrieved Nov. 2015, from 
http://www.nytimes.com/2015/02/15/books/review/the-patient-will-see-
you-now-by-eric-topol.html 
Jay, J. (2013). Navigating Paradox as a Mechanism of Change and Innovation 
in Hybrid Organizations. Academy of Management Journal, 56(1), 
137–159. https://doi.org/10.5465/amj.2010.0772 
Jennett, P. A., Affleck Hall, L., Hailey, D., Ohinmaa, A., Anderson, C., 
Thomas, R., … Scott, R. E. (2003). The socio-economic impact of 
telehealth: a systematic review. Journal of Telemedicine and Telecare, 
9(6), 311–320. https://doi.org/10.1258/135763303771005207 
Jonah Comstock. (2015). Harvard doctors argue the digital phenotype will 
change healthcare | mobihealthnews. Retrieved May 2015, from 
http://mobihealthnews.com/43327/harvard-doctors-argue-the-digital-
phenotype-will-change-healthcare/ 
Jones, C., Boxenbaum, E., & Anthony, C. (2013). The Immateriality of 
Material Practices in Institutional Logics. In M. Lounsbury & E. 
 248 
Boxenbaum (Eds.), Institutional Logics in Action, Part A: Vol. 39 Part 
A (pp. 51–75). Emerald Group Publishing Limited. 
Jorge Juan Garcia F. at Doctors 2.0 & You Paris. (2013). Retrieved June 
2015, from 
https://www.youtube.com/watch?v=UKY3scPIMd8&feature=youtube_
gdata_player 
Katila, R., Rosenberger, J. D., & Eisenhardt, K. M. (2008). Swimming with 
Sharks: Technology Ventures, Defense Mechanisms and Corporate 
Relationships. Administrative Science Quarterly, 53(2), 295–332. 
https://doi.org/10.2189/asqu.53.2.295 
Keckley, P., Coughlin, S., & Eselius, L. (2012). Consumerism in Health Care. 
Deloitte Review, (11), 70–83. 
King’s Fund. (2013). An alternative guide to the new NHS in England. 
Retrieved May 2015, from The King’s Fund website: 
http://www.kingsfund.org.uk/projects/nhs-65/alternative-guide-new-
nhs-england 
Klepper, S., & Graddy, E. (1990). The Evolution of New Industries and the 
Determinants of Market Structure. The RAND Journal of Economics, 
21(1), 27–44. https://doi.org/10.2307/2555491 
Kocher, B., & Roberts, B. (2014). Why So Many New Tech Companies Are 
Getting into Health Care. Retrieved Dec. 2014, from Harvard Business 
Review website: https://hbr.org/2014/12/why-so-many-tech-companies-
are-getting-into-health-care 
Kraatz, M. S. (2009). Leadership as institutional work: a bridge to the other 
side. In B. Leca, R. Suddaby, & T. B. Lawrence (Eds.), Institutional 
Work: Actors and Agency in Institutional Studies of Organizations (59-
91). Cambridge, U.K.: Cambridge University Press 
Kraatz, M. S., & Block, E. S. (2008). Organizational Implications of 
Institutional Pluralism. In Royston Greenwood, Christine Oliver, Roy 
Suddaby & Kerstin Sahlin (Eds.), The SAGE Handbook of 
Organizational Institutionalism (243–275). London: SAGE 
Publications Ltd. 
Kunze, E. (2015). Google Is Working On Magnetic Nanoparticles To Detect 
Cancer Cells. Retrieved May 2015, from WT VOX - Wearables And 
IoT website: https://wtvox.com/2015/02/google-is-working-on-
magnetic-nanoparticles-to-detect-cancer-cells/ 
Lamont, M., & Molnár, V. (2002). The Study of Boundaries Across the Social 
Sciences. Annual Review of Sociology, 28(1), 167-195. 
Lawrence, T. B., Suddaby, R., & Leca, B. (2009). Introduction: theorizing and 
studying institutional work. In B. Leca, R. Suddaby & T. B. Lawrence 
(Eds.), Institutional Work: Actors and Agency in Institutional Studies of 
Organizations (1-27). Cambridge University Press. 
Lawrence, T., Suddaby, R., & Leca, B. (2011). Institutional Work: Refocusing 
Institutional Studies of Organization. Journal of Management Inquiry, 
20(1), 52–58. https://doi.org/10.1177/1056492610387222 
 249 
Lebret, H. (2018). Are Biotechnology Startups Different? ArXiv:1805.12108 
[q-Fin]. Retrieved Jan. 2019, from http://arxiv.org/abs/1805.12108 
Leicht, K. T., & Fennell, M. L. (2008). Institutionalism and the Professions. In 
Royston Greenwood, Christine Oliver, Roy Suddaby & Kerstin Sahlin 
(Eds.), The SAGE Handbook of Organizational Institutionalism (431–
448). London: SAGE Publications Ltd. 
Lewis, M. (2015). UK moves ahead with Precision Medicine Catapult. 
Retrieved May 2015, from mobile   digital   health website: 
https://mobiledigitalhealth.wordpress.com/2015/02/23/uk-moves-
ahead-with-precision-medicine-catapult/ 
Lichty, P. (2012). La Cura: An Open Source Cure. An interview with Salvatore 
Iaconesi | www.furtherfield.org. Retrieved Oct. 2016, from 
http://www.furtherfield.org/features/interviews/la-cura-open-source-
cure-interview-salvatore-iaconesi 
Lim, S. Y., & Anderson, E. G. (2016). Institutional Barriers Against Innovation 
Diffusion: From the Perspective of Digital Health Startups. 2016 49th 
Hawaii International Conference on System Sciences (HICSS), 3328–
3337. https://doi.org/10.1109/HICSS.2016.415 
Loria, K. (2015). Scientists are skeptical about the secret blood test that has 
made Elizabeth Holmes a billionaire. Retrieved Apr. 2015, from 
Business Insider website: http://uk.businessinsider.com/science-of-
elizabeth-holmes-theranos-2015-4 
Lott, T. F., Blazey, M. E., & West, M. G. (1992). Patient participation in health 
care: an underused resource. The Nursing Clinics of North America, 
27(1), 61–76. 
Lupton, D. (2012). M-health and health promotion: The digital cyborg and 
surveillance society. Social Theory & Health, 10(3), 229–244. 
https://doi.org/10.1057/sth.2012.6 
Lupton, D. (2013). The digitally engaged patient: Self-monitoring and self-care 
in the digital health era. Social Theory & Health, 11(3), 256–270. 
https://doi.org/10.1057/sth.2013.10 
Lupton, D. (2014a). Apps as Artefacts: Towards a Critical Perspective on 
Mobile Health and Medical Apps. Societies, 4(4), 606–622. 
https://doi.org/10.3390/soc4040606 
Lupton, D. (2014b). Critical Perspectives on Digital Health Technologies. 
Sociology Compass, 8(12), 1344–1359. 
https://doi.org/10.1111/soc4.12226 
Lupton, D. (2014c). Health promotion in the digital era: a critical commentary. 
Health Promotion International, 30(1), 174-183. 
https://doi.org/10.1093/heapro/dau091 
Lupton, D. (2014d). The commodification of patient opinion: the digital patient 
experience economy in the age of big data. Sociology of Health & 
Illness, 36(6), 856–869. https://doi.org/10.1111/1467-9566.12109 
 250 
Maclean, M., Harvey, C., & Chia, R. (2012). Sensemaking, storytelling and the 
legitimization of elite business careers. Human Relations, 65(1), 17–40. 
https://doi.org/10.1177/0018726711425616 
Macnaughtan, L. (2014). What Have the Regulators Ever Done for Us? 
[Commercial]. Retrieved Dec. 2014, from nuviun website: 
http://nuviun.com/content/blog/what-have-the-regulators-ever-done-
for-us 
Macnaughtan, L. (2015a). You, Me and Digital Health. Retrieved Jan. 2016, 
from nuviun.com website: http://nuviun.com/content/you-me-and-
digital-health 
Macnaughtan, L. (2015b). The Curious Case of Digital Health. Retrieved June 
2015, from http://nuviun.com/content/the-curious-case-of-digital-health 
Macnaughtan, L. (2015c). All Eyes on Digital Health. Retrieved June 2015, 
from http://nuviun.com/content/all-eyes-on-digital-health 
Macnaughtan, L. (2016). Digital Health – Game on - MIRA Blog. Retrieved 
May 2016, from http://blog.mirarehab.com/2016/04/26/digital-health-
game-on/ 
Macnaughtan, L., Patriotta, G., Pinnington, L., & Sujatha Raman. (2015). 
Plurality of institutional logics in digital healthcare: The rise of the 
hybrid patient. Presented at the 31st EGOS Colloquium, Athens, 
Greece. https://doi.org/10.13140/RG.2.1.2859.3127/1 
Madrigal, A. (2008). 23andMe to California: We’re Not Ceasing or Desisting. 
Retrieved May 2015, from WIRED website: 
http://www.wired.com/2008/06/23andme-were-no/ 
Mark Sullivan. (2015). 30 days later, I’m returning my Apple Watch (full 
review) | VentureBeat | Gadgets. Retrieved May 2015, from 
http://venturebeat.com/2015/05/15/30-days-later-im-returning-my-
apple-watch-full-review/ 
Mazzucato, M. (2013). The Entrepreneurial State: Debunking Public Vs. 
Private Sector Myths. Anthem Press. 
McCollister-Slipp, A. (2014). The Grim Reality of Digital Health Today. 
Retrieved Nov. 2014, from Huffington Post website: 
http://www.huffingtonpost.com/x-prize-foundation/the-grim-reality-of-
digit_b_5984580.html 
Medicines and Healthcare Products Regulatory Agency. (2014). Medical 
devices: software applications (apps) - Publications - GOV.UK. 
Retrieved May 2015, from 
https://www.gov.uk/government/publications/medical-devices-
software-applications-apps 
Merrill Thompson, B. (2015). In-Depth: Anticipating FDA Regulation of 
Pharmaceutical Apps. Retrieved March 2015, from mobihealthnews 
website: http://mobihealthnews.com/40917/in-depth-anticipating-fda-
regulation-of-pharmaceutical-apps/ 
Meyer, J. W., & Rowan, B. (1977). Institutional organizations: formal structure 
as myth and ceremony. American Journal of Sociology, (83), 340–363. 
 251 
Miles, M. B., & Huberman, M. A. (1994). Qualitative data analysis: An 
expanded sourcebook (2nd ed.). Thousand Oaks, CA, US: Sage 
Publications, Inc. 
Mitchell, B. (2016). Maker movement at center of HHS’ innovative strategy. 
Retrieved Nov. 2016, from FedScoop website: http://fedscoop.com/hhs-
cements-maker-movement-as-a-cornerstone-of-its-innovative-strategy 
mobihealthnews. (2009). WIRELESS HEALTH: STATE OF THE INDUSTRY 
2009 Year End Report. Retrieved Jan. 2016, from 
http://mobihealthnews.com/wp-
content/Reports/2009StateoftheIndustry.pdf 
mobihealthnews. (2012). 75 FDA Regulated Mobile Medical Apps | 
mobihealthnews. Retrieved May 2015, from 
http://mobihealthnews.com/research/75-fda-regulated-mobile-medical-
apps/comment-page-1/ 
Montgomery, S. (2015). Digital Health’s Growing Conundrum: The Ethics of 
Everything. Retrieved Nov. 2016, from 
http://innovatemedtec.com/content/digital-healths-growing-conundrum-
the-ethics-of-everything 
Morrill, C. (2006). Institutional change through interstitial emergence: The 
growth of alternative dispute resolution in American law, 1965–1995. 
Retrieved from 
http://webuser.bus.umich.edu/organizations/smo/protected/resources/m
orrill.pdf 
Mulligan, C. (2011). The Communications Industries in the Era of 
Convergence. London: Routledge. 
Munro, D. (2013,). The Big Disruption That Isn’t Happening In Healthcare - 
Forbes. Retrieved May 2015, from Forbes website: 
http://www.forbes.com/sites/danmunro/2013/09/06/the-big-disruption-
that-isnt-happening-in-healthcare/ 
Navis, C., & Glynn, M. A. (2011). Legitimate Distinctiveness and The 
Entrepreneurial Identity: Influence on Investor Judgments of New 
Venture Plausibility. Academy of Management Review, 36(3), 479–499. 
Nettleton, S. (2004). The Emergence of E-Scaped Medicine? Sociology, 38(4), 
661–679. https://doi.org/10.1177/0038038504045857 
Ng, I. C. L., & Smith, L. A. (2012). An Integrative Framework of Value. In 
Review of Marketing Research: Vol. 9. Special Issue  ? Toward a Better 
Understanding of the Role of Value in Markets and Marketing (Vol. 9, 
pp. 207–243). https://doi.org/10.1108/S1548-6435(2012)0000009011 
Nicolini, D. (2006). The work to make telemedicine work: A social and 
articulative view. Social Science & Medicine, 62(11), 2754–2767. 
https://doi.org/10.1016/j.socscimed.2005.11.001 
Nicolini, D. (2007). Stretching out and expanding work practices in time and 
space: The case of telemedicine. Human Relations, 60(6), 889–920. 
https://doi.org/10.1177/0018726707080080 
 252 
Nicolini, D. (2009). Medical Innovation as a Process of Translation: a Case 
from the Field of Telemedicine. British Journal of Management, 21(4), 
1011–1026. https://doi.org/10.1111/j.1467-8551.2008.00627.x 
Nigam, A., & Ocasio, W. (2009). Event Attention, Environmental 
Sensemaking, and Change in Institutional Logics: An Inductive 
Analysis of the Effects of Public Attention to Clinton’s Health Care 
Reform Initiative. Organization Science, 21(4), 823–841. 
https://doi.org/10.1287/orsc.1090.0490 
Nosta, J. (2013). The Asymptotic Shift From Disease To Prevention--Thoughts 
For Digital Health. Retrieved Oct. 2015, from Forbes website: 
http://www.forbes.com/sites/johnnosta/2013/12/12/the-asymptotic-
shift-from-disease-to-prevention-thoughts-for-digital-health/ 
Oborn, E., Barrett, M., & Racko, G. (2013). Knowledge translation in 
healthcare: Incorporating theories of learning and knowledge from the 
management literature. Journal of Health Organization and 
Management, 27(4), 412–431. https://doi.org/10.1108/JHOM-01-2012-
0004 
Office of Arizona Governor. (2015). Governor Doug Ducey Signs Legislation 
Reducing Barriers to Efficient, Cost-Effective Health Care. Retrieved 
May 2015, from http://azgovernor.gov/governor/news/governor-doug-
ducey-signs-legislation-reducing-barriers-efficient-cost-effective 
Office of the Press Secretary. (2015). FACT SHEET: President Obama’s 
Precision Medicine Initiative [Gov]. Retrieved May 2015, from The 
White House website: https://www.whitehouse.gov/node/319876 
Orlikowski, W. J. (2010). Technology and organization: Contingency all the 
way down. In N. Phillips, G. Sewell, & D. Griffiths (Eds.), Technology 
and Organization: Essays in Honour of Joan Woodward (239–246). 
Emerald Group Publishing Limited 
Ozcan, P., & Eisenhardt, K. M. (2009). Origin of Alliance Portfolios: 
Entrepreneurs, Network Strategies, and Firm Performance. The 
Academy of Management Journal, 52(2), 246–279. 
Pache, A.-C., & Santos, F. (2010). When Worlds Collide: The Internal 
Dynamics of Organizational Responses to Conflicting Institutional 
Demands. Academy of Management Review, 35(3), 455–476. 
https://doi.org/10.5465/AMR.2010.51142368 
Patriotta, G., Gond, J.-P., & Schultz, F. (2011). Maintaining Legitimacy: 
Controversies, Orders of Worth, and Public Justifications. Journal of 
Management Studies, 48(8), 1804–1836. https://doi.org/10.1111/j.1467-
6486.2010.00990.x 
Pearce, W., & Raman, S. (2014). The new randomised controlled trials (RCT) 
movement in public policy: challenges of epistemic governance. Policy 
Sciences, 47(4), 387–402. https://doi.org/10.1007/s11077-014-9208-3 
Pennic, J. (2015). 46% of Clinicians Believe mHealth Apps Will Improve 
Patient Engagement. Retrieved April 7, 2015, from 
 253 
http://hitconsultant.net/2015/03/19/clinicians-mhealth-apps-patient-
engagement/ 
Petrakaki, D., Barber, N., & Waring, J. (2012). The possibilities of technology 
in shaping healthcare professionals: (Re/De-)Professionalisation of 
pharmacists in England. Social Science & Medicine, 75(2), 429–437. 
https://doi.org/10.1016/j.socscimed.2012.03.033 
Pfeffer, J., & Salanick, G. R. (2003). The External Control of Organizations: A 
Resource Dependence Perspective. Retrieved from 
http://www.sup.org/books/title/?id=5889 
Phillips, R., Henderson, J., Andor, L., & Hulme, D. (2006). Usurping Social 
Policy: Neoliberalism and Economic Governance in Hungary*. Journal 
of Social Policy, 35(4), 585–606. 
https://doi.org/10.1017/S0047279406000092 
Pouthier, V., Steele, C. W. J., & Ocasio, W. (2013). From Agents to Principles: 
The Changing Relationship between Hospitalist Identity and Logics of 
Health care. In M. Lounsbury & E. Boxenbaum (Eds.), Institutional 
Logics in Action: Part A (203–241). Emerald Group Publishing Limited 
Prout, A. (1996). Actor-network theory, technology and medical sociology: an 
illustrative analysis of the metered dose inhaler. Sociology of Health & 
Illness, 18(2), 198–219. https://doi.org/10.1111/1467-9566.ep10934726 
Purdy, J. M., & Gray, B. (2009). Conflicting Logics, Mechanisms of Diffusion, 
and Multilevel Dynamics in Emerging Institutional Fields. Academy of 
Management Journal, 52(2), 355–380. 
https://doi.org/10.5465/AMJ.2009.37308255 
PwC. (2012). Emerging mHealth: Paths for growth. Retrieved Jan. 2014, from 
http://www.pwc.com/gx/en/healthcare/mhealth/assets/pwc-emerging-
mhealth-full.pdf 
PwC. (2013). How supportive is the regulatory framework for mobile health 
applications? (1–4). Retrieved Jan. 2014, from 
http://www.pwc.ch/user_content/editor/files/publ_health/pwc_mhealth_
insights_january13_e.pdf 
PwC. (2015). Global health’s new entrants: Meeting the world’s consumer. 
Retrieved Jan. 2016, from http://www.pwc.com/us/en/health-
industries/healthcare-new-entrants/assets/pwc-global-new-entrant.pdf 
Raman, S., & Mohr, A. (2014). A Social Licence for Science: Capturing the 
Public or Co-Constructing Research? Social Epistemology, 28(3–4), 
258–276. https://doi.org/10.1080/02691728.2014.922642 
Rao, H., Morrill, C., & Zald, M. N. (2000). Power Plays: How Social 
Movements and Collective Action Create New Organizational Forms. 
Research in Organizational Behavior, 22, 237–281. 
https://doi.org/10.1016/S0191-3085(00)22007-8 
Reay, T., & Hinings, C. R. (2009). Managing the Rivalry of Competing 
Institutional Logics. Organization Studies, 30(6), 629–652. 
https://doi.org/10.1177/0170840609104803 
 254 
Reay, T., & Hinings, C. R. (Bob). (2005). The Recomposition of an 
Organizational Field: Health Care in Alberta. Organization Studies, 
26(3), 351–384. https://doi.org/10.1177/0170840605050872 
research2guidance. (2012). 3rd mHealth Expert Survey. Retrieved Jan 2013 
from research2guidance website: 
https://research2guidance.com/r2g/3rd-mHealth-Expert-Survey.pdf 
research2guidance. (2014). Mhealth app developer economics. Retrieved Jan. 
2015, from research2guidance website: 
http://mhealtheconomics.com/mhealth-developer-economics-report/ 
research2guidance. (2014). mHealth App Developer Economics 2014 Study. 
Retrieved Jan. 2015, from 
http://www.slideshare.net/research2guidance/research2guidance-
mhealth-app-developer-economics-2014-study-
slideshareresearch2guidance-m-health-app-developer-economics-
slideshare 
Riggare, S. (2016). FOR WHOSE SAKE IS RESEARCH DONE — 
REALLY? Retrieved Oct. 2016, from LinkedIn Pulse website: 
https://www.linkedin.com/pulse/whose-sake-research-done-really-sara-
riggare 
Rindova, V. P., & Kotha, S. (2001). Continuous “Morphing”: Competing 
Through Dynamic Capabilities, Form, and Function. Academy of 
Management Journal, 44(6), 1263–1280. 
https://doi.org/10.2307/3069400 
Rip, A., & Schot, J. W. (2002). Identifying Loci for Influencing the Dynamics 
of Technological Development. In K. H. Soerensen & R. Williams 
(Eds.), Shaping Technology. Guiding Policy; concepts Spaces and 
Tools (158–176).  
Ritvala, T., & Kleymann, B. (2012). Scientists as Midwives to Cluster 
Emergence: An Institutional Work Framework. Industry and 
Innovation, 19(6), 477–497. 
https://doi.org/10.1080/13662716.2012.718875 
Robinson, J. C. (2001). The end of managed care. JAMA, 285(20), 2622–2628. 
Rockhealth. (2012a). 2012 Digital Health Funding. Retrieved Jan. 2013, from 
http://www.slideshare.net/RockHealth/2012-year-end-funding-report 
Rockhealth. (2012b). Rock Report: Business Models in Digital Health. 
Retrieved Jan. 2013, from http://www.slideshare.net/RockHealth/rock-
report-business-models-in-digital-health-by-rockhealth 
Rudel, D., Fisk, M., & Roze, R. (2011). Definitions of Terms in Telehealth. 
Journal of the Slovenian Medical Informatics Association, 16(1), 28–
46. 
RWJF. (2015). Data for Health: Learning What Works. Retrieved April 2015, 
from RWJF website: 
http://www.rwjf.org/en/library/research/2015/04/data-for-health-
initiative.html 
 255 
Salber, P. (2015). What is Patient Engagement? Depends on Who You Are -. 
Retrieved June 2015, from The Doctor Weighs In website: 
http://thedoctorweighsin.com/patient-engagement-depends-on-who-
you-are/ 
Santos, F. M., & Eisenhardt, K. M. (2005). Organizational Boundaries and 
Theories of Organization. Organization Science, 16(5), 491–508. 
https://doi.org/10.1287/orsc.1050.0152 
Santos, F. M., & Eisenhardt, K. M. (2009). Constructing Markets and Shaping 
Boundaries: Entrepreneurial Power in Nascent Fields. Academy of 
Management Journal, 52(4), 643–671. 
https://doi.org/10.5465/AMJ.2009.43669892 
Schreinemacher, M. H., Graafland, M., & Schijven, M. P. (2014). Google 
Glass in Surgery. Surgical Innovation, 21(6), 651–652. 
https://doi.org/10.1177/1553350614546006 
Schumpeter, J. A. (1950). Chapter VII: The Process of creative destruction. In 
Capitalism, Socialism and Democracy (3rd ed.). Retrieved from 
http://www.compilerpress.ca/Competitiveness/Anno/Anno%20Schump
eter%20CSD%20Ch.%20VII%20Creative%20Destruction.htm 
Scott, W. R. (2008). Institutions and Organizations: Ideas and Interests (3rd 
ed.). Los Angeles: Sage Publications. 
Scott, W. R., Ruef, M., Mendel, P. J., & Caronna, C. A. (2000). Institutional 
Change and Healthcare Organizations: From professional dominance 
to managed care. University of Chicago Press. 
Sculley, J. (2014). Moonshot!: Game-Changing Strategies to Build Billion-
Dollar Businesses. New York: Rosettabooks. 
Selznick, P. (1948). Foundations of the Theory of Organization. American 
Sociological Review, 13(1), 25–35. https://doi.org/10.2307/2086752 
Selznick, P. (1951). Institutional Vulnerability in Mass Society. American 
Journal of Sociology, 56(4), 320–331. 
Selznick, P. (1984). Leadership in Administration: A Sociological 
Interpretation. University of California Press. 
Seres, M. (2013a). (18) e-Participation and the NHS: Michael Seres. Retrieved 
June 2015, from https://www.youtube.com/watch?v=WQGmQccP7Ss 
Seres, M. (2013b). PART 2 – Are Patients From Mars and Health Care 
Professionals from Venus? Retrieved May 2015, from 
http://beingapatient.blogspot.co.uk/2013/05/part-2-are-patients-from-
mars-and.html 
Seres, M. (2013c). Are Patients From Mars and Health Care Professionals from 
Venus? - Part 1. Retrieved May 2015, from Being a Patient isn’t easy! 
website: http://beingapatient.blogspot.co.uk/2013/05/are-patients-from-
mars-and-health-care.html 
Seres, M. (2015a). Healthcare Innovation spotlight: Michael Seres. Retrieved 
Jan 2016, from https://www.youtube.com/watch?v=M9hMybMZ8S4 
 256 
Seres, M. (2015b). What can you learn from a patient entrepreneur? Retrieved 
Nov. 2016, from MedCity News website: 
http://medcitynews.com/2015/10/patient-entrepreneur/ 
Shaywitz, D. (2016). As Ambry CEO Demonstrates, Patients Drive Data 
Sharing - Forbes. Retrieved March 2016, from Forbes website: 
http://www.forbes.com/sites/davidshaywitz/2016/03/08/as-ambry-ceo-
demonstrates-patients-drive-data-sharing/#2d30a0ea2323 
Sonnier, P. (2015a). Digital Health Startup Resources. Retrieved May 2015, 
from Story of Digital Health website: 
http://storyofdigitalhealth.com/startups/ 
Sonnier, P. (2015b). Events. Retrieved May 2015, from Story of Digital Health 
website: http://storyofdigitalhealth.com/events/ 
Spong, A. (2015). Patients Included: a global patients’ charter. Retrieved 
March 2015, from STweM website: 
http://stwem.com/2015/03/06/patients-included-a-global-patients-
charter-for-conferences/ 
Stake, R. E. (2005). Qualitative case studies. In N. K. Denzin & Y. S. Lincoln 
(Eds.), The Sage handbook of qualitative research (3rd ed.). Thousand 
Oaks, CA: SAGE Publications. 
Stanford Medicine X. (2015). About Medicine X | Ed – Stanford Medicine X. 
Retrieved Nov. 2016, from http://medicinex.stanford.edu/about-
medicine-x-ed/ 
Stinchcombe, A. L. (1965). Social Structure and Organizations (J. G. March, 
Ed.). In (pp. 142–193). Chicago: Rand McNally & Co. 
Suchman, M. C. (1995). Managing Legitimacy: Strategic and Institutional 
Approaches. The Academy of Management Review, 20(3), 571–610. 
https://doi.org/10.2307/258788 
Sullivan, M. (2014). 58 tech companies ask Congress to codify health IT laws 
so innovators know what the rules are. Retrieved May 2015, from 
VentureBeat website: http://venturebeat.com/2014/10/07/58-tech-
companies-ask-congress-to-codify-health-it-laws-so-innovators-know-
what-the-rules-are/ 
Swan, M. (2009). Emerging Patient-Driven Health Care Models: An 
Examination of Health Social Networks, Consumer Personalized 
Medicine and Quantified Self-Tracking. International Journal of 
Environmental Research and Public Health, 6(2), 492–525. 
https://doi.org/10.3390/ijerph6020492 
Swann, J., P. (2003). The Food and Drug Administration (FDA). New York: 
Nova Science Publishers. 
Swirsky, E. S., Hoop, J. G., & Labott, S. (2014). Using Social Media in 
Research: New Ethics for a New Meme? The American Journal of 
Bioethics  : AJOB, 14(10), 60–61. 
https://doi.org/10.1080/15265161.2014.948302 
 257 
Swyngedouw, E. (2005). Governance Innovation and the Citizen: The Janus 
Face of Governance-beyond-the-State. Urban Studies, 42(11), 1991–
2006. https://doi.org/10.1080/00420980500279869 
TEDx Talks. (2011). Fighting for the Right to Open his Heart Data: Hugo 
Campos at TEDxCambridge 2011. Retrieved June 2013, from 
https://www.youtube.com/watch?v=oro19-l5M8k 
The BMJ. (n.d.). Patient and public partnership | The BMJ. Retrieved July 
2018, from https://www.bmj.com/campaign/patient-partnership 
Thornton, P. H. (2002). The Rise of the Corporation in a Craft Industry: 
Conflict and Conformity in Institutional Logics. The Academy of 
Management Journal, 45(1), 81–101. https://doi.org/10.2307/3069286 
Thornton, P. H., & Ocasio, W. (1999). Institutional Logics and the Historical 
Contingency of Power in Organizations: Executive Succession in the 
Higher Education Publishing Industry, 1958‐1990. American Journal of 
Sociology, 105(3), 801–843. https://doi.org/10.1086/210361 
Thornton, P. H., Ocasio, W., & Lounsbury, M. (2012). The Institutional Logics 
Perspective: A New Approach to Culture, Structure, and Process. 
Oxford University Press. 
Topol, E. (2012). Creative Destruction of Medicine (First Trade Paper Edition, 
Revised and Expanded edition). New York: Basic Books. 
Topol, E. J. (2015). The Future of Medicine Is in Your Smartphone. Wall 
Street Journal. Retrieved Jan. 2016 from 
http://www.wsj.com/articles/the-future-of-medicine-is-in-your-
smartphone-1420828632 
UK Department of Health. (2006). Supporting people with long term 
conditions to self care – A guide to developing local strategies and 
good practice. Retrieved Jan. 2013, from 
http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www
.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/docum
ents/digitalasset/dh_4130868.pdf 
Ungerleider, N. (2014). Oscar Is A Health Insurance Startup For Digital 
Natives. Retrieved Nov. 2016, from Fast Company website: 
https://www.fastcompany.com/3026928/tech-forecast/oscar-is-a-health-
insurance-startup-for-digital-natives 
University of California, S. D. (2014). Personal Data for the Public Good. 
New Opportunities to Enrich Understanding of Individual and 
Population Health [Market]. Retrieved Jan. 2015 from Robert Wood 
Johnson Foundation website: http://www.rwjf.org/en/research-
publications/find-rwjf-research/2014/03/personal-data-for-the-public-
good.html 
UNSW Engineers. (2015). ‘Google Maps’ for the body. Retrieved May 2015, 
from Engineering website: 
http://engineering.unsw.edu.au/emag/news/%E2%80%98google-
maps%E2%80%99-body 
 258 
Validic. (2015). Digital health revitalizes pharma, life sciences and biotech. 
Retrieved Oct. 2015, from MedCity News website: 
http://medcitynews.com/?sponsored_content=digital-health-revitalizes-
pharma-life-sciences-and-biotech 
Van de Ven, A. H., & Gardu, R. (1993). Innovation and Industry Development: 
The Case of cochlear Implants. Research on Technological Innovation, 
Management and Policy, 5, 1-46. 
Wachter, R. (2015). The Digital Doctor: Hope, Hype, and Harm at the Dawn 
of Medicine’s Computer Age (1 edition). New York: McGraw-Hill 
Education. 
Wachter, R. M., & Goldman, L. (1996). The Emerging Role of “Hospitalists” 
in the American Health Care System. New England Journal of 
Medicine, 335(7), 514–517. 
https://doi.org/10.1056/NEJM199608153350713 
Waldorff, S. B., Reay, T., & Goodrick, E. (2013). A Tale of Two Countries: 
How Different Constellations of Logics Impact Action. In M. 
Lounsbury & E. Boxenbaum (Eds.), Institutional Logics in Action, Part 
A: Vol. A (pp. 99–129). Emerald Group Publishing Limited. 
Walley, K. (2007). Coopetition: An Introduction to the Subject and an Agenda 
for Research. International Studies of Management & Organization, 
37(2), 11–31. 
Wang, T., King, E., Perman, M., & Tecco, H. (2016). Digital Health Funding: 
2015 Year in Review. Retrieved Nov. 2016, from Rock Health website: 
https://rockhealth.com/reports/digital-health-funding-2015-year-in-
review/ 
Waring, J. (2015). No shit Sherlock science – why it’s still worth it. Retrieved 
April 2015, from The Conversation website: 
http://theconversation.com/no-shit-sherlock-science-why-its-still-
worth-it-40179 
Waters, G. (2015). Yes, biomedical innovation is sticking out its proverbial 
tongue! Retrieved May 2015, from LinkedIn Pulse website: 
https://www.linkedin.com/pulse/yes-biomedical-innovation-sticking-
out-its-proverbial-waters-ph-d- 
Weaver, G. R., TreviÑo, L. K., & Cochran, P. L. (1999). Integrated and 
Decoupled Corporate Social Performance: Management Commitments, 
External Pressures, and Corporate Ethics Practices. Academy of 
Management Journal, 42(5), 539–552. https://doi.org/10.5465/256975 
Webb, T. L., Joseph, J., Yardley, L., & Michie, S. (2010). Using the internet to 
promote health behavior change: a systematic review and meta-analysis 
of the impact of theoretical basis, use of behavior change techniques, 
and mode of delivery on efficacy. Journal of Medical Internet 
Research, 12(1), e4. https://doi.org/10.2196/jmir.1376 
Weick, K. E. (1988). Enacted sensemaking in crisis situations. Journal of 
Management Studies, 25, 305–317. 
 259 
Weick, K. E., Sutcliffe, K. M., & Obstfeld, D. (2005). Organizing and the 
Process of Sensemaking. Organization Science, 16(4), 409–421. 
https://doi.org/10.1287/orsc.1050.0133 
Wicks, P., Vaughan, T. E., Massagli, M. P., & Heywood, J. (2011). 
Accelerated clinical discovery using self-reported patient data collected 
online and a patient-matching algorithm. Nature Biotechnology, 29(5), 
411–414. https://doi.org/10.1038/nbt.1837 
Wikipedia. (2015). List of highest funded crowdfunding projects. In Wikipedia, 
the free encyclopedia. Retrieved Dec. 2015, from 
http://en.wikipedia.org/w/index.php?title=List_of_highest_funded_cro
wdfunding_projects&oldid=661737690 
Windrum, P., & García-Goñi, M. (2008). A neo-Schumpeterian model of 
health services innovation. Research Policy, 37(4), 649–672. 
https://doi.org/10.1016/j.respol.2007.12.011 
Windrum, P., García-Goñi, M., & Coad, H. (2016). The Impact of Patient-
Centered versus Didactic Education Programs in Chronic Patients by 
Severity: The Case of Type 2 Diabetes Mellitus. Value in Health: The 
Journal of the International Society for Pharmacoeconomics and 
Outcomes Research, 19(4), 353–362. 
https://doi.org/10.1016/j.jval.2016.01.014 
Wooten, M., & Hoffman, A. J. (2008). Organizational Fields: Past, Present and 
Future. In R Greenwood, C. Oliver, R. Suddaby, & K. Sahlin (Eds.), 
The Handbook of Organizational Institutionalism. (129–149). 
Retrieved from http://dx.doi.org/10.4135/9781849200387 
Wry, T., Lounsbury, M., & Jennings, P. D. (2014). Hybrid Vigor: Securing 
Venture Capital by Spanning Categories in Nanotechnology. Academy 
of Management Journal, 57(5), 1309–1333. 
https://doi.org/10.5465/amj.2011.0588 
Wry, Tyler, & Lounsbury, M. (2013). Contextualizing the categorical 
imperative: Category linkages, technology focus, and resource 
acquisition in nanotechnology entrepreneurship. Journal of Business 
Venturing, 28(1), 117–133. 
https://doi.org/10.1016/j.jbusvent.2012.03.001 
Xavier, P. (2015). L’avenir de la pharmacie ne dépend que d’elle-même. 
Retrieved June 2015, from La Tribune website: 
http://www.latribune.fr/opinions/tribunes/l-avenir-de-la-pharmacie-ne-
depend-que-d-elle-meme-486261.html 
Yin, R. K. (2009). Case Study Research: Design and Methods (4th ed.). In 
Applied Social Research Methods: Vol. 5 (4th ed.). London: Sage 
Publications. 
Zietsma, C., & McKnight, B. (2009). Building the Iron cage: Institutional 
creation work in the context of competing proto-institutions. In B. Leca, 
R. Suddaby, & T. B. Lawrence (Eds.), Institutional Work: Actors and 
Agency in Institutional Studies of Organizations (143-177). Cambridge: 
Cambridge University Press. 
 260 
Zietsma, C. & Lawrence, T. B. (2010). Institutional Work in the 
Transformation of an Organizational Field: The Interplay of Boundary 
Work and Practice Work. Administrative Science Quarterly, 55(2), 
189–221. https://doi.org/10.2189/asqu.2010.55.2.189 
Zilber, T. B. (2009). Institutional maintenance as narrative acts. In B. Leca, R. 
Suddaby & T. B. Lawrence (Eds.), Institutional Work: Actors and 
Agency in Institutional Studies of Organizations (pp. 205–235). 
Cambridge, U.K.: Cambridge University Press 
Zussa, F. (2012). Digital Health Summit - OnDigitalHealth.com: In Healthcare, 
Consumer Tech doesn’t mean a consumer business model. Retrieved 
May 2015, from Digital Health Summit website: 
http://digitalhealthsummit.com/news/in-healthcare-consumer-tech-
doesn%E2%80%99t-mean-a-consumer-business-model/ 
261 
 
APPENDIX A. OPINION LEADERS 
The list below contains opinion leaders who were interviewed for this research. 
Note that others marked as opinion leaders were not interviewed, but 
recognised for their influence in the field. 
Michael Seres has been identified as opinion leader, but his interviews were 
taken together with the ones on 11 Health. Similarly, John Nosta was a 
respondent for 11 Health, as he was part of the advisory board of the company. 
Interviews inside organisations also contained questions about the field, as 
explained in chapter 4, and shown in appendix B. 
- Michael Seres, patient entrepreneur, 11 Health founder & CEO, UK 
- Denise Silber, Doctors 2.0 & You founder, France 
- Sara Riggare, patient researcher, PhD student in Selfcare for 
Parkinson’s Disease at Health Informatics Centre, Karolinska Institute, 
Stockholm, Sweden 
- Lucien Engelen, healthcare intrapreneur, founder of REshape Centre, 
Radboud University, The Netherlands 
- Colleen Young, communications, Online Community Director, Mayo 
Clinic, US 
- John Nosta, digital health evangelist, founder of NostaLab, Forbes 
contributor, amonst others, US 
- David Shaywitz, doctor entrepreneur, DNAnexus Chief Medical 
Officer, Forbes contributor, US 
- Lisa Suennen, investor, Managing Partner at Venture Valkyrie, US 
- Dave Chase, entrepreneur, Health Rosetta Managing Partner, Forbes 
contributor, US 
- Sue Montgomery, nurse, freelance healthcare writer and editor, US 
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APPENDIX B. SAMPLE INTERVIEW 
QUESTIONS 
It is important to say that the interviews were semi-structured, therefore the 
questions were guiding and the conversations evolved more naturally. 
Opinion leaders guiding questions 
- When did you realise the potential of digital for healthcare? 
- Why and how did you get involved with digital health? 
- What is digital health, in your opinion? 
- Is there anything that makes digital health be a separate arena from 
healthcare? 
- Who are the stakeholders of digital health? 
- How has the digital health evolved over time, in your opinion? 
- What are opportunities/challenges? 
- How do you think digital health will evolve or what changes will 
happen? 
- What do you think is missing from the conversations surrounding 
digital health? 
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Organisation respondents guiding questions and the relevance of answers 
towards the organisation and the field, in recognising that institutional work 
develops both internally and externally. 
 
Table 15. Guiding questions for interviews inside organisations 
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APPENDIX C. TERMINOLOGY 
CLARIFICATIONS 
There are a number of terms for designating the use of technology in 
healthcare. The most common ones are telehealth, telecare, telemedicine, 
eHealth and remote patient monitoring. In the last decade though, more terms 
emerged: digital health, mHealth, personalized health systems, personalised 
medicine. 
The table below presents a selection of terms existing and competing in digital 
health 
Term Definition Source Year 
Te
le
he
al
th
 
[...] the means by which technologies and related services at a distance are 
accessed by or provided for people and/or their carers at home or in the wider 
community, in order to facilitate their empowerment, assessment or the 
provision of care and/or support in relation to needs associated with their 
health (including clinical health) and wellbeing. Telehealth always involves 
and includes the service user or client. It includes remote patient management. 
Telescope 
Rudel et al. 
2011 
The term telehealth covers systems and services linking patients with care 
providers to assist in diagnosing, monitoring, management and empowerment 
of patients with long-term conditions (chronic patients). 
Telehealth solutions use devices (interactive audio, visual and data 
communication) to remotely collect and send data to a monitoring station for 
interpretation, to support therapy management programs and to improve 
patients’ knowledge and behaviour. 
COCIR 
Telemedicine 
Toolkit 
2011 
Telehealth has been defined by the Department of Health as a service that 
‘uses equipment to monitor people’s health in their own home… [monitoring] 
vital signs such as blood pressure, blood oxygen levels or weight’. 
WSDAN 2011 
[...] as in remote vital signs monitoring. Vital signs of patients with long term 
conditions are measured daily by devices at home and the data sent to a 
monitoring centre for response by a nurse or doctor if they fall outside 
predetermined norms. 
Telecare Aware 
 
2012 
Te
le
ca
re
 
[…] from simple personal alarms (AKA pendant/panic/medical/social alarms, 
PERS, and so on) through to smart homes that focus on alerts for risk 
including, for example: falls; smoke; changes in daily activity patterns and 
'wandering'. Telecare may also be used to confirm that someone is safe and to 
prompt them to take medication. The alert generates an appropriate response 
to the situation allowing someone to live more independently, and confidently, 
in their own home for longer. 
Telecare Aware 2012 
The means by which technologies and related services at a distance are 
accessed by or provided for people and/or their carers at home or in the wider 
community, in order to facilitate empowerment or the provision of care and/or 
support in relation to needs associated with their health and well-being. 
Telescope 
Rudel et al. 
2011 
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Term Definition 
Source 
Year 
Te
le
he
al
th
ca
re
 
Telehealthcare is the convergence of telecare and telehealth to provide a 
technology-enabled and integrated approach to the delivery of effective, high 
quality health and care services.  It can be used to describe a range of care 
options available remotely by telephone, mobile, broadband and 
videoconferencing 
The Scottish 
Centre for 
Telehealth and 
Telecare 
2012 
Te
le
m
ed
ic
in
e 
Telemedicine can be defined as the delivery of healthcare services through the 
use of Information and Communication Technologies (ICT) in a situation 
where the actors are not at the same location. The actors can either be two 
healthcare professionals (e.g. teleradiology, telesurgery) or a healthcare 
professional and a patient (e.g. telemonitoring of the chronically ill such as 
those with diabetes and heart conditions, telepsychiatry etc). 
Telemedicine includes all areas where medical or social data is being 
sent/exchanged between at least two remote locations, including both 
Caregiver-Patient/Citizen as well as Doctor to Doctor communication. 
COCIR 
Telemedicine 
2011 
The delivery of medical care at a distance by clinicians and other health care 
staff, via telecommunications technologies. Telemedicine will sometimes 
involve and include the service user / patient. 
Telescope 
Rudel et al. 
2012 
Telemedicine is the use of telecommunication and information technologies in 
order to provide clinical health care at a distance. 
Wikipedia 2012 
R
em
ot
e 
Pa
tie
nt
 M
on
ito
rin
g/
 
Te
le
m
on
ito
rin
g 
Telemonitoring is the remote exchange of physiological data between a patient 
at home and medical staff at a hospital to assist in diagnosis and monitoring. 
COCIR  
eHealth 
2012 
Remote patient monitoring (RPM) is a technology to enable monitoring of 
patients outside of conventional clinical settings (e.g. in the home), which may 
increase access to care and decrease healthcare delivery costs. 
Wikipedia 2012 
Pe
rs
on
al
 H
ea
lth
 S
ys
te
m
s 
Personal Health Systems (PHS) assist in the provision of continuous, quality 
controlled, and personalised health services, including diagnosis, treatment, 
rehabilitation, disease prevention and lifestyle management, to empowered 
individuals regardless of location. 
PHS consist of: intelligent ambient and/or body devices (wearable, portable or 
implantable); intelligent processing of the acquired information; and active 
feedback from health professionals or directly from the devices to the 
individuals. 
COCIR 
Telemedicine 
Toolkit 
2011 
W
el
l-b
ei
ng
 Quality of life characterised by satisfactory levels of health and welfare. Telescope Rudel et al. 
2011 
Well-being refers to positive and sustainable characteristics which enable 
individuals [and organisations] to thrive and flourish.  
The Well-being 
Institute  
N/A 
Pe
rs
on
al
is
ed
 M
ed
ic
in
e 
Personalized medicine is a medical model that proposes the customization of 
healthcare, with decisions and practices being tailored to the individual patient 
by use of genetic or other information. 
Wikipedia 2012 
Personalized medicine is a young but rapidly advancing field of healthcare 
that is informed by each person's unique clinical, genetic, genomic, and 
environmental information. Because these factors are different for every 
person, the nature of diseases—including their onset, their course, and how 
they might respond to drugs or other interventions—is as individual as the 
people who have them. 
U.S. net 
 
2011 
Table 16. Terminology 
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The Telecare Aware organisation considers that the separation between the 
‘telehealth’ and ‘telecare’ is blurred and that eventually these terms will 
converge. “Although it is easy to predict that telecare and telehealth 
technologies will merge, and although the clients and patients they benefit are 
often one and the same individuals, we believe that it is still useful — at this 
stage of technological and linguistic evolution — to maintain a difference 
between the terms 'telecare' and 'telehealth'” (Hards, 2012).  
 ‘eHealth’ and ‘digital health’ seem to be rather overarching terms that 
designate the use of IT and communication technologies in healthcare (COCIR 
(a), 2011). COCIR includes in the definition back end and front-end 
applications. For instance, image processing and storage application, data 
exchange protocols, interfaces between doctors - doctors, patients – doctors, 
patients – nurses etc. “[...] `e-health can be considered to be the health 
industry's equivalent of e-commerce`, and this could be one key for 
understanding the sense of e-health: just medical informatics and telematics on 
the shop shelves, a fashionable name for something already existing but 
otherwise difficult to sell” (Della Mea, 2001). Similarly, ‘wireless healthcare’ 
designates the use of wireless technologies and ‘mHealth’ refers to the use of 
the mobile technologies in healthcare.  
The European Coordination Committee of the Radiological, Electromedical 
and Healthcare IT Industry (COCIR) finds the following functions of eHealth 
(COCIR (a), 2011). 
 
Fig. 51. Functions fulfilled by eHealth in the health sector (COCIR (a), 2011) 
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In 2011, in a paper produced by the Telescope (Telehealth Services Code of 
Practice for Europe) project (Rudel, Fisk, & Roze, 2011), a glossary of terms is 
presented, as the outcome of an intensive literature review effort. The focus of 
this document is to define telehealth, but it also presents a series of related 
terms and shows how they relate to each other. 
Telehealth is described here as “the means by which technologies and related 
services at a distance are accessed by or provided for people and/or their carers 
at home or in the wider community, in order to facilitate their empowerment, 
assessment or the provision of care and/or support in relation to needs 
associated with their health (including clinical health) and wellbeing. 
Telehealth always involves and includes the service user or client. It includes 
remote patient management.” (ibid., p. 32) 
 
Fig. 52. Scope of telehealth by Telescope project (Rudel et al., 2011) 
The important addition brought in by the Telescope project is the recognition 
of wellbeing as a field. “[...] it is recognised that health cannot be seen purely 
in clinical terms. Rather it is concerned with people's lives and people's homes 
– where services using telehealth technologies are provided by agencies; or, 
importantly, technologies are harnessed by individuals” (ibid., p. 34). In this 
report, telehealth includes telemedicine, because it concerns the clinical aspects 
only, the curative aspects of health. The World Health Organization (WHO) 
also acknowledges the separation between the clinical and non-clinical aspect 
of health related services, and, similarly, Telescope considers that telehealth 
can be delivered by non-healthcare agencies. This implies that telehealth can 
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be an independent domain, with its own professional codes, standards and 
service provisions. 
In 2010, COCIR published the following understanding of telemedicine, as 
encompassing all areas in the figure below. 
 
Fig. 53. Scope of telemedicine by COCIR (2010) 
The merit of this representation is fact that it brings forth the connections 
between players.  
In 2011, COCIR represented telemedicine in a bigger picture, including also 
mHealth as a standalone, but subsumed domain. 
 
Fig. 54. Scope of telemedicine by COCIR (2011) 
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Fig. 55. Digital health and the scope of CDHT 
Building on previous authors, in the figure above, I represent the digital health 
field and the CDHT, as subdomain, although the limits are more theoretical 
than practical. It is in agreement with the use of eHealth or digital health as 
overarching concepts. It shows that telemedicine implies clinical services, 
connecting doctors to doctors or doctors to patients. mHealth refers primarily 
to the delivery mode of the health and wellbeing, clinical or not, services. 
Well-being relates mainly to the social and individual aspects that help people 
“produce health”, factors are under the individual’s direct control - diet, 
exercise, and lifestyle. Education is also a very important factor for personal 
health outcomes (Windrum & García-Goñi, 2008; Windrum, García-Goñi, & 
Coad, 2016). Finally, ‘telehealth’ is encompassing many aspects of the health 
services, but the main differentiation is that it can and it should be delivered by 
telehealth services that may connect based on need to clinical services. 
‘User’ could designate a patient, but not necessarily. It could be simply a 
person interested in their own well-being. ‘Service’ provider refers to what 
Telescope names agencies (Rudel et al., 2011). In my view, service providers 
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could be organisations affiliated or not to the healthcare sector. These new 
categories of health or health enhancing providers constitute primarily the 
concern of the regulators. ‘Others’ may designate actors like the payers, 
researchers, pharma... CDHT are concerned with digital solutions that connect 
various actors across digital health, not limited to the traditional healthcare 
players – healthcare professionals and providers and payers. 
The figure above, in the interest of keeping it as simple as possible, did not 
include the emergent field of personalised medicine. This emergent field sees 
the potential of digital technologies in harnessing information on the 
environment and the person to help enhance its advances. It is also referred to 
as P4 Medicine, due to its stated guiding principles Personalised, Predictive, 
Preventive and Participatory (CEPMED, 2012). 
I will close this terminology part, by offering an alternative view of digital 
health.  
 
Fig. 56. Digital health landscape as viewed by nuviun (2014) 
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It is important to keep in mind that the terminology is changing still, including 
in respect to the meanings associated with the terms. The analysis above has 
relevance for the time data collection finished (2016).  
272 
 
APPENDIX D. DIGITAL HEALTH TIMELINE 
(2009 – EARLY 2016) 
The timeline below gives some examples of developments in the field of 
digital health; it is not an exhaustive listing. 
 2007 - 2009 2010 - 2012 2013 - 2016 
T
er
m
in
ol
og
y Health IT, eHealth, Wireless 
health, mHealth, telehealth, 
assistive technologies, 
telemedicine, remote 
monitoring, quantified self 
Apps, wellness, wearables, 
digital health (Davis, 2015), 
Big Data 
Insideables, precision  
medicine, personalised  
medicine, genomics, digital 
phenotype 
Personal Health Data (PHD) 
nuviun’s digital health 
diagram (nuviun, 2014) 
T
ec
hn
ol
og
y Existing EHR IT producers 
The Apple Store, 2008 
The Android Market, 2009 
Windows app store, 2010 
Tablets, 2010 
 
There is steady growth in 
wearables, apps, consumer 
health websites. Prices continue 
to drop. 
 
There were over 13 000 health 
apps in April 2012 on the 
Apple Store (Dolan, 2012) 
Dominant business models are 
business to business (B2B), but 
business to consumer (B2C) 
(Zussa, 2012) 
 
EHR, apps and wearables 
continue to grow 
Beginning of convergence of 
wellness and health wearables 
and apps 
Apple Watch 2014 
Microsoft Band 2014 
Apple Research Kit 2015 
Apple Research ethical 
approval required (Duhaime-
Ross, 2015) 
Google enters into medical 
research (Kunze, 2015; 
UNSW Engineers, 2015) 
In October 2014, following 
the FDASIA Health IR 
report, 58 companies sent a 
letter to the US Congress 
clarity on who regulates what 
(Sullivan, 2014). 
Increasing number of apps 
specialised on chronic 
conditions: diabetes, obesity, 
congestive heart failure, 
chronic obstructive 
pulmonary disease. Patient 
education and fitness remain 
the largest categories of apps. 
(Research2guidance, 2014) 
Theranos (US) opens first 
labs in Arizona, US, 2013. 
In
ve
st
m
en
ts
 mobihealthnews report 
highlights increased venture 
capital investments 
(mobihealthnews, 2009) 
Industry challenges (prize and 
prestige):  
Qualcomm tricorder xprize, 
2012 
Nokia Sensing xChallenge, 
2014 
Spread of incubators and 
accelerators: RockHealth 
(2010), Blueprint Health, The 
Ironyard, Health XL and 
Multitude of accelerators, 
incubators, investment hubs 
for digital health 
(Healthstartup, 2014; 
Sonnier, 2015a) 
Government sponsored 
networks (Digital Catapult 
Centre, UK 2014) and testing 
grounds (United4Health, EU, 
2014) 
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 2007 - 2009 2010 - 2012 2013 - 2016 
StartUp Health (2011), 
Healthbox and REshape  
Healthcubator (2012) 
 
Dramatic rise of venture 
capitalist funding.  
Beginning of crowdfunding 
for health.  
M
ar
ke
t r
ep
or
ts
 Market reports on mHealth, 
wireless health or Digital 
Health by niche market 
research companies 
Research2guidance 
Parks and Associates 
mobihealthnews 
Niche: RockHealth, 2010 
Established consultancy firms: 
PwC 2012,  Accenture 2011, 
Deloitte 2012 
Market reports separate 
wellness and health apps 
Segmentation of health apps 
on: 
- types of users: 
patients, doctors 
- education or health 
management 
- monitoring 
Both niche and most 
established consultancy and 
market research firms are 
providing regular updates on 
Digital Health, mHealth, 
wearables, apps… 
Pa
tie
nt
 ePatient Dave (deBronkart, 
2009a) 
Society of Participatory 
Medicine, 2009, had as 
founders a doctor and a patient, 
Dave deBronkart (ePatient 
Dave) 
 
Patient initiatives 
The Walking Gallery, Regina 
Holliday, 2011 
Being a Patient isn’t easy!, 
patient blog Michael Seres, 
2011 
Hugo Campos demands access 
to data generated by implants, 
2011 
Growing online communities of 
patients, “peer to peer” 
healthcare (Fox, 2011a) 
Journal of Participatory 
Medicine, 2010 
The BMJ partners with 
patients, 2014 
Petition collects signatures 
worldwide for patients’ 
access to medical data 
(Getmyhealthdata, 2015) 
Patients Included: a global 
patients’ charter (Spong, 
2015) 
Social media campaign 
(deBronkart, 2015) for 
including patients in the 
Meaningful Use programme 
specifications, US, 2015 
 
M
ed
ic
in
e 23andMe began direct to 
consumer genetic testing in the 
US, November 2007. 
 
Journal of Mobile Technology 
in Medicine, 2011 
There is still little uptake on 
apps by the medical community 
(PwC, 2012). 
The Creative Destruction of 
Medicine (E. Topol, 2012) 
Eric Topol named the most 
influential doctor by Modern 
Healthcare magazine I 2012 
Discoverability, evaluation 
and integration in clinical 
pathways in fitting new 
technologies in the clinical 
pathway (Editors, 2014; 
Harvard i-lab, 2014; Kocher 
& Roberts, 2014) 
23andMe offers direct to 
consumer genetic testing in 
Canada and UK, 2014 
Following the Personal 
Genome Project in US, there 
is a Personal Genome Project 
in the UK, “Liquid hospital” 
(Jorge Juan Garcia F. at 
Doctors 2.0 & You Paris, 
2013) 
Digital phenotype (Jonah 
Comstock, 2015) 
CDHT for medical and 
pharmacology research (Bort, 
2015; PwC, 2015) 
Google glass first live 
streamed surgery, 2013 
(Schreinemacher, Graafland, 
& Schijven, 2014) 
Royal College of 
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 2007 - 2009 2010 - 2012 2013 - 2016 
Physicians issues guidance 
for apps, UK, 2015 
First Theranos testing labs 
opened with Walgreens, US, 
2013. 
A
ca
de
m
ia
 Evidence for economic and 
clinical benefits. 
Awareness of Big Data for 
health, the many possibilities 
for research 
Terminology (COCIR, 2011; 
European Parliament & 
European Council, 2011; Rudel 
et al., 2011) 
Academic Programmes in 
Digital Health: 
Reshape Innovation Center, 
Radboud Univ., The 
Netherlands, 2010 
Institute of Digital Healthcare, 
Univ. of Warwick, UK, 2010  
CATCH, Univ. of Sheffield, 
UK, 2012 
Big Data for Health 
Hospitals without beds 
(Engelen, 2015) 
More academic programs for 
digital health 
St
at
e 
(r
eg
ul
at
or
s/
pa
ye
rs
) In 2008, California regulators 
served cease-and-desist orders 
to Navigenics, 23andMe and 
other genetic companies. 
Following arguments, only 
months later, these companies 
received license to conduct 
business in California. 
Arguments: “My DNA Is My 
Data.” (Goetz, 2008)  
Meaningful Use programme 
launched in 2009 in the US 
Multiple attempted 
deployments of Electronic 
Health Records (EHR or EMR) 
across Europe (UK, Germany) 
and other countries (Israel, 
Australia), which have 
generally not taken on. 
The Whole System 
Demonstrator (WSD) in the 
UK (2008 – 2010) was meant 
to be the biggest randomised 
control trial in telehealth and 
telemedicine, 2007 
The European Union (EU) 
launches the Lead Market 
Initiative, where eHealth is 
identified as one of the most 
promising markets, 2008 
 
First WSD results were 
published in 2011, pointing 
towards economic and health 
benefits. Overall, this initiative 
had little impact. 
Regulators continue to forge 
the adoption of digital 
technologies, particularly EHR 
systems 
eHealth Action Plan 2012-
2020: Innovative healthcare for 
the 21st century (European 
Commission, 2012) 
No reimbursement channels for 
CDHT 
Attention moves from evidence 
to interoperability, legacy 
systems, governance, 
accessibility, adoption… 
FDA releases first draft 
guidance on apps, 2011 
By the end of 2012, there were 
75 apps cleared by FDA 
(mobihealthnews, 2012) 
EU publishes guidelines for 
qualification and classification 
of stand alone software, 2012 
Most other countries (outside 
the EU and the US) do not have 
specific regulations on 
mHealth, or they mimic the 
ones in the EU or US (PwC, 
2013) 
Continued focus on 
interoperability, privacy and 
data ownership 
FDA issues final guidance on 
mobile apps, US, 2013 
FDASIA Health IT report 
points toward collaboration 
between FDA, and other 
governmental entities, 
possibly the Office of the 
National Coordinator for 
Health Information 
Technology (ONC) and 
the Federal Communications 
Commission (FCC), US, 
2014 
FDA announces its intend to 
exempt certain medical 
devices from premarket 
notification 
FDA issues another final 
guidance on mobile apps in 
order to have consistency 
with the guidance on medical 
devices, US, 2015 
FDA announces a draft 
guidance: “General Wellness: 
Policy for Low Risk 
Devices”, showing intention 
not to regulate such devices, 
US, 2015 
Office of the National 
Coordinator for Health 
Information Technology 
(ONC), Department of Health 
and Human Services (HHS) 
publish certification criteria 
for health IT, US 2015  
Guidelines on apps 
(Medicines and Healthcare 
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 2007 - 2009 2010 - 2012 2013 - 2016 
Products Regulatory Agency, 
2014), UK 
EU launches a public 
consultation on mHealth, 
2014. Summary report on the 
public consultation was 
published in January 2015, 
and these results are to be 
further discussed during 
eHealth Week, May 2015 
Theranos pushes a bill in 
Arizona US to allow selling 
blood tests directly to 
consumers (Office of Arizona 
Governor, 2015) 
E
ve
nt
s mHealth Summit, US, 2009, 
had initially 800 participants 
Medicine 2.0, first in Canada, 
then in various countries, 2008 
Health 2.0, first in the US, then 
also in Europe, 2007 
Patients included act (Engelen, 
2012) 
Patient included conferences, 
examples 
Doctors 2.0 & You, France, 
2011 
Stanford Medicine X, US, 2012 
Others: 
Digital Health Summit, US, 
2011 
Health Innovation Summit, US, 
2010 
Many events now related to 
Digital Health (Sonnier, 
2015b) 
mHealth Summit Europe, 
2014 
Digital Health Live, UAE, 
2015 
Digital Health World Forum, 
UK, December 2015 
D
ig
ita
l 
H
ea
lth
 
on
lin
e 
co
m
m
un
iti
es
 mHealth Linkedin group 
founded by David Dohorty, 
2008 
Digital Health Linkedin group 
founded by Paul Sonnier, 2009  
 Digital Health UK LinkedIn 
group founded by Stephen 
Davis, 2013 
Nuviun, standalone 
community platform for 
Digital Health, 2015 
Table 17. Digital health timeline, to the beginning of 2016 
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APPENDIX E – DIGITAL HEALTH EVENTS 
ATTENDED 
 
International Congress on Telehealth 
and Telecare 
March 2012, The 
King’s Fund, London, 
UK 
Telehealth and Telecare in Scotland May 2012, Edinburg, 
UK 
Healthcare Efficiency Through Technology October 2012, London, 
UK 
mHealth Summit Europe May 2014, Berlin, 
Germany 
Digital Health Pit Shop Week December 2014, 
London, UK 
The Role of Psychology in Digital Health March 2015, London, 
UK 
Digital Health Live 2015 May 2015, Dubai, UAE 
Doctors 2.0 & You June, 2015, Paris, 
France 
Stanford Medicine X Sept. 
2015, Stanford, US 
Interface – Your Body: The Next Interface Sept. 
2015, Vancouver, Cana
da 
Digital Health World Forum December 2015, 
London, UK 
Table 18. Events attended during data collection 
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APPENDIX F. EXCERPT FROM JOHN NOSTA’S 
INTERVIEW, OPINION LEADER 
 
What is digital health right now? 
The convergence of technology and medicine: we look at it from a variety of 
perspectives. There is digital fitness, which is a traditional step counter or a 
digital tool that people use in the gym, there is digital health to advance some 
of these basic concepts into the area of health and wellness, and then digital 
medicine. So they probably are three discrete areas. For me digital health is 
about leveraging technology to prolong life, it’s about longevity. So we see 
companies like Google Calico or Human Longevity that have a very specific 
pitch on life extension.  
What would be the role of the state? 
Government helps to put certain constraints on technological developments; 
sometimes for the better, sometimes for the worse. But in areas such as 
genomic research and artificial intelligence there may be a practical role for 
government to help organise some of these advances. The driverless car, as an 
example of technology, has to be put in the context of simple laws that govern 
driving. 
Do you think this field took off with the smartphone?  
I think that the smartphone is one of the pivotal aspects of digital health. It’s 
the conduit through which information flows; it can travel. And the 
development of the smartphone and its processing power has enabled people to 
create what I call "care at a distance”. So now we can measure and manage 
wellness using telemedicine, for people around the world, not only around the 
corner. So this smartphone is an important tool that is part of digital health. I 
believe that other aspects of digital health such as nanoparticles and 
nanotechnology. Nanoparticles mediate early cancer detection and are an 
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example of a very important area of digital health. Big Data’s ability to show 
interesting correlations and trends is another area. A third area will be 
genomics; the rapid evolution and adoption of genomic analysis will be a very 
important part of the digital health movement. Those will make us think of the 
smartphone as an intrinsic or as a necessary connection. Often times we see 
things like telemedicine require the smartphone. Other advances in digital 
health such as nanotechnology, genomics and Big Data applications will not 
necessarily need the smartphone, but the cell phone, tablet, wireless 
communications can be linked to this in many ways. So, the interesting thing 
about the cell phone is it tells us that the 21st century really did not begin in the 
year 2000. I would argue that it began probably closer to the year 2015 or 
2016. And one of the major steps along was the smartphone in 2007. So we are 
seeing a magical time in human history that some people call Gutenberg 
moment, the printing press moment. I would argue that it’s even bigger than 
that - it’s not only one technological achievement, it’s multiple technological, 
human and social achievements.  
When saying ‘social’, what are you thinking of? 
It's not about social achievements, but about social issues that are coming 
together. For example, right now there is a tremendous sense of urgency to fix 
healthcare, whether it would be in the United States, regarding the 
extraordinary expense, whether it be around the world with people who have 
no access to care, pregnant moms in sub-Saharan Africa… There are pressing 
social issues and yet, in contrast to that we see, the emergence of the 
democratisation of health and as people stand up in a broader democratic voice 
- that they want the opportunity to own their healthcare data and manage their 
health and received care that they feel they're entitled to. Really, the only way 
many of those people will get care is through the technological innovations of 
digital health. So, what I say it's not just the printing press, it's not just 
technology, it's not just cloud storage capacity, it's not just your ability to have 
sensors that are small and inexpensive. That combined with other issues, such 
as social issues, come together in a very unique cauldron of innovation. That's 
why the point we live in now is truly an inflection point in history. 
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When it comes to challenges in digital health, is the US different from EU? 
I'm not so sure I would say that they are different. The utility of the NHS as a 
provider of care is quite different than the United States’; it’s a single-payer 
system. But they still see the application of technology to help people who 
can't get to the doctor, who have clinical conditions in and out of the hospital… 
So I believe there are two perspectives: one is the exoteric perspective and the 
other is the esoteric perspective. The exoteric, or practical real world aspects of 
digital health, certainly makes a difference - there's a difference in the payer, a 
difference in sociological acceptance of technology, a difference in the ageing 
population. The esoteric, conceptual ideas about saving lives, about leveraging 
technology in all those things, I believe are very, very similar. 
I want to talk about very quickly - the electronics and information technology 
is one fundamental change in our in our industrial context. 
There was water and steam, second one was the electrical power, creation of 
mass production and third electronics information technology. Now I think 
there's this fourth revolution building on the third, which is the digital 
revolution. And this diffusion of technologies that are not well defined. And 
the interesting thing about the fourth revolution is that it is a little digital and a 
little about physical. It’s about all these aspects of our humanity that are being 
transformed; amazing changes in technology. 
What do you think is missing from the conversation, if anything right now, from 
conversations surrounding digital health? 
It’s a tough question to discover what's missing. I think the discussion is 
robust. I believe that we will see probably a greater degree of clinical scrutiny. 
Ideas that are interesting may not pass the type of scrutiny that makes the 
mainstream, but the interesting thing here is that it does not make the idea bad. 
It just means that the idea has to be evolved a bit. I’ll give you an example: 
remember the Apple personal assistant PDA, a personal device that you can 
write on and you could sync it to your computer by plugging it in. I was one of 
the early Apple products, it was like a phone, but there was no phone at that 
time and it failed. Failed not because technology did not support the idea and 
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people were just not ready for the idea. The idea of scrutinizing an idea of 
questioning its clinical validity, of looking at it real data to support its use, I 
think it will, well out of necessity, come to the forefront. And with that might 
come some scepticism. I think that companies like Theranos have hurt and 
helped the digital health space, because it may have directly impacted venture 
capital. Engaging in some ideas that may not be completely, fully baked, it 
may mean investors may not to be happy to take the risk. It failed up digital 
health by a lack of transparency and failure to rise above the scrutiny. I don't 
know if Theranos is successful or not, but when I look at the articles and the 
commentaries, it makes me frustrated and sad. We are all on the same digital 
health team. I love to see people succeed. You see a company like Theranos 
and you don’t even know what the problem is. They may emerge from this and 
be completely successful. But I don't know. 
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How did you kick it off the ground? Did you find somebody to finance 
anything? 
At the very beginning, after I had built the prototype and started testing that on 
myself, I realised that I needed some money in order to take a very basic 
prototype and turn it into a proper device. So I went to look for an investor to 
put in a bit of money and through recommendations of recommendations I, in 
the end, presented it to a gentleman called Adam Blooms who agreed to invest 
in the business and he gave me the first bit of money to take the prototype and 
see whether we could build a proper device. He was the first investor. 
And what year was that? 
That was 2013. 
And I guess you took it up from there. How many funding rounds did you have? 
At the very beginning, we had a funding round literally for six months to see 
whether we could take the prototype and turn it into a proper device. During 
those six months, he realised that it is possible and there was market 
opportunity for the device. And then he invested more money, which allowed 
the business to basically go through proper development, proper mobile app 
development, as well and all the regulatory requirements for the adoption of 
the device. And that took us to January of 2015. And then in January 2015, we 
started raising a further round of funding from private individuals, to allow 
business to start scale up and invest in people and invest in infrastructure, and 
we have secured that when funding came in. And so now we are starting to 
scale up the business and then, at the end of this year, we will go for venture 
capital funding from the US. 
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And at the moment, you can commercialize the device in the US, is that 
correct? You have the FDA approval? 
Correct. We can actually commercialize the device in the US and in the UK. 
The problem in the UK at the moment is that there is no mandate for 
prescribing technology. And, because our device is a consumer-driven device, 
the end user being a patient as opposed to the hospital system, we are waiting 
for the final go-ahead for our device to be adopted into the therapeutics, that it 
can be prescribed. 
What about the European Union? 
We can commercialize it. We are just having discussions now about 
distribution. 
But is it OK to be sold in the European Union? 
It is OK, yes. 
And the distribution channels at the moment are direct to consumers? 
Yes. So, we have two channels. One is direct to the hospitals where we’re 
selling direct to the colorectal surgeons and nursing teams and then the on-
going sales are direct to consumers. 
For the hospitals are you going through distributers? 
No, we’re going directly.  
And that’s for the US mainly, at the moment? 
Yes, that’s right.  
The way I see it, maybe I’m wrong, is somewhere close to a medical device, 
isn’t it?  
It’s a class one medical device. So it’s the lowest classification of medical 
device. 
So it could also go through channels in Europe, through medical devices 
distributors and things like that. 
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Correct, absolutely. 
Great, so I have a bit of history. And I saw you have a diverse background, you 
have worked in marketing, and you’ve also worked in the entertainment 
industry in a sense. 
Yes. 
And how did your experience pay off in the field? 
I was very lucky; I worked with some major sporting brands and some major 
entertainment brands. (…) It gave me a structure and an understanding for 
process that I think has been invaluable. 
And as well I guess in designing an app, to better understand user experience. 
Yes, particularly with ZZZ we developed the first mobile game and so I had an 
understanding of user journey, user experience, what would turn people off, so 
we deliberately made our user journey very simple. We’re not a gaming app, 
and therefore we don’t have to have the most beautiful graphics or the most 
beautiful look of the buttons. But what was really important was that it was an 
easy journey for the patient to use, and so having a little bit of a background in 
that has helped enormously. 
And combined I guess with your own experience as a patient. 
Yes. I’m very conscious of very high drops of rates of apps from patients and I 
wanted to make sure that as a patient you really don’t have to do very much, 
very often. 
I do not know very much about the medical side of this but are there a lot of 
children who are going through this sort of problem? The vast majority of 
patients are children? 
So 70% of the patients are adults and 30% are children or teenagers under the 
age of 21. 
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And do you have anything to facilitate this sort of patients? Like an app that 
will communicate to carers or that would be a bit educational for children, 
anything easy to customise for this sorts of patients? 
At the moment, we just have one application targeted to everybody. We are 
very active on social media and used that as a vehicle to communicate what 
we’re trying to do to the younger audience. We use Instagram a lot for 
imagery, we use Facebook and Twitter, and we’re starting to look at Snapchat 
and other social media out there, as a way of engaging with the younger 
community. But at the moment, the device and the app is one size fits all. 
Now that you talked about social media, how important do you think is social 
media for growing your business? 
It’s vital. It’s absolutely vital. At the beginning, it was vital in understanding 
the market in the sense that it helped me to talk directly to patients, to learn 
whether there even were issues, whether other patients experienced the same 
problems that I had. I then was able to use it for market research - if there was 
a device would people would use it, would they want it, would it be paid for, 
what do they think is the right cost and so I could get all that information from 
social media. And now, it is the most vital way that I communicate with 
patients. Because I think what is vitally important in this business is that this is 
patient-led technology and patient-led innovation, so I am absolutely insistent 
that everything we do in a sense gets run by patients and social media will do 
that. 
For instance, do you have any understanding, when you sell directly to 
consumers, do you think they come to you mainly through word of mouth?  
Yes, mainly through social media and word of mouth at the moment. We have 
not yet reached a big enough market share in the hospitals for it to filter down 
from the doctors to the patient. At the moment, it’s from the patients at the 
grassroots. (…) The idea is that the grassroots know about the device, and then 
the doctors know about it, and the two come together. 
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I know that you are a voice in the patient community, in the raising patient 
community. How much do you think that your role as patient goes back to 
growing a business in a sense? 
I’m very conscious of not wanting to impose my patient voice on consumers so 
I come across as someone that is just trying to sell people that I engage with on 
a daily basis. I really don’t want to be seen as someone that is just using my 
voice to purely benefit my company. There is a line, which I try not to cross, 
and so my personal voice is about trying to raise the role of the patient, trying 
to promote patients as innovators, and within that I talk about the business. But 
the business also has to have its own social media presence. So there is a fine 
line. I don’t want people to think that I am using my personal following just for 
commercial gain. I really don’t want that to come across. 
I understand that you see it as an ethical issue, and you see your role as a 
patient leader in a way should be clearly delineated from your role as an 
entrepreneur? 
Yes, it’s really important to me that people don’t feel that everything I’m doing 
is just so that I can earn some more money so I don’t want to cross the line(…) 
Do you think your company changed in its brief life? I mean, changed the 
orientation, in the way you communicate, in the design of the product? Do you 
think it changed a lot, or it followed a natural progression? 
It has changed as more people have got involved, which is probably a natural 
progression. As the company grows, and we have more shareholders, and we 
have a chairman etc., you realise that people are actually very focused on their 
own personal gain, and I’m very clear to try and keep the company focused on 
improving the life of the patient. If we are keeping the focus on this, than the 
company is going to continue to make more money. The priority is 'What are 
we trying to do?' And that is a hard balance, as we grow.  
